1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O

1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	O
15	factor	I
16	Sp1	I
17	.	O

1	100	O
2	more	O
3	than	O
4	in	O
5	the	O
6	summer	O
7	coat	O
8	).	O

1	Analysis	O
2	of	O
3	proteins	O
4	synthesized	O
5	by	O
6	plasmids	O
7	containing	O
8	deleted	O
9	forms	O
10	of	O
11	the	O
12	trfA	O
13	region	O
14	indicates	O
15	that	O
16	the	O
17	A2	B
18	protein	I
19	is	O
20	the	O
21	essential	O
22	trfA	B
23	-	O
24	encoded	O
25	replication	O
26	protein	O
27	of	O
28	plasmid	O
29	RK2	O
30	.	O

1	The	O
2	carcinoma	O
3	was	O
4	restricted	O
5	within	O
6	the	O
7	epithelium	O
8	in	O
9	one	O
10	,	O
11	the	O
12	mucosal	O
13	layer	O
14	in	O
15	five	O
16	,	O
17	and	O
18	the	O
19	submucosal	O
20	layer	O
21	in	O
22	two	O
23	.	O

1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O

1	Homozygous	O
2	protein	O
3	C	I
4	(	O
5	PC	B
6	)	I
7	deficiency	O
8	is	O
9	reported	O
10	in	O
11	two	O
12	siblings	O
13	(	O
14	girl	O
15	and	O
16	boy	O
17	)	O
18	who	O
19	received	O
20	their	O
21	proper	O
22	diagnoses	O
23	at	O
24	the	O
25	ages	O
26	of	O
27	7	B
28	4	I
29	/	O
30	12	O
31	and	O
32	1	O
33	3	O
34	/	O
35	12	O
36	years	O
37	respectively	O
38	.	O

1	The	O
2	relatively	O
3	high	O
4	level	O
5	transcription	O
6	from	O
7	this	O
8	gene	O
9	shows	O
10	that	O
11	the	O
12	polymorphic	O
13	chromosome	O
14	ends	O
15	of	O
16	P	O
17	.	O
18	falciparum	O
19	,	O
20	which	O
21	have	O
22	been	O
23	proposed	O
24	to	O
25	be	O
26	transcriptionally	O
27	silent	O
28	,	O
29	can	O
30	be	O
31	active	O
32	expression	O
33	sites	O
34	for	O
35	var	B
36	genes	I
37	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	with	O
6	autonomic	O
7	nervous	O
8	system	O
9	activity	O
10	intact	O
11	,	O
12	carotid	O
13	chemoreceptor	O
14	reflex	O
15	activation	O
16	can	O
17	elicit	O
18	an	O
19	absolute	O
20	reflexly	O
21	mediated	O
22	reduction	O
23	in	O
24	coronary	O
25	blood	O
26	flow	O
27	in	O
28	the	O
29	normal	O
30	,	O
31	conscious	O
32	dog	O
33	,	O
34	despite	O
35	an	O
36	increase	O
37	in	O
38	arterial	O
39	pressure	O
40	.	O

1	Transcription	O
2	of	O
3	the	O
4	metH	B
5	gene	I
6	in	O
7	Salmonella	O
8	typhimurium	O
9	and	O
10	Escherichia	O
11	coli	O
12	is	O
13	positively	O
14	regulated	O
15	by	O
16	the	O
17	metR	B
18	gene	I
19	product	I
20	,	O
21	a	O
22	DNA	O
23	binding	O
24	protein	O
25	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	functional	O
6	elements	O
7	,	O
8	both	O
9	located	O
10	downstream	O
11	from	O
12	the	O
13	TATA	O
14	motif	I
15	,	O
16	that	O
17	control	B
18	Id4	I
19	promoter	I
20	activity	O
21	.	O

1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	Significantly	O
2	,	O
3	pPKR	O
4	is	O
5	capable	O
6	of	O
7	specifically	O
8	phosphorylating	B
9	Ser51	I
10	in	O
11	a	O
12	synthetic	B
13	eIF	B
14	-	I
15	2alpha	I
16	peptide	I
17	,	O
18	a	O
19	key	O
20	characteristic	O
21	of	O
22	the	O
23	eIF	B
24	-	I
25	2alpha	I
26	kinase	I
27	family	I
28	.	O

1	Wnt	B
2	-	I
3	1	I
4	(	O
5	int	B
6	-	I
7	1	I
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O

1	When	O
2	the	O
3	73	O
4	-	O
5	bp	O
6	fragment	O
7	was	O
8	fused	O
9	to	O
10	an	O
11	alpha1	B
12	-	I
13	globin	I
14	promoter	I
15	-	I
16	CAT	I
17	construct	I
18	and	O
19	cotransfected	O
20	with	O
21	CCAAT	B
22	transcription	I
23	factor	I
24	1	I
25	(	O
26	CTF1	B
27	)/	O
28	NF1	B
29	into	O
30	Drosophila	B
31	Schneider	O
32	SL2	O
33	insect	O
34	cells	O
35	(	O
36	which	O
37	lack	O
38	NF1	B
39	-	I
40	like	I
41	proteins	I
42	)	O
43	trans	O
44	-	O
45	activation	O
46	of	O
47	CAT	B
48	activity	O
49	was	O
50	observed	O
51	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	B
15	(	O
16	Tris	B
17	-	I
18	Tween	I
19	80	I
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O

1	Photopic	O
2	spectral	O
3	sensitivity	O
4	determined	O
5	electroretinographically	O
6	for	O
7	the	O
8	pigeon	O
9	eye	O
10	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	O
12	dimers	O
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	I
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	Unaided	O
2	attempts	O
3	to	O
4	quit	O
5	smoking	O
6	are	O
7	generally	O
8	unsuccessful	O
9	.	O

1	Studies	O
2	on	O
3	swine	O
4	enteroviruses	O
5	.	O

1	APOE	B
2	-	O
3	epsilon4	O
4	count	O
5	predicts	O
6	age	O
7	when	O
8	prevalence	O
9	of	O
10	AD	O
11	increases	O
12	,	O
13	then	O
14	declines	O
15	:	O
16	the	O
17	Cache	O
18	County	O
19	Study	O
20	.	O

1	In	O
2	a	O
3	reconstituted	O
4	human	O
5	DNA	O
6	repair	O
7	system	O
8	containing	O
9	DNA	B
10	polymerase	I
11	beta	I
12	and	O
13	DNA	O
14	ligase	I
15	III	I
16	-	I
17	XRCC1	I
18	,	O
19	accurate	O
20	rejoining	O
21	of	O
22	a	O
23	3	O
24	'	O
25	mismatched	O
26	base	O
27	residue	O
28	at	O
29	a	O
30	single	O
31	-	O
32	strand	O
33	break	O
34	is	O
35	dependent	O
36	on	O
37	addition	O
38	of	O
39	the	O
40	exonuclease	B
41	.	O

1	Concussion	O
2	of	O
3	the	O
4	spinal	O
5	cord	O

1	However	O
2	,	O
3	despite	O
4	its	O
5	relationship	O
6	to	O
7	the	O
8	TR	B
9	,	O
10	Rev	B
11	-	I
12	Erb	I
13	bound	O
14	poorly	O
15	to	O
16	TR	B
17	binding	I
18	sites	O
19	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	observations	O
6	demonstrated	O
7	that	O
8	stratification	O
9	of	O
10	acute	O
11	MI	O
12	patients	O
13	by	O
14	plasma	O
15	ANF	O
16	level	O
17	is	O
18	a	O
19	useful	O
20	non	O
21	-	O
22	invasive	O
23	method	O
24	for	O
25	predicting	O
26	prognosis	O
27	and	O
28	for	O
29	identifying	O
30	individuals	O
31	at	O
32	high	O
33	risk	O
34	of	O
35	cardiac	O
36	death	O
37	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	O
17	region	O
18	significantly	O
19	decreased	O
20	bop	B
21	gene	I
22	mRNA	I
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	B
7	protein	O
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	O
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	B
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	Atopic	O
2	dermatitis	O
3	is	O
4	an	O
5	"	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	"	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O

1	Charcoal	O
2	-	O
3	facilitated	O
4	dialysis	O
5	.	O

1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	O
11	AF	O
12	-	O
13	2	O
14	domain	O
15	from	O
16	the	O
17	vitamin	O
18	D3	B
19	receptor	I
20	or	O
21	the	O
22	estrogen	B
23	receptor	I
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O

1	Despite	O
2	continuous	O
3	compliance	O
4	,	O
5	unexplained	O
6	resurgence	O
7	of	O
8	serum	O
9	ferritin	I
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	veteran	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O

1	Ovarian	O
2	allotransplantation	O
3	in	O
4	human	O
5	.	O

1	In	O
2	order	O
3	to	O
4	examine	O
5	the	O
6	potential	O
7	role	O
8	of	O
9	transcriptional	O
10	silencing	O
11	during	O
12	productive	O
13	HSV	O
14	-	O
15	1	O
16	infection	O
17	,	O
18	recombinant	O
19	viruses	O
20	were	O
21	generated	O
22	in	O
23	which	O
24	wild	O
25	-	O
26	type	O
27	or	O
28	mutant	O
29	ICP34	I
30	.	O
31	5	O
32	promoters	O
33	controlling	O
34	the	O
35	expression	O
36	of	O
37	a	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	gene	I
42	were	O
43	inserted	O
44	into	O
45	the	O
46	thymidine	B
47	kinase	I
48	gene	O
49	of	O
50	the	O
51	viral	O
52	genome	O
53	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	TyrRS	O
21	activity	O
22	was	O
23	produced	O
24	.	O

1	How	O
2	plants	O
3	respond	O
4	to	O
5	attack	O
6	by	O
7	the	O
8	range	O
9	of	O
10	herbivores	O
11	and	O
12	pathogens	O
13	that	O
14	confront	O
15	them	O
16	in	O
17	the	O
18	field	O
19	is	O
20	the	O
21	subject	O
22	of	O
23	considerable	O
24	research	O
25	by	O
26	both	O
27	molecular	O
28	biologists	O
29	and	O
30	ecologists	O
31	.	O

1	The	O
2	human	B
3	gp39	I
4	promoter	I
5	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	To	O
2	examine	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	apparent	O
8	differences	O
9	in	O
10	postsegregational	O
11	killing	O
12	between	O
13	the	O
14	two	O
15	E	O
16	.	O
17	coli	O
18	strains	O
19	,	O
20	transformation	O
21	assays	O
22	were	O
23	carried	O
24	out	O
25	to	O
26	determine	O
27	the	O
28	relative	O
29	sensitivities	O
30	of	O
31	the	O
32	strains	O
33	to	O
34	the	O
35	ParE	B
36	toxin	I
37	protein	I
38	.	O

1	Here	O
2	we	O
3	characterize	O
4	an	O
5	S	B
6	.	I
7	cerevisiae	I
8	Swi3	I
9	homolog	I
10	(	O
11	Swh3	I
12	)	O
13	and	O
14	present	O
15	evidence	O
16	that	O
17	it	O
18	associates	O
19	in	O
20	a	O
21	complex	O
22	with	O
23	a	O
24	Snf2	B
25	homolog	I
26	,	O
27	Sthl	B
28	.	O

1	Northern	O
2	analysis	O
3	,	O
4	to	O
5	search	O
6	for	O
7	a	O
8	pcbAB	O
9	transcript	O
10	,	O
11	showed	O
12	no	O
13	distinct	O
14	transcript	O
15	and	O
16	indicated	O
17	severely	O
18	degraded	O
19	mRNA	I
20	.	O

1	GTPase	B
2	activating	O
3	specificity	O
4	of	O
5	RGS12	B
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	B
12	spliced	I
13	PDZ	I
14	(	I
15	PSD	B
16	-	I
17	95	I
18	/	I
19	Dlg	I
20	/	I
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	The	O
2	U14	B
3	genes	I
4	of	O
5	mouse	O
6	as	O
7	well	O
8	as	O
9	rat	O
10	,	O
11	hamster	O
12	,	O
13	human	O
14	,	O
15	Xenopus	B
16	and	O
17	trout	I
18	are	O
19	encoded	O
20	within	O
21	introns	O
22	of	O
23	the	O
24	constitutively	O
25	expressed	O
26	70	B
27	-	I
28	kDa	I
29	-	I
30	cognate	I
31	-	I
32	heat	I
33	-	I
34	shock	I
35	protein	I
36	gene	I
37	(	O
38	hsc70	O
39	).	O

1	Restoration	O
2	of	O
3	impaired	O
4	immune	O
5	functions	O
6	in	O
7	aging	O
8	animals	O
9	.	O

1	Microvessels	O
2	were	O
3	counted	O
4	in	O
5	a	O
6	x200	O
7	field	O
8	(	O
9	0	O
10	.	O
11	754	O
12	mm2	O
13	)	O
14	in	O
15	the	O
16	area	O
17	of	O
18	maximal	O
19	angiogenesis	O
20	.	O

1	Examination	O
2	of	O
3	the	O
4	immediate	B
5	sequence	I
6	5	I
7	'	O
8	to	O
9	the	O
10	mRNA	B
11	start	I
12	site	I
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O

1	L	O
2	-	O
3	canavanine	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	B
11	nitric	I
12	oxide	I
13	synthase	I
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	improving	O
24	venous	O
25	return	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O

1	Spc42p	O
2	also	O
3	was	O
4	identified	O
5	as	O
6	a	O
7	component	O
8	of	O
9	a	O
10	cytoplasmic	O
11	SPB	O
12	subcomplex	O
13	containing	O
14	Spc94p	B
15	/	O
16	Nud1p	I
17	,	O
18	Cnm67p	B
19	,	O
20	and	O
21	Spc42p	O
22	.	O

1	MSSPs	O
2	are	O
3	believed	O
4	to	O
5	regulate	O
6	DNA	O
7	replication	O
8	,	O
9	transcription	O
10	,	O
11	apopotosis	O
12	and	O
13	cell	O
14	cycle	O
15	progression	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	C	B
21	-	I
22	MYC	I
23	protein	I
24	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	signals	O
6	obtained	O
7	by	O
8	ligation	O
9	of	O
10	the	O
11	TCR	B
12	,	O
13	T	O
14	cells	O
15	need	O
16	additional	O
17	,	O
18	co	O
19	-	O
20	stimulatory	O
21	signals	O
22	to	O
23	be	O
24	activated	O
25	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	O
10	molecule	O
11	.	O

1	CONCLUSION	O
2	:	O
3	Twice	O
4	daily	O
5	treatment	O
6	with	O
7	inhaled	O
8	fluticasone	O
9	propionate	O
10	50	O
11	micrograms	O
12	or	O
13	100	O
14	micrograms	O
15	was	O
16	significantly	O
17	more	O
18	effective	O
19	than	O
20	theophylline	O
21	in	O
22	the	O
23	treatment	O
24	of	O
25	mild	O
26	-	O
27	to	O
28	-	O
29	moderate	O
30	asthma	O
31	.	O

1	Distinguishing	O
2	roles	O
3	of	O
4	the	O
5	membrane	O
6	-	O
7	cytoskeleton	I
8	and	O
9	cadherin	B
10	mediated	O
11	cell	O
12	-	O
13	cell	I
14	adhesion	I
15	in	O
16	generating	O
17	different	O
18	Na	B
19	+,	I
20	K	I
21	(+)-	I
22	ATPase	I
23	distributions	O
24	in	O
25	polarized	O
26	epithelia	O
27	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	B
15	Agrocybe	I
16	aegerita	I
17	,	O
18	was	O
19	cloned	O
20	.	O

1	Cleavage	O
2	by	O
3	the	O
4	intron	O
5	-	O
6	encoded	O
7	enzyme	O
8	(	O
9	I	B
10	-	I
11	CreI	I
12	)	O
13	occurs	O
14	5	O
15	bp	O
16	and	O
17	1	O
18	bp	O
19	3	O
20	'	O
21	to	O
22	the	O
23	intron	O
24	insertion	O
25	site	O
26	(	O
27	in	O
28	the	O
29	3	O
30	'-	O
31	exon	O
32	)	O
33	in	O
34	the	O
35	top	O
36	(/)	O
37	and	O
38	bottom	B
39	(,)	I
40	strands	O
41	,	O
42	respectively	O
43	,	O
44	resulting	O
45	in	O
46	4	O
47	-	O
48	nt	O
49	single	O
50	-	O
51	stranded	O
52	overhangs	O
53	with	O
54	3	O
55	'-	O
56	OH	O
57	termini	O
58	.	O

1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	O
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	O
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O

1	Pentazocine	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	niche	O
8	for	O
9	Talwin	B
10	Nx	I
11	?	O
12	Pentazocine	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	analgesic	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O

1	The	O
2	yeast	O
3	gene	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	,	O
10	designated	O
11	TIF5	B
12	,	O
13	has	O
14	been	O
15	isolated	O
16	and	O
17	expressed	O
18	in	O
19	Escherichia	O
20	coli	O
21	to	O
22	yield	O
23	a	O
24	catalytically	O
25	active	O
26	eIF	B
27	-	I
28	5	I
29	protein	I
30	.	O

1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	B
25	fall	O
26	of	O
27	27	O
28	%.	O

1	We	O
2	have	O
3	designated	O
4	the	O
5	protein	O
6	"	O
7	cellular	O
8	NBP	O
9	"	O
10	(	O
11	CNBP	O
12	).	O

1	Ectopic	O
2	ACTH	B
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	major	B
7	IE	I
8	proteins	I
9	IE86	I
10	,	O
11	IE72	B
12	,	O
13	and	O
14	IE55	O
15	are	O
16	capable	O
17	of	O
18	trans	O
19	-	O
20	activating	O
21	the	O
22	HIV	B
23	LTR	I
24	in	O
25	a	O
26	T	O
27	-	O
28	cell	O
29	line	O
30	,	O
31	HUT	O
32	-	O
33	78	O
34	.	O

1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O

1	Monitoring	O
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	B
8	-	I
9	1	I
10	and	O
11	TNF	B
12	levels	O
13	throughout	O
14	the	O
15	clinical	O
16	course	O
17	of	O
18	disease	O
19	may	O
20	help	O
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	However	O
2	,	O
3	after	O
4	repeated	O
5	infections	O
6	,	O
7	hypobiotic	O
8	larvae	O
9	were	O
10	numerous	O
11	.	O

1	In	O
2	cell	O
3	lines	O
4	transformed	O
5	by	O
6	BCR	B
7	/	O
8	ABL	B
9	,	O
10	CRKL	B
11	was	O
12	tyrosine	O
13	phosphorylated	O
14	,	O
15	while	O
16	CRK	B
17	was	O
18	not	O
19	.	O

1	Sibling	O
2	aggregation	O
3	of	O
4	low	O
5	-	O
6	and	O
7	high	B
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	O
13	apolipoproteins	B
14	B	I
15	and	O
16	A	O
17	-	O
18	I	I
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O

1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	O
9	-	O
10	kDa	O
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	O
20	(	O
21	GCKR	O
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	O
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O

1	Despite	O
2	the	O
3	favourable	O
4	natural	O
5	history	O
6	of	O
7	acute	O
8	BI	O
9	,	O
10	mild	O
11	,	O
12	moderate	O
13	,	O
14	and	O
15	severe	O
16	posttraumatic	O
17	changes	O
18	were	O
19	shown	O
20	to	O
21	appear	O
22	as	O
23	cicatricial	O
24	-	O
25	adhesive	O
26	and	O
27	atrophic	O
28	processes	O
29	,	O
30	intracerebral	O
31	cysts	O
32	,	O
33	porencephaly	O
34	,	O
35	which	O
36	result	O
37	in	O
38	posttraumatic	O
39	epilepsy	O
40	,	O
41	hydrocephalus	O
42	,	O
43	etc	O
44	.	O

1	It	O
2	may	O
3	also	O
4	be	O
5	suggested	O
6	that	O
7	particular	O
8	care	O
9	should	O
10	be	O
11	taken	O
12	when	O
13	such	O
14	a	O
15	trans	O
16	-	O
17	dominant	O
18	Rev	I
19	mutant	I
20	is	O
21	considered	O
22	to	O
23	be	O
24	used	O
25	as	O
26	a	O
27	genetic	O
28	therapy	O
29	against	O
30	HIV	O
31	-	O
32	I	O
33	infection	O
34	,	O
35	in	O
36	individuals	O
37	infected	O
38	with	O
39	both	O
40	HIV	O
41	-	O
42	I	I
43	and	O
44	HTLV	O
45	-	O
46	1	O
47	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	polypeptide	O
7	sequence	O
8	of	O
9	the	O
10	Drosophila	B
11	protein	I
12	with	O
13	the	O
14	equivalent	O
15	subunits	O
16	from	O
17	mouse	O
18	and	O
19	yeast	O
20	suggests	O
21	that	O
22	they	O
23	are	O
24	closely	O
25	related	O
26	and	O
27	defines	O
28	three	O
29	conserved	O
30	regions	O
31	which	O
32	are	O
33	likely	O
34	to	O
35	be	O
36	important	O
37	for	O
38	enzyme	O
39	activity	O
40	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	role	O
6	of	O
7	cellular	B
8	p21ras	I
9	protein	I
10	in	O
11	insulin	B
12	and	I
13	insulin	B
14	-	I
15	like	I
16	growth	I
17	factor	I
18	-	I
19	I	I
20	(	O
21	IGF	B
22	-	I
23	I	I
24	)	O
25	signaling	O
26	pathways	O
27	.	O

1	Coimmunoprecipitation	O
2	experiments	O
3	performed	O
4	in	O
5	transfected	O
6	cells	O
7	showed	O
8	that	O
9	BCMA	O
10	associates	O
11	with	O
12	TNFR	B
13	-	I
14	associated	I
15	factor	I
16	(	O
17	TRAF	B
18	)	I
19	1	I
20	,	O
21	TRAF2	B
22	,	O
23	and	O
24	TRAF3	B
25	adaptor	O
26	proteins	O
27	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	I
10	p58	B
11	and	O
12	cdc2	B
13	/	I
14	p62	B
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	The	O
2	rad9	B
3	.	O
4	192	O
5	DNA	O
6	repair	I
7	mutant	O
8	from	O
9	the	O
10	fission	O
11	yeast	O
12	,	O
13	Schizosaccharomyces	O
14	pombe	O
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	The	O
2	used	O
3	expression	O
4	system	O
5	could	O
6	allow	O
7	to	O
8	produce	O
9	mutated	O
10	forms	O
11	of	O
12	SsEF	B
13	-	O
14	2	I
15	obtained	O
16	by	O
17	mutagenesis	O
18	of	O
19	the	O
20	corresponding	O
21	gene	O
22	.	O

1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O

1	To	O
2	explore	O
3	the	O
4	mechanism	O
5	of	O
6	RSK	B
7	activation	O
8	,	O
9	a	O
10	cloned	O
11	human	B
12	RSK	I
13	cDNA	I
14	(	O
15	RSK3	B
16	)	O
17	was	O
18	used	O
19	to	O
20	generate	O
21	and	O
22	characterize	O
23	several	O
24	site	O
25	-	O
26	directed	O
27	RSK	B
28	mutants	I
29	;	O
30	K91A	B
31	(	O
32	N	O
33	-	O
34	Lys	O
35	,	O
36	NH2	O
37	-	O
38	terminal	O
39	ATP	I
40	-	I
41	binding	I
42	mutant	I
43	),	O
44	K444A	O
45	(	O
46	C	O
47	-	O
48	Lys	O
49	,	O
50	COOH	O
51	-	O
52	terminal	O
53	ATP	I
54	-	I
55	binding	I
56	mutant	I
57	),	O
58	N	O
59	/	O
60	C	B
61	-	I
62	Lys	I
63	(	O
64	double	B
65	ATP	I
66	-	I
67	binding	I
68	mutant	I
69	)	O
70	T570A	I
71	(	O
72	C	O
73	-	O
74	Thr	O
75	,	O
76	mutant	O
77	of	O
78	the	O
79	putative	O
80	MAPK	B
81	phosphorylation	O
82	site	I
83	in	O
84	subdomain	O
85	VIII	O
86	of	O
87	the	O
88	C	O
89	-	O
90	domain	I
91	),	O
92	S218A	O
93	(	O
94	N	O
95	-	O
96	Ser	O
97	,	O
98	mutant	O
99	of	O
100	the	O
101	corresponding	O
102	NH2	O
103	-	O
104	terminal	O
105	residue	O
106	).	O

1	Cloning	O
2	and	O
3	sequence	O
4	analyses	O
5	revealed	O
6	a	O
7	second	O
8	cDNA	O
9	with	O
10	a	O
11	95	O
12	-	O
13	nt	O
14	deletion	O
15	in	O
16	the	O
17	region	O
18	coding	O
19	for	O
20	the	O
21	putative	O
22	second	O
23	intracellular	O
24	loop	O
25	and	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	of	O
31	the	O
32	5	B
33	-	I
34	HT2C	I
35	-	I
36	R	I
37	.	O

1	A	O
2	bacteriological	O
3	relapse	O
4	requiring	O
5	treatment	O
6	occurred	O
7	by	O
8	5	O
9	years	O
10	in	O
11	16	O
12	.	O
13	8	O
14	%	O
15	of	O
16	113	O
17	R3	O
18	,	O
19	5	O
20	.	O
21	2	O
22	%	O
23	of	O
24	97	O
25	R5	O
26	,	O
27	and	O
28	20	O
29	.	O
30	0	O
31	%	O
32	of	O
33	115	O
34	Z5	O
35	patients	O
36	with	O
37	organisms	O
38	sensitive	O
39	to	O
40	streptomycin	O
41	and	O
42	isoniazid	O
43	initially	O
44	.	O

1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	B
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	I
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O

1	There	O
2	was	O
3	no	O
4	significant	O
5	correlation	O
6	between	O
7	baseline	O
8	PC40	O
9	methacholine	O
10	and	O
11	the	O
12	maximal	O
13	fall	O
14	in	O
15	Vp30	O
16	after	O
17	either	O
18	the	O
19	first	O
20	(	O
21	12	O
22	micrograms	O
23	)	O
24	or	O
25	the	O
26	second	O
27	dose	O
28	(	O
29	24	O
30	micrograms	O
31	)	O
32	of	O
33	platelet	B
34	activating	I
35	factor	I
36	.	O

1	MEF	B
2	and	O
3	AML1B	B
4	synergistically	O
5	transactivated	B
6	an	O
7	interleukin	B
8	3	I
9	promoter	I
10	reporter	I
11	gene	I
12	construct	I
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	B
20	was	O
21	abolished	O
22	when	O
23	MEF	B
24	was	O
25	coexpressed	O
26	with	O
27	AML1	B
28	/	O
29	ETO	B
30	.	O

1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	negative	O
6	Smad2	B
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	B
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	A	O
2	third	O
3	prominent	O
4	component	O
5	of	O
6	apparent	O
7	molecular	O
8	mass	O
9	16	O
10	kDa	O
11	displayed	O
12	several	O
13	properties	O
14	,	O
15	including	O
16	ability	O
17	to	O
18	bind	O
19	45Ca2	O
20	+,	O
21	that	O
22	are	O
23	characteristic	O
24	of	O
25	the	O
26	regulatory	O
27	(	O
28	B	B
29	)	O
30	subunit	O
31	of	O
32	mammalian	B
33	calcineurin	I
34	and	O
35	was	O
36	recognized	O
37	by	O
38	an	O
39	antiserum	O
40	raised	O
41	against	O
42	bovine	O
43	calcineurin	O
44	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	show	O
7	that	O
8	cdk7	B
9	may	O
10	phosphorylate	O
11	the	O
12	carboxy	O
13	-	I
14	terminal	I
15	domain	I
16	(	O
17	CTD	B
18	)	O
19	of	O
20	RNA	B
21	pol	I
22	II	I
23	in	O
24	the	O
25	absence	O
26	of	O
27	promoter	O
28	opening	O
29	.	O

1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	I
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O

1	These	O
2	effects	O
3	were	O
4	abrogated	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	B
11	-	O
12	deficient	O
13	PKC	B
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	p85alpha	I
23	-	I
24	p110	I
25	by	O
26	wortmannin	O
27	,	O
28	LY294002	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	p85alpha	O
37	.	O

1	Phagocytosis	O
2	of	O
3	tubercle	O
4	bacilli	O
5	by	O
6	macrophages	O
7	.	O

1	The	O
2	gene	B
3	pairs	I
4	psbB	I
5	-	I
6	psbT	I
7	and	O
8	psbH	O
9	-	O
10	psbN	I
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	RPE65	O
7	,	O
8	a	O
9	novel	O
10	retinal	O
11	pigment	O
12	epithelium	O
13	-	O
14	specific	O
15	microsomal	O
16	protein	O
17	that	O
18	is	O
19	post	O
20	-	O
21	transcriptionally	O
22	regulated	O
23	in	O
24	vitro	O
25	.	O

1	The	O
2	therapeutic	O
3	action	O
4	of	O
5	cyclosporin	O
6	A	O
7	(	O
8	Sandimmun	O
9	):	O
10	its	O
11	application	O
12	in	O
13	rheumatoid	O
14	arthritis	O
15	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	technique	O
6	of	O
7	low	O
8	-	O
9	frequency	O
10	kindling	O
11	is	O
12	a	O
13	useful	O
14	experimental	O
15	model	O
16	in	O
17	assessing	O
18	the	O
19	effects	O
20	of	O
21	antipsychotic	O
22	or	O
23	antiepileptic	O
24	drugs	O
25	on	O
26	the	O
27	excitability	O
28	of	O
29	the	O
30	limbic	O
31	regions	O
32	.	O

1	Positive	O
2	genetic	O
3	selections	O
4	for	O
5	inhibition	O
6	of	O
7	cyclin	B
8	/	I
9	CDK	I
10	function	O
11	were	O
12	characterized	O
13	using	O
14	the	O
15	E	B
16	.	I
17	coli	I
18	neo	I
19	and	I
20	yeast	I
21	LEU2	I
22	genes	I
23	.	O

1	Similarly	O
2	,	O
3	supraventricular	B
4	tachycaydia	I
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	B
7	5	I
8	'	I
9	flanking	I
10	region	O
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	Merr	O
2	.)	O
3	embryo	O
4	library	O
5	.	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	Serum	O
2	leptin	B
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	B
8	stimulation	O
9	cycles	O
10	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	I
23	weight	O
24	protein	O
25	(	O
26	72K	B
27	protein	O
28	).	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	TEP	O
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O

1	Expression	O
2	of	O
3	the	O
4	proapoptotic	B
5	protein	I
6	Bax	I
7	under	O
8	the	O
9	control	O
10	of	O
11	a	O
12	GAL10	B
13	promoter	I
14	in	O
15	Saccharomyces	O
16	cerevisiae	O
17	resulted	O
18	in	O
19	galactose	B
20	-	O
21	inducible	O
22	cell	O
23	death	O
24	.	O

1	Efficacy	O
2	and	O
3	field	O
4	evaluation	O
5	of	O
6	Bacillus	O
7	thuringiensis	O
8	(	O
9	H	B
10	-	O
11	14	O
12	)	O
13	and	O
14	B	O
15	.	O
16	sphaericus	O
17	against	O
18	floodwater	B
19	mosquitoes	O
20	in	O
21	California	O
22	.	O

1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	I
8	sequence	I
9	stabilizes	O
10	GDP	B
11	binding	I
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O

1	All	O
2	corneal	O
3	buttons	O
4	were	O
5	processed	O
6	for	O
7	histopathologic	O
8	and	O
9	electron	O
10	microscopic	O
11	studies	O
12	.	O

1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O

1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O

1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O

1	ATP	B
2	gamma	I
3	S	I
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	B
13	,	O
14	dATP	B
15	,	O
16	araATP	B
17	,	O
18	or	O
19	ddATP	O
20	.	O

1	The	O
2	structure	O
3	of	O
4	these	O
5	genes	O
6	suggests	O
7	a	O
8	common	O
9	ancestor	O
10	for	O
11	all	O
12	viperid	B
13	PLA2	I
14	genes	I
15	.	O

1	The	O
2	assessment	O
3	using	O
4	7	O
5	H	O
6	9	O
7	liquid	O
8	medium	O
9	by	O
10	the	O
11	former	O
12	author	O
13	demonstrated	O
14	the	O
15	potent	O
16	activities	O
17	of	O
18	both	O
19	CS	B
20	-	I
21	940	I
22	*	I
23	and	O
24	sparfloxacin	B
25	(	O
26	SPFX	O
27	),	O
28	followed	O
29	by	O
30	AM	O
31	-	O
32	1155	O
33	*,	I
34	ciprofloxacin	O
35	(	O
36	CPFX	O
37	),	O
38	levofloxacin	O
39	(	O
40	LVFX	O
41	),	O
42	OPC	B
43	-	I
44	17116	I
45	*,	I
46	NM	I
47	-	I
48	394	I
49	*	I
50	in	O
51	sequence	O
52	.	O

1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	O
21	smegmatis	I
22	clones	O
23	.	O

1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	B
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	O
23	.	O

1	An	O
2	interatrial	O
3	communication	O
4	mitigates	O
5	the	O
6	impairment	O
7	of	O
8	LV	O
9	function	O
10	after	O
11	an	O
12	acute	O
13	and	O
14	sustained	O
15	drop	O
16	of	O
17	intrathoracic	O
18	pressure	O
19	.	O

1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	O
8	-	O
9	1	O
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O

1	Most	O
2	importantly	O
3	,	O
4	the	O
5	addition	O
6	of	O
7	purified	O
8	17S	I
9	U2	I
10	snRNPs	I
11	,	O
12	but	O
13	not	O
14	of	O
15	12S	B
16	U2	I
17	snRNPs	I
18	,	O
19	to	O
20	HeLa	O
21	splicing	O
22	extracts	O
23	in	O
24	which	O
25	the	O
26	endogeneous	B
27	U2	I
28	snRNPs	I
29	have	O
30	been	O
31	functionally	O
32	neutralized	B
33	with	O
34	anti	B
35	-	I
36	PRP9	I
37	antibodies	I
38	fully	O
39	restores	O
40	the	O
41	mRNA	O
42	-	O
43	splicing	O
44	activity	O
45	of	O
46	the	O
47	extracts	O
48	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	B
10	beta	I
11	receptor	I
12	blockader	I
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	B
18	-	I
19	chimaerin	I
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O

1	Endogenous	O
2	RMP	O
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	B
10	in	O
11	RNA	O
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	B
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	B
38	B	I
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	I
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	Terbutaline	O
2	;	O
3	a	O
4	beta2	B
5	-	I
6	adrenergic	I
7	agonist	O
8	,	O
9	and	O
10	aminophyllin	O
11	,	O
12	a	O
13	phosphodiesterase	B
14	inhibitor	O
15	,	O
16	were	O
17	given	O
18	separately	O
19	,	O
20	or	O
21	in	O
22	combination	O
23	,	O
24	to	O
25	rabbit	O
26	fetuses	O
27	on	O
28	the	O
29	28th	O
30	day	O
31	of	O
32	gestation	O
33	.	O

1	When	O
2	the	O
3	E1A	B
4	N	I
5	-	O
6	terminus	O
7	is	O
8	used	O
9	as	O
10	a	O
11	competitor	O
12	in	O
13	squelshing	O
14	experiments	O
15	it	O
16	abolishes	O
17	CBP	B
18	-	O
19	induced	O
20	activation	O
21	of	O
22	E2F1	B
23	/	I
24	DP1	I
25	,	O
26	whereas	O
27	an	O
28	E1A	B
29	mutant	I
30	lacking	O
31	CBP	B
32	binding	O
33	ability	O
34	fails	O
35	to	O
36	do	O
37	so	O
38	.	O

1	The	O
2	MSY2	B
3	associated	I
4	kinase	I
5	is	O
6	not	O
7	casein	B
8	kinase	I
9	2	I
10	,	O
11	the	O
12	kinase	O
13	believed	O
14	to	O
15	phosphorylate	O
16	mRNP3	B
17	+	I
18	4	I
19	in	O
20	oocytes	O
21	,	O
22	but	O
23	a	O
24	yet	O
25	unidentified	O
26	kinase	O
27	.	O

1	Acetoin	O
2	-	O
3	dependent	O
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	O
15	.	O
16	coli	O
17	acoK	I
18	mutants	I
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	O
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	Electrochemical	O
2	detection	O
3	of	O
4	depressed	O
5	circulating	O
6	levels	O
7	of	O
8	vitamin	O
9	K1	O
10	in	O
11	osteoporosis	O
12	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	or	O
5	mouse	O
6	skin	O
7	with	O
8	antisense	O
9	oligonucleotides	O
10	of	O
11	PKCzeta	O
12	impaired	O
13	UV	O
14	-	O
15	induced	O
16	activation	O
17	of	O
18	AP	B
19	-	I
20	1	I
21	in	O
22	JB6	O
23	cells	O
24	as	O
25	well	O
26	as	O
27	in	O
28	AP	B
29	-	I
30	1	I
31	-	I
32	luciferase	I
33	transgenic	O
34	mice	O
35	.	O

1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	B
9	stimulator	I
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O

1	Microdetermination	O
2	of	O
3	adrenocortical	O
4	steroids	O
5	by	O
6	double	O
7	isotope	O
8	method	O
9	.	O

1	The	O
2	DNA	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	1520	O
9	amino	O
10	acids	O
11	with	O
12	sequence	O
13	homology	O
14	to	O
15	the	O
16	human	B
17	c	I
18	-	I
19	abl	I
20	proto	I
21	-	I
22	oncogene	I
23	product	I
24	,	O
25	beginning	O
26	at	O
27	the	O
28	amino	O
29	terminus	O
30	and	O
31	extending	O
32	656	O
33	amino	O
34	acids	O
35	through	O
36	the	O
37	region	O
38	essential	O
39	for	O
40	tyrosine	B
41	kinase	I
42	activity	O
43	.	O

1	Chrispeels	O
2	[	O
3	1993	O
4	]	O
5	EMBO	O
6	J	O
7	12	O
8	:	O
9	2241	O
10	-	O
11	2247	O
12	).	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	B
8	cer	I
9	site	I
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	B
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	B
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	B
51	.	O

1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	ESS	B
2	type	I
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	B
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	I
26	,	O
27	and	O
28	the	O
29	intracellular	B
30	kinase	I
31	domain	I
32	.	O

1	Both	O
2	functional	O
3	analyses	O
4	in	O
5	undifferentiated	O
6	and	O
7	differentiated	O
8	F9	O
9	cells	O
10	and	O
11	characterization	O
12	of	O
13	DNA	O
14	-	O
15	protein	O
16	complexes	O
17	in	O
18	vitro	O
19	have	O
20	identified	O
21	the	O
22	sequence	O
23	motifs	O
24	GTGACT	I
25	(	O
26	C	O
27	),	O
28	ATTGT	B
29	,	O
30	and	O
31	GATA	B
32	as	O
33	the	O
34	key	O
35	transcription	I
36	factor	I
37	binding	I
38	sites	I
39	.	O

1	As	O
2	pH	O
3	and	O
4	Hb	B
5	can	O
6	also	O
7	affect	O
8	mixed	O
9	venous	O
10	CO2	O
11	content	O
12	,	O
13	the	O
14	effect	O
15	on	O
16	Q	O
17	was	O
18	also	O
19	assessed	O
20	.	O

1	Inactivation	O
2	of	O
3	MAP	B
4	kinases	I
5	occurs	O
6	via	O
7	a	O
8	specific	O
9	phosphatase	B
10	,	O
11	MKP	B
12	-	I
13	1	I
14	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	suppressor	I
5	of	I
6	sable	I
7	gene	I
8	,	O
9	su	B
10	(	O
11	s	O
12	),	O
13	encodes	O
14	a	O
15	novel	O
16	,	O
17	150	O
18	-	O
19	kDa	O
20	nuclear	O
21	RNA	I
22	binding	I
23	protein	I
24	,	O
25	SU	B
26	(	O
27	S	O
28	),	O
29	that	O
30	negatively	O
31	regulates	O
32	RNA	O
33	accumulation	O
34	from	O
35	mutant	O
36	alleles	O
37	of	O
38	other	O
39	genes	O
40	that	O
41	have	O
42	transposon	O
43	insertions	O
44	in	O
45	the	O
46	5	O
47	'	O
48	transcribed	O
49	region	O
50	.	O

1	Linkage	O
2	studies	O
3	have	O
4	shown	O
5	locus	O
6	heterogeneity	O
7	with	O
8	one	O
9	TSC	B
10	gene	I
11	mapped	O
12	to	O
13	chromosome	O
14	9q34	O
15	and	O
16	a	O
17	second	O
18	to	O
19	16p13	B
20	.	O
21	3	O
22	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	Effects	O
2	of	O
3	a	O
4	selective	O
5	monoamine	B
6	oxidase	I
7	(	O
8	MAO	B
9	)--	I
10	A	I
11	inhibitor	O
12	,	O
13	clorgyline	O
14	,	O
15	a	O
16	selective	O
17	MAO	B
18	-	I
19	B	I
20	inhibitor	O
21	,	O
22	deprenyl	O
23	,	O
24	and	O
25	a	O
26	non	O
27	-	O
28	selective	O
29	MAO	B
30	inhibitor	O
31	,	O
32	nialamide	O
33	,	O
34	were	O
35	investigated	O
36	on	O
37	footshock	O
38	-	O
39	induced	O
40	aggression	O
41	(	O
42	FIA	B
43	)	O
44	in	O
45	paired	O
46	rats	O
47	.	O

1	Therapy	O
2	with	O
3	dietary	O
4	modification	O
5	and	O
6	triglyceride	O
7	lowering	O
8	drugs	O
9	resulted	O
10	in	O
11	resolution	O
12	of	O
13	symptoms	O
14	and	O
15	parotid	O
16	swelling	O
17	in	O
18	one	O
19	patient	O
20	.	O

1	Thus	O
2	,	O
3	dpp	B
4	and	O
5	omb	O
6	promote	O
7	both	O
8	dorsal	O
9	leg	O
10	cell	O
11	fate	O
12	as	O
13	well	O
14	as	O
15	transdetermination	O
16	-	O
17	competent	O
18	leg	O
19	disc	O
20	cells	O
21	.	O

1	Effects	O
2	of	O
3	dopamine	O
4	and	O
5	of	O
6	a	O
7	dopaminergic	O
8	blocker	O
9	,	O
10	haloperidol	O
11	,	O
12	on	O
13	the	O
14	responses	O
15	of	O
16	carotid	O
17	body	O
18	chemoreceptors	O
19	to	O
20	hypoxia	O
21	and	O
22	hypercapnia	O
23	were	O
24	investigated	O
25	in	O
26	16	O
27	anesthetized	O
28	cats	O
29	.	O

1	In	O
2	the	O
3	VA	O
4	-	O
5	SMV	O
6	mode	O
7	,	O
8	the	O
9	connection	O
10	was	O
11	made	O
12	with	O
13	valved	O
14	conduits	O
15	from	O
16	the	O
17	LV	O
18	apex	O
19	(	O
20	inflow	O
21	)	O
22	to	O
23	the	O
24	ascending	O
25	aorta	O
26	(	O
27	outflow	O
28	)	O
29	(	O
30	n	O
31	=	O
32	11	O
33	)	O
34	or	O
35	to	O
36	the	O
37	DAo	O
38	(	O
39	n	O
40	=	O
41	12	O
42	).	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O

1	Furthermore	O
2	,	O
3	we	O
4	notice	O
5	two	O
6	potential	O
7	consensus	O
8	motifs	O
9	which	O
10	are	O
11	also	O
12	found	O
13	in	O
14	corresponding	O
15	positions	O
16	in	O
17	the	O
18	genes	O
19	for	O
20	the	O
21	nerve	B
22	growth	I
23	factor	I
24	receptor	I
25	and	O
26	the	O
27	68	O
28	-	O
29	kDa	O
30	neurofilament	B
31	protein	I
32	.	O

1	XXI	O
2	.	O

1	Management	O
2	often	O
3	involves	O
4	beta	O
5	-	O
6	and	O
7	calcium	O
8	channel	O
9	blocking	O
10	drugs	O
11	or	O
12	type	O
13	IC	O
14	antiarrhythmic	O
15	drugs	O
16	.	O

1	The	O
2	full	O
3	length	O
4	cDNA	O
5	sequence	O
6	of	O
7	a	O
8	Type	B
9	I	I
10	transforming	I
11	growth	I
12	factor	I
13	-	I
14	beta	I
15	(	O
16	TGF	B
17	-	I
18	beta	I
19	)	I
20	receptor	I
21	has	O
22	been	O
23	isolated	O
24	from	O
25	the	O
26	filarial	O
27	parasitic	O
28	nematode	O
29	Brugia	B
30	pahangi	I
31	.	O

1	After	O
2	an	O
3	initial	O
4	titration	O
5	period	O
6	and	O
7	adjustment	O
8	of	O
9	the	O
10	therapeutic	O
11	dose	O
12	,	O
13	the	O
14	individual	O
15	doses	O
16	were	O
17	from	O
18	21	O
19	to	O
20	500	O
21	micrograms	O
22	/	O
23	24	O
24	hrs	O
25	(	O
26	mean	O
27	160	O
28	micrograms	O
29	/	O
30	24	O
31	hrs	O
32	).	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	purification	O
6	of	O
7	this	O
8	larger	O
9	form	O
10	as	O
11	an	O
12	approximately	O
13	320	O
14	-	O
15	kDa	O
16	particle	O
17	that	O
18	contains	O
19	mRNP3	B
20	+	I
21	4	I
22	and	O
23	nine	O
24	additional	O
25	polypeptides	O
26	,	O
27	including	O
28	mRNA	O
29	-	O
30	binding	O
31	polypeptides	O
32	of	O
33	34	O
34	and	O
35	36	O
36	kDa	O
37	and	O
38	a	O
39	doublet	O
40	of	O
41	110	O
42	/	O
43	105	O
44	kDa	O
45	that	O
46	proved	O
47	to	O
48	be	O
49	nucleolin	B
50	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	This	O
2	conclusion	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blotting	O
8	analysis	O
9	of	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	CAD	B
17	gene	I
18	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Promoter	O
2	elements	O
3	include	O
4	an	O
5	atypical	O
6	TATA	O
7	box	O
8	(	O
9	GTTA	O
10	),	O
11	one	O
12	CCAAT	O
13	box	O
14	much	O
15	further	O
16	from	O
17	the	O
18	initiation	O
19	site	O
20	,	O
21	three	O
22	reverse	O
23	compliments	O
24	of	O
25	CCAAT	B
26	(	O
27	ATTGG	O
28	),	O
29	and	O
30	two	O
31	pyrimidine	O
32	-	O
33	rich	O
34	nucleotide	O
35	stretches	O
36	.	O

1	In	O
2	EEG	O
3	only	O
4	single	O
5	slow	O
6	waves	O
7	above	O
8	left	O
9	temporal	O
10	region	O
11	were	O
12	revealed	O
13	.	O

1	The	O
2	value	O
3	of	O
4	different	O
5	sources	O
6	of	O
7	nitrogen	O
8	in	O
9	diets	O
10	for	O
11	the	O
12	early	B
13	-	I
14	weaned	I
15	calf	I
16	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	3574	B
8	-	I
9	bp	I
10	Bacillus	I
11	subtilis	I
12	(	O
13	Bs	O
14	)	O
15	DNA	O
16	fragment	O
17	located	O
18	between	O
19	the	O
20	nrdA	B
21	and	O
22	citB	B
23	genes	I
24	at	O
25	about	O
26	169	O
27	degrees	O
28	on	O
29	the	O
30	chromosome	O
31	.	O

1	The	O
2	5	O
3	'-	O
4	nontranslated	O
5	sequences	O
6	and	O
7	parts	O
8	of	O
9	the	O
10	coding	O
11	sequences	O
12	of	O
13	various	O
14	yeast	O
15	genes	O
16	have	O
17	been	O
18	cloned	O
19	into	O
20	representative	O
21	lacZ	B
22	fusion	O
23	vectors	O
24	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	an	O
6	analysis	O
7	of	O
8	the	O
9	dynamics	O
10	in	O
11	the	O
12	closing	O
13	phase	O
14	of	O
15	the	O
16	occluder	O
17	of	O
18	a	O
19	mechanical	O
20	monoleaflet	B
21	heart	O
22	valve	O
23	prosthesis	O
24	is	O
25	presented	O
26	.	O

1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	B
6	gene	I
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	B
16	operon	I
17	.	O

1	As	O
2	in	O
3	Tb	B
4	,	O
5	U6	B
6	is	O
7	a	O
8	single	O
9	-	O
10	copy	O
11	gene	O
12	and	O
13	two	O
14	tRNA	B
15	genes	I
16	,	O
17	tRNAGln	B
18	and	O
19	tRNAIle	B
20	,	O
21	are	O
22	found	O
23	upstream	O
24	to	O
25	the	O
26	gene	O
27	.	O

1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	I
21	binding	O
22	sites	O
23	.	O

1	Dipetalonema	B
2	(	O
3	Alafilaria	B
4	)	O
5	hydrochoerus	B
6	subgen	I
7	.	O
8	et	O
9	sp	O
10	.	O
11	n	O
12	.	O

1	Research	O
2	was	O
3	carried	O
4	out	O
5	on	O
6	the	O
7	rheumatoid	B
8	factors	O
9	in	O
10	the	O
11	serum	O
12	of	O
13	917	O
14	patients	O
15	by	O
16	means	O
17	of	O
18	two	O
19	tests	O
20	(	O
21	one	O
22	using	O
23	polystyrene	O
24	and	O
25	one	O
26	with	O
27	erythrocytes	O
28	)	O
29	and	O
30	the	O
31	results	O
32	obtained	O
33	were	O
34	compared	O
35	using	O
36	a	O
37	method	O
38	of	O
39	reference	O
40	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	B
27	gene	I
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	This	O
2	sequence	O
3	is	O
4	very	O
5	similar	O
6	to	O
7	the	O
8	insulin	B
9	response	I
10	sequence	O
11	found	O
12	in	O
13	the	O
14	regulatory	O
15	region	O
16	of	O
17	other	O
18	genes	O
19	negatively	O
20	regulated	O
21	by	O
22	insulin	B
23	such	O
24	as	O
25	those	O
26	encoding	I
27	phosphoenolpyruvate	I
28	carboxykinase	I
29	,	I
30	tyrosine	I
31	aminotransferase	I
32	,	O
33	and	O
34	insulin	B
35	-	I
36	like	I
37	growth	I
38	factor	I
39	-	I
40	binding	I
41	protein	I
42	1	I
43	.	O

1	The	O
2	proliferation	O
3	-	O
4	specific	O
5	HNF	B
6	-	I
7	3	I
8	/	I
9	fork	I
10	head	I
11	homolog	I
12	-	I
13	11B	I
14	protein	I
15	(	O
16	HFH	B
17	-	I
18	11B	I
19	;	O
20	also	O
21	known	O
22	as	O
23	Trident	B
24	and	O
25	Win	B
26	)	O
27	is	O
28	a	O
29	family	O
30	member	O
31	of	O
32	the	O
33	winged	B
34	helix	I
35	/	I
36	fork	I
37	head	I
38	transcription	I
39	factors	O
40	and	O
41	in	O
42	regenerating	O
43	liver	O
44	its	O
45	expression	O
46	is	O
47	reactivated	O
48	prior	O
49	to	O
50	hepatocyte	O
51	entry	O
52	into	O
53	DNA	O
54	replication	O
55	(	O
56	S	O
57	phase	O
58	).	O

1	The	O
2	mean	O
3	percentage	O
4	of	O
5	linoleic	O
6	acid	O
7	in	O
8	the	O
9	triglycerides	O
10	of	O
11	the	O
12	subcutaneous	O
13	adipose	O
14	tissue	O
15	(	O
16	PLASAT	O
17	)	O
18	of	O
19	these	O
20	subjects	O
21	was	O
22	substantially	O
23	higher	O
24	than	O
25	that	O
26	in	O
27	a	O
28	similar	O
29	group	O
30	examined	O
31	in	O
32	1975	O
33	-	O
34	1976	O
35	.	O

1	Cardiac	O
2	preservation	O
3	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	paxillin	B
6	localizes	O
7	to	O
8	focal	O
9	adhesions	O
10	independent	O
11	of	O
12	interactions	O
13	with	O
14	vinculin	B
15	and	O
16	/	O
17	or	O
18	FAK	B
19	,	O
20	and	O
21	represents	O
22	the	O
23	first	O
24	definitive	O
25	demonstration	O
26	of	O
27	LIM	B
28	domains	I
29	functioning	O
30	as	O
31	a	O
32	primary	O
33	determinant	O
34	of	O
35	protein	O
36	subcellular	O
37	localization	O
38	to	O
39	focal	O
40	adhesions	O
41	.	O

1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O

1	The	O
2	Ets	B
3	-	I
4	1	I
5	binding	I
6	site	I
7	was	O
8	localized	O
9	to	O
10	a	O
11	17	O
12	-	O
13	base	O
14	pair	O
15	(	O
16	bp	O
17	)	O
18	region	O
19	from	O
20	the	O
21	3	O
22	'	O
23	end	O
24	of	O
25	T	B
26	alpha	I
27	2	I
28	.	O

1	Ras2p	O
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	B
15	MAPK	I
16	(	I
17	Cdc42p	B
18	/	I
19	Ste20p	I
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	B
33	/	O
34	cAMP	B
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	A	O
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O

1	Haemodynamic	O
2	responses	O
3	to	O
4	antagonism	O
5	of	O
6	bocurarine	O
7	block	O
8	with	O
9	atropine	O
10	-	O
11	neostigmine	O
12	mixture	O
13	in	O
14	children	O
15	.	O

1	Mitogen	O
2	-	O
3	induced	O
4	lymphocyte	O
5	proliferation	O
6	was	O
7	diminished	O
8	.	O

1	The	O
2	results	O
3	also	O
4	showed	O
5	that	O
6	although	O
7	oyster	B
8	shell	I
9	supplementation	O
10	generally	O
11	increased	O
12	alkaline	B
13	phosphatase	I
14	activity	O
15	,	O
16	bone	O
17	mineralization	O
18	was	O
19	relatively	O
20	uninfluenced	O
21	as	O
22	judged	O
23	by	O
24	the	O
25	low	O
26	coefficients	O
27	of	O
28	variation	O
29	(	O
30	CV	O
31	)	O
32	of	O
33	3	O
34	.	O
35	14	O
36	-	O
37	3	O
38	.	O
39	51	O
40	%	O
41	and	O
42	3	O
43	.	O
44	39	O
45	-	O
46	4	O
47	.	O
48	82	O
49	%	O
50	for	O
51	calcium	O
52	and	O
53	phosphorus	O
54	content	O
55	in	O
56	the	O
57	femur	O
58	and	O
59	tibia	O
60	respectively	O
61	.	O

1	These	O
2	kinases	O
3	belong	O
4	to	O
5	a	O
6	new	O
7	subfamily	O
8	related	O
9	to	O
10	the	O
11	Trk	B
12	subfamily	I
13	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	I
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	In	O
2	contrast	O
3	to	O
4	some	O
5	results	O
6	previously	O
7	published	O
8	for	O
9	a	O
10	very	O
11	close	O
12	sequence	O
13	variant	O
14	(	O
15	see	O
16	ref	O
17	.	O

1	Thus	O
2	E14	B
3	.	O
4	1TG3B1	O
5	is	O
6	a	O
7	useful	O
8	ES	O
9	cell	O
10	line	O
11	for	O
12	modifying	O
13	the	O
14	mouse	O
15	genome	O
16	using	O
17	the	O
18	HPRT	B
19	gene	I
20	as	O
21	a	O
22	selection	O
23	marker	O
24	and	O
25	for	O
26	transmission	O
27	at	O
28	a	O
29	high	O
30	frequency	O
31	into	O
32	the	O
33	mouse	O
34	germ	O
35	line	O
36	.	O

1	Angina	O
2	haemorrhagica	B
3	bullosa	I
4	causing	O
5	respiratory	O
6	obstruction	O
7	postoperatively	O
8	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	B
8	NAD	I
9	(	O
10	P	B
11	)	I
12	H	I
13	-	I
14	NR	I
15	sequence	I
16	in	O
17	comparison	O
18	to	O
19	NADH	B
20	-	I
21	NR	I
22	sequences	I
23	was	O
24	found	O
25	at	O
26	the	O
27	putative	O
28	pyridine	B
29	nucleotide	O
30	binding	I
31	site	I
32	.	O

1	The	O
2	subgroup	O
3	innervating	O
4	the	O
5	medial	O
6	rectus	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	oculomotor	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	longitudinal	O
26	fasciculus	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O

1	In	O
2	silicosis	O
3	,	O
4	significant	O
5	relationships	O
6	between	O
7	patients	O
8	and	O
9	sons	O
10	were	O
11	not	O
12	seen	O
13	with	O
14	respect	O
15	to	O
16	arterial	O
17	blood	O
18	gas	O
19	determinations	O
20	and	O
21	ventilatory	O
22	responses	O
23	except	O
24	for	O
25	Paco2	O
26	of	O
27	patients	O
28	and	O
29	hypercapnic	O
30	ventilatory	O
31	responses	O
32	of	O
33	sons	O
34	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	/	I
6	TGF	I
7	-	I
8	alpha	I
9	HCCs	I
10	were	O
11	also	O
12	characterized	O
13	by	O
14	a	O
15	particularly	O
16	strong	O
17	expression	O
18	of	O
19	TGF	B
20	-	I
21	alpha	I
22	and	O
23	very	O
24	low	O
25	apoptotic	O
26	index	O
27	in	O
28	contrast	O
29	to	O
30	high	O
31	levels	O
32	of	O
33	apoptosis	O
34	in	O
35	peritumorous	O
36	tissues	O
37	and	O
38	c	B
39	-	I
40	myc	I
41	HCCs	I
42	.	O

1	Two	O
2	basic	O
3	patterns	O
4	of	O
5	locomotor	O
6	behavior	O
7	and	O
8	corresponding	O
9	torso	O
10	morphology	O
11	exist	O
12	among	O
13	extant	O
14	anthropoids	O
15	.	O

1	Although	O
2	popular	O
3	this	O
4	hypothesis	O
5	is	O
6	far	O
7	from	O
8	explaining	O
9	all	O
10	the	O
11	clinical	O
12	facts	O
13	,	O
14	namely	O
15	that	O
16	rigidity	B
17	is	O
18	equal	O
19	in	O
20	extensor	O
21	and	O
22	flexor	O
23	,	O
24	proximal	O
25	and	O
26	distal	O
27	muscles	O
28	.	O

1	The	O
2	fast	O
3	real	O
4	-	O
5	time	O
6	digital	O
7	processing	O
8	of	O
9	the	O
10	N2	O
11	and	O
12	flow	O
13	signals	O
14	incorporated	O
15	filtering	O
16	,	O
17	delay	O
18	compensation	O
19	,	O
20	and	O
21	corrections	O
22	for	O
23	the	O
24	effects	O
25	of	O
26	changes	O
27	in	O
28	gas	O
29	composition	O
30	and	O
31	temperature	O
32	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	in	O
6	patients	O
7	with	O
8	first	O
9	-	O
10	attack	O
11	genital	O
12	herpes	O
13	,	O
14	the	O
15	type	O
16	of	O
17	HSV	O
18	is	O
19	the	O
20	most	O
21	important	O
22	determinant	O
23	of	O
24	subsequent	O
25	recurrences	O
26	and	O
27	that	O
28	intravenous	O
29	acyclovir	O
30	has	O
31	little	O
32	effect	O
33	on	O
34	subsequent	O
35	recurrences	O
36	.	O

1	We	O
2	examined	O
3	the	O
4	hypothesis	O
5	that	O
6	the	O
7	coronary	O
8	vasomotor	O
9	responses	O
10	to	O
11	etomidate	O
12	(	O
13	ETO	B
14	),	O
15	propofol	O
16	(	O
17	PRO	O
18	),	O
19	and	O
20	sodium	O
21	thiopental	O
22	(	O
23	STP	B
24	)	O
25	are	O
26	mediated	O
27	through	O
28	contrasting	O
29	effects	O
30	on	O
31	the	O
32	resting	O
33	nitric	B
34	oxide	O
35	(	O
36	NO	O
37	)-	O
38	dependent	O
39	vasodilator	O
40	tone	O
41	that	O
42	opposes	O
43	adrenergic	I
44	vasoconstrictor	O
45	activity	O
46	in	O
47	the	O
48	intact	O
49	dog	O
50	.	O

1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	B
15	and	O
16	PSG12	B
17	psi	I
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	B
33	psi	I
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O

1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	I299	I
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O

1	Mechanisms	O
2	of	O
3	tachyphylaxis	O
4	in	O
5	regional	O
6	anesthesia	O
7	of	O
8	long	O
9	duration	O

1	USA	O
2	80	O
3	,	O
4	3618	B
5	-	I
6	3622	I
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	17	O
2	volunteer	B
3	deaf	I
4	Ss	O
5	were	O
6	compared	O
7	with	O
8	18	O
9	volunteer	O
10	hearing	O
11	Ss	O
12	on	O
13	the	O
14	Stanford	O
15	Hypnotic	O
16	Clinical	O
17	Scale	O
18	(	O
19	SHCS	O
20	)	O
21	of	O
22	Morgan	O
23	and	O
24	J	O
25	.	O

1	We	O
2	show	O
3	that	O
4	CBF	B
5	-	I
6	A	I
7	and	O
8	CBF	B
9	-	I
10	C	I
11	interact	O
12	with	O
13	each	O
14	other	O
15	to	O
16	form	O
17	a	O
18	CBF	B
19	-	I
20	A	I
21	-	I
22	CBF	I
23	-	I
24	C	I
25	complex	I
26	and	O
27	that	O
28	CBF	B
29	-	I
30	B	I
31	does	O
32	not	O
33	interact	O
34	with	O
35	CBF	B
36	-	I
37	A	I
38	or	O
39	CBF	B
40	-	I
41	C	I
42	individually	O
43	but	O
44	that	O
45	it	O
46	associates	O
47	with	O
48	the	O
49	CBF	B
50	-	I
51	A	I
52	-	I
53	CBF	I
54	-	I
55	C	I
56	complex	I
57	.	O

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	B
10	-	O
11	AP	B
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	B
23	-	O
24	4	O
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	Triton	O
2	-	O
3	disrupted	O
4	cells	O
5	retained	O
6	capacity	O
7	for	O
8	activation	O
9	of	O
10	the	O
11	pathway	O
12	by	O
13	both	O
14	peptide	B
15	growth	I
16	factors	I
17	and	O
18	by	O
19	addition	O
20	of	O
21	GTP	B
22	-	I
23	loaded	I
24	p21	I
25	rasVal12	I
26	.	O

1	Williams	O
2	,	O
3	2	O
4	August	O
5	1977	O
6	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	Moreover	O
2	,	O
3	Western	O
4	blots	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	Ypt	B
12	in	O
13	both	O
14	Cr	B
15	and	O
16	Vc	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	Ypt	B
22	are	O
23	used	O
24	for	O
25	household	O
26	functions	O
27	responsible	O
28	for	O
29	vesicle	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O

1	Significant	O
2	immunoglobulinuria	O
3	developed	O
4	prior	O
5	to	O
6	the	O
7	development	O
8	of	O
9	azotemia	O
10	,	O
11	significantly	O
12	decreased	O
13	creatinine	O
14	clearance	O
15	,	O
16	significant	O
17	proteinuria	O
18	(	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	3	O
25	+	O
26	dipstick	O
27	or	O
28	greater	O
29	than	O
30	or	O
31	equal	O
32	to	O
33	5	O
34	gm	O
35	per	O
36	24	O
37	-	O
38	hour	O
39	urine	O
40	collection	O
41	),	O
42	or	O
43	oliguria	O
44	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serological	O
6	studies	O
7	,	O
8	the	O
9	highly	O
10	conserved	O
11	A	O
12	domain	O
13	of	O
14	HspA	O
15	was	O
16	found	O
17	to	O
18	be	O
19	the	O
20	immunodominant	O
21	domain	O
22	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	Of	O
6	the	O
7	17	O
8	men	O
9	and	O
10	17	O
11	women	O
12	,	O
13	who	O
14	were	O
15	21	O
16	to	O
17	80	O
18	years	O
19	of	O
20	age	O
21	,	O
22	27	O
23	had	O
24	hereditary	O
25	motor	O
26	and	O
27	sensory	O
28	neuropathy	O
29	type	O
30	I	O
31	and	O
32	7	O
33	had	O
34	acquired	O
35	demyelinating	O
36	polyneuropathy	O
37	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	O
8	-	O
9	3a	O
10	(	O
11	Baka	B
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	Pentachlorophenol	O
2	accelerates	O
3	the	O
4	onset	O
5	of	O
6	HCB	O
7	porphyria	O
8	,	O
9	in	O
10	other	O
11	words	O
12	it	O
13	increases	O
14	the	O
15	total	O
16	urinary	O
17	porphyrin	O
18	excretion	O
19	and	O
20	causes	O
21	an	O
22	earlier	O
23	disturbance	O
24	of	O
25	the	O
26	porphyrin	O
27	pattern	O
28	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	O
30	region	O
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	O
38	kd	O
39	cellular	O
40	Elk	B
41	-	I
42	1	I
43	kinase	I
44	.	O

1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O

1	Two	O
2	techniques	O
3	based	O
4	on	O
5	assay	O
6	coefficients	O
7	of	O
8	variation	O
9	were	O
10	employed	O
11	to	O
12	characterize	O
13	a	O
14	normal	O
15	circadian	O
16	pattern	O
17	of	O
18	cortisol	O
19	.	O

1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	I
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	I
31	NF	B
32	-	I
33	kappaB	I
34	)	I
35	complex	I
36	Rel	I
37	A	I
38	x	O
39	NF	B
40	-	I
41	kappaB1	I
42	.	O

1	These	O
2	activities	O
3	are	O
4	all	O
5	required	O
6	for	O
7	stimulation	O
8	of	O
9	cell	O
10	growth	O
11	by	O
12	middle	O
13	-	O
14	T	O
15	and	O
16	activate	O
17	members	O
18	of	O
19	the	O
20	MAP	B
21	kinase	I
22	family	I
23	.	O

1	Further	O
2	,	O
3	Tax	B
4	-	O
5	mediated	O
6	apoptosis	O
7	was	O
8	effectively	O
9	prevented	O
10	by	O
11	ectopic	O
12	expression	O
13	of	O
14	the	O
15	p300	B
16	coactivator	O
17	.	O

1	Abdominal	O
2	tumors	O
3	in	O
4	childhood	O
5	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	CDC25B	O
5	may	O
6	therefore	O
7	contribute	O
8	to	O
9	the	O
10	control	O
11	of	O
12	cell	O
13	proliferation	O
14	.	O

1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	In	O
2	the	O
3	p51	O
4	subunit	O
5	,	O
6	the	O
7	Cys181	B
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O

1	Sucrose	O
2	-	O
3	specific	O
4	regulation	O
5	of	O
6	scrB	B
7	was	O
8	also	O
9	lost	O
10	upon	O
11	deletion	O
12	of	O
13	4	O
14	bp	O
15	of	O
16	a	O
17	palindromic	O
18	sequence	O
19	(	O
20	OB	B
21	)	O
22	covering	O
23	positions	O
24	+	O
25	6	O
26	to	O
27	+	O
28	21	O
29	downstream	O
30	of	O
31	the	O
32	scrB	B
33	transcriptional	O
34	start	O
35	site	I
36	.	O

1	Chordoma	O
2	of	O
3	the	O
4	spinal	O
5	cord	O
6	in	O
7	a	O
8	F344	O
9	rat	O
10	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	These	O
2	findings	O
3	suggest	O
4	a	O
5	functional	O
6	cross	O
7	-	O
8	talk	O
9	between	O
10	RB	B
11	protein	I
12	and	O
13	p21ras	B
14	,	O
15	which	O
16	balances	O
17	the	O
18	cell	O
19	phenotype	O
20	between	O
21	normal	O
22	and	O
23	transformed	O
24	states	O
25	.	O

1	Clb	B
2	/	O
3	Cdc28	B
4	kinases	I
5	promote	O
6	nuclear	O
7	export	O
8	of	O
9	the	O
10	replication	O
11	initiator	O
12	proteins	O
13	Mcm2	O
14	-	O
15	7	O
16	.	O

1	We	O
2	couldn	O
3	'	O
4	t	O
5	detect	O
6	any	O
7	effect	O
8	of	O
9	n	O
10	-	O
11	3	O
12	FA	O
13	supplementation	O
14	on	O
15	total	O
16	cholesterol	O
17	,	O
18	HDL	B
19	cholesterol	I
20	,	O
21	LDL	B
22	cholesterol	I
23	,	O
24	apo	B
25	A1	I
26	,	O
27	Lp	B
28	(	O
29	a	O
30	),	O
31	HbA1C	B
32	,	O
33	glucose	B
34	,	O
35	fibrinogen	B
36	,	I
37	factor	I
38	VIII	I
39	,	I
40	antithrombin	B
41	III	I
42	,	I
43	plasminogen	B
44	activator	I
45	inhibitor	I
46	,	O
47	tissue	B
48	plasminogen	I
49	activator	I
50	and	O
51	von	B
52	Willebrand	I
53	factor	I
54	concentration	O
55	,	O
56	on	O
57	bleeding	O
58	time	O
59	or	O
60	on	O
61	systolic	O
62	or	O
63	diastolic	O
64	blood	O
65	pressure	O
66	.	O

1	Qualitatively	O
2	,	O
3	the	O
4	results	O
5	are	O
6	similar	O
7	for	O
8	the	O
9	two	O
10	species	O
11	:	O
12	Both	O
13	rhesus	O
14	monkey	O
15	and	O
16	man	O
17	have	O
18	photopic	O
19	and	O
20	scotopic	O
21	branches	O
22	,	O
23	which	O
24	cross	O
25	at	O
26	approximately	O
27	the	O
28	same	O
29	time	O
30	in	O
31	the	O
32	dark	O
33	and	O
34	at	O
35	approximately	O
36	the	O
37	same	O
38	background	O
39	luminance	O
40	.	O

1	Inclusion	O
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	originally	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	B
20	factor	I
21	Lef	I
22	-	I
23	1	I
24	.	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	O
8	at	O
9	one	O
10	year	O
11	(	O
12	SPK	B
13	1	O
14	.	O
15	8	O
16	,	O
17	KTA	B
18	1	O
19	.	O
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	O
29	WORDS	O
30	)	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	B
27	-	O
28	M1	O
29	-	O
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pathologic	O
5	scars	O
6	of	O
7	myocardial	O
8	infarct	O

1	Expression	O
2	of	O
3	Msp	O
4	was	O
5	toxic	O
6	to	O
7	E	O
8	.	O
9	coli	O
10	when	O
11	the	O
12	entire	O
13	msp	B
14	gene	I
15	was	O
16	present	O
17	.	O

1	In	O
2	F42A	O
3	-	O
4	stimulated	O
5	internalization	O
6	assays	O
7	on	O
8	forskolin	O
9	-	O
10	induced	O
11	YT	B
12	-	O
13	1	O
14	cells	O
15	,	O
16	the	O
17	IL	B
18	-	I
19	2R	I
20	alpha	I
21	chain	I
22	is	O
23	consistently	O
24	endocytosed	O
25	together	O
26	with	O
27	the	O
28	IL	B
29	-	I
30	2R	I
31	beta	I
32	subunit	I
33	indicating	O
34	that	O
35	IL	B
36	-	I
37	2R	I
38	alpha	I
39	is	O
40	stably	O
41	associated	O
42	with	O
43	the	O
44	F42A	B
45	-	I
46	IL	I
47	-	I
48	2R	I
49	beta	I
50	complex	O
51	even	O
52	though	O
53	the	O
54	alpha	O
55	-	O
56	subunit	O
57	contributes	O
58	little	O
59	if	O
60	any	O
61	affinity	O
62	to	O
63	the	O
64	F42A	O
65	binding	O
66	reaction	O
67	.	O

1	As	O
2	such	O
3	the	O
4	findings	O
5	support	O
6	existing	O
7	studies	O
8	that	O
9	have	O
10	identified	O
11	given	O
12	social	O
13	characteristics	O
14	of	O
15	drink	O
16	drivers	O
17	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	O
14	interferon	B
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O

1	Hemorrhagic	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	swine	O
9	model	O
10	.	O

1	Trichloroethylene	O
2	,	O
3	in	O
4	turn	O
5	,	O
6	increased	O
7	the	O
8	AUC	O
9	5	O
10	.	O
11	0	O
12	(	O
13	1	O
14	.	O
15	9	O
16	-	O
17	13	O
18	.	O
19	4	O
20	),	O
21	25	O
22	.	O
23	8	O
24	(	O
25	8	O
26	.	O
27	2	O
28	-	O
29	80	O
30	.	O
31	8	O
32	)	O
33	and	O
34	2	O
35	.	O
36	9	O
37	(	O
38	1	O
39	.	O
40	6	O
41	-	O
42	5	O
43	.	O
44	4	O
45	),	O
46	respectively	O
47	,	O
48	whereas	O
49	the	O
50	corresponding	O
51	values	O
52	for	O
53	n	O
54	-	O
55	hexane	O
56	were	O
57	1	O
58	.	O
59	9	O
60	(	O
61	0	O
62	.	O
63	7	O
64	-	O
65	5	O
66	.	O
67	1	O
68	),	O
69	1	O
70	.	O
71	5	O
72	(	O
73	0	O
74	.	O
75	5	O
76	-	O
77	4	O
78	.	O
79	6	O
80	),	O
81	and	O
82	3	O
83	.	O
84	2	O
85	(	O
86	1	O
87	.	O
88	8	O
89	-	O
90	5	O
91	.	O
92	9	O
93	).	O

1	The	O
2	determination	O
3	of	O
4	physical	O
5	performance	O
6	capacity	O
7	was	O
8	based	O
9	on	O
10	W170	O
11	,	O
12	W85	O
13	%	O
14	and	O
15	on	O
16	predicted	O
17	VO2	O
18	max	O
19	measured	O
20	with	O
21	continuously	O
22	increasing	O
23	work	O
24	load	O
25	on	O
26	a	O
27	bicycle	O
28	ergometer	O
29	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	total	O
7	number	O
8	of	O
9	subunit	O
10	c	O
11	in	O
12	F0	O
13	should	O
14	be	O
15	a	O
16	multiple	O
17	of	O
18	2	O
19	and	O
20	3	O
21	.	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	B
15	-	I
16	PAR	I
17	gene	I
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	"	O
2	In	O
3	vitro	O
4	"	O
5	study	O
6	of	O
7	dentin	O
8	adhesion	O
9	to	O
10	adhesives	O
11	made	O
12	from	O
13	urethane	O
14	molecules	O
15	with	O
16	free	O
17	groups	O
18	of	O
19	isocyanate	O

1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	B
18	levels	O
19	.	O

1	In	O
2	controls	O
3	,	O
4	most	O
5	of	O
6	the	O
7	output	O
8	from	O
9	the	O
10	conduit	O
11	occurred	O
12	during	O
13	type	O
14	I	O
15	activity	O
16	(	O
17	73	O
18	+/-	O
19	14	O
20	%).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O

1	Tristetraprolin	O
2	(	O
3	TTP	O
4	)	O
5	is	O
6	the	O
7	prototype	O
8	of	O
9	a	O
10	group	O
11	of	O
12	potential	O
13	transcription	O
14	factors	O
15	that	O
16	contain	O
17	two	O
18	or	O
19	more	O
20	unusual	O
21	CCCH	O
22	zinc	O
23	fingers	O
24	.	O

1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O

1	INTERVENTIONS	O
2	:	O
3	Subcutaneous	O
4	tissue	O
5	PO2	O
6	and	O
7	PCO2	O
8	tensions	O
9	were	O
10	measured	O
11	directly	O
12	in	O
13	patients	O
14	with	O
15	necrotising	O
16	fasciitis	O
17	and	O
18	in	O
19	healthy	O
20	volunteers	O
21	during	O
22	normobaric	O
23	and	O
24	hyperbaric	O
25	conditions	O
26	.	O

1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	I
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O

1	The	O
2	mature	O
3	AP	B
4	-	I
5	2	I
6	mRNA	I
7	is	O
8	spliced	O
9	from	O
10	7	O
11	exons	O
12	distributed	O
13	over	O
14	a	O
15	region	O
16	of	O
17	18	O
18	kb	O
19	genomic	O
20	DNA	O
21	.	O

1	Platelet	O
2	counts	O
3	and	O
4	function	O
5	as	O
6	well	O
7	as	O
8	fibrinogen	B
9	and	O
10	von	B
11	Willebrand	I
12	factor	I
13	(	O
14	vWF	B
15	)	O
16	levels	O
17	were	O
18	determined	O
19	in	O
20	each	O
21	sample	O
22	.	O

1	Diagnosis	O
2	of	O
3	phenylalanine	B
4	hydroxylase	I
5	deficiency	O
6	(	O
7	phenylketonuria	O
8	).	O

1	The	O
2	E1	B
3	nuclear	O
4	transport	O
5	motif	O
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	B
26	genes	I
27	.	O

1	We	O
2	show	O
3	also	O
4	that	O
5	RA	O
6	represses	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	a	O
12	reporter	O
13	gene	O
14	containing	O
15	a	O
16	TPA	B
17	responding	I
18	AP1	I
19	binding	I
20	site	I
21	driving	I
22	the	O
23	HSV	B
24	tk	I
25	promoter	I
26	.	O

1	To	O
2	modulate	O
3	transcription	O
4	,	O
5	regulatory	O
6	factors	O
7	communicate	O
8	with	O
9	basal	O
10	transcription	O
11	factors	O
12	and	O
13	/	O
14	or	O
15	RNA	O
16	polymerases	I
17	in	O
18	a	O
19	variety	O
20	of	O
21	ways	O
22	.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Rho1p	B
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	O
12	Bni1p	O
13	and	O
14	Pkc1p	O
15	.	O

1	Preface	O
2	.	O

1	Unlike	O
2	p59v	B
3	-	O
4	rel	O
5	,	O
6	which	O
7	is	O
8	a	O
9	nuclear	O
10	protein	O
11	in	O
12	CEF	O
13	,	O
14	indirect	O
15	immunofluorescence	O
16	showed	O
17	that	O
18	p68c	B
19	-	O
20	rel	I
21	in	O
22	JD214c	B
23	-	O
24	rel	I
25	infected	O
26	CEF	O
27	is	O
28	located	O
29	exclusively	O
30	in	O
31	the	O
32	cytoplasm	O
33	of	O
34	these	O
35	cells	O
36	,	O
37	even	O
38	though	O
39	the	O
40	sequence	O
41	of	O
42	p68c	B
43	-	I
44	rel	I
45	showed	O
46	that	O
47	it	O
48	contains	O
49	a	O
50	nuclear	O
51	localizing	O
52	sequence	O
53	identical	O
54	to	O
55	the	O
56	one	O
57	previously	O
58	identified	O
59	in	O
60	p59v	B
61	-	I
62	rel	I
63	.	O

1	Addition	O
2	of	O
3	sucralfate	O
4	or	O
5	De	O
6	-	O
7	Nol	O
8	resulted	O
9	in	O
10	increments	O
11	of	O
12	gastric	O
13	HCO3	O
14	secretion	O
15	,	O
16	reaching	O
17	about	O
18	45	O
19	%	O
20	and	O
21	59	O
22	%,	O
23	respectively	O
24	,	O
25	of	O
26	the	O
27	maximal	O
28	HCO3	O
29	response	O
30	to	O
31	16	O
32	,	O
33	16	O
34	-	O
35	dimethyl	O
36	PGE2	O
37	(	O
38	dmPGE2	O
39	).	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	B
9	alter	O
10	enhancer	I
11	factor	I
12	binding	O
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	B
18	-	I
19	1	I
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	B
51	-	I
52	1	I
53	requires	O
54	additional	O
55	factors	O
56	.	O

1	Malonate	B
2	decarboxylation	I
3	in	O
4	Malonomonas	B
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	B
11	-	I
12	S	I
13	-[	I
14	acyl	I
15	-	I
16	carrier	I
17	protein	I
18	]	O
19	from	O
20	acetyl	B
21	-	I
22	S	I
23	-[	O
24	acyl	O
25	-	I
26	carrier	I
27	protein	O
28	]	O
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	B
36	protein	I
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	B
45	mu	I
46	Na	I
47	+	I
48	generation	O
49	.	O

1	The	O
2	insulin	B
3	-	O
4	induced	O
5	DNA	O
6	-	O
7	binding	O
8	complex	O
9	was	O
10	identified	O
11	as	O
12	the	O
13	p50	B
14	/	O
15	p65	I
16	heterodimer	O
17	.	O

1	This	O
2	new	O
3	knowledge	O
4	has	O
5	contributed	O
6	to	O
7	the	O
8	development	O
9	of	O
10	a	O
11	successful	O
12	immunoprophylactic	O
13	strategy	O
14	for	O
15	eliminating	O
16	Hib	O
17	disease	O
18	.	O

1	To	O
2	further	O
3	investigate	O
4	the	O
5	nature	O
6	of	O
7	the	O
8	site	O
9	specificity	O
10	a	O
11	set	O
12	of	O
13	deletion	O
14	mutants	O
15	of	O
16	the	O
17	160	B
18	bp	O
19	sequence	O
20	were	O
21	analysed	O
22	.	O

1	RESULTS	O
2	:	O
3	Surprisingly	O
4	,	O
5	PAF	B
6	blockade	O
7	increased	O
8	mortality	O
9	after	O
10	trauma	O
11	(	O
12	5	O
13	of	O
14	11	O
15	WEB	O
16	-	O
17	2086	O
18	animals	O
19	versus	O
20	1	O
21	of	O
22	9	O
23	vehicle	O
24	animals	O
25	;	O
26	p	O
27	=	O
28	0	O
29	.	O
30	15	O
31	)	O
32	and	O
33	depressed	O
34	cardiac	O
35	index	O
36	and	O
37	O2	O
38	delivery	O
39	at	O
40	72	O
41	hours	O
42	(	O
43	p	O
44	<	O
45	0	O
46	.	O
47	05	O
48	).	O

1	Agonist	O
2	-	O
3	induced	O
4	receptor	O
5	internalization	O
6	,	O
7	determined	O
8	as	O
9	the	O
10	percent	O
11	of	O
12	total	O
13	[	O
14	125I	O
15	]	O
16	Tyr0	O
17	-	O
18	oCRF	O
19	bound	O
20	located	O
21	in	O
22	the	O
23	acid	O
24	-	O
25	resistant	O
26	fraction	O
27	of	O
28	transfected	O
29	Cos	O
30	7	O
31	cells	O
32	,	O
33	increased	O
34	with	O
35	time	O
36	(	O
37	0	O
38	-	O
39	60	O
40	min	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	)	O
46	for	O
47	both	O
48	wild	O
49	-	O
50	type	O
51	and	O
52	variant	O
53	oCRF1	O
54	.	O

1	However	O
2	,	O
3	kidneys	O
4	perfused	O
5	for	O
6	72	O
7	hr	O
8	demonstrated	O
9	more	O
10	similar	O
11	renal	O
12	functions	O
13	when	O
14	tested	O
15	by	O
16	either	O
17	IMPK	O
18	or	O
19	IBPK	O
20	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	B
6	stripes	I
7	expand	I
8	anteriorly	I
9	in	O
10	slp	B
11	mutant	I
12	embryos	O
13	and	O
14	that	O
15	slp	O
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	O
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	O
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	O
37	.	O

1	The	O
2	3	O
3	'	O
4	stem	O
5	-	O
6	loop	O
7	is	O
8	highly	O
9	divergent	O
10	in	O
11	structure	O
12	among	O
13	species	O
14	and	O
15	lies	O
16	immediately	O
17	upstream	O
18	of	O
19	the	O
20	binding	O
21	site	O
22	for	O
23	Sm	B
24	proteins	I
25	.	O

1	General	O
2	formulae	O
3	for	O
4	estimating	O
5	heritability	O
6	in	O
7	a	O
8	population	O
9	with	O
10	related	O
11	parents	O
12	.	O

1	RNA	O
2	transcripts	O
3	that	O
4	hybridize	O
5	to	O
6	the	O
7	introduced	O
8	foreign	O
9	gene	I
10	have	O
11	been	O
12	identified	O
13	.	O

1	Family	O
2	visits	O
3	and	O
4	involvement	O
5	in	O
6	treatment	O
7	of	O
8	patients	O
9	at	O
10	a	O
11	state	O
12	hospital	O
13	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	The	O
2	effects	O
3	of	O
4	high	O
5	intensity	O
6	light	O
7	emissions	O
8	,	O
9	produced	O
10	by	O
11	a	O
12	novel	O
13	pulsed	O
14	power	O
15	energization	O
16	technique	O
17	(	O
18	PPET	O
19	),	O
20	on	O
21	the	O
22	survival	O
23	of	O
24	bacterial	O
25	populations	O
26	of	O
27	verocytotoxigenic	B
28	Escherichia	I
29	coli	O
30	(	O
31	serotype	B
32	0157	I
33	:	O
34	H7	O
35	)	O
36	and	O
37	Listeria	O
38	monocytogenes	O
39	(	O
40	serotype	B
41	4b	I
42	)	O
43	were	O
44	investigated	O
45	.	O

1	Taste	O
2	reactivity	O
3	tests	O
4	were	O
5	used	O
6	to	O
7	examine	O
8	the	O
9	orofacial	O
10	responses	O
11	of	O
12	alcohol	O
13	preferring	O
14	(	O
15	P	O
16	)	O
17	rats	O
18	and	O
19	alcohol	O
20	nonpreferring	O
21	(	O
22	NP	O
23	)	O
24	rats	O
25	to	O
26	the	O
27	taste	O
28	of	O
29	alcohol	O
30	.	O

1	Cyclin	B
2	A	I
3	expression	O
4	is	O
5	repressed	O
6	in	O
7	quiescent	O
8	cells	O
9	by	O
10	E2F	B
11	acting	O
12	in	O
13	conjunction	O
14	with	O
15	its	O
16	pocket	O
17	protein	O
18	partners	O
19	Rb	B
20	,	O
21	p107	B
22	,	O
23	and	O
24	p130	B
25	;	O
26	however	O
27	,	O
28	v	B
29	-	I
30	Jun	I
31	overrides	I
32	this	O
33	control	O
34	,	O
35	causing	O
36	phosphorylated	O
37	Rb	B
38	and	O
39	proliferation	O
40	-	O
41	specific	O
42	E2F	B
43	-	I
44	p107	I
45	complexes	I
46	to	O
47	persist	O
48	after	O
49	mitogen	O
50	withdrawal	O
51	.	O

1	Such	O
2	a	O
3	change	O
4	may	O
5	involve	O
6	increased	O
7	mammary	O
8	utilization	O
9	of	O
10	pre	O
11	-	O
12	formed	O
13	long	O
14	-	O
15	chain	O
16	fatty	O
17	acid	O
18	and	O
19	increased	O
20	metabolism	O
21	of	O
22	glucose	O
23	via	O
24	glycolysis	O
25	.	O

1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	HMPAO	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	O
7	PL	O
8	visual	O
9	acuities	O
10	similar	O
11	to	O
12	those	O
13	established	O
14	by	O
15	McDonald	O
16	et	O
17	al	O
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O

1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	B
27	(	O
28	subunit	O
29	a	O
30	)	O
31	gene	O
32	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	B
17	gene	I
18	in	O
19	S	I
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	B
29	-	I
30	chain	I
31	amino	I
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O

1	Large	O
2	T	B
3	antigen	I
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	B
13	,	O
14	endogenous	B
15	TBP	I
16	,	O
17	hTAF	B
18	(	O
19	II	B
20	)	O
21	100	O
22	,	O
23	hTAF	B
24	(	O
25	II	B
26	)	O
27	130	O
28	,	O
29	and	O
30	hTAF	B
31	(	O
32	II	B
33	)	O
34	250	O
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	B
40	-	I
41	TFIID	I
42	would	O
43	be	O
44	precipitated	O
45	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O

1	Thus	O
2	,	O
3	hypoxia	O
4	-	O
5	inducible	O
6	nuclear	O
7	import	O
8	and	O
9	transactivation	O
10	by	O
11	recruitment	O
12	of	O
13	CBP	B
14	can	O
15	be	O
16	functionally	O
17	separated	O
18	from	O
19	one	O
20	another	O
21	and	O
22	play	O
23	critical	O
24	roles	O
25	in	O
26	signal	O
27	transduction	O
28	by	O
29	HIF	B
30	-	I
31	1alpha	I
32	.	O

1	In	O
2	transient	O
3	cotransfection	O
4	assays	O
5	using	O
6	Chang	O
7	liver	O
8	cells	O
9	(	O
10	CCL	O
11	13	O
12	),	O
13	pM1	O
14	DNA	O
15	exerts	O
16	a	O
17	6	O
18	-	O
19	to	O
20	10	O
21	-	O
22	fold	O
23	trans	O
24	-	O
25	activating	O
26	effect	O
27	on	O
28	the	O
29	expression	O
30	of	O
31	the	O
32	pSV2CAT	B
33	reporter	O
34	plasmid	O
35	.	O

1	Antituberculosis	O
2	agents	O
3	.	O

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	B
8	papio	I
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	Mutational	O
2	analysis	O
3	of	O
4	yeast	O
5	CEG1	O
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	O
12	conserved	O
13	motifs	O
14	are	O
15	essential	O
16	for	O
17	capping	O
18	enzyme	O
19	function	O
20	in	O
21	vivo	O
22	.	O

1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O

1	Transactivation	O
2	domain	O
3	is	O
4	located	O
5	downstream	O
6	of	O
7	the	O
8	128	O
9	-	O
10	amino	O
11	-	I
12	acid	I
13	runt	I
14	homology	I
15	region	O
16	,	O
17	referred	O
18	to	O
19	as	O
20	the	O
21	Runt	B
22	domain	I
23	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	characterization	O
7	of	O
8	an	O
9	alternatively	O
10	processed	O
11	form	O
12	of	O
13	AFAP	O
14	-	O
15	110	O
16	that	O
17	encodes	O
18	an	O
19	additional	O
20	258	O
21	base	O
22	pair	O
23	(	O
24	bp	O
25	)	O
26	of	O
27	open	O
28	reading	O
29	frame	O
30	.	O

1	Although	O
2	the	O
3	risk	O
4	of	O
5	malformation	O
6	in	O
7	children	O
8	born	O
9	after	O
10	ICSI	O
11	is	O
12	not	O
13	increased	O
14	there	O
15	is	O
16	an	O
17	increased	O
18	risk	O
19	to	O
20	transmit	O
21	genetic	O
22	abnormalities	O
23	in	O
24	case	O
25	of	O
26	NOA	O
27	(	O
28	such	O
29	as	O
30	the	O
31	rate	O
32	of	O
33	sex	O
34	chromosome	O
35	,	O
36	or	O
37	microdeletions	O
38	of	O
39	the	O
40	Y	O
41	chromosome	O
42	)	O
43	and	O
44	in	O
45	case	O
46	of	O
47	congenital	O
48	OA	O
49	(	O
50	mutations	O
51	of	O
52	the	O
53	cystic	B
54	fibrosis	I
55	gene	I
56	).	O

1	Screening	O
2	,	O
3	counseling	O
4	,	O
5	and	O
6	treatment	O
7	for	O
8	alcohol	O
9	and	O
10	illicit	O
11	drug	O
12	use	O
13	should	O
14	be	O
15	essential	O
16	components	O
17	in	O
18	comprehensive	O
19	HBP	O
20	care	O
21	.	O

1	The	O
2	13	O
3	,	O
4	14	O
5	-	O
6	dihydro	O
7	-	O
8	15	O
9	-	O
10	keto	O
11	-	O
12	metabolites	O
13	of	O
14	PGE2	O
15	and	O
16	PGF2	O
17	alpha	O
18	had	O
19	no	O
20	statistically	O
21	significant	O
22	antiarrhythmic	O
23	effect	O
24	.	O

1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O

1	Limits	O
2	of	O
3	energy	O
4	turnover	O
5	in	O
6	relation	O
7	to	O
8	physical	O
9	performance	O
10	were	O
11	addressed	O
12	in	O
13	terms	O
14	of	O
15	upper	O
16	and	O
17	lower	O
18	limit	O
19	,	O
20	changes	O
21	during	O
22	a	O
23	training	O
24	programme	O
25	and	O
26	how	O
27	to	O
28	regulate	O
29	energy	O
30	balance	O
31	at	O
32	a	O
33	changing	O
34	energy	O
35	turnover	O
36	.	O

1	The	O
2	murine	B
3	Mov	I
4	-	I
5	34	I
6	gene	I
7	:	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	and	O
13	genomic	O
14	organization	O
15	.	O

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	O
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	O
28	-	O
29	transport	O
30	system	O
31	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	NZ	O
6	-	O
7	107	O
8	may	O
9	be	O
10	a	O
11	useful	O
12	drug	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	bronchial	O
18	asthma	O
19	by	O
20	reducing	O
21	late	O
22	-	O
23	phase	O
24	airway	O
25	responses	O
26	and	O
27	airway	O
28	hyperreactivity	O
29	.	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	Consistent	O
2	with	O
3	the	O
4	in	O
5	vivo	O
6	result	O
7	,	O
8	the	O
9	pseudorevertant	B
10	endonucleases	I
11	in	O
12	the	O
13	crude	O
14	cell	O
15	extract	O
16	display	O
17	site	O
18	-	O
19	specific	O
20	partial	O
21	DNA	O
22	cleavage	O
23	activity	O
24	.	O

1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O

1	The	O
2	enhanced	O
3	cysteine	O
4	formation	O
5	in	O
6	a	O
7	pCSK4F	O
8	plant	O
9	responding	O
10	to	O
11	sulfite	O
12	was	O
13	also	O
14	observed	O
15	in	O
16	leaf	O
17	discs	O
18	.	O

1	Skin	O
2	and	O
3	bowel	O
4	TPO2	O
5	varied	O
6	with	O
7	DO2	O
8	and	O
9	each	O
10	other	O
11	(	O
12	P	O
13	<	O
14	0	O
15	.	O
16	05	O
17	).	O

1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O

1	The	O
2	hybridizing	O
3	clone	O
4	of	O
5	V	B
6	.	O
7	vulnificus	I
8	chromosomal	I
9	DNA	O
10	complemented	O
11	a	O
12	V	B
13	.	I
14	cholerae	I
15	fur	I
16	mutant	I
17	.	O

1	The	O
2	effect	O
3	of	O
4	these	O
5	cell	O
6	cycle	O
7	regulators	O
8	is	O
9	not	O
10	specific	O
11	to	O
12	the	O
13	rap1s	B
14	or	O
15	hmr	B
16	delta	I
17	A	I
18	mutation	I
19	,	O
20	since	O
21	swi6	B
22	,	O
23	swi4	B
24	,	O
25	and	O
26	clb5	B
27	mutations	O
28	also	O
29	suppress	O
30	mutations	O
31	in	O
32	SIR1	B
33	,	O
34	another	O
35	gene	O
36	implicated	O
37	in	O
38	the	O
39	establishment	O
40	of	O
41	silencing	O
42	.	O

1	Twenty	O
2	food	O
3	products	O
4	were	O
5	contaminated	O
6	with	O
7	V	O
8	.	O
9	cholerae	O
10	O1	O
11	,	O
12	Ogawa	O
13	,	O
14	toxigenic	O
15	and	O
16	not	O
17	toxigenic	O
18	strains	O
19	:	O
20	yoghurt	O
21	,	O
22	cream	O
23	cheese	O
24	,	O
25	apricot	B
26	marmelade	I
27	,	O
28	hip	O
29	rose	O
30	marmelade	O
31	,	O
32	mayonnaise	O
33	,	O
34	italian	B
35	pasta	O
36	for	O
37	"	O
38	empanadas	I
39	",	O
40	"	O
41	dulce	I
42	de	O
43	leche	O
44	",	O
45	meat	O
46	sausage	O
47	,	O
48	meat	O
49	and	O
50	spinach	O
51	ravioli	O
52	,	O
53	margarine	O
54	,	O
55	milk	O
56	dessert	O
57	(	O
58	made	O
59	with	O
60	cocoa	O
61	,	O
62	milk	O
63	confiture	O
64	,	O
65	starch	O
66	and	O
67	additives	O
68	),	O
69	lettuce	O
70	,	O
71	tuna	O
72	fish	O
73	,	O
74	ricotta	O
75	and	O
76	sterilized	O
77	milk	O
78	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	B
8	of	O
9	Hairy	I
10	-	I
11	wing	I
12	protein	I
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	When	O
2	expressed	O
3	alone	O
4	in	O
5	test	O
6	cells	O
7	,	O
8	Atr	B
9	-	O
10	I	I
11	is	O
12	unable	O
13	to	O
14	bind	O
15	TGF	B
16	-	I
17	beta	I
18	,	O
19	activin	B
20	,	O
21	or	O
22	bone	B
23	morphogenetic	I
24	protein	I
25	2	I
26	.	O

1	Treatment	O
2	of	O
3	ovarian	O
4	neoplasms	O

1	Rolandic	O
2	spikes	O
3	and	O
4	cognitive	O
5	function	O
6	.	O

1	Functional	O
2	rearranged	B
3	antibody	I
4	genes	I
5	were	O
6	detected	O
7	with	O
8	JH	B
9	and	O
10	VH	B
11	heavy	I
12	chain	I
13	probes	O
14	and	O
15	with	O
16	Jk	B
17	and	O
18	Vk	B
19	light	I
20	chain	I
21	probes	O
22	.	O

1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	HGFr	B
7	(	O
8	sHGFr	B
9	)	O
10	bound	O
11	HGF	B
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	authentic	O
21	,	O
22	membrane	B
23	-	I
24	associated	I
25	receptor	I
26	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	However	O
2	,	O
3	study	O
4	of	O
5	the	O
6	productive	O
7	gamma	I
8	gene	I
9	showed	O
10	that	O
11	the	O
12	skipped	B
13	variable	O
14	exon	O
15	was	O
16	bounded	O
17	by	O
18	normal	O
19	splicing	O
20	signals	O
21	and	O
22	that	O
23	the	O
24	adjacent	O
25	intron	O
26	organization	O
27	was	O
28	not	O
29	altered	O
30	.	O

1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	O
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	B
19	virus	I
20	40	I
21	(	O
22	SV40	B
23	)	O
24	promoter	O
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	O
45	-	O
46	SV40	B
47	-	O
48	CAT	B
49	transactivation	O
50	.	O

1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	O
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	B
6	and	I
7	HIS3	B
8	cDNAs	I
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	The	O
2	antibodies	O
3	inhibited	O
4	specifically	O
5	the	O
6	transcription	O
7	of	O
8	DNA	B
9	polymerase	I
10	alpha	I
11	promoter	I
12	in	O
13	vitro	O
14	.	O

1	We	O
2	show	O
3	that	O
4	HRI	B
5	and	I
6	dsRNA	B
7	-	I
8	PK	I
9	phosphorylate	I
10	yeast	I
11	eIF	I
12	-	I
13	2	I
14	alpha	I
15	in	O
16	vitro	O
17	and	O
18	in	O
19	vivo	O
20	and	O
21	functionally	O
22	substitute	O
23	for	O
24	GCN2	B
25	protein	I
26	to	O
27	stimulate	O
28	GCN4	B
29	translation	I
30	in	O
31	yeast	O
32	.	O

1	Furthermore	O
2	,	O
3	LB1	B
4	gene	I
5	mapped	O
6	to	O
7	chromosome	O
8	13q14	O
9	,	O
10	a	O
11	region	O
12	that	O
13	has	O
14	been	O
15	involved	O
16	as	O
17	a	O
18	chromosomal	O
19	breakpoint	O
20	in	O
21	DLBL	O
22	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	B
9	goosecoid	I
10	gene	I
11	(	O
12	GSC	B
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	of	O
5	insulin	B
6	-	O
7	secreting	O
8	tumours	O
9	.	O

1	These	O
2	adverse	O
3	effects	O
4	usually	O
5	abate	O
6	with	O
7	time	O
8	.	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	O
34	phosphatase	O
35	(	O
36	ACP	O
37	)	O
38	method	O
39	.	O

1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O

1	Demographic	O
2	and	O
3	clinical	O
4	data	O
5	were	O
6	compared	O
7	with	O
8	a	O
9	control	O
10	group	O
11	of	O
12	339	O
13	healthy	O
14	age	O
15	-	O
16	matched	O
17	women	O
18	and	O
19	with	O
20	a	O
21	sample	O
22	of	O
23	224	O
24	women	O
25	with	O
26	wrist	O
27	fracture	O
28	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	I
17	cortisol	O
18	release	O
19	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	I
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	B
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	B
32	-	I
33	GAP	I
34	activity	O
35	.	O

1	Wave	B
2	cybernetics	I
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	Grossly	O
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O

1	In	O
2	26	O
3	patients	O
4	with	O
5	angina	O
6	pectoris	O
7	,	O
8	the	O
9	changes	O
10	of	O
11	LVEF	O
12	,	O
13	LVESV	B
14	and	O
15	PSP	B
16	/	O
17	LVESV	O
18	were	O
19	more	O
20	sensitive	O
21	for	O
22	the	O
23	detection	O
24	of	O
25	exercise	O
26	-	O
27	induced	O
28	ischemia	O
29	than	O
30	the	O
31	appearance	O
32	of	O
33	chest	O
34	pain	O
35	and	O
36	the	O
37	changes	O
38	of	O
39	ECG	O
40	.	O

1	Role	O
2	of	O
3	c	B
4	-	I
5	myc	I
6	in	O
7	simian	B
8	virus	I
9	40	I
10	large	I
11	tumor	I
12	antigen	I
13	-	O
14	induced	O
15	DNA	O
16	synthesis	O
17	in	O
18	quiescent	O
19	3T3	O
20	-	O
21	L1	O
22	mouse	O
23	fibroblasts	O
24	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	O
13	+	O
14	concentration	O
15	rises	O
16	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	O
38	delta	O
39	mutation	O
40	.	O

1	The	O
2	227	O
3	-	O
4	to	O
5	-	O
6	239	O
7	region	O
8	blocked	O
9	ADR1	B
10	activity	O
11	independently	O
12	of	O
13	the	O
14	TAD	B
15	present	O
16	on	O
17	ADR1	B
18	,	O
19	ADR1	B
20	DNA	I
21	binding	I
22	,	O
23	and	O
24	specific	O
25	ADH2	I
26	promoter	I
27	sequences	I
28	.	O

1	In	O
2	patients	O
3	with	O
4	osteomyelitis	O
5	and	O
6	joint	O
7	empyema	O
8	(	O
9	n	O
10	=	O
11	48	B
12	)	O
13	PMN	B
14	elastase	I
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	exceeded	O
25	by	O
26	that	O
27	of	O
28	the	O
29	unspecific	O
30	erythrocyte	O
31	sedimentation	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O

1	IE2	B
2	-	O
3	IE2	I
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	I
18	motif	I
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	B
33	.	O

1	Inspired	O
2	CO2	O
3	causing	O
4	changes	O
5	from	O
6	hypo	O
7	-	O
8	to	O
9	normocapnia	O
10	has	O
11	previously	O
12	been	O
13	shown	O
14	to	O
15	improve	O
16	arterial	O
17	O2	O
18	tension	O
19	(	O
20	PaO2	O
21	)	O
22	and	O
23	to	O
24	reduce	O
25	alveolar	O
26	-	O
27	arterial	O
28	O2	O
29	difference	O
30	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	B
5	-	O
6	III	I
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	7R	I
10	alpha	I
11	chains	I
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	JAKs	B
20	and	O
21	STATs	B
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	proliferative	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Pneumothorax	O
2	complicated	O
3	by	O
4	chronic	O
5	steroid	O
6	treatment	O
7	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	RAD30	I
5	gene	I
6	,	O
7	a	O
8	homologue	B
9	of	O
10	Escherichia	B
11	coli	I
12	dinB	I
13	and	O
14	umuC	B
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	B
8	-	I
9	p86	I
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	O
26	.	O

1	Although	O
2	further	O
3	studies	O
4	are	O
5	required	O
6	to	O
7	determine	O
8	the	O
9	precise	O
10	role	O
11	of	O
12	PEBP2	B
13	in	O
14	the	O
15	GM	B
16	-	I
17	CSF	I
18	promoter	I
19	activity	O
20	,	O
21	the	O
22	present	O
23	findings	O
24	suggested	O
25	the	O
26	importance	O
27	of	O
28	the	O
29	relative	O
30	ratio	O
31	of	O
32	different	O
33	PEBP2	B
34	isoforms	O
35	in	O
36	regulating	O
37	the	O
38	levels	O
39	of	O
40	the	O
41	promoter	O
42	activity	O
43	.	O

1	The	O
2	putative	O
3	immunity	O
4	protein	O
5	was	O
6	detected	O
7	among	O
8	the	O
9	[	O
10	35S	O
11	]	O
12	methionine	O
13	-	O
14	labelled	O
15	proteins	O
16	produced	O
17	by	O
18	minicells	O
19	carrying	O
20	cni	B
21	cloned	O
22	under	O
23	lac	B
24	promoter	I
25	control	O
26	,	O
27	and	O
28	when	O
29	the	O
30	gene	O
31	was	O
32	subcloned	O
33	into	O
34	expression	O
35	vectors	O
36	under	O
37	the	O
38	control	O
39	of	O
40	a	O
41	bacteriophage	B
42	T7	I
43	promoter	I
44	.	O

1	The	O
2	appearance	O
3	of	O
4	dyskinetic	O
5	movement	O
6	disorders	O
7	in	O
8	humans	O
9	following	O
10	the	O
11	chronic	O
12	use	O
13	of	O
14	levodopa	B
15	or	O
16	amphetamine	O
17	may	O
18	be	O
19	a	O
20	manifestation	O
21	of	O
22	similarly	O
23	increased	O
24	dopamine	B
25	receptor	I
26	site	I
27	sensitivity	O
28	within	O
29	the	O
30	striatum	B
31	.	O

1	Native	B
2	human	I
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	End	O
2	-	O
3	tidal	O
4	PO2	O
5	and	O
6	the	O
7	ratio	O
8	of	O
9	minute	O
10	ventilation	O
11	to	O
12	oxygen	O
13	consumption	O
14	(	O
15	VE	O
16	/	O
17	VO2	O
18	)	O
19	were	O
20	lower	O
21	while	O
22	PETCO2	O
23	was	O
24	higher	O
25	for	O
26	Hyp	O
27	(	O
28	P	O
29	<	O
30	or	O
31	=	O
32	0	O
33	.	O
34	01	O
35	).	O

1	However	O
2	,	O
3	in	O
4	some	O
5	of	O
6	them	O
7	either	O
8	pattern	O
9	may	O
10	predominate	O
11	or	O
12	be	O
13	exclusively	O
14	present	O
15	.	O

1	The	O
2	performance	O
3	of	O
4	three	O
5	commonly	O
6	used	O
7	chemical	O
8	cartridge	O
9	respirators	O
10	for	O
11	SO2	O
12	was	O
13	measured	O
14	under	O
15	working	O
16	conditions	O
17	in	O
18	a	O
19	copper	O
20	smelter	O
21	.	O

1	Risk	O
2	factors	O
3	influencing	O
4	lymph	O
5	nodes	O
6	metastasis	O
7	in	O
8	lung	O
9	cancer	O
10	with	O
11	stage	O
12	I	O
13	,	O
14	II	O
15	or	O
16	IIIA	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	the	O
6	type	O
7	of	O
8	tyrosine	B
9	kinase	I
10	receptor	I
11	stimulated	O
12	also	O
13	participates	O
14	in	O
15	the	O
16	nature	O
17	of	O
18	the	O
19	cAMP	O
20	effect	O
21	.	O

1	A	O
2	cdc33	B
3	-	I
4	1	I
5	strain	O
6	expressing	O
7	either	O
8	stable	O
9	Cln3p	B
10	(	O
11	Cln3	B
12	-	I
13	1p	I
14	)	O
15	or	O
16	a	O
17	hybrid	O
18	UBI4	B
19	5	I
20	'-	I
21	CLN3	I
22	mRNA	I
23	,	O
24	whose	O
25	translation	O
26	displays	O
27	decreased	O
28	dependence	O
29	on	O
30	eIF4E	O
31	,	O
32	arrested	O
33	randomly	O
34	in	O
35	the	O
36	cell	O
37	cycle	O
38	.	O

1	Unlike	O
2	most	O
3	other	O
4	small	O
5	G	I
6	proteins	I
7	which	O
8	are	O
9	expressed	O
10	ubiquitously	O
11	,	O
12	TTF	B
13	was	O
14	transcribed	O
15	only	O
16	in	O
17	hemopoietic	O
18	cells	O
19	as	O
20	a	O
21	2	O
22	.	O
23	2	O
24	kb	O
25	transcript	O
26	.	O

1	The	O
2	addition	O
3	of	O
4	diatrizoate	O
5	to	O
6	the	O
7	IPRK	O
8	led	O
9	to	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	biphasic	O
15	change	O
16	in	O
17	RPF	B
18	and	O
19	GFR	O
20	characterized	O
21	by	O
22	an	O
23	initial	O
24	transient	O
25	increase	O
26	followed	O
27	by	O
28	a	O
29	marked	O
30	and	O
31	sustained	O
32	decrease	O
33	.	O

1	CONCLUSIONS	O
2	:	O
3	A	O
4	50	O
5	-	O
6	mg	O
7	daily	O
8	dose	O
9	of	O
10	bicalutamide	O
11	is	O
12	sufficient	O
13	when	O
14	given	O
15	in	O
16	combination	O
17	with	O
18	an	O
19	agent	O
20	,	O
21	such	O
22	as	O
23	a	O
24	LHRH	B
25	-	O
26	A	O
27	,	O
28	that	O
29	lowers	O
30	serum	O
31	testosterone	O
32	,	O
33	but	O
34	higher	O
35	doses	O
36	of	O
37	bicalutamide	O
38	may	O
39	be	O
40	needed	O
41	when	O
42	the	O
43	drug	O
44	is	O
45	given	O
46	as	O
47	monotherapy	O
48	.	O

1	No	O
2	systematic	O
3	L	O
4	-	O
5	R	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	O
22	core	B
23	promoter	I
24	through	O
25	liver	O
26	-	I
27	specific	I
28	enhancer	I
29	II	I
30	and	O
31	HBx	B
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	O
22	,	O
23	the	O
24	leucine	B
25	zipper	I
26	transcription	I
27	factor	I
28	MafB	I
29	/	I
30	Kr	I
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	I
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	O
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	At	O
2	necropsy	O
3	28	O
4	days	O
5	post	O
6	-	O
7	inoculation	O
8	,	O
9	F344	O
10	rats	O
11	had	O
12	no	O
13	gross	O
14	lung	O
15	lesions	O
16	,	O
17	even	O
18	those	O
19	given	O
20	the	O
21	maximum	O
22	dose	O
23	of	O
24	1	O
25	.	O
26	4	O
27	X	O
28	10	O
29	(	O
30	9	O
31	)	O
32	colony	O
33	-	O
34	forming	O
35	units	O
36	of	O
37	M	O
38	.	O
39	pulmonis	O
40	.	O

1	Striking	O
2	sequence	O
3	similarities	O
4	(	O
5	57	O
6	and	O
7	53	O
8	%)	O
9	were	O
10	observed	O
11	with	O
12	yeast	O
13	mitochondrial	I
14	proteins	I
15	,	O
16	SMF1	B
17	and	O
18	SMF2	O
19	,	O
20	especially	O
21	within	O
22	putative	O
23	functional	O
24	domains	O
25	:	O
26	exon	O
27	6	O
28	encoding	O
29	the	O
30	second	O
31	transmembrane	O
32	spanning	O
33	domain	O
34	,	O
35	site	O
36	of	O
37	the	O
38	murine	O
39	susceptibility	O
40	mutation	O
41	;	O
42	and	O
43	exon	O
44	11	O
45	encoding	O
46	a	O
47	conserved	O
48	transport	O
49	motif	O
50	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	-	I
8	derived	O
9	construct	O
10	(	O
11	a	O
12	-	O
13	Src	B
14	),	O
15	that	O
16	was	O
17	excluded	O
18	from	O
19	detergent	O
20	-	O
21	resistant	O
22	membranes	O
23	,	O
24	could	O
25	not	O
26	restore	O
27	the	O
28	series	O
29	of	O
30	phagocytosis	O
31	signaling	O
32	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	In	O
2	summary	O
3	,	O
4	DDC	B
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O

1	ID	B
2	-	I
3	PaGIA	I
4	diphtheria	I
5	toxin	I
6	polymer	O
7	particle	O
8	diagnostic	O
9	agent	O
10	manufactured	O
11	by	O
12	DiaMed	O
13	AG	O
14	,	O
15	Switzerland	O
16	,	O
17	was	O
18	tried	O
19	at	O
20	bacteriological	O
21	laboratory	O
22	of	O
23	Institute	O
24	of	O
25	Childhood	O
26	Infections	O
27	in	O
28	St	O
29	.	O

1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	I
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	B
29	proteins	I
30	.	O

1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	O
21	-	O
22	5	O
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	B
8	(	O
9	2	O
10	)	O
11	sgRNAs	O
12	of	O
13	TMV	O
14	U1	B
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	O
30	(	O
31	MP	O
32	,	O
33	75	O
34	)	O
35	(	O
36	HIRES	O
37	(	O
38	MP	O
39	),	O
40	(	O
41	75	O
42	)(	O
43	CR	O
44	)-	O
45	MP	O
46	-	O
47	CP	B
48	-	I
49	3	I
50	'	O
51	UTR	O
52	;	O
53	HIRES	O
54	(	O
55	MP	O
56	,	O
57	75	O
58	)(	O
59	U1	B
60	)-	O
61	MP	O
62	-	I
63	CP	I
64	-	I
65	3	I
66	'	I
67	UTR	I
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	O
75	gene	O
76	in	O
77	vitro	O
78	.	O

1	Only	O
2	two	O
3	patients	O
4	(	O
5	0	O
6	.	O
7	3	O
8	%)	O
9	had	O
10	a	O
11	CA	O
12	125	O
13	response	O
14	at	O
15	the	O
16	time	O
17	of	O
18	clinical	O
19	progression	O
20	.	O

1	Consistent	O
2	with	O
3	the	O
4	protein	O
5	expression	O
6	data	O
7	,	O
8	V	B
9	beta	I
10	8	I
11	.	I
12	3	I
13	gene	I
14	transcripts	I
15	were	O
16	found	O
17	only	O
18	in	O
19	the	O
20	transgenic	O
21	lines	O
22	with	O
23	the	O
24	wild	O
25	-	O
26	type	I
27	promoter	I
28	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	putative	O
6	RBP1	B
7	protein	I
8	contains	O
9	two	O
10	copies	O
11	of	O
12	an	O
13	RNA	O
14	recognition	I
15	motif	I
16	,	O
17	two	O
18	glutamine	O
19	stretches	O
20	,	O
21	an	O
22	asparagine	O
23	-	O
24	rich	O
25	region	O
26	,	O
27	a	O
28	methionine	O
29	-	O
30	rich	O
31	region	O
32	,	O
33	and	O
34	two	O
35	long	O
36	potential	O
37	alpha	B
38	-	I
39	helixes	I
40	.	O

1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	B
14	ferrochelatase	I
15	gene	I
16	(	O
17	HEM15	B
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O

1	Studies	O
2	on	O
3	the	O
4	organic	O
5	matrix	O
6	of	O
7	human	O
8	ear	O
9	ossicles	O

1	The	O
2	presence	O
3	of	O
4	local	O
5	abnormalities	O
6	in	O
7	both	O
8	patients	O
9	can	O
10	support	O
11	the	O
12	hypothesis	O
13	that	O
14	the	O
15	cortex	O
16	,	O
17	especially	O
18	of	O
19	the	O
20	temporal	O
21	anterior	O
22	lobe	O
23	,	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	origin	O
29	of	O
30	the	O
31	laughing	O
32	seizures	O
33	.	O

1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	O
7	damaged	O
8	E44D	B
9	mutant	I
10	detected	O
11	in	O
12	(	O
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	I
31	I	I
32	motif	I
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	O
40	the	O
41	active	O
42	site	O
43	region	O
44	.	O

1	The	O
2	class	B
3	II	I
4	Escherichia	I
5	coli	I
6	alanine	I
7	tRNA	I
8	synthetase	I
9	aminoacylates	I
10	RNA	I
11	miniduplexes	I
12	,	O
13	which	O
14	reconstruct	O
15	the	O
16	acceptor	O
17	end	O
18	of	O
19	alanine	B
20	tRNA	I
21	with	O
22	the	O
23	critical	O
24	G3	O
25	:	O
26	U70	O
27	base	O
28	pair	O
29	.	O

1	Reactivities	O
2	to	O
3	horse	B
4	anti	I
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O

1	These	O
2	data	O
3	do	O
4	not	O
5	support	O
6	the	O
7	use	O
8	of	O
9	LDD	O
10	to	O
11	reduce	O
12	risk	O
13	of	O
14	progression	O
15	to	O
16	MSOF	O
17	in	O
18	sepsis	O
19	.	O

1	To	O
2	address	O
3	the	O
4	biological	O
5	effect	O
6	of	O
7	specific	O
8	isoform	O
9	expression	O
10	,	O
11	NIH3T3	O
12	cells	O
13	were	O
14	transfected	O
15	with	O
16	a	O
17	eukaryotic	O
18	expression	O
19	vector	O
20	containing	O
21	cDNA	O
22	for	O
23	FGF8a	B
24	,	O
25	FGF8b	B
26	,	O
27	or	O
28	FGF8e	O
29	.	O

1	PRL	B
2	receptor	I
3	also	O
4	activates	O
5	SHP	B
6	-	I
7	2	I
8	,	O
9	a	O
10	cytosolic	B
11	tyrosine	I
12	phosphatase	I
13	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	B
17	SF	I
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	B
24	COUP	I
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	we	O
6	concluded	O
7	that	O
8	this	O
9	ORF	O
10	is	O
11	the	O
12	FRDS	B
13	gene	I
14	.	O

1	Antithrombin	B
2	III	I
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	O
10	?	O
11	Thrombosis	O
12	ABC	B
13	,	O
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I

1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O

1	This	O
2	GAP	B
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	B
10	adipocyte	I
11	lysates	O
12	,	O
13	and	O
14	was	O
15	able	O
16	to	O
17	accelerate	O
18	the	O
19	hydrolysis	O
20	of	O
21	the	O
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	O
27	GTP	O
28	bound	O
29	to	O
30	GST	B
31	-	O
32	Rab4	O
33	into	O
34	[	O
35	alpha	O
36	-	O
37	32P	O
38	]	O
39	GDP	O
40	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	From	O
2	S3	O
3	(	O
4	CBF	B
5	:	O
6	79	O
7	-	O
8	60	O
9	%)	O
10	to	O
11	S5	B
12	(	O
13	CBF	B
14	:	O
15	39	O
16	-	O
17	0	O
18	%),	O
19	%	O
20	WTh	O
21	,	O
22	1	O
23	/	O
24	TPC	B
25	and	O
26	1	O
27	/	O
28	T	O
29	were	O
30	significantly	O
31	decreased	O
32	from	O
33	those	O
34	of	O
35	the	O
36	control	O
37	levels	O
38	(	O
39	all	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	01	O
46	).	O

1	However	O
2	,	O
3	a	O
4	similar	O
5	mutation	O
6	of	O
7	a	O
8	leucine	O
9	residue	O
10	to	O
11	arginine	O
12	at	O
13	position	O
14	422	O
15	showed	O
16	no	O
17	alteration	O
18	of	O
19	heterodimerization	O
20	,	O
21	DNA	O
22	binding	O
23	,	O
24	or	O
25	transcriptional	O
26	activation	O
27	.	O

1	We	O
2	established	O
3	that	O
4	the	O
5	2	B
6	.	I
7	6	I
8	kb	I
9	mRNA	I
10	V	I
11	-	I
12	1	I
13	and	O
14	the	O
15	2	B
16	.	I
17	3	I
18	kb	I
19	GGT	I
20	mRNA	I
21	V	I
22	-	I
23	2	I
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	B
42	GGT	I
43	gene	I
44	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	O
19	early	O
20	regions	O
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O

1	Also	O
2	,	O
3	the	O
4	anti	B
5	-	O
6	inflammatory	O
7	activities	O
8	of	O
9	an	O
10	aqueous	O
11	extract	O
12	of	O
13	Buddleia	B
14	cordata	I
15	and	O
16	its	O
17	principal	O
18	glycoside	O
19	linarin	O
20	were	O
21	evaluated	O
22	.	O

1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	B
6	CD3	I
7	-	I
8	TCR	I
9	complex	I
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	B
17	,	O
18	CD3	B
19	zeta	I
20	and	I
21	CD3	B
22	epsilon	I
23	,	O
24	autonomously	B
25	couple	I
26	antigenic	I
27	recognition	I
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O

1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	B
33	4	I
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	B
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	B
12	gene	I
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	In	O
2	the	O
3	normal	O
4	,	O
5	basal	O
6	(	O
7	unstimulated	O
8	)	O
9	condition	O
10	there	O
11	were	O
12	no	O
13	significant	O
14	correlations	O
15	(	O
16	p	O
17	greater	O
18	than	O
19	0	O
20	.	O
21	05	O
22	)	O
23	between	O
24	the	O
25	systolic	O
26	blood	O
27	pressure	O
28	and	O
29	dopamine	O
30	(	O
31	r	O
32	=	O
33	0	O
34	.	O
35	09	O
36	),	O
37	norepinephrine	O
38	(	O
39	r	O
40	=	O
41	0	O
42	.	O
43	26	O
44	),	O
45	or	O
46	epinephrine	O
47	(	O
48	r	O
49	=	O
50	0	O
51	.	O
52	27	O
53	),	O
54	nor	O
55	were	O
56	there	O
57	significant	O
58	correlations	O
59	between	O
60	melatonin	O
61	and	O
62	dopamine	O
63	(	O
64	r	O
65	=	O
66	-	O
67	0	O
68	.	O
69	01	O
70	),	O
71	norepinephrine	O
72	(	O
73	r	O
74	=	O
75	-	O
76	0	O
77	.	O
78	26	O
79	),	O
80	or	O
81	growth	O
82	hormone	O
83	(	O
84	r	O
85	=	O
86	0	O
87	.	O
88	17	O
89	).	O

1	Clin	O
2	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	O
61	-	O
62	2	O
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	Further	O
2	studies	O
3	in	O
4	T	O
5	-	O
6	24	O
7	cells	O
8	demonstrated	O
9	that	O
10	HA	B
11	fragments	I
12	also	O
13	induced	O
14	I	B
15	kappa	I
16	B	I
17	alpha	I
18	phosphorylation	O
19	and	O
20	degradation	O
21	,	O
22	kappa	B
23	B	I
24	-	I
25	linked	I
26	reporter	I
27	gene	I
28	expression	O
29	,	O
30	and	O
31	ICAM	B
32	-	I
33	1	I
34	promoter	I
35	activity	O
36	in	O
37	an	O
38	NF	B
39	-	I
40	kappa	I
41	B	I
42	-	I
43	dependent	O
44	manner	O
45	.	O

1	A	O
2	transparent	O
3	overlay	O
4	for	O
5	assessing	O
6	amplitude	O
7	of	O
8	ECG	O
9	wave	O
10	forms	O
11	.	O

1	For	O
2	the	O
3	present	O
4	work	O
5	we	O
6	used	O
7	water	O
8	saturated	O
9	with	O
10	a	O
11	50	O
12	/	O
13	50	O
14	mixture	O
15	of	O
16	H2	O
17	and	O
18	O2	O
19	gases	O
20	,	O
21	for	O
22	which	O
23	the	O
24	heat	O
25	defect	O
26	is	O
27	calculated	O
28	to	O
29	be	O
30	-	O
31	2	O
32	.	O
33	1	O
34	%.	O

1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O

1	The	O
2	Siglecs	O
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	B
8	-	I
9	type	I
10	lectins	I
11	(	I
12	immunoglobulin	B
13	superfamily	I
14	proteins	I
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	B
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	I
25	alpha	I
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	B
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	O
38	for	O
39	p21rac	B
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	Its	O
2	application	O
3	in	O
4	Madagascar	O
5	:	O
6	advantages	O
7	and	O
8	disadvantages	O

1	The	O
2	response	O
3	chain	O
4	in	O
5	each	O
6	component	O
7	was	O
8	maintained	O
9	by	O
10	food	O
11	presentation	O
12	under	O
13	a	O
14	fixed	O
15	-	O
16	ratio	O
17	schedule	O
18	.	O

1	In	O
2	vitro	O
3	interaction	O
4	studies	O
5	,	O
6	using	O
7	proteins	O
8	fused	O
9	to	O
10	glutathione	B
11	-	I
12	S	I
13	-	I
14	transferase	I
15	,	O
16	showed	O
17	that	O
18	RBP	B
19	-	I
20	J	I
21	kappa	I
22	and	O
23	Su	B
24	(	O
25	H	O
26	)	O
27	bind	O
28	directly	O
29	to	O
30	the	O
31	RAM23	O
32	regions	O
33	of	O
34	mouse	B
35	Notch1	I
36	and	O
37	Drosophila	B
38	Notch	I
39	,	O
40	respectively	O
41	.	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	B
16	p53	I
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	The	O
2	effect	O
3	of	O
4	maternal	O
5	ingestion	O
6	of	O
7	the	O
8	reduced	O
9	energy	O
10	sweetener	B
11	erythritol	I
12	was	O
13	investigated	O
14	in	O
15	KBL	O
16	:	O
17	JW	O
18	strain	O
19	pregnant	O
20	rabbits	O
21	.	O

1	After	O
2	hemodynamic	O
3	stabilization	O
4	,	O
5	the	O
6	goal	O
7	of	O
8	therapy	O
9	is	O
10	to	O
11	diminish	O
12	the	O
13	chance	O
14	that	O
15	an	O
16	ulcer	O
17	will	O
18	continue	O
19	to	O
20	bleed	O
21	or	O
22	will	O
23	rebleed	O
24	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	Analysis	O
2	of	O
3	electrically	O
4	evoked	O
5	response	O
6	(	O
7	EER	O
8	)	O
9	in	O
10	relation	O
11	to	O
12	the	O
13	central	O
14	visual	O
15	pathway	O
16	of	O
17	the	O
18	cat	O
19	(	O
20	1	O
21	).	O

1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	B
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	B
29	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Full	B
2	thyroid	O
3	function	O
4	testing	O
5	was	O
6	performed	O
7	on	O
8	600	O
9	randomly	O
10	selected	O
11	samples	O
12	with	O
13	normal	O
14	TSH	O
15	values	O
16	and	O
17	also	O
18	on	O
19	subjects	O
20	with	O
21	abnormal	O
22	TSH	O
23	levels	O
24	.	O

1	Effect	O
2	of	O
3	bromazepam	B
4	on	O
5	growth	I
6	hormone	I
7	and	O
8	prolactin	B
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	Xaa	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	sequons	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O

1	A	O
2	short	O
3	history	O
4	of	O
5	dermatology	O
6	in	O
7	Lagos	O
8	,	O
9	Nigeria	O
10	.	O

1	Segments	O
2	with	O
3	more	O
4	reduced	O
5	BMIPP	O
6	uptake	O
7	than	O
8	MIBI	O
9	uptake	O
10	(	O
11	mismatching	O
12	)	O
13	showed	O
14	either	O
15	normal	O
16	wall	O
17	motion	O
18	or	O
19	demonstrated	O
20	inotropic	O
21	reserve	O
22	during	O
23	dobutamine	O
24	stimulation	O
25	.	O

1	The	O
2	infection	O
3	rate	O
4	was	O
5	five	O
6	times	O
7	greater	O
8	in	O
9	patients	O
10	with	O
11	Hickman	O
12	catheters	O
13	than	O
14	in	O
15	those	O
16	with	O
17	Broviac	O
18	catheters	O
19	(	O
20	p	O
21	=	O
22	0	O
23	.	O
24	01	O
25	).	O

1	PAS1	O
2	,	O
3	a	O
4	yeast	O
5	gene	O
6	required	O
7	for	O
8	peroxisome	O
9	biogenesis	O
10	,	O
11	encodes	O
12	a	O
13	member	O
14	of	O
15	a	O
16	novel	O
17	family	O
18	of	O
19	putative	O
20	ATPases	O
21	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	identified	O
6	four	O
7	open	O
8	reading	O
9	frames	O
10	(	O
11	ORFs	O
12	)	O
13	which	O
14	are	O
15	designated	O
16	UL1	B
17	,	O
18	UL2	B
19	,	O
20	UL3	B
21	,	O
22	and	O
23	UL3	O
24	.	O
25	5	O
26	based	O
27	on	O
28	their	O
29	homology	O
30	with	O
31	proteins	O
32	of	O
33	herpes	O
34	simplex	O
35	virus	I
36	-	I
37	1	I
38	(	O
39	HSV	O
40	-	O
41	1	O
42	),	O
43	pseudorabies	O
44	virus	O
45	(	O
46	PRV	O
47	),	O
48	equine	B
49	herpesvirus	O
50	-	O
51	1	O
52	,	O
53	and	O
54	varicella	B
55	-	I
56	zoster	I
57	virus	I
58	.	O

1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	B
10	CD6	I
11	cDNA	I
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	CD6	B
31	-	I
32	PB1	I
33	.	O

1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O

1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	B
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	I
23	protein	I
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O

1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	B
10	receptor	I
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	O
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	B
33	-	I
34	type	I
35	receptor	I
36	,	O
37	RAP	O
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	B
44	markers	O
45	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O

1	BIM	O
2	130	O
3	.	O

1	The	O
2	healing	O
3	rate	O
4	in	O
5	HIV	O
6	-	O
7	positive	O
8	patients	O
9	was	O
10	66	O
11	percent	O
12	after	O
13	14	O
14	weeks	O
15	and	O
16	100	O
17	percent	O
18	after	O
19	32	O
20	weeks	O
21	;	O
22	the	O
23	corresponding	O
24	figures	O
25	for	O
26	patients	O
27	with	O
28	acquired	O
29	immunodeficiency	O
30	syndrome	O
31	were	O
32	0	O
33	and	O
34	50	O
35	percent	O
36	.	O

1	The	O
2	cell	O
3	cycle	O
4	-	I
5	regulated	I
6	transcription	I
7	factor	I
8	E2F	I
9	is	O
10	also	O
11	known	O
12	to	O
13	bend	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O

1	This	O
2	mechanism	O
3	is	O
4	in	O
5	contrast	O
6	to	O
7	other	O
8	cases	O
9	of	O
10	splicing	O
11	regulation	O
12	by	O
13	PTB	B
14	,	O
15	in	O
16	which	O
17	the	O
18	protein	O
19	represses	O
20	the	O
21	splice	O
22	site	O
23	to	O
24	which	O
25	it	O
26	binds	O
27	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	O
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	putative	O
10	cytokine	O
11	which	O
12	is	O
13	induced	O
14	by	O
15	stimulation	O
16	via	O
17	the	O
18	CD2	B
19	structure	O
20	on	O
21	human	O
22	T	O
23	lymphocytes	O
24	.	O

1	By	O
2	in	O
3	vitro	O
4	immunoprecipitations	O
5	and	O
6	gel	O
7	shift	O
8	assays	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	classes	O
14	of	O
15	high	O
16	affinity	O
17	Engrailed	B
18	-	I
19	binding	I
20	sites	I
21	upstream	O
22	of	O
23	each	O
24	of	O
25	the	O
26	two	O
27	polyhomeotic	B
28	transcription	O
29	units	O
30	.	O

1	The	O
2	presence	O
3	of	O
4	cutaneous	O
5	xanthomas	O
6	with	O
7	normal	O
8	serum	O
9	lipid	O
10	levels	O
11	is	O
12	due	O
13	to	O
14	the	O
15	antibetalipoproteic	O
16	activity	O
17	of	O
18	the	O
19	monoclonal	B
20	immunoglobulin	I
21	.	O

1	Endogenous	O
2	release	O
3	of	O
4	neuronal	O
5	serotonin	O
6	and	O
7	5	O
8	-	I
9	hydroxyindoleacetic	I
10	acid	O
11	in	O
12	the	O
13	caudate	O
14	-	O
15	putamen	O
16	of	O
17	the	O
18	rat	O
19	as	O
20	revealed	O
21	by	O
22	intracerebral	O
23	dialysis	O
24	coupled	O
25	to	O
26	high	O
27	-	O
28	performance	O
29	liquid	O
30	chromatography	O
31	with	O
32	fluorimetric	O
33	detection	O
34	.	O

1	Employing	O
2	this	O
3	sequence	O
4	information	O
5	from	O
6	c11	B
7	/	O
8	1	O
9	,	O
10	the	O
11	c11	B
12	/	O
13	1	I
14	-	I
15	specific	O
16	cDNA	O
17	was	O
18	generated	O
19	from	O
20	poly	O
21	(	O
22	A	O
23	)+	O
24	RNA	O
25	of	O
26	bovine	O
27	PMNLs	O
28	by	O
29	reverse	O
30	transcription	O
31	and	O
32	a	O
33	combination	O
34	of	O
35	polymerase	O
36	chain	O
37	reaction	O
38	(	O
39	PCR	O
40	)	O
41	methods	O
42	.	O

1	Prognosis	O
2	in	O
3	Bowen	O
4	'	O
5	s	O
6	disease	O
7	localized	O
8	to	O
9	the	O
10	ano	O
11	-	O
12	genital	O
13	region	O
14	.	O

1	In	O
2	addition	O
3	,	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	increase	O
9	in	O
10	postdexamethasone	O
11	cortical	O
12	concentrations	O
13	with	O
14	age	O
15	(	O
16	p	O
17	less	O
18	than	O
19	0	O
20	.	O
21	01	O
22	;	O
23	r	O
24	=	O
25	0	O
26	.	O
27	31	O
28	).	O

1	We	O
2	have	O
3	used	O
4	mutation	O
5	-	O
6	directed	O
7	chemical	O
8	cross	O
9	-	O
10	linking	O
11	with	O
12	bis	O
13	(	O
14	sulfosuccinimidyl	B
15	)	O
16	suberate	O
17	(	O
18	BS3	O
19	)	O
20	to	O
21	investigate	O
22	the	O
23	architecture	O
24	of	O
25	the	O
26	gp41	B
27	oligomer	O
28	.	O

1	Since	O
2	one	O
3	group	O
4	of	O
5	adolescents	O
6	more	O
7	difficult	O
8	to	O
9	influence	O
10	are	O
11	those	O
12	whose	O
13	parents	O
14	smoke	O
15	,	O
16	parental	O
17	involvement	O
18	in	O
19	smoking	O
20	prevention	O
21	may	O
22	be	O
23	a	O
24	powerful	O
25	enhancer	O
26	.	O

1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	O
6	the	O
7	genome	O
8	can	O
9	be	O
10	folded	O
11	into	O
12	a	O
13	tRNA	B
14	-	O
15	like	O
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	B
26	-	I
27	like	I
28	structure	I
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	B
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	Overproduction	O
2	of	O
3	HrcA	B
4	protein	O
5	from	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	hrcA	O
11	derived	O
12	from	O
13	a	O
14	plasmid	O
15	(	O
16	phrcA	O
17	+)	O
18	in	O
19	B	B
20	.	O
21	subtilis	O
22	wild	I
23	-	I
24	type	I
25	and	O
26	delta	B
27	hrcA	I
28	strains	O
29	prevented	O
30	heat	O
31	shock	O
32	induction	O
33	of	O
34	the	O
35	dnaK	B
36	and	O
37	groE	B
38	operons	I
39	at	O
40	the	O
41	level	O
42	of	O
43	transcription	O
44	almost	O
45	completely	O
46	and	O
47	strongly	O
48	reduced	O
49	the	O
50	amounts	O
51	of	O
52	mRNA	O
53	at	O
54	a	O
55	low	O
56	temperature	O
57	as	O
58	well	O
59	.	O

1	Plasma	B
2	thromboxane	I
3	B2	I
4	levels	O
5	in	O
6	the	O
7	older	O
8	group	O
9	were	O
10	about	O
11	double	O
12	those	O
13	in	O
14	younger	O
15	piglets	O
16	.	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	When	O
2	phencyclidine	O
3	was	O
4	administered	O
5	alone	O
6	,	O
7	overall	O
8	response	O
9	rate	O
10	decreased	O
11	and	O
12	percent	O
13	errors	O
14	increased	O
15	with	O
16	increasing	O
17	doses	O
18	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O

1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O

1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O

1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	B
25	.	O
26	5	I
27	gene	I
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O

1	Domains	B
2	I	I
3	and	O
4	II	O
5	of	O
6	B	O
7	"	O
8	are	O
9	buried	O
10	upon	O
11	assembly	O
12	of	O
13	the	O
14	TFIIIB	B
15	-	I
16	DNA	O
17	complex	O
18	,	O
19	as	O
20	determined	O
21	by	O
22	protein	O
23	footprinting	O
24	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	protection	O
6	assay	O
7	and	O
8	specific	O
9	blocking	O
10	oligonucleotides	O
11	,	O
12	we	O
13	find	O
14	that	O
15	recognition	O
16	of	O
17	the	O
18	5	O
19	'	O
20	splice	O
21	-	I
22	site	I
23	(	O
24	5	O
25	'	O
26	ss	O
27	)	O
28	and	O
29	branchpoint	O
30	sequence	O
31	(	O
32	BPS	O
33	)	O
34	elements	O
35	by	O
36	U11	O
37	and	O
38	U12	O
39	snRNPs	O
40	,	O
41	respectively	O
42	,	O
43	displays	O
44	strong	O
45	cooperativity	O
46	,	O
47	requiring	O
48	both	O
49	sites	O
50	in	O
51	the	O
52	pre	O
53	-	O
54	mRNA	O
55	substrate	O
56	for	O
57	efficient	O
58	complex	O
59	formation	O
60	.	O

1	The	O
2	319	O
3	base	O
4	pair	O
5	region	O
6	immediately	O
7	upstream	O
8	of	O
9	the	O
10	CAP	B
11	site	I
12	is	O
13	characterized	O
14	by	O
15	the	O
16	lack	O
17	of	O
18	a	O
19	proximal	O
20	TATA	O
21	box	O
22	and	O
23	the	O
24	presence	O
25	of	O
26	sequences	O
27	similar	O
28	to	O
29	GC	O
30	boxes	O
31	,	O
32	CACCC	O
33	boxes	O
34	,	O
35	CCAAT	B
36	boxes	I
37	,	O
38	activator	B
39	protein	I
40	2	I
41	(	O
42	Ap	B
43	-	I
44	2	I
45	)	O
46	sites	O
47	,	O
48	partial	O
49	glucocorticoid	O
50	response	O
51	elements	O
52	(	O
53	GREs	O
54	),	O
55	and	O
56	partial	O
57	cyclic	O
58	AMP	O
59	response	O
60	elements	O
61	(	O
62	CREs	O
63	).	O

1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	B
18	Speech	I
19	Processor	I
20	(	O
21	MSP	B
22	).	O

1	272	O
2	,	O
3	19107	B
4	-	O
5	19110	O
6	).	O

1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O

1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	B
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	O
23	module	O
24	,	O
25	with	O
26	inner	O
27	nuclear	O
28	membrane	O
29	proteins	O
30	lamina	O
31	-	O
32	associated	O
33	polypeptide	O
34	2	O
35	and	O
36	emerin	O
37	.	O

1	Allelic	B
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	I
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	O

1	Urinary	B
2	urate	O
3	excretion	O
4	,	O
5	urate	O
6	clearance	O
7	,	O
8	and	O
9	fractional	O
10	excretion	O
11	of	O
12	urate	O
13	all	O
14	increased	O
15	significantly	O
16	during	O
17	water	O
18	immersion	O
19	,	O
20	and	O
21	decreased	O
22	in	O
23	the	O
24	hour	O
25	following	O
26	water	O
27	immersion	O
28	.	O

1	Having	O
2	an	O
3	LRR	B
4	domain	I
5	and	O
6	an	O
7	SH3	B
8	-	I
9	binding	I
10	domain	I
11	,	O
12	Acan125	O
13	and	O
14	the	O
15	C	O
16	.	O
17	elegans	O
18	homologue	I
19	define	I
20	a	O
21	novel	O
22	family	O
23	of	O
24	bifunctional	O
25	binding	I
26	proteins	I
27	.	O

1	We	O
2	have	O
3	found	O
4	a	O
5	satisfactory	O
6	reproducibility	O
7	in	O
8	vitro	O
9	(	O
10	T1	O
11	:	O
12	1	O
13	.	O
14	9	O
15	%;	O
16	T2	O
17	:	O
18	6	O
19	.	O
20	2	O
21	%),	O
22	while	O
23	the	O
24	reproducibility	O
25	was	O
26	less	O
27	satisfactory	O
28	in	O
29	vivo	O
30	(	O
31	T1	O
32	:	O
33	16	O
34	.	O
35	4	O
36	%;	O
37	T2	O
38	:	O
39	13	O
40	.	O
41	4	O
42	%).	O

1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	identify	O
6	the	O
7	USH1C	B
8	disease	O
9	gene	O
10	we	O
11	have	O
12	isolated	O
13	the	O
14	region	O
15	between	O
16	these	O
17	markers	O
18	in	O
19	yeast	O
20	artificial	O
21	chromosomes	O
22	(	O
23	YACs	O
24	)	O
25	using	O
26	a	O
27	combination	O
28	of	O
29	STS	O
30	content	O
31	mapping	O
32	and	O
33	Alu	O
34	-	O
35	PCR	O
36	hybridization	O
37	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	B
9	-	I
10	ended	I
11	double	I
12	-	I
13	stranded	I
14	DNA	I
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	In	O
2	group	O
3	I	O
4	,	O
5	Paw	O
6	,	O
7	delta	B
8	V	I
9	,	O
10	PaO2	O
11	,	O
12	Vinj	O
13	and	O
14	VT	O
15	significantly	O
16	decreased	O
17	whereas	O
18	operating	O
19	pressure	O
20	and	O
21	E	O
22	significantly	O
23	increased	O
24	when	O
25	the	O
26	internal	O
27	diameter	O
28	of	O
29	the	O
30	injector	O
31	cannula	O
32	was	O
33	reduced	O
34	.	O

1	[	O
2	82Br	O
3	]	O
4	MISO	O
5	was	O
6	prepared	O
7	by	O
8	irradiating	O
9	samples	O
10	of	O
11	Br	O
12	-	O
13	MISO	O
14	in	O
15	a	O
16	SLOWPOKE	O
17	reactor	O
18	for	O
19	2	O
20	h	O
21	at	O
22	a	O
23	thermal	O
24	neutron	O
25	flux	O
26	of	O
27	10	O
28	(	O
29	12	O
30	)	O
31	n	O
32	cm	O
33	-	O
34	2	O
35	s	O
36	-	O
37	1	O
38	.	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	The	O
2	dying	O
3	tTG	O
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	The	O
2	resurgence	O
3	of	O
4	drug	O
5	-	O
6	resistant	O
7	malaria	O
8	makes	O
9	urgent	O
10	the	O
11	evaluation	O
12	of	O
13	new	O
14	antimalarial	O
15	agents	O
16	.	O

1	Two	O
2	additional	O
3	cis	O
4	-	O
5	acting	O
6	sequences	O
7	,	O
8	conserved	O
9	in	O
10	both	O
11	the	O
12	region	O
13	1	O
14	and	O
15	3	O
16	promoters	O
17	,	O
18	were	O
19	identified	O
20	,	O
21	suggesting	O
22	a	O
23	role	O
24	for	O
25	these	O
26	sequences	O
27	in	O
28	the	O
29	coordinate	O
30	regulation	O
31	of	O
32	transcription	O
33	from	O
34	these	O
35	promoters	O
36	.	O

1	CONCLUSION	O
2	:	O
3	A	O
4	valve	O
5	-	O
6	like	O
7	mechanism	O
8	formed	O
9	by	O
10	the	O
11	capsulorhexis	O
12	rim	O
13	partially	O
14	adhered	O
15	to	O
16	the	O
17	IOL	O
18	optic	O
19	can	O
20	occur	O
21	postoperatively	O
22	.	O

1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	O
14	-	O
15	associated	O
16	plasma	I
17	protein	I
18	-	I
19	A	I
20	(	O
21	PAPP	B
22	-	I
23	A	I
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	O
33	-	O
34	YD1	I
35	).	O

1	RT	O
2	-	O
3	PCR	O
4	using	O
5	1	O
6	.	O
7	D	O
8	-	O
9	specific	O
10	primers	O
11	showed	O
12	that	O
13	kidney	O
14	,	O
15	brain	O
16	and	O
17	prostate	O
18	do	O
19	not	O
20	express	O
21	1	O
22	.	O
23	D	I
24	mRNA	I
25	even	O
26	though	O
27	kidney	O
28	and	O
29	brain	O
30	are	O
31	the	O
32	most	O
33	abundant	O
34	source	O
35	for	O
36	aFGF	B
37	protein	O
38	.	O

1	However	O
2	,	O
3	the	O
4	truncated	B
5	deer	I
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O

1	Although	O
2	the	O
3	Src	B
4	tyrosine	I
5	kinase	I
6	induces	O
7	constitutive	O
8	Stat3	B
9	phosphorylation	O
10	on	O
11	tyrosine	O
12	,	O
13	activation	O
14	of	O
15	Stat3	B
16	-	I
17	mediated	O
18	gene	O
19	regulation	O
20	requires	O
21	both	O
22	tyrosine	O
23	and	O
24	serine	O
25	phosphorylation	O
26	of	O
27	Stat3	B
28	.	O

1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	O
13	,	O
14	both	O
15	A134C	B
16	and	O
17	G232A	B
18	BALB	I
19	/	O
20	c	B
21	-	I
22	specific	O
23	variants	O
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	I
39	CDK4	I
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O

1	Desmethylferrochloroquine	B
2	1a	I
3	and	O
4	didesmethylferrochloroquine	B
5	2	O
6	would	O
7	be	O
8	more	O
9	potent	O
10	against	O
11	schizontocides	O
12	than	O
13	CQ	O
14	in	O
15	vitro	O
16	against	O
17	two	O
18	strains	O
19	(	O
20	HB3	O
21	and	O
22	Dd2	O
23	)	O
24	of	O
25	Plasmodium	O
26	falciparum	O
27	.	O

1	Ninety	O
2	-	O
3	four	O
4	percent	O
5	of	O
6	the	O
7	EPs	O
8	were	O
9	tubal	O
10	,	O
11	and	O
12	90	O
13	%	O
14	of	O
15	the	O
16	tubes	O
17	exhibited	O
18	some	O
19	pathologic	O
20	changes	O
21	,	O
22	including	O
23	chronic	O
24	salpingitis	O
25	(	O
26	49	O
27	.	O
28	5	O
29	%)	O
30	and	O
31	follicular	O
32	salpingitis	O
33	(	O
34	10	O
35	%),	O
36	among	O
37	others	O
38	.	O

1	The	O
2	p55	B
3	mRNA	I
4	is	O
5	undetectable	O
6	in	O
7	non	O
8	-	O
9	EBV	O
10	-	O
11	infected	O
12	B	O
13	-	O
14	and	O
15	T	O
16	-	O
17	cell	O
18	lines	O
19	or	O
20	in	O
21	a	O
22	myelomonocytic	O
23	cell	O
24	line	O
25	(	O
26	U937	O
27	).	O

1	(	O
2	1991	O
3	).	O

1	Homology	O
2	with	O
3	the	O
4	human	B
5	protein	O
6	is	O
7	only	O
8	34	O
9	%	O
10	in	O
11	the	O
12	tandem	O
13	repeat	O
14	domain	O
15	,	O
16	mainly	O
17	showing	O
18	conservation	O
19	of	O
20	serines	B
21	and	O
22	threonines	B
23	,	O
24	presumed	O
25	sites	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	attachment	O
32	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	B
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	O
26	group	O
27	of	O
28	the	O
29	esterase	B
30	/	I
31	lipase	I
32	family	I
33	.	O

1	The	O
2	primary	O
3	CT	O
4	findings	O
5	were	O
6	misinterpreted	O
7	as	O
8	a	O
9	brain	O
10	infarct	O
11	or	O
12	possibly	O
13	a	O
14	tumour	O
15	.	O

1	These	O
2	tumors	O
3	were	O
4	classified	O
5	into	O
6	three	O
7	broad	O
8	groups	O
9	:	O
10	I	O
11	,	O
12	cystadenoma	O
13	;	O
14	II	O
15	,	O
16	cystadenocarcinoma	O
17	;	O
18	and	O
19	III	O
20	,	O
21	adenocarcinoma	O
22	with	O
23	mucin	B
24	production	O
25	or	O
26	an	O
27	associated	O
28	cyst	O
29	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	B
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	O
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O

1	The	O
2	workup	O
3	included	O
4	skin	O
5	tests	O
6	(	O
7	up	O
8	to	O
9	1	O
10	microgram	O
11	/	O
12	ml	O
13	,	O
14	Pharmacia	O
15	),	O
16	measurement	O
17	of	O
18	specific	O
19	serum	O
20	IgE	I
21	with	O
22	RAST	O
23	-	O
24	CAP	I
25	(	O
26	Pharmacia	O
27	),	O
28	and	O
29	CAST	O
30	with	O
31	three	O
32	concentrations	O
33	of	O
34	bee	B
35	(	O
36	Apis	B
37	mellifera	I
38	)	O
39	and	O
40	wasp	B
41	(	O
42	Vespula	B
43	spec	I
44	.)	O
45	venom	O
46	(	O
47	Aquagen	B
48	ALK	I
49	).	O

1	The	O
2	IE13	B
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	I
31	gene	I
32	.	O

1	Multizone	O
2	PRK	O
3	has	O
4	been	O
5	suggested	O
6	to	O
7	increase	O
8	the	O
9	predictability	O
10	of	O
11	higher	O
12	myopic	O
13	corrections	O
14	.	O

1	Current	O
2	status	O
3	of	O
4	zinc	O
5	deficiency	O
6	in	O
7	the	O
8	pathogenesis	O
9	of	O
10	neurological	O
11	,	O
12	dermatological	O
13	and	O
14	musculoskeletal	O
15	disorders	O
16	.	O

1	Km	O
2	values	O
3	for	O
4	ammonium	O
5	,	O
6	2	O
7	-	O
8	oxoglutarate	O
9	,	O
10	NADH	O
11	,	O
12	glutamate	O
13	and	O
14	NAD	B
15	+	I
16	were	O
17	6	O
18	.	O
19	5	O
20	,	O
21	3	O
22	.	O
23	5	O
24	,	O
25	0	O
26	.	O
27	06	O
28	,	O
29	37	O
30	.	O
31	1	O
32	and	O
33	0	O
34	.	O
35	046	O
36	mM	O
37	,	O
38	respectively	O
39	.	O

1	Therefore	O
2	,	O
3	the	O
4	amino	O
5	-	O
6	terminal	O
7	sequence	O
8	of	O
9	the	O
10	purified	O
11	carA	I
12	product	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	derived	O
18	from	O
19	the	O
20	nucleotide	O
21	sequence	O
22	in	O
23	both	O
24	organisms	O
25	,	O
26	P	O
27	.	O
28	stutzeri	O
29	having	O
30	four	O
31	additional	O
32	amino	O
33	acids	O
34	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	B
16	alpha	I
17	1	I
18	(	I
19	II	B
20	)	I
21	collagen	I
22	gene	I
23	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	O
13	mutations	O
14	in	O
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	B
20	activation	O
21	domain	I
22	.	O

1	Effect	O
2	of	O
3	hyperglycemia	O
4	on	O
5	pain	O
6	threshold	O
7	in	O
8	alloxan	O
9	-	O
10	diabetic	O
11	rats	O
12	.	O

1	We	O
2	conclude	O
3	that	O
4	administration	O
5	of	O
6	the	O
7	calcium	O
8	antagonist	O
9	Verapamil	O
10	is	O
11	of	O
12	no	O
13	additional	O
14	value	O
15	in	O
16	tocolytic	O
17	treatment	O
18	with	O
19	beta	O
20	-	O
21	mimetics	O
22	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	O
14	receptor	B
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	I
45	.	O

1	Plants	O
2	transformed	O
3	with	O
4	the	O
5	35S	B
6	-	I
7	1	I
8	-	I
9	sst	I
10	construct	I
11	accumulated	O
12	the	O
13	oligofructans	B
14	1	I
15	-	I
16	kestose	I
17	(	O
18	GF2	B
19	),	O
20	1	B
21	,	O
22	1	B
23	-	I
24	nystose	I
25	(	O
26	GF3	B
27	)	O
28	and	O
29	1	O
30	,	O
31	1	O
32	,	O
33	1	B
34	-	I
35	fructosylnystose	I
36	(	O
37	GF4	O
38	).	O

1	The	O
2	significance	O
3	of	O
4	these	O
5	palindromic	O
6	domains	O
7	in	O
8	this	O
9	ORF	O
10	is	O
11	unclear	O
12	but	O
13	the	O
14	coincidence	O
15	of	O
16	the	O
17	end	O
18	of	O
19	one	O
20	larger	O
21	palindrome	O
22	with	O
23	the	O
24	end	O
25	of	O
26	the	O
27	translated	O
28	protein	O
29	sequence	O
30	that	O
31	has	O
32	homology	O
33	with	O
34	the	O
35	B	B
36	chain	I
37	of	O
38	insulin	B
39	suggests	O
40	that	O
41	the	O
42	palindromes	B
43	may	O
44	divide	O
45	the	O
46	T2	B
47	protein	I
48	into	O
49	several	O
50	functional	O
51	units	O
52	.	O

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	O
8	on	O
9	the	O
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	Adjustment	O
2	for	O
3	age	O
4	,	O
5	total	O
6	cholesterol	O
7	,	O
8	HDL	B
9	cholesterol	I
10	,	O
11	triglycerides	O
12	,	O
13	current	O
14	smoking	O
15	,	O
16	and	O
17	systolic	O
18	pressure	O
19	slightly	O
20	reduced	O
21	the	O
22	association	O
23	between	O
24	fibrinogen	B
25	and	O
26	atherosclerosis	O
27	.	O

1	Sci	O
2	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	significant	O
6	pulmonary	O
7	metabolism	O
8	of	O
9	5	O
10	-	O
11	HT	O
12	followed	O
13	by	O
14	efflux	O
15	of	O
16	5	O
17	-	O
18	HIAA	O
19	into	O
20	venous	O
21	output	O
22	occurs	O
23	during	O
24	single	O
25	-	O
26	pass	O
27	circulation	O
28	.	O

1	Our	O
2	previous	O
3	study	O
4	suggested	O
5	that	O
6	pertussis	B
7	toxin	I
8	(	I
9	IAP	B
10	)-	I
11	sensitive	O
12	GTP	B
13	-	I
14	binding	I
15	protein	I
16	(	O
17	s	B
18	)	O
19	(	O
20	G	B
21	-	I
22	protein	I
23	)	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	process	O
29	of	O
30	differentiation	O
31	by	O
32	hormones	O
33	/	O
34	IBMX	O
35	,	O
36	accompanied	O
37	by	O
38	c	B
39	-	I
40	fos	I
41	induction	O
42	.	O

1	Substitution	O
2	of	O
3	the	O
4	DR1	B
5	beta	I
6	chain	I
7	with	O
8	H	B
9	-	I
10	2E	I
11	beta	I
12	k	O
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	O
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	B
35	Function	I
36	(	O
37	IIEF	O
38	).	O

1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	I
15	in	O
16	Saccharopolyspora	B
17	erythraea	I
18	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	neuron	B
10	-	I
11	specific	I
12	protein	I
13	kinase	I
14	C	I
15	substrate	I
16	neurogranin	I
17	(	O
18	RC3	B
19	protein	I
20	).	O

1	This	O
2	correlated	O
3	with	O
4	reduced	O
5	levels	O
6	of	O
7	secreted	O
8	hepatitis	B
9	B	I
10	e	I
11	antigen	I
12	and	O
13	increased	O
14	intracellular	O
15	levels	O
16	of	O
17	core	B
18	and	O
19	Pol	B
20	proteins	I
21	and	O
22	replicative	O
23	HBV	O
24	DNA	O
25	intermediates	O
26	.	O

1	Constipation	O
2	is	O
3	not	O
4	a	O
5	risk	O
6	factor	O
7	for	O
8	hemorrhoids	O
9	:	O
10	a	O
11	case	O
12	-	O
13	control	O
14	study	O
15	of	O
16	potential	O
17	etiological	O
18	agents	O
19	.	O

1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	B
8	(	O
9	PTFE	B
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O

1	Furthermore	O
2	,	O
3	the	O
4	DNA	B
5	polymerase	I
6	II	I
7	complex	I
8	was	O
9	difficult	O
10	to	O
11	obtain	O
12	from	O
13	dpb2	B
14	-	I
15	1	I
16	mutant	O
17	cells	O
18	,	O
19	suggesting	O
20	that	O
21	a	O
22	stable	O
23	DNA	O
24	polymerase	I
25	II	I
26	complex	I
27	requires	O
28	DPB2	O
29	and	O
30	is	O
31	essential	O
32	for	O
33	chromosomal	O
34	replication	O
35	.	O

1	SF	B
2	-	I
3	1	I
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	These	O
2	HPV16	B
3	E6	I
4	/	I
5	E7	B
6	cDNAs	I
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	I
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	I
44	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	graft	O
8	survival	O
9	between	O
10	groups	O
11	with	O
12	early	O
13	graft	O
14	function	O
15	(	O
16	EGF	B
17	)	O
18	and	O
19	DGF	O
20	,	O
21	either	O
22	in	O
23	first	O
24	transplantations	O
25	or	O
26	retransplantations	O
27	.	O

1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O

1	Serum	O
2	induction	O
3	of	O
4	a	O
5	MEF2	B
6	reporter	I
7	gene	I
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	O
21	MEF2	B
22	site	I
23	binding	I
24	activity	O
25	.	O

1	Green	O
2	pepper	O
3	significantly	O
4	inhibited	O
5	N	O
6	-	O
7	nitrosothiazolidine	O
8	-	O
9	carboxylic	O
10	acid	O
11	formation	O
12	relative	O
13	to	O
14	ascorbic	O
15	acid	O
16	alone	O
17	.	O

1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O

1	SCFFWD1	O
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	B
7	and	O
8	hmg2	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	O
15	-	O
16	and	O
17	spatially	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	IRF	B
2	-	I
3	1	I
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	O
11	IRF	B
12	-	I
13	2	I
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	O
31	(	O
32	Suvar3	O
33	-	O
34	9	O
35	,	O
36	Enhancer	O
37	-	O
38	of	O
39	-	O
40	zeste	O
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	O
51	.	O

1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	O
21	cassette	O
22	.	O

1	No	O
2	mutations	O
3	were	O
4	found	O
5	in	O
6	follicular	O
7	adenomas	O
8	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	proteins	O
7	,	O
8	we	O
9	have	O
10	characterized	O
11	domains	O
12	responsible	O
13	for	O
14	activation	O
15	or	O
16	repression	O
17	.	O

1	The	O
2	nifJ	B
3	and	O
4	nifH	B
5	promoters	I
6	of	O
7	Klebsiella	B
8	pneumoniae	I
9	are	O
10	divergently	O
11	transcribed	O
12	sigma	B
13	54	I
14	-	I
15	dependent	O
16	promoters	O
17	that	O
18	are	O
19	positively	O
20	activated	O
21	by	O
22	the	O
23	NifA	B
24	protein	I
25	.	O

1	This	O
2	revealed	O
3	a	O
4	minimum	O
5	of	O
6	six	O
7	novel	O
8	OSBP	B
9	-	I
10	related	I
11	proteins	I
12	,	O
13	designated	O
14	ORP	B
15	-	I
16	1	I
17	to	O
18	ORP	B
19	-	I
20	6	I
21	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	retrospective	O
6	study	O
7	was	O
8	to	O
9	demonstrate	O
10	that	O
11	in	O
12	certain	O
13	cases	O
14	of	O
15	expulsive	O
16	choroidal	O
17	hemorrhage	O
18	(	O
19	ECH	O
20	)	O
21	anatomical	O
22	success	O
23	and	O
24	useful	O
25	vision	O
26	can	O
27	be	O
28	obtained	O
29	with	O
30	repeated	O
31	vitreoretinal	O
32	surgery	O
33	.	O

1	In	O
2	sorted	O
3	bone	O
4	marrow	O
5	cells	O
6	expression	O
7	of	O
8	both	O
9	VpreB	B
10	genes	I
11	was	O
12	detected	O
13	in	O
14	pro	O
15	-	O
16	B	O
17	/	O
18	pre	O
19	-	O
20	BI	O
21	and	O
22	large	O
23	pre	O
24	-	O
25	BII	O
26	cells	O
27	,	O
28	while	O
29	the	O
30	RNA	O
31	steady	O
32	state	O
33	levels	O
34	were	O
35	at	O
36	least	O
37	100	O
38	-	O
39	fold	O
40	lower	O
41	in	O
42	small	O
43	pre	O
44	-	O
45	BII	I
46	and	O
47	immature	O
48	/	O
49	mature	O
50	B	O
51	cells	O
52	.	O

1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	B
15	(	O
16	zinc	B
17	finger	I
18	homeodomain	I
19	enhancer	I
20	-	I
21	binding	I
22	protein	I
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	O
32	and	O
33	ZD2	O
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	B
44	.	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	Only	O
2	one	O
3	ADR	O
4	was	O
5	related	O
6	definitely	O
7	to	O
8	ciprofloxacin	O
9	therapy	O
10	.	O

1	We	O
2	have	O
3	now	O
4	located	O
5	the	O
6	5	O
7	'	O
8	ends	O
9	of	O
10	the	O
11	two	O
12	remaining	O
13	late	O
14	mRNAs	O
15	.	O

1	The	O
2	patient	O
3	was	O
4	homozygous	O
5	for	O
6	the	O
7	underlying	O
8	mutation	O
9	,	O
10	which	O
11	was	O
12	found	O
13	to	O
14	be	O
15	a	O
16	G	O
17	-->	O
18	T	O
19	transversion	O
20	within	O
21	the	O
22	acceptor	O
23	splice	O
24	site	O
25	between	O
26	intron	O
27	e	O
28	and	O
29	exon	O
30	6	O
31	,	O
32	abolishing	O
33	normal	O
34	RNA	O
35	splicing	O
36	.	O

1	We	O
2	thus	O
3	conclude	O
4	that	O
5	the	O
6	NFAT	B
7	RIR	O
8	plays	O
9	an	O
10	essential	O
11	dual	O
12	role	O
13	in	O
14	DNA	O
15	recognition	O
16	and	O
17	cooperative	O
18	binding	O
19	to	O
20	AP	B
21	-	I
22	1	I
23	family	I
24	transcription	I
25	factors	O
26	.	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	O
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	O
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O

1	Appl	O
2	.	O

1	RESULTS	O
2	:	O
3	Closure	O
4	time	O
5	of	O
6	fistulas	O
7	in	O
8	patients	O
9	receiving	O
10	TPN	O
11	+	O
12	somatostatin	I
13	was	O
14	significantly	O
15	shorter	O
16	(	O
17	13	O
18	.	O
19	86	O
20	+/-	O
21	1	O
22	.	O
23	84	O
24	versus	O
25	20	O
26	.	O
27	4	O
28	+/-	O
29	2	O
30	.	O
31	89	O
32	days	O
33	)	O
34	than	O
35	in	O
36	those	O
37	receiving	O
38	TPN	O
39	alone	O
40	.	O

1	Mutations	O
2	at	O
3	two	O
4	neighboring	O
5	sites	O
6	,	O
7	serine	O
8	242	O
9	and	O
10	threonine	O
11	255	O
12	,	O
13	exacerbated	O
14	the	O
15	effect	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	healthy	O
5	individuals	O
6	,	O
7	whole	O
8	body	O
9	insulin	B
10	sensitivity	I
11	is	O
12	related	O
13	,	O
14	or	O
15	"	O
16	coupled	O
17	,	O
18	"	O
19	to	O
20	the	O
21	anaerobic	O
22	threshold	O
23	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	O
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	I
13	and	O
14	dimeric	O
15	complexes	O
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	Rats	O
2	underwent	O
3	either	O
4	a	O
5	90	O
6	-	O
7	95	O
8	%	O
9	JIB	O
10	or	O
11	a	O
12	sham	O
13	operation	O
14	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	B
5	18	I
6	beta	I
7	-	I
8	glycyrrhetate	I
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O

1	Angionephroscintigraphy	O
2	in	O
3	the	O
4	diagnosis	O
5	of	O
6	diseases	O
7	of	O
8	the	O
9	kidney	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	B
27	lit	I
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	The	O
2	Epstein	O
3	-	O
4	Barr	O
5	virus	I
6	transactivator	I
7	Zta	I
8	triggers	O
9	lytic	O
10	gene	O
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	O
23	.	O

1	Relapse	O
2	of	O
3	leukemia	O
4	after	O
5	prolonged	O
6	remission	O
7	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	B
7	proteins	I
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	O
15	NHP6A	I
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	Muscle	O
2	GSH	O
3	-	O
4	Px	O
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	O
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	B
23	gene	I
24	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O

1	We	O
2	suggest	O
3	that	O
4	MotA	B
5	and	O
6	AsiA	B
7	may	O
8	function	O
9	like	O
10	certain	O
11	eukaryotic	O
12	TAFs	I
13	(	O
14	TATA	B
15	binding	I
16	protein	I
17	(	O
18	TBP	B
19	)	I
20	associated	O
21	factors	I
22	)	O
23	whose	O
24	binding	O
25	to	O
26	TBP	B
27	results	O
28	in	O
29	transcription	O
30	from	O
31	new	O
32	core	B
33	promoter	O
34	sequences	O
35	.	O

1	These	O
2	are	O
3	two	O
4	regions	O
5	of	O
6	known	O
7	conserved	O
8	synteny	O
9	,	O
10	providing	O
11	further	O
12	evidence	O
13	that	O
14	the	O
15	human	B
16	STEP	I
17	is	O
18	a	O
19	true	O
20	homolog	O
21	of	O
22	the	O
23	murine	B
24	STEP	I
25	gene	I
26	.	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	B
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O

1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O

1	The	O
2	present	O
3	study	O
4	was	O
5	designed	O
6	to	O
7	evaluate	O
8	the	O
9	sensitivity	O
10	and	O
11	specificity	O
12	of	O
13	AMP	O
14	CT	I
15	(	O
16	Gen	B
17	-	I
18	Probe	I
19	Incorporated	I
20	,	O
21	San	O
22	Diego	O
23	,	O
24	CA	O
25	,	O
26	USA	O
27	)	O
28	on	O
29	urogenital	O
30	specimens	O
31	taken	O
32	from	O
33	symptomatic	O
34	patients	O
35	and	O
36	on	O
37	first	O
38	void	O
39	urine	O
40	(	O
41	FVU	O
42	)	O
43	specimens	O
44	from	O
45	asymptomatic	O
46	patients	O
47	.	O

1	Regarding	O
2	"	O
3	the	O
4	relation	O
5	between	O
6	sexual	O
7	orientation	O
8	and	O
9	penile	O
10	size	O
11	,"	O
12	by	O
13	A	O
14	.	O

1	Hepatitis	O
2	B	O
3	virus	O
4	and	O
5	hepatoma	O
6	.	O

1	Electronic	O
2	data	O
3	processing	O
4	(	O
5	EDP	O
6	)	O
7	latex	O
8	immunoassay	O
9	using	O
10	anti	B
11	-	I
12	human	I
13	seminal	I
14	acid	I
15	phosphatase	I
16	(	O
17	anti	B
18	-	I
19	HSAP	I
20	)	O
21	immune	O
22	serum	O
23	was	O
24	applied	O
25	for	O
26	the	O
27	species	O
28	and	O
29	organ	O
30	identification	O
31	of	O
32	human	O
33	seminal	O
34	stains	O
35	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	O
7	N2417	I
8	and	O
9	N2403	O
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	B
22	maltosa	I
23	cycloheximide	I
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	B
30	interleukin	I
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	overall	O
6	chance	O
7	that	O
8	a	O
9	patient	O
10	would	O
11	undergo	O
12	ET	O
13	was	O
14	greater	O
15	in	O
16	a	O
17	cycle	O
18	in	O
19	which	O
20	more	O
21	than	O
22	one	O
23	follicle	O
24	20	O
25	mm	O
26	or	O
27	larger	O
28	was	O
29	developing	O
30	than	O
31	in	O
32	a	O
33	cycle	O
34	in	O
35	which	O
36	a	O
37	single	O
38	large	O
39	follicle	O
40	was	O
41	developing	O
42	.	O

1	For	O
2	replication	O
3	reporter	O
4	constructs	O
5	where	O
6	E1	B
7	and	O
8	E2	B
9	are	O
10	supplied	O
11	in	O
12	trans	O
13	by	O
14	the	O
15	respective	O
16	expression	O
17	vectors	O
18	,	O
19	distance	O
20	between	O
21	the	O
22	half	O
23	sites	O
24	seems	O
25	to	O
26	play	O
27	a	O
28	major	O
29	role	O
30	,	O
31	yet	O
32	the	O
33	phasing	O
34	relationships	O
35	are	O
36	measurable	O
37	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	rep	B
6	strongly	O
7	enhances	O
8	the	O
9	function	O
10	of	O
11	negative	O
12	regulatory	O
13	elements	O
14	of	O
15	the	O
16	LTR	B
17	.	O

1	Development	O
2	of	O
3	a	O
4	yeast	O
5	system	O
6	to	O
7	assay	O
8	mutational	O
9	specificity	O
10	.	O

1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	O
6	in	O
7	the	O
8	decrease	O
9	in	O
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	O
19	and	O
20	alpha	B
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	B
31	-	I
32	treated	O
33	group	O
34	.	O

1	Three	O
2	sequence	O
3	elements	O
4	are	O
5	shown	O
6	to	O
7	be	O
8	required	O
9	for	O
10	accurate	O
11	and	O
12	efficient	O
13	transcription	O
14	termination	O
15	by	O
16	RNA	B
17	polymerase	I
18	I	I
19	(	O
20	pol	B
21	I	I
22	)	O
23	assayed	O
24	both	O
25	in	O
26	a	O
27	cell	O
28	-	O
29	free	O
30	transcription	O
31	system	O
32	and	O
33	in	O
34	vivo	O
35	after	O
36	transfection	O
37	of	O
38	rDNA	O
39	minigene	O
40	constructs	I
41	into	O
42	3T6	O
43	cells	O
44	.	O

1	Salient	O
2	applications	O
3	of	O
4	PB	O
5	-	I
6	PK	I
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	METHODS	O
2	:	O
3	We	O
4	obtained	O
5	maximal	O
6	inspiratory	O
7	and	O
8	expiratory	O
9	flow	O
10	-	O
11	volume	O
12	curves	O
13	in	O
14	41	O
15	unselected	O
16	patients	O
17	with	O
18	essential	O
19	tremor	O
20	(	O
21	14	O
22	males	O
23	,	O
24	27	O
25	females	O
26	,	O
27	age	O
28	61	O
29	.	O
30	7	O
31	+/-	O
32	2	O
33	.	O
34	14	O
35	years	O
36	).	O

1	Plethysmographic	O
2	technique	O
3	and	O
4	indirect	O
5	blood	O
6	pressure	O
7	recordings	O
8	were	O
9	used	O
10	.	O

1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	B
7	,	O
8	the	O
9	ppg1	B
10	gene	I
11	product	I
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O

1	SPECT	O
2	examination	O
3	of	O
4	the	O
5	TMJ	O
6	using	O
7	99m	O
8	Tc	O
9	-	O
10	MDP	O
11	was	O
12	performed	O
13	in	O
14	43	O
15	patients	O
16	with	O
17	arthrographically	O
18	proven	O
19	anterior	O
20	dislocation	O
21	of	O
22	the	O
23	disc	O
24	and	O
25	in	O
26	30	O
27	normals	O
28	.	O

1	Rabbits	O
2	developed	O
3	profound	O
4	hypocalcemia	O
5	,	O
6	with	O
7	levels	O
8	falling	O
9	from	O
10	15	O
11	.	O
12	5	O
13	+/-	O
14	0	O
15	.	O
16	2	O
17	to	O
18	7	O
19	.	O
20	6	O
21	+/-	O
22	0	O
23	.	O
24	4	O
25	mg	O
26	/	O
27	dl	O
28	under	O
29	the	O
30	influence	O
31	of	O
32	TSST	B
33	-	I
34	1	I
35	.	O

1	Phase	O
2	II	O
3	study	O
4	of	O
5	VP	O
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O

1	BACKGROUND	O
2	:	O
3	Defensins	O
4	,	O
5	also	O
6	known	O
7	as	O
8	human	O
9	neutrophil	O
10	peptides	I
11	,	O
12	are	O
13	antimicrobial	O
14	peptides	O
15	present	O
16	in	O
17	the	O
18	azurophil	O
19	granules	O
20	of	O
21	neutrophils	O
22	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	O
22	pause	O
23	region	O
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	I
65	IRFs	B
66	)	I
67	nuclear	I
68	proteins	I
69	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Limited	O
5	Joint	O
6	Mobility	O
7	(	O
8	LJM	O
9	)	O
10	in	O
11	diabetes	O
12	is	O
13	unknown	O
14	,	O
15	but	O
16	the	O
17	abnormality	O
18	is	O
19	said	O
20	to	O
21	be	O
22	associated	O
23	with	O
24	an	O
25	increased	O
26	incidence	O
27	of	O
28	microangiopathy	O
29	.	O

1	Comparative	O
2	mapping	O
3	of	O
4	the	O
5	Brassica	B
6	S	I
7	locus	I
8	region	I
9	and	O
10	its	O
11	homeolog	O
12	in	O
13	Arabidopsis	O
14	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	Transient	O
2	co	O
3	-	O
4	transfection	O
5	assays	O
6	involving	O
7	NFKB2	O
8	expression	O
9	vectors	O
10	and	O
11	kappa	B
12	B	I
13	-	I
14	driven	O
15	reporter	O
16	plasmids	O
17	indicate	O
18	that	O
19	NFKB2	B
20	p85	I
21	has	O
22	lost	O
23	the	O
24	transcriptional	O
25	repressor	O
26	functions	O
27	typical	O
28	of	O
29	normal	O
30	NFKB2	B
31	p52	I
32	.	O

1	Ceftazidime	O
2	shows	O
3	promise	O
4	as	O
5	single	O
6	-	O
7	agent	O
8	therapy	O
9	for	O
10	serious	O
11	gram	O
12	-	O
13	negative	O
14	bacillary	O
15	infections	O
16	.	O

1	During	O
2	conventional	O
3	hemofiltration	O
4	using	O
5	substitution	O
6	fluid	O
7	with	O
8	a	O
9	Na	O
10	+	O
11	concentration	O
12	of	O
13	140	O
14	mEq	O
15	/	O
16	L	O
17	,	O
18	a	O
19	decrease	O
20	in	O
21	extracellular	O
22	fluid	O
23	volume	O
24	was	O
25	noted	O
26	whereas	O
27	the	O
28	intracellular	O
29	fluid	O
30	volume	O
31	was	O
32	unaltered	O
33	.	O

1	We	O
2	examined	O
3	behavioral	O
4	alterations	O
5	in	O
6	the	O
7	brown	O
8	cockroach	O
9	,	O
10	Periplaneta	O
11	brunnea	O
12	,	O
13	infected	O
14	with	O
15	the	O
16	acanthocephalan	B
17	,	O
18	Moniliformis	B
19	moniliformis	I
20	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	complete	O
7	structure	O
8	of	O
9	the	O
10	human	B
11	topoisomerase	I
12	IIalpha	I
13	gene	I
14	,	O
15	which	O
16	consists	O
17	of	O
18	35	O
19	exons	O
20	spanning	O
21	27	O
22	.	O
23	5	O
24	kb	O
25	.	O

1	In	O
2	doses	O
3	of	O
4	0	O
5	.	O
6	03	O
7	-	O
8	0	O
9	.	O
10	3	O
11	mg	O
12	/	O
13	kg	O
14	i	O
15	.	O
16	v	O
17	.,	O
18	SG	O
19	-	O
20	75	O
21	did	O
22	not	O
23	significantly	O
24	affect	O
25	pulse	O
26	pressure	O
27	,	O
28	heart	O
29	rate	O
30	,	O
31	aortic	O
32	blood	O
33	flow	O
34	,	O
35	left	O
36	ventricular	O
37	pressure	O
38	(	O
39	LVP	O
40	)	O
41	and	O
42	LVdP	O
43	/	O
44	dt	O
45	max	O
46	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	Ca	O
6	entry	O
7	blocker	O
8	nitrendipine	O
9	,	O
10	the	O
11	antioxidant	B
12	superoxide	I
13	dismutase	I
14	(	O
15	SOD	B
16	),	O
17	and	O
18	a	O
19	combination	O
20	of	O
21	nitrendipine	B
22	and	O
23	superoxide	B
24	dismutase	I
25	on	O
26	postischemic	B
27	renal	O
28	function	O
29	was	O
30	studied	O
31	in	O
32	four	O
33	groups	O
34	(	O
35	n	O
36	=	O
37	24	O
38	)	O
39	of	O
40	rats	O
41	.	O

1	Therefore	O
2	,	O
3	we	O
4	studied	O
5	ninety	O
6	coagulopathic	O
7	patients	O
8	with	O
9	the	O
10	aim	O
11	of	O
12	determining	O
13	the	O
14	prevalence	O
15	of	O
16	hepatitis	O
17	C	O
18	virus	O
19	(	O
20	HCV	O
21	)	O
22	antibodies	O
23	using	O
24	the	O
25	ELISA	O
26	and	O
27	RIBA	O
28	methods	O
29	.	O

1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	O
14	agents	O
15	(	O
16	apomorphine	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	piribedil	O
22	,	O
23	rye	B
24	-	I
25	ergot	O
26	derivatives	I
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	pharmacological	O
38	properties	O
39	.	O

1	In	O
2	the	O
3	artificial	O
4	lung	O
5	,	O
6	like	O
7	in	O
8	the	O
9	natural	O
10	lung	O
11	and	O
12	peripheral	O
13	tissues	O
14	,	O
15	gas	O
16	exchanges	O
17	depend	O
18	on	O
19	several	O
20	parameters	O
21	:	O
22	blood	O
23	inlet	O
24	conditions	O
25	,	O
26	blood	O
27	flow	O
28	rate	O
29	,	O
30	temperature	O
31	,	O
32	composition	O
33	of	O
34	the	O
35	gas	O
36	mixture	O
37	used	O
38	for	O
39	ventilation	O
40	,	O
41	blood	O
42	tissue	O
43	perfusion	O
44	,	O
45	O2	O
46	consumption	O
47	,	O
48	etc	O
49	.	O

1	Bailey	B
2	Instruments	I
3	and	O
4	Owen	B
5	Mumford	I
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	KRN2391	O
2	and	O
3	cromakalim	O
4	produced	O
5	a	O
6	dose	O
7	-	O
8	dependent	O
9	increase	O
10	in	O
11	aortic	O
12	and	O
13	coronary	O
14	blood	O
15	flow	O
16	.	O

1	Thus	O
2	,	O
3	IHHNV	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	densoviruses	O
9	of	O
10	the	O
11	genus	O
12	Brevidensovirus	O
13	in	O
14	the	O
15	family	O
16	Parvoviridae	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	rename	B
24	this	O
25	virus	B
26	Penaeus	I
27	stylirostris	I
28	densovirus	I
29	(	O
30	PstDNV	B
31	).	O

1	APETALA3	B
2	transcripts	I
3	are	O
4	first	O
5	detected	O
6	in	O
7	a	O
8	meristematic	O
9	region	O
10	that	O
11	will	O
12	give	O
13	rise	O
14	to	O
15	the	O
16	petal	B
17	and	O
18	stamen	B
19	primordia	I
20	,	O
21	and	O
22	expression	O
23	is	O
24	maintained	O
25	in	O
26	this	O
27	region	O
28	during	O
29	subsequent	O
30	development	O
31	of	O
32	these	O
33	organs	O
34	.	O

1	Proximal	B
2	CBD	I
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	However	O
2	,	O
3	the	O
4	element	O
5	proximal	O
6	to	O
7	the	O
8	transcription	O
9	start	O
10	site	O
11	is	O
12	dependent	O
13	on	O
14	the	O
15	SRE	O
16	-	O
17	1	O
18	.	O

1	Here	O
2	the	O
3	cloning	O
4	and	O
5	molecular	O
6	analysis	O
7	of	O
8	the	O
9	Zm	B
10	-	I
11	ERabp1	I
12	,	O
13	Zm	B
14	-	I
15	ERabp4	I
16	,	O
17	and	O
18	Zm	B
19	-	I
20	ERabp5	I
21	genes	I
22	is	O
23	presented	O
24	.	O

1	The	O
2	human	B
3	RAD30B	I
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	B
21	LRR	I
22	.	O

1	The	O
2	proliferation	O
3	potential	O
4	protein	O
5	-	O
6	related	O
7	(	O
8	P2P	B
9	-	I
10	R	I
11	)	O
12	gene	O
13	with	O
14	domains	O
15	encoding	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoprotein	O
19	association	O
20	and	O
21	Rb1	B
22	binding	O
23	shows	O
24	repressed	O
25	expression	O
26	during	O
27	terminal	O
28	differentiation	O
29	.	O

1	Five	O
2	healthy	O
3	male	O
4	subjects	O
5	inspired	O
6	air	O
7	for	O
8	20	O
9	min	O
10	and	O
11	then	O
12	5	O
13	%	O
14	CO2	O
15	/	O
16	95	O
17	%	O
18	O2	O
19	for	O
20	30	O
21	min	O
22	,	O
23	of	O
24	which	O
25	the	O
26	first	O
27	10	O
28	min	O
29	was	O
30	used	O
31	to	O
32	achieve	O
33	a	O
34	steady	O
35	-	O
36	state	O
37	end	O
38	-	O
39	tidal	O
40	CO2	O
41	measurement	O
42	.	O

1	255	O
2	-	O
3	61	O
4	.	O

1	SETTING	O
2	:	O
3	University	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	tertiary	O
9	care	O
10	infertility	O
11	center	O
12	.	O

1	It	O
2	was	O
3	shown	O
4	that	O
5	administration	O
6	of	O
7	immunomodulator	B
8	neurotropin	I
9	(	O
10	NSP	B
11	)	O
12	results	O
13	in	O
14	more	O
15	steady	O
16	consolidation	O
17	and	O
18	retention	O
19	of	O
20	feeding	O
21	and	O
22	avoidance	O
23	behavior	O
24	,	O
25	and	O
26	some	O
27	neurophysiological	O
28	mechanisms	O
29	of	O
30	that	O
31	phenomena	O
32	were	O
33	revealed	O
34	.	O

1	Is	O
2	nisoldipine	O
3	capable	O
4	of	O
5	reducing	O
6	left	O
7	ventricular	O
8	preload	O
9	?	O
10	In	O
11	ten	O
12	anesthetized	O
13	pigs	O
14	,	O
15	nisoldipine	O
16	(	O
17	2	O
18	-	O
19	4	O
20	micrograms	O
21	X	O
22	kg	O
23	-	O
24	1	O
25	X	O
26	min	O
27	-	O
28	1	O
29	),	O
30	a	O
31	calcium	O
32	channel	O
33	blocker	O
34	structurally	O
35	related	O
36	to	O
37	nifedipine	O
38	,	O
39	reduced	O
40	left	O
41	ventricular	O
42	systolic	O
43	pressure	O
44	(	O
45	40	O
46	%)	O
47	and	O
48	systemic	O
49	vascular	O
50	resistance	O
51	(	O
52	35	O
53	%),	O
54	whereas	O
55	maxLVdP	O
56	/	O
57	dt	O
58	decreased	O
59	by	O
60	20	O
61	%	O
62	and	O
63	cardiac	O
64	output	O
65	was	O
66	unchanged	O
67	.	O

1	Reversal	O
2	of	O
3	the	O
4	increase	O
5	in	O
6	apomorphine	O
7	-	O
8	induced	O
9	stereotypy	O
10	and	O
11	aggression	O
12	in	O
13	REM	O
14	sleep	O
15	deprived	O
16	rats	O
17	by	O
18	dopamine	O
19	agonist	O
20	pretreatments	O
21	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	,	O
9	the	O
10	oncoprotein	O
11	of	O
12	the	O
13	avian	B
14	retrovirus	I
15	Rev	I
16	-	I
17	T	I
18	,	O
19	can	O
20	increase	O
21	expression	O
22	from	O
23	promoters	O
24	containing	O
25	binding	O
26	sites	O
27	for	O
28	the	O
29	cellular	B
30	transcription	I
31	factor	I
32	Sp1	I
33	in	O
34	chicken	O
35	embryo	O
36	fibroblasts	O
37	(	O
38	S	O
39	.	O

1	Extracellular	O
2	-	O
3	regulated	O
4	kinase	I
5	(	O
6	ERK	B
7	)	O
8	activation	O
9	and	O
10	molecular	O
11	coupling	O
12	of	O
13	the	O
14	adaptor	B
15	proteins	I
16	p130	I
17	Crk	I
18	-	I
19	associated	O
20	substrate	O
21	(	O
22	CAS	B
23	)	O
24	and	O
25	c	B
26	-	I
27	CrkII	I
28	(	O
29	Crk	B
30	)	O
31	represent	O
32	two	O
33	distinct	O
34	pathways	O
35	that	O
36	induce	O
37	cell	O
38	invasion	O
39	and	O
40	protect	O
41	cells	O
42	from	O
43	apoptosis	O
44	in	O
45	a	O
46	three	O
47	-	O
48	dimensional	O
49	collagen	B
50	matrix	I
51	.	O

1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	B
26	,	O
27	and	O
28	H11	O
29	.	O

1	The	O
2	hematopoietic	B
3	colony	I
4	-	I
5	stimulating	I
6	factors	I
7	(	O
8	CSF	B
9	)	O
10	have	O
11	been	O
12	introduced	O
13	into	O
14	clinical	O
15	practice	O
16	as	O
17	additional	O
18	supportive	O
19	measures	O
20	that	O
21	can	O
22	reduce	O
23	the	O
24	incidence	O
25	of	O
26	infectious	O
27	complications	O
28	in	O
29	patients	O
30	with	O
31	cancer	O
32	and	O
33	neutropenia	O
34	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	I
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	Some	O
2	reflexions	O
3	apropos	O
4	of	O
5	a	O
6	personal	O
7	statistical	O
8	study	O
9	of	O
10	513	O
11	arterial	O
12	embolisms	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	However	O
2	,	O
3	no	O
4	genetic	O
5	alteration	O
6	was	O
7	detected	O
8	in	O
9	any	O
10	of	O
11	the	O
12	cancers	O
13	examined	O
14	.	O

1	Controlled	O
2	versus	O
3	uncontrolled	O
4	reperfusion	O
5	of	O
6	ischemic	O
7	myocardium	O
8	after	O
9	experimental	O
10	coronary	O
11	artery	O
12	occlusion	O
13	was	O
14	studied	O
15	to	O
16	determine	O
17	the	O
18	effect	O
19	on	O
20	regional	O
21	ventricular	O
22	wall	O
23	motion	O
24	and	O
25	associated	O
26	biochemical	O
27	alterations	O
28	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O

1	The	O
2	murine	O
3	chromosomal	O
4	locations	O
5	of	O
6	the	O
7	five	O
8	NMDA	B
9	receptor	I
10	channel	O
11	subunits	O
12	,	O
13	the	O
14	epsilon	B
15	1	I
16	(	O
17	Grin2a	B
18	),	O
19	epsilon	B
20	2	I
21	(	O
22	Grin2b	B
23	),	O
24	epsilon	B
25	3	I
26	(	O
27	Grin2c	B
28	),	O
29	epsilon	B
30	4	I
31	(	I
32	Grin2d	B
33	)	I
34	and	O
35	zeta	B
36	1	I
37	(	O
38	Grinl	B
39	)	O
40	subunits	O
41	,	O
42	were	O
43	determined	O
44	using	O
45	an	O
46	interspecific	O
47	backcross	O
48	mapping	O
49	panel	O
50	derived	O
51	from	O
52	crosses	O
53	of	O
54	[(	B
55	C57BL	O
56	/	O
57	6JxM	B
58	.	O
59	spretus	O
60	)	O
61	F1xC57BL	O
62	/	O
63	6J	O
64	]	O
65	mice	O
66	.	O

1	(	O
2	iv	O
3	)	O
4	The	O
5	accumulation	O
6	of	O
7	cyclin	B
8	D3	I
9	protein	I
10	in	O
11	Vero	O
12	cells	O
13	infected	O
14	with	O
15	an	O
16	alpha0	B
17	deletion	O
18	mutant	O
19	was	O
20	reduced	O
21	relative	O
22	to	O
23	that	O
24	of	O
25	cells	O
26	infected	O
27	with	O
28	wild	O
29	-	O
30	type	O
31	virus	O
32	or	O
33	a	O
34	recombinant	O
35	virus	O
36	in	O
37	which	O
38	the	O
39	deleted	O
40	alpha0	O
41	sequences	O
42	were	O
43	restored	O
44	.	O

1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O

1	A	O
2	single	O
3	rectal	O
4	dose	O
5	of	O
6	25	O
7	mg	O
8	/	O
9	kg	O
10	will	O
11	obtain	O
12	this	O
13	lower	O
14	concentration	O
15	within	O
16	1	O
17	h	O
18	of	O
19	administration	O
20	and	O
21	maintain	O
22	it	O
23	for	O
24	up	O
25	to	O
26	6	O
27	h	O
28	.	O

1	Circularized	B
2	Ac	I
3	/	O
4	Ds	B
5	transposons	I
6	:	O
7	formation	O
8	,	O
9	structure	O
10	and	O
11	fate	O
12	.	O

1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	O
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O

1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O

1	When	O
2	ligated	O
3	to	O
4	the	O
5	proIL	B
6	-	I
7	1	I
8	beta	I
9	cap	I
10	site	O
11	-	O
12	proximal	O
13	region	O
14	(	O
15	located	O
16	between	O
17	-	O
18	131	O
19	to	O
20	+	O
21	12	O
22	),	O
23	both	O
24	the	O
25	proIL	B
26	-	I
27	1	I
28	beta	I
29	and	O
30	the	O
31	simian	B
32	virus	I
33	40	I
34	enhancer	I
35	elements	I
36	functioned	O
37	more	O
38	efficiently	O
39	in	O
40	monocytes	O
41	than	O
42	in	O
43	HeLa	O
44	cells	O
45	,	O
46	which	O
47	are	O
48	not	O
49	normally	O
50	competent	O
51	for	O
52	IL	B
53	-	I
54	1	I
55	beta	I
56	expression	O
57	.	O

1	In	O
2	Xenopus	O
3	,	O
4	BMPs	O
5	act	O
6	as	O
7	epidermal	B
8	inducers	I
9	and	O
10	also	O
11	as	O
12	negative	O
13	regulators	O
14	of	O
15	neurogenesis	O
16	.	O

1	The	O
2	physicians	O
3	in	O
4	charge	O
5	of	O
6	all	O
7	patients	O
8	with	O
9	evidence	O
10	of	O
11	acute	O
12	Q	O
13	fever	O
14	(	O
15	seroconversion	O
16	and	O
17	/	O
18	or	O
19	presence	O
20	of	O
21	IgM	B
22	)	O
23	or	O
24	chronic	O
25	Q	O
26	fever	O
27	(	O
28	prolonged	O
29	disease	O
30	and	O
31	/	O
32	or	O
33	IgG	B
34	antibody	O
35	titer	O
36	to	O
37	phase	O
38	I	O
39	of	O
40	Coxiella	O
41	burnetii	O
42	>	O
43	or	O
44	=	O
45	800	O
46	)	O
47	were	O
48	asked	O
49	to	O
50	complete	O
51	a	O
52	questionnaire	O
53	,	O
54	which	O
55	was	O
56	computerized	O
57	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	such	O
6	lesions	O
7	in	O
8	two	O
9	cases	O
10	were	O
11	evaluated	O
12	by	O
13	ultrasonography	O
14	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	The	O
2	similar	O
3	phenotypes	O
4	of	O
5	bur6	B
6	and	O
7	bur3	B
8	(	O
9	mot1	B
10	)	O
11	mutations	O
12	suggest	O
13	that	O
14	Bur6p	B
15	and	O
16	Mot1p	B
17	have	O
18	related	O
19	,	O
20	but	O
21	not	O
22	identical	O
23	,	O
24	functions	O
25	in	O
26	modulating	O
27	the	O
28	activity	O
29	of	O
30	the	O
31	general	O
32	transcription	O
33	machinery	O
34	in	O
35	vivo	O
36	.	O

1	A	O
2	study	O
3	of	O
4	human	B
5	genes	O
6	coding	O
7	for	O
8	U4	B
9	small	O
10	nuclear	O
11	RNA	O
12	is	O
13	presented	O
14	.	O

1	Determination	O
2	of	O
3	20	B
4	alpha	I
5	-	I
6	hydroxy	I
7	-	I
8	9	I
9	beta	I
10	,	O
11	10	O
12	alpha	I
13	-	I
14	pregna	I
15	-	I
16	4	I
17	,	O
18	6	O
19	-	O
20	dien	O
21	-	O
22	3	O
23	-	O
24	one	O
25	in	O
26	plasma	O
27	by	O
28	selected	O
29	ion	O
30	monitoring	O
31	.	O

1	Both	O
2	NUP98	B
3	-	O
4	HOXA9	O
5	chimeras	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	HOXA9	O
17	domains	O
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	PBX	O
23	interaction	O
24	.	O

1	Further	O
2	outbreaks	O
3	of	O
4	ocular	O
5	disease	O
6	in	O
7	farmed	O
8	red	O
9	deer	O
10	calves	O
11	caused	O
12	by	O
13	HVC	B
14	-	I
15	1	I
16	were	O
17	investigated	O
18	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	The	O
2	strong	O
3	conservation	O
4	of	O
5	the	O
6	inverted	O
7	terminal	O
8	repeat	O
9	sequence	O
10	may	O
11	reflect	O
12	a	O
13	common	O
14	integration	O
15	mechanism	O
16	for	O
17	VL30	O
18	elements	O
19	and	O
20	MuLV	O
21	proviruses	O
22	.	O

1	A	O
2	full	O
3	-	I
4	length	I
5	human	I
6	pim	I
7	-	I
8	1	I
9	cDNA	I
10	was	O
11	subcloned	O
12	into	O
13	the	O
14	bacterial	O
15	vector	O
16	pGEX	O
17	-	O
18	2T	O
19	and	O
20	the	O
21	Pim	B
22	-	I
23	1	I
24	protein	O
25	expressed	O
26	as	O
27	a	O
28	fusion	O
29	product	O
30	with	O
31	bacterial	B
32	glutathione	I
33	S	I
34	-	I
35	transferase	I
36	(	O
37	GST	B
38	).	O

1	Moreover	O
2	,	O
3	it	O
4	also	O
5	discusses	O
6	the	O
7	effects	O
8	of	O
9	antihypertensive	O
10	drugs	O
11	currently	O
12	regarded	O
13	as	O
14	first	O
15	-	O
16	choice	O
17	agents	O
18	,	O
19	i	O
20	.	O
21	e	O
22	.	O
23	calcium	O
24	antagonists	O
25	and	O
26	the	O
27	angiotensin	B
28	converting	I
29	enzyme	O
30	inhibitors	O
31	,	O
32	on	O
33	intrarenal	O
34	hemodynamics	O
35	.	O

1	Unlike	O
2	the	O
3	MAR	O
4	-	O
5	binding	O
6	domain	O
7	,	O
8	the	O
9	homeodomain	B
10	when	O
11	isolated	O
12	binds	O
13	poorly	O
14	and	O
15	with	O
16	low	O
17	specificity	O
18	to	O
19	DNA	O
20	.	O

1	Skin	O
2	pH	O
3	changes	O
4	associated	O
5	with	O
6	iontophoresis	O
7	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	O
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	B
25	factor	I
26	mitogenic	O
27	signals	O
28	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	The	O
2	negative	O
3	calcium	O
4	balance	O
5	with	O
6	hyperparathyroidemia	O
7	occurred	O
8	after	O
9	continuous	O
10	oral	O
11	administration	O
12	of	O
13	Cd	O
14	and	O
15	developed	O
16	via	O
17	increased	O
18	urinary	O
19	excretion	O
20	of	O
21	calcium	O
22	.	O

1	This	O
2	rapid	O
3	and	O
4	extensive	O
5	penetration	O
6	of	O
7	intrathecally	O
8	administered	O
9	chemotherapy	O
10	may	O
11	offer	O
12	insight	O
13	into	O
14	the	O
15	myelopathy	O
16	observed	O
17	with	O
18	these	O
19	treatments	O
20	.	O

1	MS	O
2	characteristics	O
3	of	O
4	coumarins	O
5	,	O
6	psoralens	O
7	and	O
8	polymethoxylated	O
9	flavones	O
10	with	O
11	different	O
12	substitution	O
13	patterns	O
14	were	O
15	determined	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	the	O
21	response	O
22	obtained	O
23	with	O
24	the	O
25	APcI	O
26	interface	O
27	.	O

1	Many	O
2	mammary	O
3	tumors	O
4	induced	O
5	by	O
6	mouse	O
7	mammary	O
8	tumor	O
9	virus	O
10	(	O
11	MMTV	O
12	)	O
13	contain	O
14	a	O
15	provirus	O
16	in	O
17	the	O
18	same	O
19	region	O
20	of	O
21	the	O
22	host	O
23	-	O
24	cell	O
25	genome	O
26	,	O
27	leading	O
28	to	O
29	expression	O
30	of	O
31	a	O
32	putative	O
33	cellular	B
34	oncogene	I
35	called	O
36	int	B
37	-	I
38	1	I
39	.	O

1	The	O
2	serum	B
3	erythropoietin	I
4	(	O
5	EPO	B
6	)	O
7	concentrations	O
8	of	O
9	15	O
10	male	O
11	triathletes	O
12	(	O
13	26	O
14	.	O
15	3	O
16	U	O
17	.	O
18	ml	O
19	-	O
20	1	O
21	)	O
22	were	O
23	significantly	O
24	lower	O
25	than	O
26	those	O
27	of	O
28	45	O
29	male	O
30	distance	O
31	runners	O
32	(	O
33	31	O
34	.	O
35	6	O
36	U	O
37	.	O
38	ml	O
39	-	O
40	1	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	).	O

1	Dilutions	O
2	of	O
3	H	B
4	-	I
5	2b	I
6	or	O
7	H	B
8	-	I
9	2d	I
10	NP	O
11	peptides	O
12	indicated	O
13	that	O
14	3	B
15	-	I
16	4	I
17	logs	I
18	less	O
19	H	B
20	-	I
21	2b	I
22	NP	I
23	peptide	I
24	was	O
25	required	O
26	to	O
27	sensitize	O
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	B
44	-	I
45	2b	I
46	and	O
47	H	B
48	-	I
49	2d	I
50	major	I
51	histocompatibility	I
52	complex	I
53	molecules	O
54	for	O
55	their	O
56	peptides	O
57	likely	O
58	account	O
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	B
69	-	O
70	2b	I
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O

1	Effects	O
2	of	O
3	estrogen	O
4	and	O
5	glucocorticoids	O
6	on	O
7	the	O
8	adrenal	O
9	development	O
10	of	O
11	the	O
12	fetus	O
13	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	O
35	ID	B
36	ANA	I
37	II	I
38	panel	O
39	.	O

1	Normal	O
2	alpha1	B
3	(	O
4	I	B
5	)	I
6	collagen	B
7	mRNA	I
8	showed	O
9	no	O
10	significant	O
11	reduction	O
12	when	O
13	AR	B
14	or	O
15	IR	B
16	was	O
17	expressed	O
18	from	O
19	the	O
20	pHbetaAPr	B
21	-	I
22	1	I
23	-	I
24	neo	I
25	vector	O
26	and	O
27	a	O
28	small	O
29	(	O
30	10	O
31	-	O
32	20	O
33	%)	O
34	but	O
35	significant	O
36	reduction	O
37	when	O
38	either	O
39	ribozyme	O
40	was	O
41	expressed	O
42	from	O
43	the	O
44	pCI	B
45	.	O
46	neo	B
47	vector	O
48	.	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	mouse	B
10	Elavl1	I
11	(	I
12	mHuA	B
13	)	I
14	gene	I
15	reveals	O
16	a	O
17	transcriptional	O
18	regulatory	O
19	element	O
20	and	O
21	evidence	O
22	for	O
23	conserved	O
24	genomic	O
25	organization	O
26	.	O
27	mHuA	B
28	(	O
29	Elavl1	B
30	)	O
31	belongs	O
32	to	O
33	a	O
34	highly	O
35	conserved	O
36	family	O
37	of	O
38	genes	O
39	encoding	O
40	RNA	B
41	-	I
42	binding	I
43	proteins	I
44	and	O
45	has	O
46	been	O
47	linked	O
48	to	O
49	cell	O
50	growth	O
51	and	O
52	proliferation	O
53	through	O
54	its	O
55	regulation	O
56	of	O
57	mRNA	O
58	stability	O
59	.	O

1	Anisotropic	B
2	heat	O
3	transport	O
4	in	O
5	the	O
6	octylcyanobiphenyl	B
7	(	O
8	8CB	B
9	)	O
10	liquid	O
11	crystal	O
12	.	O

1	Thus	O
2	,	O
3	it	O
4	was	O
5	confirmed	O
6	that	O
7	the	O
8	sodium	O
9	lauryl	O
10	sulfate	O
11	method	O
12	of	O
13	estimating	O
14	hemoglobin	B
15	concentration	O
16	is	O
17	an	O
18	appropriate	O
19	alternative	O
20	to	O
21	the	O
22	cyanmethemoglobin	O
23	method	O
24	and	O
25	avoids	O
26	the	O
27	generation	O
28	of	O
29	toxic	O
30	wastes	O
31	.	O

1	An	O
2	NF1	B
3	-	I
4	related	I
5	vitellogenin	I
6	activator	I
7	element	I
8	mediates	O
9	transcription	O
10	from	O
11	the	O
12	estrogen	B
13	-	O
14	regulated	O
15	Xenopus	B
16	laevis	I
17	vitellogenin	I
18	promoter	I
19	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	O
14	leukemia	O
15	factor	I
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	I
28	DBP	I
29	fusion	I
30	proteins	I
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Although	O
2	within	O
3	normal	O
4	limits	O
5	,	O
6	latency	O
7	was	O
8	high	O
9	.	O

1	This	O
2	c	B
3	-	I
4	Jun	I
5	activity	O
6	is	O
7	inhibited	O
8	by	O
9	c	B
10	-	I
11	Fos	I
12	,	O
13	another	O
14	protooncoprotein	O
15	that	O
16	can	O
17	dimerize	O
18	with	O
19	c	B
20	-	I
21	Jun	I
22	to	O
23	form	O
24	the	O
25	transcription	O
26	factor	I
27	AP	I
28	-	I
29	1	I
30	.	O

1	Mapping	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	allelic	O
14	to	O
15	the	O
16	ag	B
17	alpha	I
18	1	I
19	mutation	I
20	identified	O
21	previously	O
22	.	O

1	Human	B
2	antitetanus	I
3	serum	O
4	:	O
5	an	O
6	unused	B
7	wealth	I

1	Mutations	O
2	in	O
3	genes	O
4	encoding	O
5	PR65	B
6	/	I
7	A	I
8	subunits	I
9	have	O
10	been	O
11	identified	O
12	in	O
13	several	O
14	different	O
15	human	O
16	cancers	O
17	and	O
18	the	O
19	PP2A	B
20	inhibitor	O
21	,	O
22	termed	O
23	fostriecin	O
24	,	O
25	is	O
26	being	O
27	tested	O
28	as	O
29	an	O
30	anticancer	O
31	drug	O
32	.	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	B
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	Doppler	O
2	ultrasound	O
3	studies	O
4	of	O
5	long	O
6	-	O
7	term	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	children	O
13	with	O
14	hemolytic	O
15	-	O
16	uremic	O
17	syndrome	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	B
20	.	O
21	8Ss	I
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	Internal	O
2	modes	O
3	of	O
4	a	O
5	soliton	O
6	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	insulin	B
6	effect	O
7	to	O
8	increase	O
9	ras	B
10	GTP	I
11	formation	I
12	and	O
13	MAP	B
14	kinase	I
15	activity	O
16	was	O
17	negligible	O
18	in	O
19	A	O
20	/	O
21	K1018	O
22	cells	O
23	but	O
24	normal	O
25	,	O
26	or	O
27	supernormal	O
28	,	O
29	in	O
30	Y	O
31	/	O
32	F2	O
33	cells	O
34	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	'	O
6	morning	O
7	dip	O
8	'	O
9	observed	O
10	in	O
11	asthmatic	O
12	patients	O
13	cannot	O
14	simply	O
15	be	O
16	explained	O
17	by	O
18	changes	O
19	in	O
20	cell	O
21	receptor	O
22	number	O
23	or	O
24	affinity	O
25	,	O
26	as	O
27	our	O
28	results	O
29	suggest	O
30	that	O
31	both	O
32	groups	O
33	have	O
34	intact	O
35	beta	I
36	-	I
37	adrenoceptor	I
38	function	O
39	.	O

1	Observations	O
2	on	O
3	saccules	O
4	of	O
5	rats	O
6	exposed	O
7	to	O
8	long	O
9	-	O
10	term	O
11	hypergravity	O
12	.	O

1	Although	O
2	diagnostic	O
3	laparoscopy	O
4	is	O
5	still	O
6	considered	O
7	the	O
8	standard	O
9	reference	O
10	in	O
11	the	O
12	diagnosis	O
13	of	O
14	ectopic	O
15	pregnancy	O
16	(	O
17	EP	O
18	),	O
19	use	O
20	of	O
21	high	O
22	-	O
23	resolution	O
24	endovaginal	O
25	sonography	O
26	,	O
27	in	O
28	conjunction	O
29	with	O
30	qualitative	O
31	serum	O
32	assays	O
33	of	O
34	the	O
35	beta	B
36	subunit	I
37	of	I
38	human	I
39	chorionic	I
40	gonadotropin	I
41	(	O
42	beta	B
43	-	I
44	hCG	I
45	),	O
46	allows	O
47	detection	O
48	of	O
49	earlier	O
50	and	O
51	smaller	O
52	EPs	O
53	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	B
11	and	O
12	Escherichia	B
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	Therefore	O
2	,	O
3	the	O
4	results	O
5	indicate	O
6	that	O
7	repeated	O
8	exposure	O
9	to	O
10	amphetamine	O
11	or	O
12	apomorphine	O
13	overcomes	O
14	the	O
15	context	O
16	-	O
17	dependent	O
18	component	O
19	of	O
20	sensitization	O
21	of	O
22	amphetamine	O
23	-	O
24	or	O
25	apomorphine	O
26	-	O
27	induced	O
28	stereotyped	O
29	behavior	O
30	.	O

1	Thus	O
2	,	O
3	the	O
4	B	B
5	-	I
6	S	I
7	mutant	I
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	B
14	GAPDHs	I
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	O
58	GAPDH	O
59	.	O

1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	O
6	were	O
7	compared	O
8	in	O
9	elderly	O
10	female	O
11	runners	O
12	(	O
13	RU	O
14	:	O
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	O
47	-	O
48	1	O
49	min	O
50	-	O
51	1	O
52	,	O
53	mean	O
54	+/-	O
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	O
64	UT	O
65	:	O
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	O
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	O
82	26	O
83	+/-	O
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	O
90	-	O
91	1	O
92	).	O

1	Combined	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	and	O
8	p65	B
9	induced	O
10	vigorous	O
11	transcription	O
12	of	O
13	IL	B
14	-	I
15	2	I
16	promoter	I
17	-	I
18	and	O
19	CD28RE	O
20	-	O
21	driven	O
22	reporter	O
23	constructs	O
24	in	O
25	both	O
26	LFA	B
27	-	I
28	3	I
29	-	I
30	and	O
31	B7	B
32	-	I
33	1	I
34	-	I
35	costimulated	I
36	Jurkat	O
37	cells	O
38	.	O

1	Also	O
2	like	O
3	the	O
4	thrombin	B
5	receptor	I
6	,	O
7	PAR2	B
8	can	O
9	be	O
10	activated	O
11	by	O
12	the	O
13	hexapeptide	O
14	corresponding	O
15	to	O
16	its	O
17	tethered	O
18	ligand	O
19	sequence	O
20	independent	O
21	of	O
22	receptor	O
23	cleavage	O
24	.	O

1	Thus	O
2	,	O
3	the	O
4	synergistic	O
5	effects	O
6	of	O
7	HNF	B
8	-	I
9	1beta	I
10	and	O
11	the	O
12	GR	B
13	on	O
14	dexamethasone	O
15	-	O
16	stimulated	O
17	promoter	O
18	activity	O
19	require	O
20	that	O
21	they	O
22	are	O
23	bound	O
24	to	O
25	the	O
26	HNF	B
27	-	I
28	1	I
29	site	I
30	and	O
31	the	O
32	GRE	B
33	,	O
34	respectively	O
35	,	O
36	and	O
37	may	O
38	involve	O
39	protein	O
40	-	O
41	protein	O
42	interactions	O
43	between	O
44	the	O
45	transcription	O
46	factors	O
47	,	O
48	or	O
49	between	O
50	them	O
51	and	O
52	the	O
53	basal	O
54	transcription	O
55	machinery	O
56	or	O
57	a	O
58	steroid	B
59	receptor	I
60	coactivator	O
61	.	O

1	This	O
2	fragment	O
3	can	O
4	bind	O
5	several	O
6	trans	O
7	-	O
8	acting	O
9	factors	O
10	in	O
11	vitro	O
12	,	O
13	including	O
14	GATA	B
15	-	I
16	1	I
17	and	O
18	members	O
19	of	O
20	the	O
21	Ets	B
22	family	I
23	.	O

1	Alternative	O
2	processing	O
3	of	O
4	the	O
5	tryptophanyl	B
6	-	I
7	tRNA	I
8	synthetase	I
9	mRNA	I
10	from	O
11	interferon	B
12	-	I
13	treated	O
14	human	O
15	cells	O
16	.	O

1	Modern	O
2	cancer	O
3	therapy	O
4	has	O
5	included	O
6	surgery	O
7	,	O
8	radiotherapy	O
9	,	O
10	chemotherapy	O
11	,	O
12	and	O
13	most	O
14	recently	O
15	,	O
16	immunotherapy	O
17	and	O
18	hyperthermia	O
19	.	O

1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	B
6	EGFR	B
7	/	I
8	ErbB	I
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	I
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	B
9	Dsg	I
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	with	O
6	each	O
7	of	O
8	these	O
9	sequences	O
10	demonstrated	O
11	complexes	O
12	with	O
13	mobilities	O
14	identical	O
15	to	O
16	those	O
17	of	O
18	the	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	site	I
24	from	O
25	the	O
26	kappa	B
27	light	I
28	-	I
29	chain	I
30	gene	I
31	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	B
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	O
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	The	O
2	protein	O
3	predicted	O
4	by	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	human	B
10	pim	I
11	-	I
12	1	I
13	proto	I
14	-	I
15	oncogene	I
16	shares	O
17	extensive	O
18	homology	O
19	with	O
20	known	O
21	serine	B
22	/	I
23	threonine	I
24	protein	I
25	kinases	I
26	,	O
27	and	O
28	yet	O
29	the	O
30	human	B
31	Pim	I
32	-	I
33	1	I
34	enzyme	O
35	has	O
36	previously	O
37	been	O
38	reported	O
39	to	O
40	exhibit	O
41	protein	O
42	tyrosine	O
43	kinase	I
44	activity	O
45	both	O
46	in	O
47	vitro	O
48	and	O
49	in	O
50	vivo	O
51	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	O
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	O
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	O
7	-	O
8	1	O
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	O
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	B
29	templates	O
30	.	O

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	ORF	O
2	2	O
3	potentially	O
4	encoded	O
5	a	O
6	hydrophobic	O
7	protein	O
8	of	O
9	29	O
10	,	O
11	705	O
12	Da	O
13	with	O
14	six	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	regions	O
20	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	O
24	transcriptosomal	I
25	component	O
26	scaffold	O
27	attachment	O
28	factor	B
29	B	I
30	,	O
31	and	O
32	the	O
33	68	O
34	-	O
35	kDa	O
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	B
22	homolog	I
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O

1	Anti	B
2	-	I
3	HBc	I
4	production	O
5	of	O
6	PBMC	O
7	was	O
8	enhanced	O
9	remarkably	O
10	in	O
11	this	O
12	case	O
13	.	O

1	High	O
2	-	O
3	resolution	O
4	structure	O
5	of	O
6	the	O
7	diphtheria	O
8	toxin	I
9	repressor	I
10	complexed	O
11	with	O
12	cobalt	O
13	and	O
14	manganese	O
15	reveals	O
16	an	O
17	SH3	B
18	-	O
19	like	O
20	third	O
21	domain	O
22	and	O
23	suggests	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	phosphate	O
29	as	O
30	co	O
31	-	O
32	corepressor	O
33	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	O
16	and	O
17	serum	O
18	lysozyme	B
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	The	O
2	acfD	B
3	gene	I
4	encompasses	O
5	254	O
6	nt	O
7	that	O
8	are	O
9	predicted	O
10	to	O
11	encode	O
12	an	O
13	88	O
14	-	O
15	amino	O
16	-	O
17	acid	O
18	(	O
19	aa	O
20	)	O
21	protein	O
22	.	O

1	In	O
2	nine	O
3	patients	O
4	with	O
5	renal	O
6	failure	O
7	routine	O
8	haemodialysis	O
9	was	O
10	accompanied	O
11	by	O
12	a	O
13	30	O
14	per	O
15	cent	O
16	reduction	O
17	in	O
18	plasma	O
19	ANP	B
20	concentration	O
21	.	O

1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O

1	A	O
2	simple	O
3	method	O
4	for	O
5	measuring	O
6	urinary	O
7	iron	O
8	following	O
9	the	O
10	administration	O
11	of	O
12	desferrioxamine	O
13	(	O
14	DF	O
15	)	O
16	is	O
17	described	O
18	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	effect	O
7	of	O
8	acute	O
9	administration	O
10	of	O
11	various	O
12	doses	O
13	of	O
14	malathion	O
15	via	O
16	oral	O
17	and	O
18	dermal	O
19	routes	O
20	to	O
21	mice	O
22	and	O
23	rats	O
24	on	O
25	serum	O
26	levels	O
27	of	O
28	histamine	O
29	was	O
30	evaluated	O
31	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	Pneumoscrotum	O
2	is	O
3	a	O
4	rare	O
5	condition	O
6	that	O
7	receives	O
8	little	O
9	discussion	O
10	in	O
11	standard	O
12	texts	O
13	of	O
14	urology	O
15	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	B
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	B
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	I
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	I
37	.	O

1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	tip	O
6	acts	O
7	at	O
8	an	O
9	early	O
10	stage	O
11	of	O
12	the	O
13	T	O
14	-	O
15	cell	O
16	signal	O
17	transduction	O
18	cascade	O
19	by	O
20	associating	O
21	with	O
22	Lck	B
23	and	O
24	downregulating	B
25	Lck	I
26	-	I
27	mediated	O
28	activation	O
29	.	O

1	Reye	O
2	'	O
3	s	O
4	syndrome	O
5	:	O
6	reports	O
7	of	O
8	7	O
9	cases	O
10	in	O
11	the	O
12	period	O
13	1982	O
14	-	O
15	1987	O

1	Ten	O
2	volunteers	O
3	were	O
4	tested	O
5	at	O
6	18	O
7	,	O
8	000	O
9	ft	O
10	(	O
11	5	O
12	,	O
13	486	O
14	m	O
15	),	O
16	and	O
17	through	O
18	12	O
19	,	O
20	000	O
21	,	O
22	8	O
23	,	O
24	000	O
25	,	O
26	and	O
27	5	O
28	,	O
29	000	O
30	ft	O
31	(	O
32	3	O
33	,	O
34	657	O
35	,	O
36	2	O
37	,	O
38	438	O
39	,	O
40	and	O
41	1	O
42	,	O
43	524	O
44	m	O
45	)	O
46	with	O
47	directional	O
48	sounds	O
49	recorded	O
50	via	O
51	a	O
52	dummy	O
53	head	O
54	microphone	O
55	and	O
56	presented	O
57	binaurally	O
58	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterisation	O
5	of	O
6	the	O
7	two	O
8	homologous	B
9	genes	I
10	coding	I
11	for	O
12	nitrate	B
13	reductase	I
14	in	O
15	tobacco	O
16	.	O

1	Similar	O
2	experiments	O
3	with	O
4	TR	O
5	support	O
6	the	O
7	high	O
8	affinity	O
9	of	O
10	RIP140	O
11	to	O
12	the	O
13	RXR	B
14	subunit	I
15	and	O
16	also	O
17	suggest	O
18	that	O
19	either	O
20	partner	B
21	in	O
22	the	O
23	TR	B
24	/	I
25	RXR	I
26	heterodimer	O
27	can	O
28	independently	O
29	respond	O
30	to	O
31	ligand	O
32	.	O

1	74	O
2	,	O
3	193	O
4	-	O
5	197	O
6	).	O

1	Cervicovaginal	B
2	foetal	I
3	fibronectin	I
4	in	O
5	the	O
6	prediction	O
7	of	O
8	preterm	O
9	labour	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O

1	Obstruction	O
2	of	O
3	the	O
4	ERF	B
5	repressor	I
6	function	O
7	by	O
8	the	O
9	transactivating	O
10	members	O
11	of	O
12	the	O
13	ets	B
14	family	I
15	of	I
16	genes	I
17	(	O
18	i	B
19	.	I
20	e	I
21	.	I
22	gag	I
23	-	I
24	myb	I
25	-	I
26	ets	I
27	)	O
28	may	O
29	be	O
30	essential	O
31	for	O
32	the	O
33	control	O
34	of	O
35	genes	O
36	involved	O
37	in	O
38	cell	O
39	proliferation	O
40	and	O
41	may	O
42	also	O
43	underlie	O
44	their	O
45	tumorigenic	O
46	effects	O
47	.	O

1	MEK	B
2	itself	O
3	is	O
4	activated	O
5	via	O
6	serine	O
7	phosphorylation	O
8	by	O
9	upstream	B
10	activator	I
11	kinases	I
12	,	O
13	including	O
14	c	B
15	-	I
16	raf	I
17	,	I
18	mos	B
19	and	I
20	MEK	B
21	kinase	I
22	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O

1	The	O
2	clinical	O
3	tolerance	O
4	and	O
5	pharmacokinetics	O
6	of	O
7	FCE	O
8	22101	O
9	(	O
10	sodium	O
11	(	O
12	5R	O
13	,	O
14	6S	B
15	)-	O
16	6	I
17	-[(	O
18	1R	B
19	)-	O
20	hydroxyethyl	B
21	]-	O
22	2	I
23	-	I
24	carbamoyloxymethyl	I
25	-	I
26	2	I
27	-	I
28	penem	I
29	-	I
30	3	I
31	-	O
32	carboxylate	O
33	),	O
34	a	O
35	new	O
36	penem	O
37	antibiotic	O
38	,	O
39	have	O
40	been	O
41	studied	O
42	after	O
43	giving	O
44	a	O
45	single	O
46	i	O
47	.	O
48	v	O
49	.	O
50	dose	O
51	of	O
52	4	O
53	mg	O
54	.	O
55	kg	O
56	-	O
57	1	O
58	to	O
59	ten	O
60	healthy	O
61	male	O
62	volunteers	O
63	.	O

1	The	O
2	3	O
3	'	O
4	fragment	O
5	was	O
6	shown	O
7	to	O
8	accumulate	O
9	as	O
10	full	O
11	-	O
12	length	O
13	mRNA	O
14	disappeared	O
15	in	O
16	actinomycin	O
17	D	O
18	-	O
19	treated	O
20	cells	O
21	,	O
22	indicating	O
23	a	O
24	precursor	B
25	-	I
26	product	I
27	relationship	O
28	.	O

1	These	O
2	mutations	O
3	alter	O
4	two	O
5	regions	O
6	of	O
7	GAL4	B
8	protein	I
9	:	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	,	O
15	and	O
16	the	O
17	transcription	O
18	activation	O
19	domain	O
20	.	O

1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	B
8	-	I
9	2	I
10	protein	I
11	was	O
12	a	O
13	unique	O
14	alpha1	B
15	,	O
16	4	O
17	-	O
18	N	O
19	-	I
20	acetylglucosaminyltransferase	I
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	B
30	sulfate	O
31	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	B
12	-	I
13	PTP2	I
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O

1	Purified	B
2	spleen	I
3	GAP	I
4	accelerated	O
5	hydrolysis	O
6	of	O
7	GTP	O
8	bound	O
9	to	O
10	recombinant	B
11	ARF1	I
12	,	O
13	ARF3	B
14	,	O
15	ARF5	B
16	,	O
17	and	O
18	ARF6	B
19	;	O
20	no	O
21	effect	O
22	of	O
23	NH2	O
24	-	O
25	terminal	O
26	myristoylation	O
27	was	O
28	observed	O
29	.	O

1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O

1	Mutation	O
2	of	O
3	TTF	B
4	-	I
5	1	I
6	-	I
7	binding	I
8	sites	I
9	(	O
10	TBE	B
11	)	I
12	1	O
13	,	O
14	3	O
15	,	O
16	and	O
17	4	O
18	in	O
19	combination	O
20	markedly	O
21	decreased	O
22	transcriptional	O
23	activity	O
24	of	O
25	SP	B
26	-	I
27	A	I
28	promoter	I
29	-	I
30	chloramphenicol	I
31	acetyltransferase	I
32	constructs	I
33	containing	O
34	SP	B
35	-	I
36	A	I
37	gene	I
38	sequences	O
39	from	O
40	-	O
41	256	O
42	to	O
43	+	O
44	45	O
45	.	O

1	The	O
2	single	O
3	most	O
4	important	O
5	element	O
6	,	O
7	by	O
8	linker	O
9	-	O
10	scanning	O
11	analysis	O
12	,	O
13	is	O
14	a	O
15	10	O
16	-	O
17	bp	O
18	region	O
19	that	O
20	contains	O
21	a	O
22	CCAAT	O
23	motif	O
24	.	O

1	Shape	B
2	factor	I
3	correlated	O
4	well	O
5	with	O
6	hemodynamic	O
7	data	O
8	for	O
9	RV	O
10	/	O
11	LV	O
12	systolic	O
13	pressure	O
14	ratios	O
15	(	O
16	r	O
17	=	O
18	0	O
19	.	O
20	93	O
21	,	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	001	O
28	)	O
29	for	O
30	normalized	O
31	interventricular	O
32	pressure	O
33	differences	O
34	(	O
35	r	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	,	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	).	O

1	Recently	O
2	,	O
3	a	O
4	protein	O
5	designated	O
6	GF14	B
7	has	O
8	been	O
9	isolated	O
10	that	O
11	is	O
12	associated	O
13	with	O
14	the	O
15	GBF	B
16	protein	I
17	complex	I
18	.	O

1	The	O
2	enteric	O
3	route	O
4	is	O
5	the	O
6	principal	O
7	mode	O
8	of	O
9	transmission	O
10	for	O
11	hepatitis	O
12	A	O
13	,	O
14	but	O
15	maximal	O
16	levels	O
17	of	O
18	hepatitis	O
19	A	O
20	virus	O
21	excretion	O
22	occur	O
23	before	O
24	the	O
25	onset	O
26	of	O
27	jaundice	O
28	.	O

1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	monophosphoryl	O
15	lipid	O
16	A	O
17	(	O
18	MLA	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	stunning	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	occlusions	O
36	were	O
37	studied	O
38	in	O
39	barbital	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O

1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	O
8	F	B
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	B
20	4	I
21	,	O
22	5	O
23	bisphosphate	I
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O

1	Primary	O
2	amenorrhoea	O
3	in	O
4	a	O
5	phenotypically	O
6	female	O
7	individual	O
8	with	O
9	a	O
10	karyotype	O
11	46	O
12	,	O
13	xy	O
14	and	O
15	bilateral	O
16	gonadoblastoma	O

1	3	O
2	.	O

1	Monkeys	O
2	were	O
3	evaluated	O
4	before	O
5	and	O
6	after	O
7	unilateral	O
8	and	O
9	serial	O
10	bilateral	O
11	removal	O
12	of	O
13	superior	O
14	temporal	O
15	cortex	O
16	.	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	The	O
2	growing	O
3	drug	O
4	problem	O
5	is	O
6	also	O
7	reflected	O
8	in	O
9	the	O
10	increasing	O
11	number	O
12	of	O
13	cases	O
14	of	O
15	hepatitis	O
16	B	O
17	and	O
18	of	O
19	drug	O
20	-	O
21	related	O
22	deaths	O
23	.	O

1	The	O
2	progression	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	to	O
13	chronic	O
14	diseases	O
15	,	O
16	and	O
17	the	O
18	transformation	O
19	to	O
20	hepatocellular	O
21	carcinoma	O

1	BRCA1	B
2	protein	O
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	In	O
2	contrast	O
3	,	O
4	COUP	B
5	-	I
6	TF	I
7	alone	O
8	had	O
9	no	O
10	effect	O
11	on	O
12	repCRS2	O
13	-	O
14	dependent	O
15	reporter	O
16	gene	O
17	activity	O
18	.	O

1	The	O
2	functions	O
3	of	O
4	isolated	O
5	portions	O
6	of	O
7	the	O
8	insulin	B
9	,	O
10	IAPP	B
11	,	O
12	and	O
13	beta	B
14	GK	I
15	promoters	I
16	were	O
17	studied	O
18	by	O
19	using	O
20	transient	O
21	expression	O
22	and	O
23	DNA	O
24	binding	O
25	assays	O
26	.	O

1	Frozen	B
2	/	O
3	thawed	O
4	extensor	I
5	digitorum	I
6	longus	I
7	muscle	O
8	tendon	O
9	units	O
10	had	O
11	significantly	O
12	lower	O
13	values	O
14	for	O
15	load	O
16	to	O
17	failure	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	01	O
24	),	O
25	energy	O
26	absorbed	O
27	to	O
28	failure	O
29	(	O
30	p	O
31	<	O
32	0	O
33	.	O
34	01	O
35	),	O
36	and	O
37	strain	O
38	at	O
39	failure	O
40	(	O
41	p	O
42	<	O
43	0	O
44	.	O
45	01	O
46	),	O
47	and	O
48	they	O
49	tended	O
50	to	O
51	fail	O
52	at	O
53	a	O
54	different	O
55	anatomic	O
56	location	O
57	(	O
58	p	O
59	<	O
60	0	O
61	.	O
62	01	O
63	)	O
64	(	O
65	broadly	O
66	at	O
67	the	O
68	fascia	O
69	-	O
70	muscle	O
71	interface	O
72	as	O
73	compared	O
74	with	O
75	horizontally	O
76	at	O
77	the	O
78	musculotendinous	O
79	junction	O
80	)	O
81	than	O
82	fresh	O
83	units	O
84	.	O

1	The	O
2	cdr1	O
3	sequence	O
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	B
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	I
11	activated	O
12	protein	I
13	kinase	I
14	-	I
15	2	O
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O

1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O

1	The	O
2	HOI	O
3	induced	O
4	a	O
5	nearly	O
6	fourfold	O
7	increase	O
8	in	O
9	ANF	O
10	in	O
11	the	O
12	elderly	O
13	,	O
14	whereas	O
15	that	O
16	for	O
17	the	O
18	young	O
19	was	O
20	threefold	O
21	.	O

1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O

1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	O
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O

1	Teratological	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	837	O
7	.	O

1	Viral	O
2	genomic	O
3	RNA	O
4	for	O
5	these	O
6	reactions	O
7	was	O
8	obtained	O
9	directly	O
10	from	O
11	fecal	O
12	specimens	O
13	of	O
14	infected	O
15	infant	O
16	rats	O
17	.	O

1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	B
9	matrix	I
10	glycoprotein	I
11	undulin	I
12	.	O

1	Because	O
2	of	O
3	concerns	B
4	regarding	O
5	blood	O
6	transfusion	O
7	-	O
8	related	O
9	communicable	O
10	disease	O
11	(	O
12	eg	O
13	,	O
14	acquired	O
15	immune	O
16	deficiency	O
17	syndrome	O
18	and	O
19	non	O
20	-	O
21	A	O
22	,	O
23	non	O
24	-	O
25	B	O
26	hepatitis	O
27	),	O
28	there	O
29	has	O
30	been	O
31	increasing	O
32	research	O
33	effort	O
34	into	O
35	postoperative	O
36	hemorrhage	O
37	related	O
38	to	O
39	cardiopulmonary	O
40	bypass	O
41	with	O
42	extracorporeal	O
43	circulation	O
44	.	O

1	In	O
2	yeast	O
3	,	O
4	the	O
5	products	O
6	of	O
7	the	O
8	UPF1	B
9	and	O
10	UPF3	B
11	genes	I
12	are	O
13	required	O
14	for	O
15	this	O
16	decay	O
17	pathway	O
18	,	O
19	and	O
20	in	O
21	this	O
22	report	O
23	we	O
24	focus	O
25	on	O
26	the	O
27	identification	O
28	and	O
29	characterization	O
30	of	O
31	additional	O
32	factors	O
33	required	O
34	for	O
35	rapid	O
36	decay	O
37	of	O
38	nonsense	O
39	-	O
40	containing	O
41	mRNAs	O
42	.	O

1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O

1	This	O
2	inhibitory	O
3	domain	O
4	has	O
5	been	O
6	deleted	O
7	in	O
8	all	O
9	naturally	O
10	occurring	O
11	AHC	O
12	deletion	O
13	mutants	O
14	described	O
15	to	O
16	date	O
17	.	O

1	A	O
2	concentration	O
3	of	O
4	12	O
5	.	O
6	5	O
7	ppm	O
8	SO2	O
9	induced	O
10	a	O
11	decrease	O
12	from	O
13	baseline	O
14	values	O
15	of	O
16	approximately	O
17	80	O
18	%	O
19	in	O
20	mean	O
21	MCA	O
22	and	O
23	of	O
24	roughly	O
25	70	O
26	%	O
27	in	O
28	mean	O
29	CBF	O
30	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mRNA	O
5	capping	I
6	enzyme	O
7	identifies	O
8	amino	O
9	acids	O
10	involved	O
11	in	O
12	GTP	O
13	binding	O
14	,	O
15	enzyme	O
16	-	O
17	guanylate	O
18	formation	O
19	,	O
20	and	O
21	GMP	O
22	transfer	O
23	to	O
24	RNA	O
25	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	B
7	-	I
8	length	I
9	promoter	I
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	About	O
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	B
6	),	O
7	and	O
8	Efs	B
9	/	O
10	Sin	O
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	[	O
2	Ala85	O
3	]	O
4	Dk	O
5	(	O
6	69	O
7	-	O
8	85	O
9	)	O
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	Selected	O
2	topics	O
3	in	O
4	laboratory	O
5	animal	O
6	medicine	O
7	.	O

1	Biol	O
2	.	O

1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O

1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	O
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	B
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	B
31	beta	I
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	B
43	locus	I
44	was	O
45	not	O
46	deleted	O
47	.	O

1	Most	O
2	pituitary	B
3	hormone	I
4	-	I
5	coding	I
6	gene	I
7	promoters	O
8	are	O
9	activated	O
10	by	O
11	Ptx1	O
12	.	O

1	Hemodynamics	O
2	changes	O
3	in	O
4	man	O
5	during	O
6	flight	O

1	Endothelial	O
2	cell	O
3	seeding	O
4	.	O

1	Comparison	O
2	with	O
3	the	O
4	bHLH	B
5	/	I
6	PAS	I
7	family	I
8	genes	I
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	O
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	O
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	O
31	and	O
32	Ahr	O
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	O
46	gene	O
47	.	O

1	With	O
2	aging	O
3	,	O
4	many	O
5	aspects	O
6	of	O
7	immune	O
8	function	O
9	change	O
10	.	O

1	A	O
2	region	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	adenovirus	B
10	2	I
11	/	I
12	5	I
13	E1a	I
14	protein	I
15	is	O
16	required	O
17	for	O
18	association	O
19	with	O
20	a	O
21	cellular	O
22	phosphoprotein	O
23	and	O
24	important	O
25	for	O
26	the	O
27	negative	O
28	modulation	O
29	of	O
30	T24	B
31	-	I
32	ras	I
33	mediated	O
34	transformation	O
35	,	O
36	tumorigenesis	O
37	and	O
38	metastasis	O
39	.	O

1	The	O
2	pilE	B
3	gene	I
4	product	I
5	of	O
6	Pseudomonas	B
7	aeruginosa	I
8	,	O
9	required	O
10	for	O
11	pilus	O
12	biogenesis	O
13	,	O
14	shares	O
15	amino	O
16	acid	O
17	sequence	O
18	identity	O
19	with	O
20	the	O
21	N	O
22	-	O
23	termini	O
24	of	O
25	type	B
26	4	I
27	prepilin	I
28	proteins	I
29	.	O

1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O

1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	NS2	B
18	gene	I
19	.	O

1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O

1	Complexes	O
2	of	O
3	qTBP42	O
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	Brandt	B
6	'	O
7	s	O
8	double	O
9	cuff	O
10	-	O
11	tubes	I
12	(	O
13	G2	B
14	)	O
15	succeed	O
16	in	O
17	avoiding	O
18	uncontrolled	O
19	increase	O
20	of	O
21	cuff	O
22	-	O
23	pressure	O
24	during	O
25	anaesthesia	O
26	with	O
27	N2O	O
28	.	O

1	Nonlocal	O
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	The	O
2	mean	O
3	transfer	O
4	ratios	O
5	of	O
6	the	O
7	drug	O
8	into	O
9	the	O
10	genital	O
11	tissues	O
12	to	O
13	the	O
14	concentration	O
15	in	O
16	the	O
17	uterine	O
18	arterial	O
19	blood	O
20	were	O
21	such	O
22	that	O
23	the	O
24	transfer	O
25	ratio	O
26	into	O
27	the	O
28	portio	O
29	vaginalis	O
30	was	O
31	the	O
32	highest	O
33	,	O
34	followed	O
35	by	O
36	the	O
37	uterine	O
38	cervix	O
39	and	O
40	the	O
41	myometrium	O
42	,	O
43	and	O
44	that	O
45	into	O
46	the	O
47	oviduct	O
48	was	O
49	the	O
50	lowest	O
51	with	O
52	about	O
53	1	O
54	/	O
55	2	O
56	that	O
57	into	O
58	the	O
59	portio	B
60	vaginalis	I
61	.	O

1	A	O
2	family	O
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O

1	To	O
2	evaluate	O
3	the	O
4	relative	O
5	accuracy	O
6	of	O
7	continuous	O
8	wave	O
9	(	O
10	CW	O
11	)	O
12	and	O
13	high	O
14	pulse	O
15	repetition	O
16	frequency	O
17	(	O
18	HPRF	O
19	)	O
20	Doppler	O
21	for	O
22	estimating	O
23	aortic	O
24	transvalvular	O
25	pressure	O
26	gradients	O
27	,	O
28	Doppler	O
29	examinations	O
30	with	O
31	both	O
32	devices	O
33	were	O
34	obtained	O
35	in	O
36	87	O
37	consecutive	O
38	patients	O
39	with	O
40	aortic	O
41	valve	O
42	disease	O
43	.	O

1	Mutations	O
2	in	O
3	the	O
4	nuclear	O
5	gene	I
6	CBP1	I
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	result	O
11	in	O
12	degradation	O
13	of	O
14	mitochondrially	B
15	encoded	I
16	cytochrome	I
17	b	I
18	(	O
19	cob	B
20	)	O
21	RNA	O
22	;	O
23	thus	O
24	,	O
25	the	O
26	cells	O
27	are	O
28	unable	O
29	to	O
30	respire	O
31	.	O

1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	B
11	neurohormones	I
12	.	O

1	A	O
2	site	O
3	-	O
4	directed	O
5	R618K	B
6	mutation	O
7	in	O
8	the	O
9	Stat5	B
10	SH2	I
11	domain	I
12	abolished	O
13	the	O
14	phosphorylation	O
15	by	O
16	Jak2	B
17	,	O
18	while	O
19	deletion	O
20	of	O
21	the	O
22	C	O
23	terminus	O
24	led	O
25	to	O
26	Stat5	B
27	hyperphosphorylation	I
28	.	O

1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	B
16	gene	I
17	(	O
18	named	O
19	porCa	B
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	O
7	and	O
8	does	O
9	it	O
10	have	O
11	educational	O
12	value	O
13	?	O
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	O
19	improved	O
20	patient	O
21	care	O

1	Comparable	B
2	amounts	I
3	of	O
4	alpha	I
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	I
23	-	I
24	binding	I
25	fragment	I
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	O
9	chains	O
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	I
15	YBa2Cu3O7	I
16	-	I
17	delta	I
18	crystal	I
19	.	O

1	The	O
2	major	O
3	findings	O
4	of	O
5	our	O
6	studies	O
7	are	O
8	as	O
9	follows	O
10	:	O
11	1	O
12	)	O
13	There	O
14	are	O
15	no	O
16	detectable	O
17	signals	O
18	around	O
19	GDF	O
20	-	O
21	9	O
22	-	O
23	deficient	O
24	follicles	O
25	for	O
26	several	O
27	theca	O
28	cell	O
29	layer	O
30	markers	O
31	[	O
32	i	O
33	.	O
34	e	O
35	.	O

1	All	O
2	four	O
3	of	O
4	the	O
5	genes	O
6	have	O
7	a	O
8	similar	O
9	structure	O
10	,	O
11	with	O
12	the	O
13	receptor	B
14	protein	O
15	encoded	O
16	in	O
17	a	O
18	single	O
19	exon	O
20	.	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	O
18	--	O
19	phenylalanine	I
20	-	I
21	8	I
22	-	I
23	lysine	I
24	vasopressin	I
25	(	O
26	Octapressin	O
27	).	O

1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O

1	The	O
2	same	O
3	rhythmic	O
4	structure	O
5	enables	O
6	a	O
7	prediction	O
8	to	O
9	be	O
10	made	O
11	concerning	O
12	when	O
13	vowels	O
14	of	O
15	stressed	O
16	syllables	O
17	will	O
18	be	O
19	auditorily	O
20	perceived	O
21	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	One	O
2	of	O
3	the	O
4	sequelae	O
5	of	O
6	the	O
7	antiphospholipid	O
8	-	I
9	antibodies	I
10	is	O
11	an	O
12	impaired	O
13	uteroplacental	O
14	circulation	O
15	.	O

1	After	O
2	transfection	O
3	,	O
4	specific	O
5	TSH	B
6	beta	I
7	promoter	I
8	activity	O
9	was	O
10	evident	O
11	in	O
12	both	O
13	TRH	B
14	-	O
15	responsive	O
16	pituitary	O
17	-	I
18	derived	O
19	GH3	O
20	and	O
21	primary	O
22	pituitary	O
23	cell	O
24	cultures	O
25	.	O

1	There	O
2	have	O
3	been	O
4	five	O
5	problems	O
6	(	O
7	extravasation	O
8	2	O
9	,	O
10	suspected	O
11	sepsis	O
12	1	O
13	,	O
14	and	O
15	hematoma	O
16	2	O
17	)	O
18	during	O
19	a	O
20	total	O
21	of	O
22	2	O
23	,	O
24	927	O
25	days	O
26	of	O
27	exposure	O
28	.	O

1	A	B
2	receptor	I
3	-	I
4	like	I
5	protein	I
6	kinase	I
7	,	O
8	OsPK10	O
9	,	O
10	has	O
11	been	O
12	cloned	O
13	from	O
14	rice	O
15	(	O
16	Oryza	O
17	sativa	O
18	).	O

1	Value	O
2	of	O
3	the	O
4	EMG	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	a	O
10	cardiomyopathy	O
11	associated	O
12	with	O
13	a	O
14	myotonic	O
15	myopathy	O
16	.	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	O
11	-	I
12	1	I
13	allergen	I
14	of	O
15	Ascaris	B
16	,	O
17	the	O
18	gp15	B
19	/	O
20	400	O
21	'	O
22	ladder	I
23	'	I
24	protein	I
25	of	O
26	Brugia	B
27	malayi	I
28	,	O
29	Brugia	B
30	pahangi	I
31	and	O
32	Wuchereria	B
33	bancrofti	I
34	,	O
35	and	O
36	a	O
37	15	O
38	-	O
39	kDa	I
40	antigen	I
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	Sequencing	O
2	analysis	O
3	has	O
4	shown	O
5	that	O
6	each	O
7	rap1t	B
8	allele	O
9	contains	O
10	a	O
11	nonsense	O
12	mutation	O
13	within	O
14	a	O
15	discrete	O
16	region	O
17	between	O
18	amino	O
19	acids	O
20	663	O
21	and	O
22	684	O
23	.	O

1	The	O
2	first	O
3	group	O
4	of	O
5	sequential	O
6	BMB	O
7	showed	O
8	a	O
9	significant	O
10	progress	O
11	to	O
12	myelofibrosis	O
13	in	O
14	so	O
15	-	O
16	called	O
17	"	O
18	Chronic	O
19	Megakaryocytic	B
20	-	I
21	Granulocytic	I
22	Myelosis	I
23	"--	I
24	CMGM	I
25	-,	O
26	which	O
27	corresponds	O
28	to	O
29	Agnogenic	B
30	Myeloid	I
31	Metaplasia	I
32	-	I
33	AMM	I
34	-	I
35	in	O
36	72	O
37	.	O
38	4	O
39	%	O
40	(	O
41	21	O
42	/	O
43	29	O
44	patients	O
45	),	O
46	as	O
47	well	O
48	as	O
49	in	O
50	CML	O
51	with	O
52	megakaryocytic	O
53	increase	O
54	-	O
55	CML	O
56	.	O
57	MI	O
58	-	O
59	in	O
60	39	O
61	.	O
62	2	O
63	%	O
64	(	O
65	20	O
66	/	O
67	51	O
68	).	O

1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	B
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	B
40	replicon	I
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	B
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	While	O
2	TGF	B
3	-	I
4	beta1	I
5	does	O
6	not	O
7	alter	O
8	the	O
9	mitogen	O
10	-	O
11	induced	O
12	expression	O
13	and	O
14	abundance	O
15	of	O
16	G1	B
17	phase	O
18	cyclin	B
19	D1	I
20	and	I
21	cdks	B
22	4	I
23	and	O
24	2	O
25	in	O
26	MCs	O
27	,	O
28	it	O
29	inhibits	O
30	cyclin	B
31	E	I
32	-	I
33	cdk	I
34	2	I
35	activity	O
36	,	O
37	thus	O
38	preventing	O
39	mitogen	B
40	-	I
41	elicited	O
42	phosphorylation	O
43	and	O
44	inactivation	O
45	of	O
46	pRb	B
47	in	O
48	G1	O
49	phase	O
50	and	O
51	transition	O
52	to	O
53	S	O
54	phase	O
55	.	O

1	The	O
2	ParaSight	B
3	-	O
4	F	I
5	test	O
6	alone	O
7	was	O
8	used	O
9	to	O
10	monitor	O
11	serum	O
12	antigen	I
13	levels	O
14	after	O
15	treatment	O
16	in	O
17	24	O
18	patients	O
19	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Whereas	O
2	both	O
3	MAP	B
4	and	O
5	MSNA	O
6	increase	O
7	during	O
8	SHG	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	SHG	O
14	to	O
15	PHI	B
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	B
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	MSNA	O
29	,	O
30	facilitating	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O

1	Neither	O
2	ethanol	O
3	nor	O
4	estrogen	O
5	has	O
6	been	O
7	shown	O
8	to	O
9	cause	O
10	UROD	O
11	-	O
12	deficiency	O
13	in	O
14	animals	O
15	.	O

1	Fulminant	B
2	hepatitis	I
3	A	O
4	in	O
5	chronic	O
6	HBV	O
7	carrier	O
8	.	O

1	DNA	O
2	sequencing	O
3	of	O
4	the	O
5	DPM1	B
6	gene	I
7	revealed	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	of	O
13	801	O
14	bases	O
15	.	O

1	Gap1	O
2	(	O
3	IP4BP	O
4	),	O
5	one	O
6	of	O
7	a	O
8	member	O
9	of	O
10	Ras	B
11	GTPase	I
12	-	I
13	activating	I
14	proteins	I
15	,	O
16	has	O
17	been	O
18	identified	O
19	as	O
20	a	O
21	specific	O
22	inositol	B
23	1	I
24	,	O
25	3	O
26	,	O
27	4	O
28	,	O
29	5	B
30	-	I
31	tetrakisphosphate	I
32	(	O
33	IP4	B
34	)-	I
35	binding	I
36	protein	I
37	(	O
38	Cullen	O
39	,	O
40	P	O
41	.	O

1	Different	O
2	cortical	O
3	malformations	O
4	were	O
5	produced	O
6	in	O
7	rats	O
8	by	O
9	a	O
10	single	O
11	dose	O
12	of	O
13	X	O
14	-	O
15	rays	O
16	(	O
17	200	O
18	cGy	O
19	)	O
20	given	O
21	on	O
22	different	O
23	days	O
24	during	O
25	gestation	O
26	.	O

1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	B
7	Notch	I
8	/	O
9	translocation	O
10	-	I
11	associated	I
12	Notch	I
13	homologue	I
14	has	I
15	I	I
16	kappa	I
17	B	I
18	-	I
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	B
26	factor	I
27	-	I
28	kappa	I
29	B	I
30	proteins	I
31	in	O
32	T	O
33	cells	O
34	.	O

1	A	O
2	fusion	O
3	protein	O
4	composed	O
5	of	O
6	beta	B
7	-	I
8	galactosidase	I
9	and	O
10	full	O
11	-	O
12	length	O
13	Ahr	O
14	translocates	O
15	from	O
16	the	O
17	cytoplasm	O
18	to	O
19	the	O
20	nucleus	O
21	in	O
22	a	O
23	ligand	O
24	-	O
25	dependent	O
26	manner	O
27	.	O

1	The	O
2	monoclonal	O
3	immunoglobulin	B
4	products	I
5	of	O
6	plasma	O
7	cell	O
8	neoplasm	I
9	can	O
10	give	O
11	rise	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	manifestations	O
17	including	O
18	hyperviscosity	O
19	,	O
20	amyloidosis	O
21	,	O
22	cryoglobulinemia	O
23	,	O
24	neuropathy	O
25	,	O
26	and	O
27	renal	O
28	failure	O
29	.	O

1	The	O
2	entire	O
3	human	B
4	teneurin	I
5	-	I
6	1	I
7	(	O
8	TEN1	B
9	)	I
10	gene	O
11	is	O
12	contained	O
13	in	O
14	eight	O
15	PAC	O
16	clones	O
17	representing	O
18	part	O
19	of	O
20	the	O
21	chromosomal	B
22	locus	I
23	Xq25	I
24	.	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	O
22	-	O
23	lactamase	I
24	.	O

1	In	O
2	all	O
3	tissues	O
4	examined	O
5	only	O
6	transcripts	O
7	positive	O
8	for	O
9	insert	O
10	3	O
11	,	O
12	an	O
13	18	O
14	bp	O
15	insertion	O
16	in	O
17	repeat	O
18	21	O
19	,	O
20	were	O
21	amplified	O
22	,	O
23	even	O
24	under	O
25	conditions	O
26	in	O
27	which	O
28	a	O
29	30	O
30	%	O
31	level	O
32	of	O
33	insert	O
34	3	O
35	negative	O
36	transcript	O
37	could	O
38	be	O
39	easily	O
40	detected	O
41	in	O
42	artificially	O
43	prepared	O
44	control	O
45	samples	O
46	.	O

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	Drug	O
2	inhibition	O
3	of	O
4	whole	O
5	blood	O
6	aspirin	O
7	esterase	I
8	.	O

1	Five	O
2	of	O
3	these	O
4	have	O
5	ocular	O
6	or	O
7	oculocutaneous	O
8	albinism	O
9	.	O

1	The	O
2	generally	O
3	adopted	O
4	criteria	O
5	enabling	O
6	to	O
7	classify	O
8	the	O
9	examined	O
10	persons	O
11	into	O
12	the	O
13	following	O
14	3	O
15	groups	O
16	have	O
17	been	O
18	used	O
19	:	O
20	(	O
21	a	O
22	)	O
23	diseased	O
24	of	O
25	BEN	O
26	;	O
27	(	O
28	b	O
29	)	O
30	suspect	O
31	to	O
32	be	O
33	diseased	O
34	of	O
35	BEN	O
36	,	O
37	and	O
38	(	O
39	c	B
40	)	O
41	individuals	O
42	without	O
43	signs	O
44	of	O
45	a	O
46	renal	O
47	disease	O
48	.	O

1	Though	O
2	the	O
3	BACTEC	B
4	9000	O
5	MB	I
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	POU	B
2	-	I
3	domain	I
4	proteins	I
5	,	O
6	such	O
7	as	O
8	the	O
9	pituitary	B
10	-	I
11	specific	I
12	factor	I
13	Pit	I
14	-	I
15	1	I
16	,	O
17	are	O
18	members	O
19	of	O
20	the	O
21	homeodomain	B
22	family	I
23	of	O
24	proteins	I
25	which	O
26	are	O
27	important	O
28	in	O
29	development	O
30	and	O
31	homeostasis	O
32	,	O
33	acting	O
34	constitutively	O
35	or	O
36	in	O
37	response	O
38	to	O
39	signal	O
40	-	O
41	transduction	O
42	pathways	O
43	to	O
44	either	O
45	repress	O
46	or	O
47	activate	O
48	the	O
49	expression	O
50	of	O
51	specific	O
52	genes	O
53	.	O

1	Using	O
2	a	O
3	3	O
4	'-	O
5	rapid	O
6	amplification	O
7	of	O
8	cDNA	O
9	ends	O
10	strategy	O
11	,	O
12	we	O
13	have	O
14	cloned	O
15	cDNAs	O
16	representing	O
17	the	O
18	3	O
19	'-	O
20	termini	O
21	of	O
22	both	O
23	the	O
24	native	O
25	and	O
26	mutant	O
27	transcripts	O
28	from	O
29	both	O
30	P388	O
31	/	O
32	ADR	O
33	/	O
34	3	O
35	and	O
36	P388	O
37	/	O
38	ADR	O
39	/	O
40	7	O
41	cells	O
42	.	O

1	Genomic	O
2	libraries	O
3	were	O
4	stored	O
5	as	O
6	frozen	O
7	cultures	O
8	in	O
9	a	O
10	96	O
11	-	O
12	well	O
13	format	O
14	,	O
15	each	O
16	well	O
17	containing	O
18	approximately	O
19	300	O
20	-	O
21	600	O
22	colonies	O
23	(	O
24	12	O
25	plates	O
26	for	O
27	small	O
28	library	O
29	,	O
30	four	O
31	for	O
32	medium	O
33	-	O
34	size	O
35	library	O
36	and	O
37	four	O
38	for	O
39	large	O
40	library	O
41	).	O

1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	Infant	O
2	aged	O
3	3	O
4	.	O
5	5	O
6	years	O
7	presents	O
8	persistence	O
9	of	O
10	primordial	O
11	vitreous	O
12	body	O
13	with	O
14	crystalline	O
15	dislocation	O
16	in	O
17	the	O
18	camera	O
19	aquosa	O
20	and	O
21	secondary	O
22	buphthalmos	O
23	of	O
24	the	O
25	left	O
26	eye	O
27	and	O
28	microphthalmos	O
29	with	O
30	dislocation	O
31	of	O
32	the	O
33	crystalline	O
34	in	O
35	the	O
36	vitreous	O
37	body	O
38	of	O
39	the	O
40	right	O
41	eye	O
42	.	O

1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	O
12	nucleotide	O
13	resolution	O
14	along	O
15	the	O
16	human	B
17	JUN	I
18	gene	I
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	O
25	efficient	O
26	repair	O
27	of	O
28	sequences	O
29	near	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	B
8	families	I
9	Tydeidae	I
10	,	O
11	Nanorchestidae	B
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O

1	A	O
2	catalytic	O
3	domain	O
4	of	O
5	eukaryotic	B
6	DNA	I
7	topoisomerase	I
8	I	I
9	.	O

1	Therefore	O
2	,	O
3	use	O
4	of	O
5	presaturation	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	cine	O
14	PC	I
15	velocity	O
16	data	O
17	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	only	O
6	one	O
7	-	O
8	half	O
9	and	O
10	one	O
11	-	O
12	third	O
13	the	O
14	size	O
15	of	O
16	the	O
17	proteolipids	O
18	from	O
19	M	B
20	.	O
21	thermoautotrophicum	I
22	and	O
23	M	O
24	.	O
25	jannaschii	O
26	,	O
27	respectively	O
28	.	O
29	ahaK	O
30	is	O
31	expressed	O
32	in	O
33	Escherichia	O
34	coli	O
35	,	O
36	and	O
37	it	O
38	is	O
39	incorporated	O
40	into	O
41	the	O
42	cytoplasmic	O
43	membrane	O
44	despite	O
45	the	O
46	different	O
47	chemical	O
48	natures	O
49	of	O
50	lipids	O
51	from	O
52	archaea	O
53	and	O
54	bacteria	O
55	.	O

1	The	O
2	mean	O
3	day	O
4	of	O
5	diagnosis	O
6	of	O
7	periventricular	O
8	echodensities	O
9	was	O
10	3	O
11	+/-	O
12	2	O
13	days	O
14	(	O
15	range	O
16	1	O
17	-	O
18	11	O
19	days	O
20	),	O
21	and	O
22	of	O
23	cystic	O
24	PVL	O
25	21	O
26	+/-	O
27	8	O
28	days	O
29	(	O
30	range	O
31	2	O
32	-	O
33	47	O
34	days	O
35	).	O

1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O

1	Human	O
2	AP	B
3	-	I
4	2rep	I
5	repressed	O
6	both	O
7	reporter	O
8	expression	O
9	from	O
10	a	O
11	transiently	O
12	transfected	O
13	AP	B
14	-	I
15	2alpha	I
16	promoter	I
17	and	O
18	the	O
19	endogenous	B
20	AP	I
21	-	I
22	2alpha	I
23	gene	I
24	and	O
25	inversely	O
26	was	O
27	negatively	O
28	regulated	O
29	by	O
30	AP	B
31	-	I
32	2alpha	I
33	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	B
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	time	O
6	to	O
7	engraftment	O
8	was	O
9	significantly	O
10	shorter	O
11	in	O
12	the	O
13	amifostine	O
14	arm	O
15	in	O
16	both	O
17	cohorts	O
18	.	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	I
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	O
8	was	O
9	to	O
10	analyze	O
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	3	O
2	--	O
3	It	O
4	is	O
5	necessary	O
6	to	O
7	think	O
8	about	O
9	cosmetic	O
10	consequences	O
11	of	O
12	the	O
13	chinese	O
14	flap	O
15	and	O
16	consider	O
17	other	O
18	possibilities	O
19	of	O
20	the	O
21	flap	O
22	choice	O
23	.	O

1	Since	O
2	1990	O
3	the	O
4	University	O
5	Hospital	O
6	of	O
7	Tromso	O
8	has	O
9	provided	O
10	local	O
11	hospitals	O
12	in	O
13	northern	O
14	Norway	O
15	with	O
16	a	O
17	remote	O
18	frozen	O
19	section	O
20	service	O
21	and	O
22	with	O
23	access	O
24	to	O
25	video	O
26	conferences	O
27	for	O
28	the	O
29	review	O
30	of	O
31	microscopic	O
32	findings	O
33	and	O
34	for	O
35	the	O
36	discussion	O
37	of	O
38	major	O
39	diagnostic	O
40	issues	O
41	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	The	O
2	study	O
3	disclosed	O
4	generalized	O
5	atrophy	O
6	and	O
7	diffuse	O
8	symmetric	O
9	white	O
10	matter	O
11	hypodensities	O
12	.	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	B
20	-	I
21	p32	I
22	.	O

1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	B
6	Borrelia	I
7	burgdorferi	I
8	motility	I
9	operon	I
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	B
16	sigma70	I
17	promoter	I
18	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	B
5	B	I
6	surface	I
7	antigen	I
8	(	O
9	HBsAg	B
10	)	O
11	and	O
12	anti	B
13	-	I
14	HBs	I
15	was	O
16	determined	O
17	by	O
18	a	O
19	sensitive	O
20	double	O
21	-	I
22	antibody	I
23	radio	O
24	-	O
25	immunoassay	O
26	technique	O
27	in	O
28	a	O
29	series	O
30	of	O
31	patients	O
32	with	O
33	chronic	O
34	liver	O
35	diseases	O
36	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	did	O
5	not	O
6	change	O
7	in	O
8	response	O
9	to	O
10	head	O
11	-	O
12	up	O
13	tilt	O
14	or	O
15	isoprenaline	O
16	infusion	O
17	in	O
18	the	O
19	patients	O
20	.	O

1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	O
6	of	O
7	pp60src	O
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	I
16	and	O
17	p110	B
18	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	Elk	B
5	-	I
6	3	I
7	,	O
8	a	O
9	new	O
10	member	O
11	of	O
12	the	O
13	Ets	B
14	family	I
15	expressed	O
16	during	O
17	mouse	O
18	embryogenesis	O
19	and	O
20	analysis	O
21	of	O
22	its	O
23	transcriptional	O
24	repression	O
25	activity	O
26	.	O

1	The	O
2	kinase	B
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	B
17	growth	I
18	factor	I
19	-	I
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	I
26	MAP	B
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	B
33	protein	I
34	kinase	I
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	B
6	strain	I
7	7120	I
8	leuA	I
9	gene	I
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	I
18	efficiently	O
19	.	O

1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	O
16	,	O
17	HC	B
18	-	O
19	Pro	O
20	,	O
21	P1	O
22	,	O
23	P3	O
24	,	O
25	and	O
26	CP	O
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O

1	BACKGROUND	O
2	/	O
3	PURPOSE	O
4	:	O
5	Anomalous	O
6	arrangement	O
7	of	O
8	the	O
9	pancreaticobiliary	O
10	duct	O
11	(	O
12	AAPBD	B
13	)	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	congenital	O
19	biliary	O
20	dilatation	O
21	and	O
22	frequently	O
23	associated	O
24	with	O
25	biliary	O
26	tract	O
27	malignancy	O
28	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	B
6	finger	I
7	protein	I
8	,	O
9	dsRBP	B
10	-	I
11	ZFa	I
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O

1	As	O
2	predicted	O
3	by	O
4	the	O
5	Wing	O
6	and	O
7	Kristofferson	O
8	model	O
9	,	O
10	the	O
11	durations	O
12	of	O
13	successive	O
14	ISIs	O
15	tended	O
16	to	O
17	be	O
18	negatively	O
19	correlated	O
20	.	O

1	Although	O
2	pathological	O
3	thyroid	O
4	function	O
5	is	O
6	related	O
7	to	O
8	changes	O
9	in	O
10	energy	O
11	expenditure	O
12	and	O
13	body	O
14	composition	O
15	,	O
16	its	O
17	possible	O
18	influence	O
19	on	O
20	leptin	B
21	levels	O
22	remains	O
23	to	O
24	be	O
25	determined	O
26	.	O

1	The	O
2	other	O
3	model	O
4	was	O
5	a	O
6	continuous	O
7	exponential	O
8	plus	O
9	constant	O
10	of	O
11	the	O
12	form	O
13	La	B
14	-	O
15	=	O
16	a	O
17	+	O
18	b	O
19	[	O
20	exp	O
21	(	O
22	cVO2	O
23	)].	O

1	We	O
2	conclude	O
3	from	O
4	these	O
5	studies	O
6	that	O
7	CKII	B
8	may	O
9	act	O
10	as	O
11	a	O
12	positive	O
13	regulator	O
14	of	O
15	myogenesis	O
16	by	O
17	preventing	O
18	E	B
19	protein	I
20	homodimers	I
21	from	O
22	binding	O
23	to	O
24	muscle	B
25	gene	I
26	regulatory	I
27	elements	O
28	.	O

1	Glucose	B
2	disappearance	O
3	rate	O
4	and	O
5	changes	O
6	in	O
7	plasma	O
8	nutrients	O
9	after	O
10	intravenouly	O
11	injected	O
12	glucose	O
13	in	O
14	normoglycaemic	O
15	and	O
16	hypoglycaemic	O
17	underweight	O
18	newborns	O
19	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	O
29	expression	O
30	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	O
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	B
20	promoter	I
21	.	O

1	Transient	O
2	expression	O
3	of	O
4	human	B
5	and	O
6	chicken	B
7	progesterone	I
8	receptors	I
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O

1	Slp1	O
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	B
22	stripes	I
23	in	O
24	interstripe	B
25	regions	I
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	Outflow	O
2	obstruction	O
3	of	O
4	pancreatic	O
5	juice	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	"	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	papilla	O
18	,"	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	papilla	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	I
41	papilla	I
42	might	O
43	suffer	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	drainage	O
51	of	O
52	pancreatic	O
53	juice	O
54	and	O
55	excessive	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	duct	O
61	.	O

1	Compensative	B
2	justice	I
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	Ly	B
2	-	I
3	49	I
4	is	O
5	a	O
6	family	B
7	type	I
8	II	I
9	transmembrane	I
10	proteins	O
11	encoded	O
12	by	O
13	a	O
14	gene	O
15	cluster	O
16	on	O
17	murine	O
18	chromosome	O
19	6	O
20	.	O

1	Treatment	O
2	of	O
3	keratinocytes	O
4	expressing	O
5	a	O
6	normal	O
7	epidermal	B
8	growth	I
9	factor	I
10	receptor	I
11	(	O
12	EGFR	B
13	)	O
14	with	O
15	TGFalpha	O
16	or	O
17	epidermal	B
18	growth	I
19	factor	I
20	for	O
21	5	O
22	min	O
23	induced	O
24	PKCdelta	O
25	tyrosine	O
26	phosphorylation	O
27	.	O

1	The	O
2	Myc	B
3	LZ	I
4	was	O
5	found	O
6	to	O
7	prevent	O
8	homodimeric	O
9	interactions	O
10	,	O
11	thus	O
12	explaining	B
13	Myc	I
14	inability	O
15	to	O
16	homodimerize	O
17	efficiently	O
18	.	O

1	The	O
2	number	O
3	of	O
4	muricidal	O
5	rats	O
6	increased	O
7	with	O
8	increase	O
9	in	O
10	the	O
11	duration	O
12	of	O
13	Cd	O
14	administration	O
15	in	O
16	association	O
17	with	O
18	greater	O
19	accumulation	O
20	of	O
21	Cd	O
22	in	O
23	the	O
24	olfactory	O
25	bulb	O
26	than	O
27	in	O
28	any	O
29	other	O
30	region	O
31	of	O
32	the	O
33	brain	O
34	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	Deletion	O
2	of	O
3	an	O
4	intergenic	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	B
15	beta	I
16	-	I
17	globin	I
18	locus	I
19	construct	I
20	results	O
21	in	O
22	delayed	O
23	human	O
24	gamma	O
25	-	O
26	to	O
27	beta	B
28	-	I
29	globin	I
30	switching	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	PYR	O
39	complex	O
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	switch	O
45	.	O

1	Furthermore	O
2	,	O
3	a	O
4	p21X	O
5	protein	O
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O

1	The	O
2	regulation	O
3	of	O
4	Myf	B
5	-	I
6	5	I
7	and	O
8	MyoD	B
9	function	O
10	by	O
11	a	O
12	cAMP	O
13	-	O
14	dependent	O
15	pathway	O
16	may	O
17	partly	O
18	explain	O
19	how	O
20	external	O
21	signals	O
22	generated	O
23	by	O
24	serum	O
25	and	O
26	certain	O
27	peptide	B
28	growth	I
29	factors	O
30	can	O
31	be	O
32	transduced	O
33	to	O
34	the	O
35	nucleus	O
36	and	O
37	inhibit	O
38	dominant	O
39	-	O
40	acting	O
41	factors	O
42	that	O
43	are	O
44	responsible	O
45	for	O
46	myoblast	O
47	differentiation	O
48	.	O

1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	O
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O

1	Encompassing	O
2	tamponade	O
3	and	O
4	pericardiocentesis	O
5	data	O
6	,	O
7	left	O
8	ventricular	O
9	stroke	O
10	work	O
11	index	O
12	showed	O
13	positive	O
14	correlation	O
15	with	O
16	TMFP1	O
17	(	O
18	r	O
19	=	O
20	.	O
21	59	O
22	)	O
23	and	O
24	TMFP2	O
25	(	O
26	r	O
27	=	O
28	.	O
29	52	O
30	)	O
31	but	O
32	not	O
33	with	O
34	TMFP3	O
35	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	O
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	B
11	9000	I
12	MB	I
13	and	O
14	BACTEC	B
15	460	I
16	TB	I
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	Commutative	O
2	saccadic	O
3	generator	O
4	is	O
5	sufficient	O
6	to	O
7	control	O
8	a	O
9	3	O
10	-	O
11	D	O
12	ocular	O
13	plant	O
14	with	O
15	pulleys	O
16	.	O

1	Mouse	B
2	mast	O
3	cell	O
4	protease	O
5	9	O
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	O
17	proteases	O
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O

1	Analysis	O
2	of	O
3	the	O
4	upstream	O
5	untranslated	O
6	region	O
7	of	O
8	CHL15	O
9	revealed	O
10	the	O
11	presence	O
12	of	O
13	the	O
14	hexamer	O
15	element	O
16	,	O
17	ACGCGT	O
18	(	O
19	an	O
20	MluI	B
21	restriction	I
22	site	I
23	)	O
24	controlling	O
25	both	O
26	the	O
27	periodic	O
28	expression	O
29	and	O
30	coordinate	O
31	regulation	O
32	of	O
33	the	O
34	DNA	O
35	synthesis	O
36	genes	O
37	in	O
38	budding	O
39	yeast	O
40	.	O

1	Male	O
2	-	I
3	enhanced	I
4	antigen	I
5	gene	I
6	is	O
7	phylogenetically	O
8	conserved	O
9	and	O
10	expressed	O
11	at	O
12	late	O
13	stages	O
14	of	O
15	spermatogenesis	O
16	.	O

1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	B
6	-	I
7	1	I
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	In	O
2	the	O
3	37	O
4	patients	O
5	without	O
6	lung	O
7	disease	O
8	respiratory	O
9	muscle	O
10	weakness	O
11	was	O
12	accompanied	O
13	by	O
14	significant	O
15	decreases	O
16	in	O
17	vital	O
18	capacity	O
19	,	O
20	total	O
21	lung	O
22	capacity	O
23	,	O
24	and	O
25	maximum	O
26	voluntary	O
27	ventilation	O
28	;	O
29	by	O
30	significant	O
31	increases	O
32	in	O
33	residual	O
34	volume	O
35	and	O
36	arterial	O
37	carbon	O
38	dioxide	O
39	tension	O
40	(	O
41	PaCO2	O
42	);	O
43	and	O
44	greater	O
45	likelihood	O
46	of	O
47	dependence	O
48	on	O
49	ventilators	O
50	,	O
51	atelectasis	O
52	,	O
53	and	O
54	pneumonia	O
55	.	O

1	TIEG	O
2	expression	O
3	in	O
4	hFOB	O
5	cells	O
6	was	O
7	highly	O
8	induced	O
9	by	O
10	TGF	B
11	-	I
12	beta	I
13	and	I
14	bone	I
15	morphogenetic	I
16	protein	I
17	-	I
18	2	I
19	(	O
20	BMP	B
21	-	I
22	2	I
23	),	O
24	with	O
25	a	O
26	moderate	O
27	induction	O
28	by	O
29	epidermal	B
30	growth	I
31	factor	I
32	(	O
33	EGF	B
34	),	O
35	but	O
36	no	O
37	induction	O
38	by	O
39	other	O
40	growth	O
41	factors	O
42	/	O
43	cytokines	O
44	was	O
45	observed	O
46	.	O

1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	disrupt	O
8	collagen	B
9	synthesis	O
10	and	O
11	deposition	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	angiogenesis	O
17	inhibitors	O
18	.	O

1	Immunologically	B
2	reactive	I
3	insulin	I
4	levels	O
5	were	O
6	determined	O
7	in	O
8	freely	O
9	-	O
10	moving	O
11	normal	O
12	rats	O
13	offered	O
14	three	O
15	different	O
16	test	O
17	-	O
18	meals	O
19	.	O

1	Rifabutin	O
2	has	O
3	substantial	O
4	efficacy	O
5	when	O
6	combined	O
7	with	O
8	other	O
9	agents	O
10	.	O

1	Thus	O
2	,	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	active	O
8	S	B
9	-	I
10	CDKs	I
11	and	O
12	Dbf4	B
13	/	O
14	Cdc7	B
15	,	O
16	Mcms	B
17	may	O
18	open	O
19	origins	O
20	and	O
21	thereby	O
22	facilitate	O
23	the	O
24	loading	O
25	of	O
26	RPA	B
27	.	O

1	Differential	O
2	expression	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blot	O
8	analysis	O
9	employing	O
10	multiple	O
11	normal	O
12	and	O
13	tumor	O
14	cell	O
15	lines	O
16	.	O

1	Recurrence	O
2	of	O
3	oxalate	O
4	deposition	O
5	in	O
6	a	O
7	renal	O
8	transplant	O
9	during	O
10	ciclosporin	O
11	A	O
12	therapy	O
13	.	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	O
21	in	O
22	Escherichia	O
23	coli	O
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	O
40	(	O
41	Ecc	O
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	B
54	in	O
55	Erwinia	B
56	carotovora	I
57	.	O

1	In	O
2	addition	O
3	serum	O
4	IgE	I
5	concentrations	O
6	were	O
7	not	O
8	statistically	O
9	different	O
10	.	O

1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	O
10	from	O
11	the	O
12	TRE	O
13	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	Recombinant	B
2	BRI1	I
3	-	I
4	KD	O
5	autophosphorylated	I
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O

1	Therefore	O
2	,	O
3	ICSBP	O
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	I
15	inducible	I
16	genes	I
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	Two	O
2	closely	O
3	related	O
4	IgH	O
5	constant	O
6	region	O
7	genes	O
8	,	O
9	CHA	O
10	and	O
11	CHB	O
12	,	O
13	have	O
14	been	O
15	sequenced	O
16	completely	O
17	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	O
5	5	O
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	B
11	protein	I
12	E12	I
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	B
11	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	O
20	-	O
21	kDa	O
22	component	O
23	of	O
24	cleavage	O
25	stimulation	O
26	factor	I
27	(	O
28	CstF	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	O
53	.	O

1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	Halothane	O
2	is	O
3	metabolized	O
4	by	O
5	an	O
6	oxidative	O
7	pathway	O
8	to	O
9	stable	O
10	,	O
11	nonvolatile	O
12	end	O
13	products	O
14	,	O
15	trifluoroacetic	B
16	acid	O
17	(	O
18	TFAA	B
19	)	O
20	and	O
21	bromide	O
22	(	O
23	Br	O
24	-),	O
25	and	O
26	by	O
27	reductive	O
28	pathways	O
29	to	O
30	Br	O
31	-	O
32	and	O
33	inorganic	O
34	fluoride	O
35	(	O
36	F	O
37	-).	O

1	Urine	O
2	specimens	O
3	containing	O
4	either	O
5	phencyclidine	B
6	(	O
7	PCP	B
8	)	O
9	or	O
10	11	O
11	-	O
12	nor	O
13	-	O
14	delta	O
15	9	O
16	-	O
17	tetrahydrocannabinol	I
18	-	O
19	9	O
20	-	O
21	carboxylic	O
22	acid	O
23	(	O
24	9	O
25	-	O
26	THC	O
27	-	O
28	COOH	O
29	)	O
30	were	O
31	adulterated	O
32	with	O
33	sodium	O
34	chloride	O
35	,	O
36	bleach	O
37	,	O
38	vinegar	O
39	,	O
40	potassium	O
41	hydroxide	O
42	,	O
43	liquid	O
44	soap	O
45	,	O
46	2	O
47	-	O
48	propanol	O
49	,	O
50	and	O
51	ammonia	O
52	.	O

1	Laser	O
2	ablation	O
3	has	O
4	been	O
5	employed	O
6	as	O
7	a	O
8	therapeutic	O
9	measure	O
10	for	O
11	chronic	O
12	pulmonary	O
13	emphysema	O
14	.	O

1	CAL	O
2	gain	O
3	amounted	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	CAL	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	Isolation	O
2	and	O
3	genomic	O
4	structure	O
5	of	O
6	a	O
7	human	O
8	homolog	O
9	of	O
10	the	O
11	yeast	B
12	periodic	I
13	tryptophan	I
14	protein	I
15	2	I
16	(	O
17	PWP2	B
18	)	I
19	gene	O
20	mapping	O
21	to	O
22	21q22	O
23	.	O
24	3	O
25	.	O

1	Potential	O
2	indicators	O
3	were	O
4	assessed	O
5	for	O
6	the	O
7	two	O
8	classifications	O
9	of	O
10	protein	O
11	-	O
12	energy	O
13	malnutrition	O
14	in	O
15	the	O
16	guidelines	O
17	for	O
18	integrated	O
19	management	O
20	of	O
21	childhood	O
22	illness	O
23	:	O
24	severe	O
25	malnutrition	O
26	,	O
27	which	O
28	requires	O
29	immediate	O
30	referral	O
31	to	O
32	hospital	O
33	,	O
34	and	O
35	very	O
36	low	O
37	weight	O
38	,	O
39	which	O
40	calls	O
41	for	O
42	feeding	O
43	assessment	O
44	,	O
45	nutritional	O
46	counselling	O
47	and	O
48	follow	O
49	-	O
50	up	O
51	.	O

1	Analysis	O
2	of	O
3	a	O
4	set	O
5	of	O
6	deletion	O
7	constructs	O
8	in	O
9	transient	O
10	transfection	O
11	assays	O
12	measuring	O
13	heterologous	O
14	reporter	O
15	gene	O
16	(	O
17	luciferase	B
18	)	O
19	activity	O
20	demonstrated	O
21	that	O
22	the	O
23	182	O
24	-	O
25	bp	O
26	5	O
27	'-	O
28	flanking	O
29	region	O
30	provides	O
31	full	O
32	promoter	I
33	activity	O
34	in	O
35	IL	B
36	-	I
37	2	I
38	-	O
39	stimulated	O
40	L2	O
41	cells	O
42	.	O

1	Isopenicillin	B
2	N	I
3	isomerase	I
4	(	O
5	epimerase	B
6	)	O
7	has	O
8	been	O
9	purified	O
10	from	O
11	Streptomyces	O
12	clavuligerus	O
13	,	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	sequence	O
19	of	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	has	O
25	been	O
26	determined	O
27	.	O

1	Unlike	O
2	P135gag	B
3	-	I
4	myb	I
5	-	I
6	ets	I
7	and	O
8	the	O
9	Mr	O
10	75	O
11	,	O
12	000	O
13	translation	O
14	product	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	(	O
20	P75c	B
21	-	I
22	myb	I
23	),	O
24	which	O
25	are	O
26	nuclear	O
27	proteins	O
28	,	O
29	P54c	B
30	-	I
31	ets	I
32	was	O
33	found	O
34	to	O
35	be	O
36	predominantly	O
37	cytoplasmic	O
38	.	O

1	The	O
2	six	O
3	commonest	O
4	causes	O
5	of	O
6	death	O
7	varied	O
8	in	O
9	the	O
10	three	O
11	ethnic	O
12	groups	O
13	.	O

1	Analysis	O
2	of	O
3	the	O
4	consensus	O
5	binding	O
6	sequence	O
7	and	O
8	the	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	of	O
14	ZF5	B
15	.	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	O
7	guinea	O
8	pig	O
9	organ	O
10	of	O
11	Corti	O
12	after	O
13	electron	O
14	microscopic	O
15	silver	O
16	staining	O

1	The	O
2	requirement	O
3	of	O
4	different	O
5	essential	O
6	fatty	O
7	acids	O
8	in	O
9	patients	O
10	with	O
11	total	O
12	parenteral	O
13	nutrition	O
14	after	O
15	heavy	O
16	injury	O
17	is	O
18	of	O
19	special	O
20	interest	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	development	O
26	and	O
27	prognosis	O
28	of	O
29	shock	O
30	,	O
31	sepsis	O
32	or	O
33	adult	O
34	respiratory	O
35	distress	O
36	syndrome	O
37	.	O

1	A	O
2	degenerate	O
3	DNA	O
4	transposon	O
5	,	O
6	Pat	O
7	,	O
8	was	O
9	identified	O
10	in	O
11	the	O
12	genomes	O
13	of	O
14	various	O
15	wild	O
16	-	O
17	type	O
18	strains	O
19	of	O
20	the	O
21	filamentous	O
22	fungus	O
23	Podospora	I
24	anserina	I
25	.	O

1	Upon	O
2	differentiation	O
3	with	O
4	retinoic	O
5	acid	O
6	(	O
7	RA	O
8	),	O
9	transcription	O
10	of	O
11	the	O
12	Rex	B
13	-	I
14	1	I
15	gene	I
16	decreases	O
17	rapidly	O
18	.	O

1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O

1	Overexpression	O
2	of	O
3	SCS1	B
4	could	O
5	not	O
6	complement	O
7	an	O
8	HSP60	B
9	-	O
10	null	O
11	allele	O
12	,	O
13	indicating	O
14	that	O
15	suppression	O
16	was	O
17	not	O
18	due	O
19	to	O
20	the	O
21	bypassing	O
22	of	O
23	Hsp60	O
24	activity	O
25	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	Fc	B
7	epsilon	I
8	R1	I
9	is	O
10	a	O
11	33	O
12	-	O
13	kDa	O
14	tyrosine	O
15	phosphoprotein	I
16	,	O
17	but	O
18	the	O
19	p33	B
20	Grb2	I
21	-	I
22	binding	I
23	protein	I
24	described	O
25	in	O
26	the	O
27	present	O
28	report	O
29	is	O
30	not	O
31	the	O
32	Fc	B
33	epsilon	I
34	R1	I
35	beta	I
36	chain	I
37	and	O
38	its	O
39	identity	O
40	is	O
41	unknown	O
42	.	O

1	Although	O
2	both	O
3	transcripts	O
4	share	O
5	the	O
6	first	O
7	nine	O
8	exons	O
9	,	O
10	exon	O
11	10	O
12	of	O
13	ZIS	O
14	-	O
15	2	O
16	is	O
17	lacking	O
18	in	O
19	ZIS	O
20	-	O
21	1	O
22	,	O
23	and	O
24	instead	O
25	,	O
26	exon	O
27	11	O
28	(	O
29	10th	O
30	exon	O
31	)	O
32	of	O
33	ZIS	B
34	-	I
35	1	I
36	is	O
37	larger	O
38	in	O
39	size	O
40	,	O
41	leading	O
42	to	O
43	the	O
44	longer	O
45	3	O
46	'-	O
47	UTR	O
48	.	O

1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O

1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	B
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	B
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	B
39	protein	I
40	and	O
41	terminase	B
42	interaction	I
43	sites	I
44	.	O

1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O

1	Tyrosine	B
2	kinase	I
3	oncogenes	O
4	abrogate	O
5	interleukin	B
6	-	I
7	3	I
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	B
18	-	I
19	myc	I
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	B
25	-	I
26	myc	I
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	B
33	-	I
34	abl	I
35	.	O

1	It	O
2	has	O
3	been	O
4	shown	O
5	in	O
6	experiments	O
7	in	O
8	vitro	O
9	that	O
10	the	O
11	hepatotrophic	O
12	organic	O
13	anions	O
14	,	O
15	the	O
16	radiographic	O
17	contrast	O
18	agent	O
19	(	O
20	RCA	O
21	)	O
22	bilignost	O
23	used	O
24	in	O
25	cholecystography	O
26	and	O
27	Bengal	O
28	pink	O
29	,	O
30	have	O
31	an	O
32	affinity	O
33	,	O
34	unlike	O
35	the	O
36	urographic	B
37	RCA	I
38	triombrin	I
39	and	O
40	renotrophic	O
41	dye	O
42	indigo	O
43	-	O
44	carmine	O
45	,	O
46	for	O
47	the	O
48	plasmatic	O
49	membranes	O
50	(	O
51	PM	O
52	)	O
53	of	O
54	liver	O
55	cells	O
56	.	O

1	METHODS	O
2	:	O
3	Von	B
4	Willebrand	I
5	factor	I
6	(	O
7	vWF	B
8	)	O
9	and	O
10	the	O
11	fibrinolytic	B
12	factors	I
13	tissue	I
14	plasminogen	I
15	activator	I
16	(	O
17	tPA	O
18	),	O
19	measured	O
20	as	O
21	tPA	O
22	capacity	O
23	,	O
24	and	O
25	plasminogen	B
26	activator	I
27	inhibitor	I
28	1	I
29	(	O
30	PAI	B
31	-	I
32	1	I
33	),	O
34	platelets	O
35	,	O
36	fibrinogen	B
37	,	O
38	and	O
39	inflammatory	O
40	markers	O
41	were	O
42	measured	O
43	in	O
44	74	O
45	patients	O
46	with	O
47	active	O
48	seropositive	O
49	RA	O
50	.	O

1	Surface	O
2	-	O
3	coil	O
4	experiments	O
5	on	O
6	phantoms	O
7	and	O
8	on	O
9	human	O
10	calf	O
11	muscles	O
12	in	O
13	vivo	O
14	are	O
15	presented	O
16	.	O

1	Isoform	B
2	C	I
3	beta	I
4	2	I
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	O
13	subunit	O
14	of	O
15	cAMP	B
16	-	I
17	dependent	I
18	protein	I
19	kinase	I
20	.	O

1	It	O
2	is	O
3	considered	O
4	that	O
5	the	O
6	recurrent	O
7	annular	O
8	erythema	O
9	is	O
10	a	O
11	specific	O
12	skin	O
13	manifestation	O
14	of	O
15	SjS	O
16	with	O
17	anti	B
18	SS	I
19	-	I
20	A	I
21	/	O
22	SS	O
23	-	I
24	B	I
25	antibodies	I
26	.	O

1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O

1	Modulation	O
2	of	O
3	25	O
4	-	O
5	hydroxyvitamin	I
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	O
18	450	O
19	monooxygenase	I
20	system	O
21	.	O

1	Following	O
2	seven	O
3	days	O
4	'	O
5	incubation	O
6	both	O
7	at	O
8	20	O
9	degrees	O
10	C	O
11	and	O
12	28	O
13	degrees	O
14	C	O
15	,	O
16	Ae	B
17	.	O
18	vexans	B
19	nip	I
20	.	O
21	was	O
22	capable	O
23	of	O
24	transmitting	O
25	the	O
26	virus	O
27	.	O

1	Beyond	O
2	the	O
3	Tower	O
4	of	O
5	Babel	O
6	:	O
7	a	O
8	nomenclature	O
9	for	O
10	suicidology	O
11	.	O

1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O

1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	B
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O

1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	mediastinal	O
11	drainage	O
12	blood	O
13	,	O
14	shed	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	washing	O
25	in	O
26	a	O
27	MBRS	O
28	.	O

1	Botulinum	B
2	toxin	I
3	A	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	hemiplegic	O
9	spastic	O
10	foot	O
11	drop	O
12	--	O
13	clinical	O
14	and	O
15	functional	O
16	outcomes	O
17	.	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	protein	B
7	kinase	I
8	MEKK1	I
9	can	O
10	induce	O
11	reporter	O
12	gene	O
13	expression	O
14	from	O
15	the	O
16	atrial	B
17	natriuretic	I
18	factor	I
19	(	O
20	ANF	B
21	)	I
22	promoter	O
23	,	O
24	a	O
25	genetic	O
26	marker	O
27	that	O
28	is	O
29	activated	O
30	during	O
31	in	O
32	vivo	O
33	hypertrophy	O
34	.	O

1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	I
8	gene	O
9	expression	O
10	in	O
11	the	O
12	CNS	O
13	are	O
14	poorly	O
15	understood	O
16	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	EF	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	NS	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	NS	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	gp54	B
6	structural	I
7	gene	I
8	is	O
9	required	O
10	for	O
11	initiation	O
12	or	O
13	amplification	O
14	of	O
15	the	O
16	splenic	O
17	erythroblast	O
18	hyperplasia	O
19	which	O
20	characterizes	O
21	the	O
22	preleukemic	O
23	phase	O
24	of	O
25	Rauscher	O
26	disease	O
27	.	O

1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	B
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O

1	Intracellular	O
2	recordings	O
3	were	O
4	performed	O
5	on	O
6	the	O
7	optic	O
8	tectum	O
9	of	O
10	the	O
11	carp	O
12	in	O
13	vitro	O
14	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	Precipitation	B
2	using	O
3	GST	B
4	fusion	I
5	proteins	I
6	containing	O
7	Fyn	B
8	SH2	I
9	,	O
10	SH3	B
11	,	O
12	and	O
13	SH2	B
14	/	I
15	SH3	B
16	domains	I
17	revealed	O
18	that	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	bound	O
24	principally	O
25	to	O
26	the	O
27	SH3	B
28	domain	I
29	of	O
30	Fyn	B
31	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	B
7	-	I
8	helix	I
9	domain	I
10	of	O
11	p57	B
12	(	O
13	Kip2	B
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	Cip	B
21	/	I
22	Kip	I
23	proteins	I
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	confers	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	Cdk	O
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	p57	B
51	(	O
52	Kip2	B
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O

1	There	O
2	was	O
3	no	O
4	difference	O
5	in	O
6	the	O
7	hormone	O
8	receptor	O
9	status	O
10	between	O
11	the	O
12	cases	O
13	without	O
14	lymph	O
15	node	O
16	metastases	O
17	and	O
18	with	O
19	lymph	O
20	node	O
21	metastases	O
22	,	O
23	'	O
24	clandestine	O
25	'	O
26	or	O
27	macrometastases	O
28	.	O

1	Petko	O
2	,	O
3	and	O
4	S	O
5	.	O

1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	Identification	O
2	of	O
3	mutations	O
4	in	O
5	the	O
6	coding	O
7	sequence	O
8	of	O
9	the	O
10	proto	B
11	-	I
12	oncogene	I
13	c	I
14	-	I
15	kit	I
16	in	O
17	a	O
18	human	O
19	mast	O
20	cell	O
21	leukemia	O
22	cell	O
23	line	O
24	causing	O
25	ligand	O
26	-	O
27	independent	O
28	activation	O
29	of	O
30	c	B
31	-	I
32	kit	I
33	product	I
34	.	O

1	W	O
2	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	was	O
6	then	O
7	used	O
8	to	O
9	clone	O
10	from	O
11	human	O
12	poly	O
13	(	O
14	A	O
15	)+	O
16	RNA	O
17	the	O
18	cDNA	O
19	corresponding	O
20	to	O
21	the	O
22	expressed	O
23	homolog	B
24	of	I
25	psi	I
26	ARF	I
27	4	I
28	,	O
29	referred	O
30	to	O
31	as	O
32	human	B
33	ARF	I
34	4	I
35	.	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	I
10	binding	I
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	We	O
2	have	O
3	reviewed	O
4	the	O
5	experience	O
6	of	O
7	a	O
8	major	O
9	MMT	O
10	general	O
11	practice	O
12	with	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	infection	O
20	from	O
21	1991	O
22	to	O
23	1995	O
24	.	O

1	Examination	O
2	of	O
3	immediate	B
4	-	I
5	early	I
6	transcription	I
7	factor	I
8	expression	O
9	during	O
10	the	O
11	MDI	O
12	regimen	O
13	revealed	O
14	that	O
15	RA	O
16	mediated	O
17	an	O
18	elevated	O
19	,	O
20	prolonged	O
21	expression	O
22	of	O
23	c	B
24	-	I
25	Jun	I
26	mRNA	I
27	accompanied	O
28	by	O
29	diminished	O
30	expression	O
31	of	O
32	c	B
33	-	I
34	Fos	I
35	and	O
36	Jun	B
37	-	I
38	B	I
39	mRNAs	I
40	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	genetic	O
6	evidence	O
7	in	O
8	Saccharomyces	O
9	cerevisiae	O
10	for	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	the	O
16	DEAH	B
17	protein	I
18	Prp16	I
19	,	O
20	and	O
21	the	O
22	U6	B
23	and	I
24	U2	B
25	spliceosomal	I
26	snRNAs	I
27	.	O

1	Neither	O
2	RD19	B
3	nor	O
4	RD21	B
5	mRNA	I
6	synthesis	O
7	was	O
8	responsive	O
9	to	O
10	cold	O
11	or	O
12	to	O
13	heat	O
14	stress	O
15	.	O

1	Dominant	O
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	I
12	ERK2	I
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	O
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	O
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	GHB	O
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	B
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O

1	Essentially	O
2	,	O
3	2	O
4	'-	O
5	O	O
6	-	I
7	methyl	O
8	oligoribonucleotides	I
9	(	O
10	2	O
11	'	O
12	OMeRNA	O
13	)	O
14	were	O
15	delivered	O
16	to	O
17	the	O
18	nuclei	O
19	of	O
20	primary	O
21	mdx	O
22	myoblasts	O
23	in	O
24	culture	O
25	.	O

1	These	O
2	differences	O
3	are	O
4	smaller	O
5	than	O
6	those	O
7	described	O
8	in	O
9	standard	O
10	textbooks	O
11	.	O

1	In	O
2	PC12	O
3	cells	O
4	,	O
5	nerve	B
6	growth	I
7	factor	I
8	induces	O
9	neuronal	O
10	differentiation	O
11	and	O
12	repressed	O
13	expression	O
14	of	O
15	nrg	B
16	-	I
17	1	I
18	.	O

1	However	O
2	,	O
3	the	O
4	signaling	O
5	cascade	O
6	utilized	O
7	by	O
8	the	O
9	urokinase	B
10	receptor	I
11	is	O
12	only	O
13	incompletely	O
14	understood	O
15	.	O

1	Successful	O
2	treatment	O
3	with	O
4	nasal	O
5	continuous	O
6	positive	O
7	airway	O
8	pressure	O
9	(	O
10	8	O
11	.	O
12	3	O
13	+/-	O
14	1	O
15	.	O
16	5	O
17	cmH2O	O
18	)	O
19	for	O
20	3	O
21	days	O
22	caused	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	mean	O
28	blood	O
29	pressure	O
30	in	O
31	OSAS	O
32	.	O

1	The	O
2	mature	O
3	protein	O
4	also	O
5	contains	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	,	O
11	highly	O
12	hydrophilic	O
13	region	O
14	homologous	O
15	to	O
16	the	O
17	ovomucoid	B
18	serine	I
19	protease	I
20	inhibitors	O
21	(	O
22	residues	O
23	76	I
24	-	O
25	132	O
26	).	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	BACKGROUND	O
2	:	O
3	Checkpoint	O
4	pathways	O
5	prevent	O
6	cell	O
7	-	O
8	cycle	O
9	progression	O
10	in	O
11	the	O
12	event	O
13	of	O
14	DNA	O
15	lesions	O
16	.	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	Two	O
2	activities	O
3	of	O
4	the	O
5	D	B
6	protein	O
7	of	O
8	the	O
9	miniF	B
10	plasmid	O
11	have	O
12	been	O
13	found	O
14	.	O

1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	B
9	polymerase	I
10	II	I
11	,	O
12	TATA	B
13	-	I
14	binding	I
15	protein	I
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	I
28	(	O
29	CTD	B
30	)	O
31	of	O
32	RNA	B
33	polymerase	I
34	II	I
35	a	O
36	"	B
37	portable	I
38	enhancer	I
39	domain	I
40	"?	I
41	Regions	I
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	B
70	TATA	I
71	-	I
72	binding	I
73	proteins	I
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	B
6	-	O
7	19	O
8	amino	O
9	acid	O
10	sequence	O
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	B
23	TEF	I
24	-	I
25	1A	I
26	,	O
27	mouse	B
28	TEF	I
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	O
34	embryonic	O
35	TEA	O
36	domain	O
37	-	O
38	containing	O
39	factor	I
40	,	O
41	respectively	O
42	.	O

1	An	O
2	automated	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	the	O
10	polyamines	B
11	putrescine	I
12	,	O
13	spermidine	O
14	and	O
15	spermine	B
16	in	O
17	cerebrospinal	B
18	fluid	O
19	(	O
20	CSF	B
21	)	O
22	was	O
23	used	O
24	to	O
25	analyze	O
26	CSF	O
27	samples	O
28	from	O
29	37	O
30	patients	O
31	with	O
32	central	O
33	nervous	O
34	system	O
35	(	O
36	CNS	O
37	)	O
38	tumors	O
39	and	O
40	from	O
41	13	O
42	patients	O
43	without	O
44	tumors	O
45	.	O

1	This	O
2	fraction	O
3	is	O
4	resistant	O
5	to	O
6	digestions	O
7	by	O
8	DNase	B
9	I	I
10	and	O
11	RNase	B
12	T1	I
13	and	O
14	disappears	O
15	completely	O
16	upon	O
17	alkali	O
18	hydrolysis	O
19	.	O

1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	I
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	B
18	,	O
19	the	O
20	stimulatory	B
21	regulator	I
22	of	O
23	adenylyl	B
24	cyclase	I
25	.	O

1	The	O
2	spermicide	B
3	nonoxynol	I
4	-	I
5	9	O
6	is	O
7	a	O
8	member	O
9	of	O
10	a	O
11	homologous	O
12	series	O
13	of	O
14	alkylphenol	B
15	-	I
16	ethoxylates	I
17	(	O
18	polyethoxyethanols	B
19	)	O
20	of	O
21	general	B
22	formula	I
23	C9H19	I
24	-	I
25	C6H6	I
26	-	I
27	O	I
28	-(	O
29	CH2CH2O	B
30	)	O
31	n	B
32	-	I
33	1	I
34	CH2CH2OH	O
35	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	highly	O
6	expressed	O
7	ADH1	B
8	gene	I
9	is	O
10	represented	O
11	in	O
12	this	O
13	database	O
14	by	O
15	no	O
16	less	O
17	than	O
18	20	O
19	EST	O
20	sequences	O
21	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	Hyperprolactinaemia	O
2	,	O
3	moderate	O
4	hypogonadism	O
5	,	O
6	infraclinical	O
7	neuropathies	O
8	,	O
9	arterial	O
10	stenoses	O
11	and	O
12	moderate	O
13	venous	O
14	leakages	O
15	seem	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	starter	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	psychological	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	failures	O
45	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	are	O
7	consistent	O
8	with	O
9	the	O
10	possibility	O
11	that	O
12	p202	B
13	protein	I
14	contributes	O
15	to	O
16	the	O
17	cell	O
18	growth	O
19	retardation	O
20	activity	O
21	of	O
22	the	O
23	IFNs	O
24	,	O
25	at	O
26	least	O
27	in	O
28	part	O
29	,	O
30	by	O
31	modulating	O
32	p21	B
33	protein	O
34	levels	O
35	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	RESULTS	O
2	:	O
3	Nodular	O
4	opacities	O
5	,	O
6	mainly	O
7	centrilobular	O
8	in	O
9	distribution	O
10	,	O
11	were	O
12	the	O
13	most	O
14	common	O
15	finding	O
16	,	O
17	seen	O
18	in	O
19	21	O
20	(	O
21	72	O
22	%)	O
23	and	O
24	15	O
25	(	O
26	65	O
27	%)	O
28	of	O
29	patients	O
30	with	O
31	MTB	O
32	and	O
33	NTMB	O
34	,	O
35	respectively	O
36	.	O

1	Alpha	B
2	-	I
3	1	I
4	antitrypsin	I
5	and	O
6	Indian	O
7	childhood	O
8	cirrhosis	O
9	.	O

1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O

1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	O
8	age	O
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	O
13	Escherichia	O
14	coli	O
15	RNA	I
16	polymerase	I
17	.	O

1	The	O
2	30	O
3	-	O
4	day	O
5	mortality	O
6	in	O
7	the	O
8	CPB	O
9	group	O
10	and	O
11	the	O
12	non	O
13	-	O
14	CPB	O
15	group	O
16	were	O
17	20	O
18	%	O
19	and	O
20	4	O
21	.	O
22	6	O
23	%,	O
24	respectively	O
25	which	O
26	was	O
27	not	O
28	statistically	O
29	significant	O
30	(	O
31	p	O
32	=	O
33	0	O
34	.	O
35	06	O
36	).	O

1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	B
8	-	I
9	inducible	I
10	CBF	I
11	/	I
12	cdc2	I
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	B
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	B
25	shock	I
26	protein	I
27	70	I
28	promoter	O
29	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	O
26	deletions	O
27	.	O

1	The	O
2	Scales	O
3	of	O
4	Cognitive	B
5	Impairment	I
6	Rated	I
7	From	O
8	Institutional	I
9	Records	I
10	(	O
11	SCIRFIR	O
12	),	O
13	a	O
14	battery	O
15	based	O
16	on	O
17	commonly	O
18	used	O
19	dementia	O
20	rating	O
21	instruments	O
22	,	O
23	was	O
24	tested	O
25	on	O
26	the	O
27	records	O
28	of	O
29	26	O
30	chronically	O
31	institutionalized	O
32	,	O
33	elderly	O
34	schizophrenia	O
35	patients	O
36	,	O
37	for	O
38	the	O
39	purpose	O
40	of	O
41	retrospectively	O
42	evaluating	O
43	the	O
44	long	O
45	-	O
46	term	O
47	course	O
48	of	O
49	cognitive	O
50	change	O
51	in	O
52	schizophrenia	O
53	and	O
54	relating	O
55	it	O
56	to	O
57	available	O
58	autopsy	O
59	materials	O
60	.	O

1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	UmuD	B
14	and	O
15	UmuD	B
16	'	I
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	B
23	(	O
24	UmuD	B
25	-	I
26	UmuD	I
27	and	O
28	UmuD	B
29	'-	I
30	UmuD	I
31	')	O
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	UmuD	B
37	-	O
38	UmuD	I
39	').	O

1	Similarly	O
2	,	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	U2	B
8	RNA	I
9	region	I
10	shown	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	pre	O
16	-	O
17	mRNA	O
18	branchpoint	O
19	recognition	O
20	in	O
21	yeast	O
22	,	O
23	and	O
24	exactly	O
25	conserved	O
26	in	O
27	metazoan	O
28	U2	I
29	RNAs	I
30	,	O
31	was	O
32	totally	O
33	divergent	O
34	in	O
35	trypanosomes	O
36	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	I
13	tRNA	I
14	can	I
15	confer	I
16	a	O
17	mutator	B
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	O
29	and	O
30	mutC	O
31	cells	O
32	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	Then	O
2	we	O
3	correlated	O
4	HRCT	O
5	findings	O
6	with	O
7	the	O
8	clinical	O
9	features	O
10	,	O
11	pulmonary	O
12	functions	O
13	and	O
14	methacholine	O
15	PC20	O
16	(	O
17	PC20M	O
18	)	O
19	and	O
20	studied	O
21	their	O
22	clinical	O
23	significance	O
24	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	LvUSF2	B
8	is	O
9	nearly	O
10	identical	O
11	to	O
12	LvUSF1	O
13	except	O
14	at	O
15	the	O
16	amino	O
17	end	O
18	,	O
19	where	O
20	they	O
21	are	O
22	sharply	O
23	divergent	O
24	.	O

1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O

1	It	O
2	has	O
3	been	O
4	calculated	O
5	that	O
6	600	O
7	,	O
8	000	O
9	new	O
10	cases	O
11	of	O
12	lung	O
13	cancer	O
14	occur	O
15	worldwide	O
16	every	O
17	year	O
18	,	O
19	most	O
20	of	O
21	them	O
22	due	O
23	to	O
24	smoking	O
25	.	O

1	By	O
2	order	O
3	of	O
4	decreasing	O
5	rate	O
6	,	O
7	finger	O
8	flexors	O
9	,	O
10	jaw	O
11	,	O
12	crossed	O
13	adductors	O
14	,	O
15	and	O
16	triceps	O
17	reflexes	O
18	were	O
19	less	O
20	frequently	O
21	elicited	O
22	in	O
23	both	O
24	groups	O
25	.	O

1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	O
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	jun	B
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O

1	Microcirculatory	O
2	oxygenation	O
3	and	O
4	shunting	O
5	in	O
6	sepsis	O
7	and	O
8	shock	O
9	.	O

1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	B
13	hsp70	I
14	,	I
15	trout	B
16	hsp70	I
17	,	O
18	Xenopus	B
19	hsp70	I
20	,	O
21	yeast	B
22	hsp70	I
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	B
30	-	I
31	inducible	I
32	dnaK	I
33	gene	I
34	product	I
35	of	O
36	Escherichia	O
37	coli	O
38	.	O

1	Thus	O
2	,	O
3	although	O
4	p28	O
5	may	O
6	play	O
7	only	O
8	a	O
9	limited	O
10	role	O
11	during	O
12	the	O
13	early	O
14	embryonic	O
15	cleavages	O
16	,	O
17	it	O
18	may	O
19	function	O
20	later	O
21	in	O
22	development	O
23	to	O
24	establish	O
25	a	O
26	somatic	O
27	type	O
28	of	O
29	cell	O
30	cycle	O
31	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	B
14	translating	I
15	tnaC	I
16	blocks	I
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	B
24	and	O
25	rut	B
26	sites	O
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	O
10	mutants	O
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	O
20	plate	O
21	inducer	O
22	shh	O
23	.	O

1	Some	O
2	of	O
3	the	O
4	peptide	O
5	:	O
6	MBP	B
7	fusions	I
8	were	O
9	also	O
10	analyzed	O
11	using	O
12	surface	O
13	plasmon	O
14	resonance	O
15	.	O

1	Since	O
2	the	O
3	regulation	O
4	of	O
5	SWI4	B
6	is	O
7	required	O
8	for	O
9	normal	O
10	cell	O
11	cycle	O
12	progression	O
13	,	O
14	we	O
15	have	O
16	characterized	O
17	cis	O
18	-	O
19	and	O
20	trans	O
21	-	O
22	acting	O
23	regulators	O
24	of	O
25	SWI4	B
26	transcription	O
27	.	O

1	Angiography	O
2	was	O
3	performed	O
4	following	O
5	the	O
6	rCBF	O
7	study	O
8	and	O
9	the	O
10	degree	O
11	of	O
12	vasospasm	O
13	was	O
14	measured	O
15	on	O
16	the	O
17	angiograms	O
18	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	B
10	eccrine	I
11	sweat	I
12	duct	O
13	units	O
14	.	O

1	The	O
2	gene	O
3	is	O
4	contained	O
5	within	O
6	a	O
7	1	O
8	.	O
9	8	O
10	-	O
11	kilobase	I
12	AccI	I
13	-	I
14	EcoRI	I
15	restriction	I
16	fragment	I
17	mapping	O
18	at	O
19	map	O
20	coordinates	O
21	0	O
22	.	O
23	136	O
24	to	O
25	0	O
26	.	O
27	148	O
28	in	O
29	the	O
30	UL	O
31	region	O
32	of	O
33	the	O
34	EHV	O
35	-	O
36	1	O
37	genome	O
38	and	O
39	is	O
40	transcribed	O
41	from	O
42	right	O
43	to	O
44	left	O
45	.	O

1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	I
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	B
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O

1	These	O
2	cells	O
3	averaged	O
4	17	O
5	microns	O
6	in	O
7	diameter	O
8	and	O
9	reproduced	O
10	by	O
11	fission	O
12	,	O
13	forming	O
14	clusters	O
15	of	O
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	The	O
2	defect	O
3	in	O
4	these	O
5	proteins	O
6	was	O
7	also	O
8	uniformly	O
9	suppressed	O
10	by	O
11	either	O
12	Mn2	O
13	+,	O
14	or	O
15	the	O
16	Mu	O
17	B	O
18	protein	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	ATP	O
24	and	O
25	target	O
26	DNA	O
27	.	O

1	Interleukin	B
2	-	I
3	6	I
4	(	O
5	IL	B
6	-	I
7	6	I
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O

1	Recombinant	O
2	soluble	O
3	pMCP	O
4	that	O
5	lacked	O
6	transmembrane	I
7	and	O
8	cytoplasmic	O
9	domains	I
10	had	I
11	factor	I
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	O
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	O
32	.	O

1	Hepatitis	O
2	B	O
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	B
15	hepatitis	I
16	B	I
17	endemicity	I
18	.	O

1	The	O
2	IDF	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	penicillin	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	sulphonamide	O
20	residues	O
21	in	O
22	milk	O
23	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	B
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	O
23	.	O

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O

1	Several	O
2	authors	O
3	have	O
4	recently	O
5	reported	O
6	interference	O
7	in	O
8	theophylline	O
9	analysis	O
10	by	O
11	paraxanthine	O
12	(	O
13	1	O
14	,	O
15	7	O
16	-	O
17	dimethylxanthine	O
18	),	O
19	an	O
20	important	O
21	metabolite	O
22	of	O
23	caffeine	O
24	.	O

1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	I
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	Protein	O
2	phosphorylation	O
3	appears	O
4	to	O
5	play	O
6	a	O
7	critical	O
8	role	O
9	in	O
10	uPA	B
11	gene	I
12	expression	O
13	in	O
14	these	O
15	cells	O
16	;	O
17	protein	B
18	kinase	I
19	C	I
20	-	O
21	activating	O
22	phorbol	O
23	esters	O
24	cooperate	O
25	with	O
26	pp60v	B
27	-	I
28	src	I
29	to	O
30	synergistically	O
31	increase	O
32	uPA	B
33	mRNA	I
34	,	O
35	whereas	O
36	cyclic	O
37	AMP	O
38	(	O
39	cAMP	O
40	)-	O
41	dependent	O
42	protein	I
43	kinase	I
44	-	O
45	activating	O
46	agents	O
47	(	O
48	e	O
49	.	O
50	g	O
51	.,	O
52	8	O
53	-	O
54	bromo	O
55	cAMP	O
56	)	O
57	repress	O
58	uPA	B
59	mRNA	O
60	levels	O
61	.	O

1	Indeed	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	it	O
8	mediates	O
9	the	O
10	formation	O
11	of	O
12	disulfide	O
13	-	O
14	linked	O
15	homodimers	O
16	and	O
17	that	O
18	the	O
19	formation	O
20	of	O
21	homo	O
22	-	O
23	and	O
24	heterodimers	O
25	are	O
26	mutually	O
27	excluded	O
28	.	O

1	The	O
2	results	O
3	raise	O
4	the	O
5	possibility	O
6	that	O
7	pH	O
8	induced	O
9	post	O
10	-	O
11	translational	O
12	modifications	O
13	of	O
14	DdRPA	O
15	are	O
16	involved	O
17	in	O
18	events	O
19	that	O
20	halt	O
21	cell	O
22	proliferation	O
23	and	O
24	induce	O
25	differentiation	O
26	in	O
27	Dictyostelium	O
28	.	O

1	Droperidol	O
2	-	O
3	induced	O
4	extrapyramidal	O
5	symptoms	O
6	in	O
7	an	O
8	adolescent	O
9	following	O
10	strabismus	O
11	surgery	O
12	.	O

1	Evidence	O
2	for	O
3	such	O
4	peak	O
5	shifts	O
6	has	O
7	been	O
8	found	O
9	in	O
10	the	O
11	responses	O
12	of	O
13	auditory	O
14	nerve	O
15	fibers	O
16	,	O
17	cochlear	O
18	microphonics	O
19	,	O
20	and	O
21	the	O
22	responses	O
23	of	O
24	outer	O
25	hair	O
26	cells	O
27	and	O
28	supporting	O
29	cells	O
30	in	O
31	the	O
32	cochlea	O
33	,	O
34	as	O
35	well	O
36	as	O
37	in	O
38	basilar	O
39	membrane	O
40	vibration	O
41	measurements	O
42	,	O
43	and	O
44	indirectly	O
45	,	O
46	in	O
47	psychophysical	O
48	data	O
49	.	O

1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	B
13	-	I
14	FUT5	I
15	-	I
16	FUT6	I
17	cluster	I
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O

1	This	O
2	protein	O
3	with	O
4	a	O
5	hydrophobic	O
6	amino	O
7	terminus	O
8	appears	O
9	to	O
10	be	O
11	a	O
12	secreted	O
13	protein	O
14	.	O

1	Two	O
2	other	O
3	patients	O
4	underwent	O
5	PRFR	O
6	.	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	B
11	)	I
12	and	O
13	renin	B
14	(	O
15	PRC	O
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	Survival	O
2	of	O
3	111	O
4	Indium	O
5	-	O
6	labelled	O
7	autologous	O
8	platelets	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	shortened	O
24	.	O

1	The	O
2	downstream	O
3	,	O
4	TATA	O
5	-	O
6	less	O
7	promoter	O
8	has	O
9	high	O
10	G	O
11	+	O
12	C	O
13	content	O
14	,	O
15	and	O
16	exon	O
17	1b	B
18	predominates	I
19	among	O
20	abundantly	O
21	expressed	O
22	mRNA	O
23	species	O
24	.	O

1	Expense	O
2	limits	O
3	the	O
4	use	O
5	of	O
6	hepatitis	B
7	B	I
8	vaccines	O
9	,	O
10	but	O
11	low	O
12	-	O
13	dose	O
14	intradermal	O
15	immunization	O
16	has	O
17	been	O
18	evaluated	O
19	as	O
20	a	O
21	cost	O
22	-	O
23	saving	O
24	strategy	O
25	in	O
26	numerous	O
27	studies	O
28	.	O

1	Out	O
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	leprosy	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O

1	It	O
2	is	O
3	shown	O
4	that	O
5	the	O
6	(	O
7	G	O
8	+	O
9	C	I
10	)-	O
11	rich	O
12	element	O
13	of	O
14	the	O
15	aldolase	B
16	C	I
17	promoter	I
18	directs	O
19	transcription	O
20	in	O
21	neuronal	O
22	as	O
23	well	O
24	as	O
25	in	O
26	nonneuronal	O
27	cells	O
28	.	O

1	Increased	O
2	PTHRP	O
3	production	O
4	by	O
5	a	O
6	tyrosine	B
7	kinase	I
8	oncogene	I
9	,	O
10	Tpr	B
11	-	O
12	Met	O
13	:	O
14	role	O
15	of	O
16	the	O
17	Ras	B
18	signaling	O
19	pathway	O
20	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	hCG	B
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	B
17	levels	O
18	suggest	O
19	that	O
20	hCG	B
21	has	O
22	thyrotropic	O
23	activity	O
24	.	O

1	The	O
2	nm23	B
3	-	I
4	H1	I
5	/	I
6	nm23	I
7	-	I
8	H2	I
9	gene	I
10	transcriptional	O
11	activity	O
12	ratio	O
13	varied	O
14	depending	O
15	on	O
16	the	O
17	cell	O
18	line	O
19	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	However	O
2	,	O
3	unlike	O
4	Bcl	B
5	-	I
6	2	I
7	and	O
8	the	O
9	E1B	B
10	19K	I
11	proteins	I
12	,	O
13	which	O
14	completely	O
15	block	O
16	apoptosis	O
17	but	O
18	not	O
19	p53	B
20	-	I
21	dependent	O
22	growth	I
23	arrest	O
24	,	O
25	H	B
26	-	I
27	ras	I
28	expression	O
29	permitted	O
30	DNA	O
31	synthesis	O
32	and	O
33	cell	O
34	proliferation	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	high	O
40	levels	O
41	of	O
42	wild	B
43	-	I
44	type	I
45	p53	I
46	.	O

1	Comparisons	O
2	of	O
3	rrnB	B
4	P1	I
5	-	I
6	lacZ	I
7	expression	O
8	at	O
9	different	O
10	ppGpp	O
11	levels	O
12	is	O
13	interpreted	O
14	for	O
15	the	O
16	rpoD	B
17	(	O
18	P504L	B
19	)	I
20	mutant	O
21	as	O
22	resulting	O
23	from	O
24	a	O
25	hypersensitivity	O
26	to	O
27	ppGpp	O
28	.	O

1	Pharmacological	O
2	action	O
3	of	O
4	eptazocine	O
5	(	O
6	l	O
7	-	O
8	1	O
9	,	O
10	4	O
11	-	O
12	dimethyl	O
13	-	O
14	10	O
15	-	O
16	hydroxy	O
17	-	I
18	2	I
19	,	O
20	3	O
21	,	O
22	4	O
23	,	O
24	5	O
25	,	O
26	6	O
27	,	O
28	7	B
29	-	I
30	hexahydro	I
31	-	I
32	1	I
33	,	O
34	6	B
35	-	I
36	methano	I
37	-	I
38	1H	I
39	-	I
40	4	I
41	-	I
42	benz	I
43	azonine	I
44	).	O

1	Thus	O
2	,	O
3	the	O
4	multidomained	B
5	ROK	I
6	alpha	I
7	appears	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	reorganization	O
13	of	O
14	the	O
15	cytoskeleton	O
16	,	O
17	with	O
18	the	O
19	N	O
20	and	O
21	C	O
22	termini	O
23	acting	O
24	as	O
25	positive	O
26	and	O
27	negative	O
28	regulators	O
29	,	O
30	respectively	O
31	,	O
32	of	O
33	the	O
34	kinase	O
35	domain	O
36	whose	O
37	activity	O
38	is	O
39	crucial	O
40	for	O
41	formation	O
42	of	O
43	stress	O
44	fibers	O
45	and	O
46	focal	O
47	adhesion	O
48	complexes	O
49	.	O

1	A	O
2	second	O
3	isotype	B
4	of	I
5	Raja	B
6	immunoglobulin	I
7	heavy	I
8	chain	I
9	genes	I
10	has	O
11	been	O
12	detected	O
13	by	O
14	screening	O
15	a	O
16	spleen	O
17	cDNA	O
18	library	O
19	with	O
20	homologous	B
21	Raja	I
22	VH	I
23	-	I
24	and	O
25	CH1	B
26	-	O
27	specific	O
28	probes	O
29	complementing	O
30	the	O
31	respective	O
32	regions	O
33	of	O
34	the	O
35	mu	B
36	-	I
37	like	I
38	isotype	I
39	.	O

1	This	O
2	Mr	O
3	is	O
4	similar	O
5	to	O
6	those	O
7	of	O
8	the	O
9	purified	O
10	smg	I
11	p25A	I
12	GDI	I
13	estimated	O
14	by	O
15	sodium	O
16	dodecyl	O
17	sulfate	O
18	-	O
19	polyacrylamide	O
20	gel	O
21	electrophoresis	O
22	and	O
23	sucrose	O
24	density	O
25	gradient	O
26	ultracentrifugation	O
27	,	O
28	which	O
29	are	O
30	about	O
31	54	O
32	,	O
33	000	O
34	and	O
35	65	O
36	,	O
37	000	O
38	,	O
39	respectively	O
40	.	O

1	It	O
2	could	O
3	be	O
4	detected	O
5	exclusively	O
6	in	O
7	the	O
8	culture	O
9	medium	O
10	of	O
11	cDNA	O
12	-	O
13	transfected	O
14	COS	O
15	cells	O
16	.	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	O
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	B
17	peptide	I
18	transport	I
19	gene	I
20	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	B
40	mucosae	I
41	.	O

1	These	O
2	motifs	O
3	include	O
4	a	O
5	Chi	O
6	motif	O
7	and	O
8	a	O
9	Chi	O
10	-	O
11	like	O
12	element	O
13	previously	O
14	found	O
15	in	O
16	the	O
17	recombination	O
18	hotspot	O
19	region	O
20	of	O
21	the	O
22	Bcl	B
23	-	I
24	2	I
25	proto	I
26	-	I
27	oncogene	I
28	and	O
29	close	O
30	to	O
31	chromosomal	O
32	breakpoints	O
33	in	O
34	T	O
35	-	O
36	ALL	O
37	lines	O
38	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	complete	O
6	6	O
7	-	O
8	kilobase	O
9	cDNA	O
10	sequence	O
11	coding	O
12	for	O
13	a	O
14	chain	O
15	of	O
16	1775	O
17	amino	O
18	acids	O
19	,	O
20	as	O
21	well	O
22	as	O
23	the	O
24	genomic	O
25	structure	O
26	.	O

1	Association	O
2	with	O
3	HL	B
4	-	I
5	A	I
6	W	I
7	-	O
8	27	O
9	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	B
19	and	O
20	S1	B
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	O
28	-	O
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	The	O
2	plasmatic	B
3	albumin	I
4	concentration	O
5	(	O
6	3	O
7	.	O
8	5	O
9	-	O
10	4	O
11	.	O
12	5	O
13	g	O
14	/	O
15	dl	O
16	)	O
17	represents	O
18	about	O
19	60	O
20	%	O
21	of	O
22	the	O
23	total	O
24	plasma	O
25	protein	O
26	.	O

1	The	O
2	intracellular	O
3	basic	O
4	region	O
5	/	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	(	O
12	bHLH	B
13	)	I
14	dioxin	I
15	receptor	I
16	mediates	O
17	signal	O
18	transduction	O
19	by	O
20	dioxin	O
21	(	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	)	O
36	and	O
37	functions	O
38	as	O
39	a	O
40	ligand	O
41	-	O
42	activated	O
43	DNA	O
44	binding	O
45	protein	O
46	directly	O
47	interacting	O
48	with	O
49	target	O
50	genes	O
51	by	O
52	binding	O
53	to	O
54	dioxin	O
55	response	O
56	elements	O
57	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	conservation	O
6	of	O
7	nucleotides	O
8	154	O
9	to	O
10	156	O
11	is	O
12	likely	O
13	to	O
14	be	O
15	a	O
16	consequence	O
17	of	O
18	their	O
19	role	O
20	as	O
21	a	O
22	sequence	O
23	-	O
24	specific	O
25	recognition	O
26	element	O
27	for	O
28	the	O
29	SRP54	B
30	protein	I
31	.	O

1	Routine	O
2	clinical	O
3	analysis	O
4	revealed	O
5	lower	O
6	hematocrit	O
7	and	O
8	hemoglobin	B
9	,	O
10	and	O
11	elevated	O
12	BUN	B
13	and	O
14	alkaline	B
15	phosphatase	I
16	in	O
17	the	O
18	treated	O
19	group	O
20	.	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	As	O
2	was	O
3	observed	O
4	previously	O
5	for	O
6	MATa	B
7	cna1	I
8	cna2	I
9	double	I
10	mutants	I
11	,	O
12	MATa	B
13	cnb1	I
14	mutants	I
15	were	O
16	defective	O
17	in	O
18	their	O
19	ability	O
20	to	O
21	recover	O
22	from	O
23	alpha	B
24	-	I
25	factor	I
26	-	O
27	induced	O
28	growth	O
29	arrest	O
30	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	of	O
6	infected	O
7	children	O
8	,	O
9	an	O
10	age	O
11	-	O
12	specific	O
13	z	O
14	score	O
15	<	O
16	-	O
17	2	O
18	for	O
19	weight	O
20	and	O
21	for	O
22	FFM	O
23	was	O
24	significantly	O
25	associated	O
26	with	O
27	an	O
28	increased	O
29	risk	O
30	of	O
31	death	O
32	[	O
33	relative	O
34	risk	O
35	(	O
36	95	O
37	%	O
38	CI	O
39	)	O
40	=	O
41	11	O
42	.	O
43	4	O
44	(	O
45	3	O
46	.	O
47	1	O
48	,	O
49	41	O
50	.	O
51	0	O
52	)	O
53	and	O
54	5	O
55	.	O
56	1	O
57	(	O
58	1	O
59	.	O
60	5	O
61	,	O
62	18	O
63	.	O
64	2	O
65	),	O
66	respectively	O
67	];	O
68	when	O
69	only	O
70	children	O
71	with	O
72	more	O
73	severe	O
74	disease	O
75	were	O
76	considered	O
77	,	O
78	only	O
79	z	O
80	score	O
81	for	O
82	weight	O
83	was	O
84	significantly	O
85	associated	O
86	with	O
87	an	O
88	increased	O
89	risk	O
90	[	O
91	4	O
92	.	O
93	6	O
94	(	O
95	1	O
96	.	O
97	4	O
98	,	O
99	14	O
100	.	O
101	9	O
102	)].	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	B
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	I
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	O
9	-	I
10	stranded	I
11	-	I
12	RNA	I
13	-	I
14	specific	I
15	adenosine	I
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	B
28	.	O

1	Induced	O
2	expression	O
3	of	O
4	Rnd3	O
5	is	O
6	associated	O
7	with	O
8	transformation	O
9	of	O
10	polarized	O
11	epithelial	O
12	cells	O
13	by	O
14	the	O
15	Raf	B
16	-	I
17	MEK	I
18	-	I
19	extracellular	I
20	signal	I
21	-	I
22	regulated	I
23	kinase	I
24	pathway	O
25	.	O

1	Electron	O
2	microscopic	O
3	picture	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	cooled	O
11	to	O
12	22	O
13	degrees	O
14	C	O

1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	influence	O
6	of	O
7	NaFe3	O
8	+	O
9	EDTA	O
10	,	O
11	and	O
12	of	O
13	increasing	O
14	dietary	O
15	levels	O
16	of	O
17	Na2EDTA	O
18	,	O
19	on	O
20	Zn	B
21	,	O
22	Cu	O
23	and	O
24	Ca	O
25	metabolism	O
26	in	O
27	rats	O
28	fed	O
29	on	O
30	Zn	O
31	-	O
32	sufficient	O
33	and	O
34	Zn	O
35	-	O
36	deficient	O
37	soya	O
38	-	O
39	bean	O
40	-	O
41	isolate	O
42	-	O
43	based	O
44	diets	O
45	.	O

1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	B
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	B
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	O
32	.	O

1	The	O
2	second	O
3	group	O
4	of	O
5	homologous	O
6	elements	O
7	is	O
8	present	O
9	in	O
10	the	O
11	upstream	O
12	region	O
13	of	O
14	both	O
15	genes	O
16	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	O
6	-	O
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	I
13	SMMHC	I
14	fusion	I
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	B
26	wild	I
27	-	I
28	type	I
29	or	O
30	fusion	O
31	protein	O
32	.	O

1	Isoelectric	O
2	focusing	O
3	of	O
4	tryptic	O
5	peptides	O
6	generated	O
7	from	O
8	MHC	B
9	-	I
10	B	I
11	phosphorylated	O
12	with	O
13	cdc2	B
14	kinase	I
15	revealed	O
16	one	O
17	major	O
18	phosphopeptide	O
19	that	O
20	was	O
21	purified	O
22	by	O
23	reverse	O
24	-	O
25	phase	O
26	high	O
27	performance	O
28	liquid	O
29	chromatography	O
30	and	O
31	sequenced	O
32	.	O

1	Effect	O
2	of	O
3	2	O
4	-(	O
5	p	O
6	-	O
7	chlorophenyl	O
8	)	O
9	cyclopropylamine	O
10	on	O
11	5	B
12	-	I
13	hydroxyindole	I
14	concentration	O
15	and	O
16	monoamine	B
17	oxidase	I
18	activity	O
19	in	O
20	rat	O
21	brain	O
22	.	O

1	Canine	O
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O

1	An	O
2	intact	O
3	neurovascular	O
4	supply	O
5	is	O
6	essential	O
7	for	O
8	the	O
9	viability	O
10	of	O
11	a	O
12	muscle	O
13	flap	O
14	.	O

1	Man	O
2	and	O
3	insect	O
4	,	O
5	past	O
6	,	O
7	present	O
8	,	O
9	future	O

1	To	O
2	determine	O
3	the	O
4	signal	B
5	recognition	I
6	particle	I
7	(	I
8	SRP	I
9	)-	I
10	SRP	I
11	receptor	I
12	(	O
13	Srb	B
14	)	O
15	system	O
16	in	O
17	Bacillus	B
18	subtilis	O
19	(	O
20	Bs	O
21	),	O
22	we	O
23	cloned	O
24	the	O
25	Bs	B
26	srb	I
27	gene	I
28	,	O
29	which	O
30	encodes	O
31	a	O
32	homologue	O
33	of	O
34	the	O
35	mammalian	B
36	SRP	I
37	receptor	I
38	alpha	I
39	-	I
40	subunit	I
41	[	O
42	Oguro	O
43	et	O
44	al	O
45	.,	O
46	DNA	O
47	Res	O
48	.	O

1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	transposable	O
11	elements	O
12	.	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	Hb	B
2	levels	O
3	remained	O
4	adequate	O
5	(	O
6	Hb	B
7	=	O
8	10	O
9	.	O
10	68	O
11	+/-	O
12	0	O
13	.	O
14	77	O
15	g	O
16	/	O
17	dl	O
18	)	O
19	after	O
20	14	O
21	.	O
22	6	O
23	+/-	O
24	7	O
25	.	O
26	64	O
27	months	O
28	.	O

1	Underlying	O
2	the	O
3	clustering	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O

1	Most	O
2	important	O
3	,	O
4	infection	O
5	of	O
6	the	O
7	cells	O
8	with	O
9	an	O
10	adenoviral	O
11	construct	O
12	expressing	O
13	this	O
14	mutant	O
15	inhibited	O
16	the	O
17	induction	O
18	of	O
19	VEGF	B
20	mRNA	I
21	under	O
22	conditions	O
23	that	O
24	mimic	O
25	hypoxia	O
26	.	O

1	The	O
2	effects	O
3	of	O
4	coenzyme	B
5	Q10	O
6	(	O
7	CoQ	B
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O

1	In	O
2	a	O
3	112	O
4	-	O
5	d	O
6	feedlot	O
7	trial	O
8	,	O
9	105	O
10	heifers	O
11	were	O
12	assigned	O
13	to	O
14	light	O
15	,	O
16	medium	O
17	and	O
18	heavy	O
19	weight	O
20	blocks	O
21	on	O
22	five	O
23	treatments	O
24	:	O
25	dietary	O
26	MGA	O
27	(.	O
28	5	O
29	mg	O
30	.	O
31	hd	O
32	-	O
33	1	O
34	.	O
35	d	O
36	-	O
37	1	O
38	),	O
39	control	O
40	(	O
41	no	O
42	MGA	O
43	)	O
44	or	O
45	DEPO	O
46	-	O
47	MGA	O
48	on	O
49	d	O
50	1	O
51	at	O
52	.	O
53	5	O
54	,	O
55	1	O
56	.	O
57	0	O
58	or	O
59	1	O
60	.	O
61	5	O
62	ml	O
63	/	O
64	hd	O
65	(	O
66	30	O
67	,	O
68	60	O
69	or	O
70	90	O
71	mg	O
72	MGA	O
73	/	O
74	hd	O
75	,	O
76	respectively	O
77	).	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	B
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	O
35	deiodinase	I
36	system	O
37	.	O

1	The	O
2	discordant	O
3	behaviour	O
4	in	O
5	weakly	O
6	infected	O
7	mice	O
8	was	O
9	due	O
10	to	O
11	the	O
12	occurrence	O
13	in	O
14	some	O
15	animals	O
16	of	O
17	a	O
18	second	O
19	phase	O
20	of	O
21	more	O
22	rapid	O
23	increase	O
24	of	O
25	the	O
26	parasitemia	O
27	.	O

1	Specific	O
2	class	B
3	I	I
4	and	O
5	II	B
6	histone	I
7	deacetylases	I
8	(	O
9	HDACs	B
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	O
16	,	O
17	suggesting	O
18	that	O
19	BCoR	O
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	O
28	.	O

1	Position	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	B
8	nerve	I
9	growth	I
10	factor	I
11	-	I
12	luciferase	I
13	reporter	I
14	gene	I
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O

1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O

1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	B
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	Electrophoretic	O
2	mobility	O
3	-	O
4	shift	O
5	assays	O
6	performed	O
7	with	O
8	the	O
9	HNF	B
10	-	I
11	3	I
12	X	I
13	and	O
14	Y	B
15	sites	O
16	demonstrated	O
17	that	O
18	both	O
19	sites	O
20	are	O
21	capable	O
22	of	O
23	binding	O
24	HNF	B
25	-	I
26	3alpha	I
27	and	O
28	HNF	B
29	-	I
30	3beta	I
31	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	alignment	O
5	between	O
6	mouse	O
7	and	O
8	human	B
9	CA	I
10	IV	I
11	shows	O
12	69	O
13	%	O
14	identity	O
15	in	O
16	the	O
17	coding	O
18	region	O
19	and	O
20	all	O
21	of	O
22	the	O
23	exon	O
24	-	O
25	intron	O
26	boundaries	O
27	are	O
28	conserved	O
29	,	O
30	as	O
31	are	O
32	the	O
33	sizes	O
34	of	O
35	the	O
36	introns	O
37	.	O

1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	B
12	mRNA	I
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	I
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	B
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	During	O
2	V	O
3	-	O
4	A	O
5	bypass	O
6	,	O
7	hemodynamics	O
8	were	O
9	stable	O
10	.	O

1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	O
8	mediated	O
9	formation	O
10	of	O
11	a	O
12	SHP	B
13	-	I
14	2	I
15	-	I
16	pp120	I
17	complex	I
18	and	O
19	its	O
20	inhibition	O
21	by	O
22	Fc	B
23	gamma	I
24	RIIB1	I
25	-	I
26	BCR	I
27	coligation	I
28	.	O

1	The	O
2	addition	O
3	of	O
4	a	O
5	Paf	O
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	hly	O
20	target	O
21	sequences	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	PrfA	B
27	but	O
28	converts	O
29	the	O
30	complex	O
31	(	O
32	CIII	O
33	)	O
34	consisting	O
35	of	O
36	PrfA	B
37	and	O
38	the	O
39	109	O
40	bp	O
41	hly	B
42	DNA	O
43	fragment	I
44	to	O
45	a	O
46	slower	O
47	migrating	B
48	PrfA	I
49	-	I
50	Paf	O
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O

1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	B
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O

1	We	O
2	identified	O
3	telSMN	O
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	SMA	O
11	-	O
12	like	O
13	individuals	O
14	who	O
15	carry	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	telSMN	O
21	:	O
22	these	O
23	include	O
24	two	O
25	frameshift	O
26	mutations	O
27	(	O
28	800ins11	B
29	and	O
30	542delGT	B
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	A2G	B
38	,	O
39	S262I	B
40	,	O
41	and	O
42	T274I	O
43	).	O

1	Forty	O
2	-	O
3	eight	O
4	sequences	O
5	,	O
6	30	O
7	not	O
8	previously	O
9	identified	O
10	as	O
11	IR	B
12	-	I
13	responsive	O
14	,	O
15	were	O
16	significantly	O
17	regulated	O
18	by	O
19	IR	B
20	.	O

1	Private	O
2	hospital	O
3	accreditation	O
4	.	O

1	Am	O
2	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	Conjugated	O
2	estrogens	O
3	shorten	I
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O

1	We	O
2	cloned	O
3	a	O
4	complete	O
5	cDNA	O
6	(	O
7	2	O
8	.	O
9	9	O
10	kb	O
11	)	O
12	for	O
13	HET	O
14	from	O
15	an	O
16	MCF	O
17	-	O
18	7	O
19	cDNA	O
20	library	O
21	.	O

1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O

1	In	O
2	a	O
3	screen	O
4	for	O
5	genes	O
6	with	O
7	oncogenic	O
8	potential	O
9	expressed	O
10	by	O
11	the	O
12	murine	B
13	B6SUtA1	I
14	myeloid	I
15	progenitor	I
16	cell	O
17	line	O
18	,	O
19	we	O
20	isolated	O
21	a	O
22	2	O
23	.	O

1	The	O
2	rrd1	B
3	,	O
4	2delta	B
5	mutant	I
6	was	O
7	partially	O
8	rescued	O
9	by	O
10	inactivation	O
11	of	O
12	HOG1	B
13	or	O
14	PBS2	B
15	,	O
16	suggesting	O
17	an	O
18	interaction	O
19	between	O
20	the	O
21	RRD	B
22	genes	I
23	and	O
24	the	O
25	Hog1p	O
26	signal	O
27	transduction	O
28	pathway	O
29	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O

1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O

1	The	O
2	diagnosis	O
3	of	O
4	metachromatic	B
5	leukodystrophy	I
6	(	O
7	MLD	B
8	)	O
9	was	O
10	confirmed	O
11	by	O
12	the	O
13	finding	O
14	of	O
15	low	O
16	arylsulfatase	B
17	A	O
18	(	O
19	ASA	O
20	)	O
21	levels	O
22	in	O
23	cultured	O
24	fibroblasts	O
25	in	O
26	both	O
27	sisters	O
28	.	O

1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	The	O
2	contraceptive	O
3	pattern	O
4	of	O
5	157	O
6	women	O
7	was	O
8	analysed	O
9	and	O
10	13	O
11	.	O
12	8	O
13	percent	O
14	were	O
15	using	O
16	inefficient	O
17	methods	O
18	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	cDNA	O
9	that	O
10	encodes	O
11	a	O
12	new	O
13	member	O
14	of	O
15	the	O
16	GTPase	B
17	-	I
18	activating	I
19	protein	I
20	(	O
21	GAP	B
22	)	I
23	family	I
24	of	O
25	GTPase	B
26	regulators	I
27	.	O

1	We	O
2	report	O
3	herein	O
4	the	O
5	case	O
6	of	O
7	a	O
8	30	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	in	O
15	whom	O
16	ectopic	O
17	mediastinal	O
18	parathyroid	I
19	adenoma	O
20	was	O
21	detected	O
22	by	O
23	99mTc	O
24	-	O
25	methoxyisobutylisonitrile	O
26	scintigraphy	O
27	(	O
28	99mTc	O
29	-	O
30	MIBI	O
31	).	O

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	B
26	.	O

1	Multifunctional	B
2	protein	I
3	kinase	I
4	(	O
5	MFPK	B
6	)	O
7	phosphorylates	O
8	ATP	B
9	-	I
10	citrate	I
11	lyase	I
12	on	O
13	peptide	B
14	B	I
15	on	O
16	two	O
17	sites	O
18	,	O
19	BT	B
20	and	O
21	BS	O
22	,	O
23	on	O
24	threonine	O
25	and	O
26	serine	O
27	,	O
28	respectively	O
29	,	O
30	inhibitor	O
31	2	O
32	on	O
33	a	O
34	threonyl	B
35	residue	O
36	,	O
37	and	O
38	glycogen	B
39	synthase	I
40	at	O
41	sites	I
42	2	I
43	and	O
44	3	O
45	.	O

1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	B
17	receptor	I
18	genes	I
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	corresponding	O
3	differences	O
4	in	O
5	FVIIa	B
6	and	O
7	PAI	B
8	-	I
9	1	I
10	were	O
11	not	O
12	statistically	O
13	significant	O
14	.	O

1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	O
6	-	O
7	specific	O
8	RNA	O
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	B
27	.	O

1	The	O
2	growth	B
3	factor	I
4	receptor	I
5	-	I
6	bound	O
7	protein	I
8	2	I
9	(	O
10	Grb2	B
11	)	O
12	adaptor	O
13	when	O
14	complexed	O
15	with	O
16	Sos	B
17	(	O
18	Son	O
19	of	O
20	sevenless	B
21	),	O
22	the	O
23	exchange	B
24	factor	I
25	of	O
26	Ras	B
27	,	O
28	conveys	O
29	the	O
30	signal	O
31	induced	O
32	by	O
33	tyrosine	B
34	kinase	I
35	-	I
36	activated	I
37	receptor	I
38	to	O
39	Ras	B
40	by	O
41	recruiting	B
42	Sos	I
43	to	O
44	the	O
45	membrane	O
46	,	O
47	allowing	O
48	activation	O
49	of	O
50	Ras	B
51	.	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	B
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	B
18	ribonuclease	I
19	H	I
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	O
52	O	I
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	I
67	structure	I
68	,	O
69	respectively	O
70	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	I
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	O
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	In	O
2	the	O
3	rat	O
4	rnu	I
5	allele	O
6	described	O
7	here	O
8	,	O
9	a	O
10	nonsense	O
11	mutation	O
12	in	O
13	exon	O
14	8	O
15	of	O
16	the	O
17	whn	B
18	gene	I
19	was	O
20	identified	O
21	.	O

1	1	O
2	A	O
3	colonic	O
4	delivery	O
5	system	O
6	is	O
7	described	O
8	to	O
9	deliver	O
10	orally	O
11	ingested	O
12	drugs	O
13	to	O
14	the	O
15	colon	O
16	and	O
17	release	O
18	them	O
19	at	O
20	that	O
21	site	O
22	by	O
23	coating	O
24	with	O
25	an	O
26	acrylic	O
27	based	O
28	resin	O
29	(	O
30	Eudragit	O
31	S	O
32	).	O

1	Surprisingly	O
2	,	O
3	the	O
4	results	O
5	of	O
6	several	O
7	experiments	O
8	suggest	O
9	that	O
10	the	O
11	TSF	B
12	genes	I
13	encode	O
14	global	O
15	regulatory	O
16	factors	O
17	.	O
18	tsf1	O
19	to	O
20	tsf6	O
21	mutations	O
22	derepressed	O
23	expression	O
24	from	O
25	yeast	O
26	CYC	I
27	-	I
28	GAL	I
29	hybrid	O
30	promoters	O
31	(	O
32	fused	O
33	to	O
34	lacZ	B
35	)	O
36	that	O
37	harbor	O
38	a	O
39	variety	O
40	of	O
41	operator	O
42	sequences	O
43	,	O
44	and	O
45	caused	O
46	pleiotropic	O
47	defects	O
48	in	O
49	cell	O
50	growth	O
51	,	O
52	mating	O
53	,	O
54	and	O
55	sporulation	O
56	.	O

1	The	O
2	various	O
3	forms	O
4	of	O
5	sickle	O
6	cell	O
7	disease	O
8	share	O
9	the	O
10	common	O
11	feature	O
12	of	O
13	an	O
14	abnormal	O
15	globin	B
16	chain	O
17	that	O
18	,	O
19	under	O
20	certain	O
21	conditions	O
22	such	O
23	as	O
24	hypoxia	O
25	,	O
26	results	O
27	in	O
28	the	O
29	sickling	O
30	of	O
31	red	O
32	blood	O
33	cells	O
34	and	O
35	obstruction	O
36	of	O
37	blood	O
38	vessels	O
39	.	O

1	MATERIALS	O
2	AND	O
3	METHODS	O
4	:	O
5	Coronal	B
6	3D	O
7	GRE	O
8	imaging	O
9	was	O
10	used	O
11	to	O
12	study	O
13	the	O
14	volar	O
15	,	O
16	middle	O
17	,	O
18	and	O
19	dorsal	O
20	portions	O
21	of	O
22	the	O
23	SLL	O
24	in	O
25	14	O
26	patients	O
27	with	O
28	an	O
29	arthroscopically	O
30	normal	O
31	SLL	O
32	and	O
33	in	O
34	five	O
35	cadaveric	O
36	wrists	O
37	that	O
38	had	O
39	a	O
40	normal	O
41	SLL	O
42	proved	O
43	with	O
44	dissection	O
45	.	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	B
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	O
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	In	O
2	eight	O
3	groups	O
4	of	O
5	subjects	O
6	operating	O
7	various	O
8	hand	O
9	-	O
10	held	O
11	vibrating	O
12	tools	O
13	and	O
14	aged	O
15	from	O
16	30	O
17	to	O
18	59	O
19	years	O
20	,	O
21	the	O
22	prevalence	O
23	rates	O
24	of	O
25	vibration	O
26	-	O
27	induced	O
28	white	O
29	finger	O
30	(	O
31	VWF	O
32	)	O
33	and	O
34	numbness	O
35	,	O
36	pain	O
37	,	O
38	or	O
39	stiffness	O
40	in	O
41	the	O
42	upper	O
43	and	O
44	lower	O
45	extremities	O
46	were	O
47	investigated	O
48	.	O

1	We	O
2	examined	O
3	the	O
4	effects	O
5	of	O
6	long	O
7	-	O
8	term	O
9	perfusion	O
10	with	O
11	pyridoxalated	B
12	hemoglobin	I
13	polyoxyethylene	I
14	conjugate	I
15	(	O
16	PHP	O
17	)	O
18	solution	O
19	on	O
20	cardiac	O
21	function	O
22	of	O
23	isolated	O
24	rat	O
25	hearts	O
26	.	O

1	Truncated	O
2	ICSBP	O
3	lacking	O
4	the	O
5	first	O
6	33	O
7	amino	O
8	-	O
9	terminal	O
10	amino	O
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	B
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	Genome	O
2	plasticity	O
3	in	O
4	the	O
5	distal	O
6	tail	O
7	fiber	O
8	locus	O
9	of	O
10	the	O
11	T	O
12	-	O
13	even	O
14	bacteriophage	O
15	:	O
16	recombination	O
17	between	O
18	conserved	O
19	motifs	O
20	swaps	O
21	adhesin	O
22	specificity	O
23	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	B
24	chain	I
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O

1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	Felodipine	O
2	did	O
3	not	O
4	alter	O
5	the	O
6	baseline	O
7	FEV1	O
8	,	O
9	but	O
10	showed	O
11	a	O
12	small	O
13	significant	O
14	inhibitory	O
15	effect	O
16	upon	O
17	histamine	O
18	and	O
19	AMP	O
20	induced	O
21	bronchoconstriction	O
22	.	O

1	The	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	indicated	O
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	binding	I
20	site	I
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	PRDII	B
27	/	I
28	kappaB	I
29	domain	I
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	O
40	by	O
41	pp60	O
42	(	O
43	v	B
44	-)	I
45	src	I
46	.	O

1	Furthermore	O
2	,	O
3	rhoA	O
4	-	O
5	mediated	O
6	SRE	O
7	activation	O
8	was	O
9	blocked	O
10	by	O
11	dominant	O
12	negative	O
13	mutants	O
14	of	O
15	PKC	B
16	-	I
17	alpha	I
18	or	O
19	PKC	B
20	-	I
21	epsilon	I
22	.	O

1	Exposure	O
2	of	O
3	endothelium	O
4	to	O
5	pulsatile	O
6	shear	O
7	stresses	O
8	that	O
9	followed	O
10	a	O
11	tape	O
12	recording	O
13	of	O
14	physiological	O
15	flow	O
16	waveforms	O
17	(	O
18	electromagnetic	O
19	flowmeter	O
20	)	O
21	did	O
22	not	O
23	cause	O
24	gross	O
25	injury	O
26	or	O
27	denudation	O
28	even	O
29	when	O
30	peak	O
31	shear	O
32	exceeded	O
33	1500	O
34	dyne	O
35	/	O
36	cm2	O
37	.	O

1	Symposium	B
2	on	O
3	presenile	B
4	spongy	I
5	encephalopathies	I
6	.	O

1	A	O
2	safe	O
3	and	O
4	simple	O
5	system	O
6	for	O
7	the	O
8	detection	O
9	of	O
10	sudden	O
11	infant	O
12	death	O
13	syndrome	O
14	(	O
15	SIDS	O
16	)	O
17	is	O
18	proposed	O
19	.	O

1	"	O
2	Complex	O
3	partial	O
4	"	O
5	seizures	O
6	.	O

1	A	O
2	major	O
3	task	O
4	for	O
5	sports	O
6	scientists	O
7	may	O
8	be	O
9	to	O
10	verify	O
11	empirically	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	O
19	the	O
20	sport	B
21	performer	I
22	.	O

1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	B
6	,	O
7	glutathione	B
8	peroxidase	I
9	and	I
10	superoxide	I
11	dismutase	I
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O

1	Echocardiography	O
2	revealed	O
3	right	O
4	ventricular	O
5	diastolic	O
6	collapse	O
7	(	O
8	RVDC	O
9	)	O
10	without	O
11	physical	O
12	signs	O
13	of	O
14	cardiac	O
15	tamponade	O
16	.	O

1	The	O
2	CT	O
3	characteristics	O
4	are	O
5	discussed	O
6	and	O
7	the	O
8	recent	O
9	literature	O
10	is	O
11	reviewed	O
12	.	O

1	Drug	O
2	and	O
3	nutrient	O
4	interactions	O
5	.	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	B
9	-	I
10	kb	I
11	EcoRI	I
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	B
32	gene	I
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	The	O
2	remainder	O
3	(	O
4	18	O
5	.	O
6	4	O
7	%)	O
8	was	O
9	with	O
10	IgA	B
11	nephropathy	O
12	,	O
13	which	O
14	was	O
15	histologically	O
16	mild	O
17	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	both	O
8	the	O
9	N	O
10	-	O
11	and	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	talin	B
18	bind	O
19	actin	B
20	,	O
21	the	O
22	properties	O
23	of	O
24	these	O
25	two	O
26	regions	O
27	of	O
28	the	O
29	protein	O
30	are	O
31	distinct	O
32	.	O

1	In	O
2	rubella	O
3	patients	O
4	with	O
5	serologic	O
6	confirmation	O
7	by	O
8	HI	O
9	,	O
10	the	O
11	IF	O
12	test	O
13	detected	O
14	significant	O
15	rises	O
16	in	O
17	219	O
18	(	O
19	99	O
20	.	O
21	1	O
22	%)	O
23	of	O
24	221	O
25	patients	O
26	and	O
27	the	O
28	PHA	O
29	test	O
30	detected	O
31	antibody	O
32	conversion	O
33	in	O
34	68	O
35	(	O
36	93	O
37	%)	O
38	of	O
39	73	O
40	patients	O
41	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	Cell	O
2	viability	O
3	and	O
4	lysosomal	B
5	enzymes	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	O
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	High	O
2	-	O
3	mobility	I
4	-	I
5	group	I
6	protein	O
7	I	O
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	O
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O

1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O

1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	influence	O
7	of	O
8	iron	O
9	overload	O
10	on	O
11	the	O
12	polymorphonuclear	O
13	leucocyte	O
14	(	O
15	PMN	O
16	)	O
17	metabolism	O
18	of	O
19	patients	O
20	on	O
21	chronic	O
22	hemodialysis	O
23	,	O
24	generation	O
25	of	O
26	superoxide	B
27	anion	I
28	(	O
29	O2	O
30	-)	O
31	by	O
32	PMN	O
33	in	O
34	whole	O
35	blood	O
36	was	O
37	compared	O
38	in	O
39	two	O
40	groups	O
41	of	O
42	hemodialyzed	O
43	patients	O
44	:	O
45	group	O
46	A	O
47	consisted	O
48	of	O
49	twenty	O
50	-	O
51	one	O
52	individuals	O
53	with	O
54	serum	O
55	ferritin	B
56	levels	O
57	above	O
58	1000	O
59	ng	O
60	/	O
61	ml	O
62	and	O
63	group	O
64	B	O
65	of	O
66	nineteen	O
67	individuals	O
68	with	O
69	serum	O
70	ferritin	I
71	levels	O
72	below	O
73	1000	O
74	ng	O
75	/	O
76	ml	O
77	.	O

1	Serine	O
2	528	O
3	is	O
4	phosphorylated	O
5	in	O
6	vivo	O
7	in	O
8	several	O
9	cell	O
10	lines	O
11	,	O
12	and	O
13	substitution	O
14	of	O
15	serine	O
16	528	O
17	to	O
18	alanine	O
19	(	O
20	S528A	O
21	)	O
22	resulted	O
23	in	O
24	an	O
25	increased	O
26	ability	O
27	of	O
28	Myb	B
29	to	O
30	transactivate	O
31	a	O
32	synthetic	O
33	promoter	O
34	containing	O
35	five	O
36	copies	O
37	of	O
38	the	O
39	mim	B
40	-	I
41	1A	I
42	Myb	I
43	-	I
44	responsive	I
45	element	I
46	and	O
47	a	O
48	minimal	O
49	herpes	O
50	tk	B
51	promoter	I
52	.	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Thus	O
2	,	O
3	the	O
4	class	O
5	C	O
6	-	I
7	Vps	I
8	complex	I
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	novel	O
9	beta1	B
10	,	O
11	6	I
12	-	I
13	N	I
14	-	I
15	acetylglucosaminyltransferase	I
16	forming	O
17	core	B
18	2	I
19	and	O
20	core	B
21	4	I
22	.	O

1	A	O
2	randomized	O
3	clinical	O
4	trial	O
5	in	O
6	sixty	O
7	-	O
8	two	O
9	adult	O
10	patients	O
11	suffering	O
12	from	O
13	typhoid	O
14	fever	O
15	,	O
16	proved	O
17	by	O
18	blood	O
19	and	O
20	marrow	O
21	culture	O
22	,	O
23	showed	O
24	that	O
25	amoxycillin	O
26	in	O
27	a	O
28	dosage	O
29	schedule	O
30	of	O
31	1	O
32	g	O
33	8	O
34	-	O
35	hourly	O
36	orally	O
37	for	O
38	fourteen	O
39	days	O
40	was	O
41	better	O
42	than	O
43	chloramphenicol	O
44	with	O
45	regard	O
46	to	O
47	clinical	O
48	and	O
49	temperature	O
50	response	O
51	and	O
52	in	O
53	respect	O
54	of	O
55	carriers	O
56	and	O
57	relapse	O
58	rates	O
59	.	O

1	Penicillinase	O
2	production	O
3	in	O
4	Staphylococcus	O
5	aureus	O
6	strains	O
7	of	O
8	clinical	O
9	importance	O
10	.	O

1	The	O
2	distribution	O
3	of	O
4	their	O
5	fibrinogen	B
6	levels	O
7	was	O
8	Gaussian	O
9	,	O
10	but	O
11	more	O
12	wide	O
13	-	O
14	based	O
15	than	O
16	the	O
17	distribution	O
18	of	O
19	our	O
20	normal	O
21	controls	O
22	.	O

1	Basal	O
2	FSH	B
3	and	O
4	LH	B
5	levels	O
6	were	O
7	significantly	O
8	lower	O
9	in	O
10	addicts	O
11	;	O
12	after	O
13	GnRH	B
14	stimulation	O
15	the	O
16	addicts	B
17	'	I
18	FSH	I
19	and	O
20	LH	B
21	values	O
22	increased	O
23	but	O
24	not	O
25	significantly	O
26	compared	O
27	to	O
28	controls	O
29	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	I
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	O
29	element	O
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	O
37	transcriptional	O
38	element	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	the	O
6	mutants	O
7	define	O
8	two	O
9	complementation	O
10	groups	O
11	,	O
12	designated	O
13	cgs1	B
14	+	I
15	and	O
16	cgs2	I
17	+	I
18	(	O
19	continues	O
20	to	O
21	grow	O
22	in	O
23	stationary	O
24	).	O

1	RESULTS	O
2	:	O
3	The	O
4	main	O
5	effect	O
6	of	O
7	muscle	O
8	pain	O
9	,	O
10	compared	O
11	to	O
12	non	O
13	-	O
14	painful	O
15	stimulation	O
16	,	O
17	was	O
18	a	O
19	significant	O
20	and	O
21	long	O
22	-	O
23	lasting	O
24	increase	O
25	of	O
26	delta	B
27	(	O
28	1	O
29	-	I
30	3	I
31	Hz	O
32	)	O
33	power	O
34	and	O
35	an	O
36	alpha	O
37	-	O
38	1	O
39	(	O
40	9	O
41	-	O
42	11	O
43	Hz	O
44	)	O
45	power	O
46	increase	O
47	over	O
48	the	O
49	contralateral	O
50	parietal	O
51	locus	O
52	.	O

1	Sensitivities	O
2	of	O
3	thromboplastins	B
4	to	O
5	factor	I
6	VII	I
7	deficiency	O
8	.	O

1	Chem	O
2	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	p33	O
7	subunit	O
8	of	O
9	eIF3	B
10	plays	O
11	an	O
12	important	O
13	role	O
14	in	O
15	the	O
16	initiation	O
17	phase	O
18	of	O
19	protein	O
20	synthesis	O
21	and	O
22	that	O
23	its	O
24	RNA	O
25	-	O
26	binding	O
27	domain	O
28	is	O
29	required	O
30	for	O
31	optimal	O
32	activity	O
33	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	Each	O
2	recombinant	B
3	product	I
4	was	O
5	a	O
6	fusion	O
7	protein	O
8	with	O
9	a	O
10	B	O
11	domain	O
12	of	O
13	Staphylococcal	B
14	protein	I
15	A	I
16	(	O
17	SPA	O
18	).	O

1	Sixty	O
2	-	O
3	nine	O
4	(	O
5	44	O
6	%)	O
7	patients	O
8	were	O
9	administered	O
10	250	O
11	MBq	O
12	(	O
13	7	O
14	mCi	O
15	)	O
16	99Tcm	O
17	-	O
18	tetrofosmin	O
19	at	O
20	rest	O
21	followed	O
22	4	O
23	h	O
24	later	O
25	by	O
26	750	O
27	MBq	O
28	(	O
29	21	O
30	mCi	O
31	)	O
32	during	O
33	stress	O
34	(	O
35	the	O
36	1	O
37	day	O
38	protocol	O
39	),	O
40	whereas	O
41	88	O
42	(	O
43	56	O
44	%)	O
45	patients	O
46	had	O
47	rest	O
48	and	O
49	stress	O
50	imaging	O
51	studies	O
52	on	O
53	two	O
54	separate	O
55	days	O
56	,	O
57	receiving	O
58	a	O
59	500	O
60	MBq	O
61	(	O
62	14	O
63	mCi	O
64	)	O
65	dose	O
66	of	O
67	99Tcm	O
68	-	O
69	tetrofosmin	O
70	on	O
71	each	O
72	occasion	O
73	(	O
74	the	O
75	2	O
76	day	O
77	protocol	O
78	).	O

1	To	O
2	date	O
3	,	O
4	two	O
5	such	O
6	proteins	O
7	,	O
8	PLZF	B
9	and	O
10	LAZ	B
11	-	I
12	3	I
13	/	O
14	BCL	B
15	-	I
16	6	I
17	,	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	oncogenesis	O
23	.	O

1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O

1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	I
22	.	O

1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O

1	A	O
2	sharp	O
3	outbreak	O
4	of	O
5	influenza	O
6	A	O
7	occurred	O
8	on	O
9	the	O
10	base	O
11	during	O
12	February	O
13	that	O
14	was	O
15	due	O
16	to	O
17	an	O
18	A	O
19	/	O
20	Texas	B
21	/	O
22	1	O
23	/	O
24	77	O
25	-	O
26	like	O
27	virus	O
28	,	O
29	a	O
30	variant	O
31	of	O
32	the	O
33	A	O
34	/	O
35	Victoria	B
36	/	O
37	3	O
38	/	O
39	75	O
40	prototpye	O
41	.	O

1	Premature	O
2	initiation	O
3	of	O
4	mitosis	O
5	in	O
6	yeast	O
7	lacking	O
8	RCC1	B
9	or	O
10	an	O
11	interacting	B
12	GTPase	I
13	.	O

1	These	O
2	findings	O
3	and	O
4	the	O
5	differential	O
6	tissue	O
7	distribution	O
8	of	O
9	p54	B
10	suggest	O
11	that	O
12	this	O
13	novel	O
14	SR	B
15	protein	I
16	may	O
17	participate	O
18	in	O
19	regulation	O
20	of	O
21	alternative	O
22	splicing	O
23	in	O
24	a	O
25	tissue	O
26	-	O
27	and	O
28	substrate	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	ISIS	O
2	5	O
3	possibilities	O
4	.	O

1	A	O
2	G22V	I
3	mutant	I
4	of	O
5	M	B
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	O
20	IL	B
21	-	I
22	3	I
23	)-	O
24	dependent	O
25	mast	O
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Results	O
2	from	O
3	our	O
4	and	O
5	other	O
6	laboratories	O
7	have	O
8	suggested	O
9	that	O
10	UCN	O
11	-	O
12	01	O
13	induces	O
14	preferential	O
15	G1	O
16	-	O
17	phase	O
18	accumulation	O
19	in	O
20	several	O
21	human	O
22	tumor	O
23	cell	O
24	lines	O
25	tested	O
26	.	O

1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O

1	Some	O
2	artificial	O
3	promoter	O
4	constructs	O
5	containing	O
6	multiple	O
7	Sp1	B
8	sites	I
9	were	O
10	highly	O
11	responsive	O
12	to	O
13	ethanol	O
14	,	O
15	but	O
16	others	O
17	were	O
18	not	O
19	,	O
20	suggesting	O
21	that	O
22	the	O
23	organization	O
24	of	O
25	the	O
26	proximal	O
27	promoter	O
28	region	O
29	was	O
30	an	O
31	additional	O
32	factor	O
33	that	O
34	affected	O
35	the	O
36	ethanol	O
37	response	O
38	.	O

1	Research	O
2	on	O
3	ethylene	O
4	glycol	O
5	and	O
6	diethylene	O
7	glycol	O
8	for	O
9	carcinogenic	O
10	effects	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	O
6	and	O
7	Z	O
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	I
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	B
18	)	I
19	kinases	I
20	,	O
21	p38	B
22	and	O
23	JNK	B
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	B
35	transcription	O
36	factor	I
37	ATF2	I
38	.	O

1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O

1	Histochemistry	O
2	and	O
3	electron	O
4	microscopy	O
5	of	O
6	acute	O
7	liver	O
8	lesions	O
9	induced	O
10	by	O
11	Aflatoxin	O
12	B1	O
13	in	O
14	ducklings	O
15	.	O

1	Ischaemia	O
2	was	O
3	induced	O
4	by	O
5	a	O
6	low	O
7	flow	O
8	rate	O
9	of	O
10	0	O
11	.	O
12	8	O
13	mL	O
14	min	O
15	-	O
16	1	O
17	for	O
18	30	O
19	min	O
20	,	O
21	and	O
22	was	O
23	followed	O
24	by	O
25	a	O
26	40	O
27	-	O
28	minute	O
29	reperfusion	O
30	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	showed	O
8	no	O
9	TATA	O
10	box	O
11	but	O
12	identified	O
13	consensus	O
14	binding	O
15	motifs	O
16	for	O
17	Sp1	B
18	,	O
19	CREB	B
20	,	O
21	and	O
22	half	O
23	sites	O
24	of	O
25	the	O
26	estrogen	B
27	receptor	I
28	binding	I
29	site	I
30	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	Ischemic	O
2	stroke	O
3	due	O
4	to	O
5	protein	O
6	C	O
7	deficiency	O
8	.	O

1	The	O
2	enzyme	O
3	activities	O
4	studied	O
5	are	O
6	important	O
7	elements	O
8	in	O
9	the	O
10	pathophysiology	O
11	of	O
12	dental	O
13	caries	O
14	and	O
15	may	O
16	even	O
17	be	O
18	addressed	O
19	as	O
20	virulence	O
21	factors	O
22	.	O

1	The	O
2	immune	O
3	response	O
4	of	O
5	past	O
6	-	O
7	infection	O
8	of	O
9	cytomegalovirus	O
10	in	O
11	the	O
12	patients	O
13	of	O
14	RTID	O
15	is	O
16	rather	O
17	remarkable	O
18	.	O

1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O

1	Moreover	O
2	,	O
3	radiolabeled	O
4	EFI	O
5	,	O
6	NF	B
7	-	I
8	Y	I
9	,	O
10	or	O
11	CBF	B
12	DNAs	O
13	give	O
14	rise	O
15	to	O
16	identical	O
17	gel	O
18	retardation	O
19	patterns	O
20	in	O
21	extracts	O
22	from	O
23	a	O
24	variety	O
25	of	O
26	different	O
27	cell	O
28	types	O
29	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	hrpRS	B
6	and	O
7	hrpL	O
8	are	O
9	part	O
10	of	O
11	a	O
12	regulatory	O
13	cascade	O
14	in	O
15	which	O
16	HrpR	O
17	and	O
18	HrpS	O
19	activate	O
20	expression	O
21	of	O
22	hrpL	B
23	and	O
24	HrpL	O
25	,	O
26	a	O
27	putative	O
28	sigma	B
29	factor	I
30	,	O
31	induces	O
32	expression	O
33	of	O
34	HrpL	B
35	-	I
36	responsive	I
37	genes	I
38	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	ClC	O
5	-	O
6	6	O
7	(	O
8	a	O
9	member	O
10	of	O
11	the	O
12	CIC	O
13	chloride	O
14	-	O
15	channel	O
16	family	O
17	)	O
18	transcripts	O
19	generates	O
20	three	O
21	truncated	O
22	isoforms	O
23	one	O
24	of	O
25	which	O
26	,	O
27	ClC	B
28	-	I
29	6c	I
30	,	O
31	is	O
32	kidney	O
33	-	O
34	specific	O
35	.	O

1	Grade	O
2	3	O
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	Allergy	O
2	and	O
3	Tourette	O
4	'	O
5	s	O
6	syndrome	O
7	.	O

1	Reward	O
2	value	O
3	of	O
4	prosodic	O
5	features	O
6	of	O
7	language	O
8	for	O
9	autistic	O
10	,	O
11	mentally	O
12	retarded	O
13	,	O
14	and	O
15	normal	O
16	children	O
17	.	O

1	Southern	O
2	analysis	O
3	on	O
4	genomic	O
5	DNA	O
6	isolated	O
7	from	O
8	tissues	O
9	and	O
10	cell	O
11	lines	O
12	from	O
13	several	O
14	mouse	O
15	strains	O
16	using	O
17	mCD22	B
18	cDNA	O
19	demonstrated	O
20	that	O
21	the	O
22	Cd22	B
23	locus	I
24	encoding	I
25	mCD22	I
26	is	O
27	a	O
28	single	O
29	copy	O
30	gene	O
31	of	O
32	<	O
33	or	O
34	=	O
35	30	O
36	kb	O
37	.	O

1	RESULTS	O
2	:	O
3	At	O
4	the	O
5	beginning	O
6	of	O
7	the	O
8	QA	B
9	/	O
10	QI	O
11	process	O
12	,	O
13	monitoring	O
14	of	O
15	blood	O
16	administration	O
17	practices	O
18	revealed	O
19	that	O
20	a	O
21	variance	O
22	from	O
23	institutional	O
24	blood	O
25	administration	O
26	policy	O
27	occurred	O
28	during	O
29	50	O
30	percent	O
31	of	O
32	blood	O
33	and	O
34	component	O
35	transfusions	O
36	.	O

1	Osmotic	B
2	shock	O
3	stimulates	O
4	GLUT4	B
5	translocation	O
6	in	O
7	3T3L1	O
8	adipocytes	O
9	by	O
10	a	O
11	novel	O
12	tyrosine	B
13	kinase	I
14	pathway	O
15	.	O

1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	O
9	hemoglobin	B
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	Berthelot	O
16	classic	O
17	and	O
18	Berthelot	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	plasmatic	O
26	urea	O
27	.	O

1	ATX	O
2	,	O
3	like	O
4	PC	I
5	-	I
6	1	I
7	,	O
8	was	O
9	found	O
10	to	O
11	hydrolyze	O
12	the	O
13	type	B
14	I	I
15	phosphodiesterase	I
16	substrate	I
17	p	I
18	-	I
19	nitrophenyl	I
20	thymidine	I
21	-	I
22	5	I
23	'-	O
24	monophosphate	O
25	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	Structural	O
2	analysis	O
3	and	O
4	characterization	O
5	of	O
6	tissue	O
7	and	O
8	hormonal	O
9	responsive	O
10	expression	O
11	of	O
12	the	O
13	avian	B
14	bone	I
15	sialoprotein	I
16	(	I
17	BSP	B
18	)	I
19	gene	I
20	.	O

1	BACKGROUND	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	predictors	O
7	of	O
8	desipramine	O
9	-	O
10	refractory	O
11	depression	O
12	,	O
13	the	O
14	authors	O
15	examined	O
16	the	O
17	outcome	O
18	in	O
19	patients	O
20	with	O
21	major	O
22	depression	O
23	who	O
24	were	O
25	admitted	O
26	to	O
27	a	O
28	general	O
29	hospital	O
30	and	O
31	treated	O
32	with	O
33	desipramine	O
34	adjusted	O
35	to	O
36	an	O
37	adequate	O
38	blood	O
39	level	O
40	.	O

1	Both	O
2	methods	O
3	were	O
4	employed	O
5	for	O
6	various	O
7	focal	O
8	-	O
9	film	O
10	distances	O
11	,	O
12	image	O
13	intensifier	O
14	tube	O
15	modes	O
16	and	O
17	laser	O
18	printer	O
19	formats	O
20	.	O

1	The	O
2	Oct	B
3	and	I
4	HMG2	I
5	proteins	I
6	also	O
7	interact	O
8	in	O
9	vivo	O
10	.	O

1	Facts	O
2	on	O
3	the	O
4	Economic	B
5	Recovery	O
6	Tax	B
7	Act	I
8	of	O
9	1981	O
10	for	O
11	speech	O
12	-	O
13	language	O
14	pathologists	I
15	and	O
16	audiologists	O
17	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	I
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	I
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	B
47	oocyte	I
48	germinal	I
49	vesicles	O
50	.	O

1	Vibrio	B
2	fluvialis	I
3	(	O
4	group	B
5	F	I
6	vibrio	I
7	)	O
8	in	O
9	Maharashtra	O
10	.	O

1	A	O
2	causal	O
3	analysis	O
4	of	O
5	secondary	O
6	variables	O
7	showed	O
8	that	O
9	the	O
10	formation	O
11	of	O
12	FB	O
13	memories	O
14	was	O
15	primarily	O
16	associated	O
17	with	O
18	the	O
19	level	O
20	of	O
21	importance	O
22	attached	O
23	to	O
24	the	O
25	event	O
26	and	O
27	level	O
28	of	O
29	affective	O
30	response	O
31	to	O
32	the	O
33	news	O
34	.	O

1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	B
19	-	I
20	2	I
21	64B	I
22	EME	I
23	).	O

1	Then	O
2	,	O
3	pure	O
4	pancreatic	O
5	juice	O
6	was	O
7	infused	O
8	into	O
9	the	O
10	duodenum	O
11	.	O

1	Handgrip	B
2	dynamometry	I
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	Mutations	O
2	within	O
3	conserved	O
4	region	O
5	2	I
6	(	O
7	CR2	B
8	)	O
9	of	O
10	E1A	B
11	that	O
12	inhibit	O
13	the	O
14	binding	O
15	of	O
16	E1A	B
17	to	O
18	the	O
19	retinoblastoma	B
20	gene	I
21	product	I
22	(	O
23	pRb	B
24	)	O
25	further	O
26	enhanced	O
27	the	O
28	stimulation	O
29	of	O
30	transcription	O
31	from	O
32	the	O
33	PEPCK	B
34	promoter	I
35	by	O
36	2	O
37	3	O
38	-	O
39	fold	O
40	compared	O
41	with	O
42	wild	B
43	type	I
44	E1A	I
45	.	O

1	A	O
2	miracle	O
3	cure	O
4	and	O
5	its	O
6	solution	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	Cytosolic	O
2	extracts	O
3	from	O
4	a	O
5	variety	O
6	of	O
7	mammalian	O
8	cell	O
9	lines	O
10	(	O
11	monkey	O
12	Cos7	O
13	,	O
14	several	O
15	mouse	O
16	fibrosarcomas	I
17	and	O
18	human	B
19	HeLa	I
20	S3	I
21	)	O
22	demonstrated	O
23	similar	O
24	TGF	B
25	-	I
26	beta	I
27	1	I
28	dependent	O
29	RNA	I
30	-	I
31	protein	I
32	band	O
33	shifts	O
34	as	O
35	cell	O
36	extract	O
37	from	O
38	BALB	O
39	/	O
40	c	O
41	3T3	O
42	mouse	O
43	fibroblasts	O
44	.	O

1	The	O
2	beta	O
3	chain	O
4	contains	O
5	five	O
6	potential	O
7	N	O
8	-	O
9	linked	O
10	glycosylation	O
11	sites	O
12	,	O
13	and	O
14	endoglycosidase	B
15	digestion	O
16	suggested	O
17	that	O
18	the	O
19	beta	O
20	chain	O
21	contained	O
22	multiple	O
23	complex	O
24	carbohydrate	O
25	side	O
26	chains	O
27	.	O

1	The	O
2	C	O
3	terminus	O
4	of	O
5	TRBP	B
6	binds	O
7	to	O
8	CBP	B
9	/	I
10	p300	B
11	and	O
12	DRIP130	B
13	,	O
14	a	O
15	component	O
16	of	O
17	the	O
18	DRIP	B
19	/	I
20	TRAP	I
21	/	I
22	ARC	I
23	complex	I
24	,	O
25	which	O
26	suggests	O
27	that	O
28	TRBP	O
29	may	O
30	activate	O
31	transcription	O
32	by	O
33	means	O
34	of	O
35	such	O
36	interactions	O
37	.	O

1	Oncogenic	O
2	activation	O
3	of	O
4	the	O
5	tyrosine	B
6	kinase	I
7	domain	O
8	of	O
9	the	O
10	human	B
11	trk	I
12	proto	I
13	-	I
14	oncogene	I
15	by	O
16	fusion	O
17	to	O
18	a	O
19	cell	O
20	adhesion	O
21	molecule	O
22	.	O

1	Cytogenetic	O
2	and	O
3	molecular	O
4	characterization	O
5	of	O
6	random	O
7	chromosomal	O
8	rearrangements	O
9	activating	O
10	the	O
11	drug	O
12	resistance	B
13	gene	I
14	,	O
15	MDR1	B
16	/	I
17	P	I
18	-	I
19	glycoprotein	I
20	,	O
21	in	O
22	drug	O
23	-	O
24	selected	O
25	cell	O
26	lines	O
27	and	O
28	patients	O
29	with	O
30	drug	O
31	refractory	O
32	ALL	O
33	.	O

1	In	O
2	HCMV	O
3	(	O
4	Towne	O
5	)-	O
6	infected	O
7	HF	O
8	cells	O
9	at	O
10	24	O
11	to	O
12	48	O
13	h	O
14	,	O
15	IE2	O
16	also	O
17	accumulated	O
18	in	O
19	newly	O
20	formed	O
21	viral	O
22	DNA	O
23	replication	O
24	compartments	O
25	containing	O
26	the	O
27	polymerase	B
28	processivity	O
29	factor	I
30	(	O
31	UL44	O
32	),	O
33	the	O
34	single	O
35	-	O
36	stranded	I
37	DNA	I
38	binding	I
39	protein	I
40	(	O
41	SSB	B
42	;	O
43	UL57	O
44	),	O
45	the	O
46	UL112	B
47	-	I
48	113	I
49	accessory	O
50	protein	O
51	,	O
52	and	O
53	newly	O
54	incorporated	O
55	bromodeoxyuridine	O
56	(	O
57	BrdU	O
58	).	O

1	Finally	O
2	,	O
3	in	O
4	situ	O
5	RNA	O
6	hybridization	O
7	studies	O
8	revealed	O
9	a	O
10	very	O
11	specific	O
12	pattern	O
13	of	O
14	EphA8	B
15	gene	I
16	expression	O
17	restricted	O
18	to	O
19	the	O
20	rostral	O
21	region	O
22	of	O
23	midbrain	O
24	tectum	O
25	during	O
26	embryonic	O
27	development	O
28	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	role	O
5	interleukin	B
6	-	I
7	6	I
8	(	O
9	IL	B
10	-	I
11	6	I
12	)	O
13	in	O
14	the	O
15	treatment	O
16	of	O
17	congenital	O
18	thrombocytopenias	O
19	is	O
20	unknown	O
21	.	O

1	The	O
2	SCMV	B
3	SNE	I
4	sites	I
5	contain	O
6	potential	O
7	overlapping	O
8	core	O
9	recognition	I
10	binding	I
11	motifs	I
12	for	O
13	SRF	B
14	,	O
15	Rel	B
16	/	I
17	NFkappaB	I
18	,	O
19	ETS	B
20	,	O
21	and	O
22	YY1	B
23	class	I
24	transcription	I
25	factors	O
26	but	O
27	fail	O
28	to	O
29	respond	O
30	to	O
31	either	O
32	serum	O
33	or	O
34	tumor	B
35	necrosis	I
36	factor	I
37	alpha	I
38	.	O

1	Amiodarone	O
2	,	O
3	seldom	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O

1	Interleukin	B
2	-	I
3	8	I
4	(	O
5	IL	B
6	-	I
7	8	I
8	)	O
9	is	O
10	a	O
11	potent	O
12	inflammatory	O
13	mediator	O
14	that	O
15	belongs	O
16	to	O
17	the	O
18	family	O
19	of	O
20	C	O
21	-	I
22	X	I
23	-	I
24	C	I
25	chemokines	O
26	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O

1	Xenopus	B
2	Ran	I
3	-	I
4	binding	I
5	protein	I
6	1	I
7	:	O
8	molecular	O
9	interactions	O
10	and	O
11	effects	O
12	on	O
13	nuclear	O
14	assembly	O
15	in	O
16	Xenopus	O
17	egg	O
18	extracts	O
19	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	O
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	Nevertheless	O
2	cryopreservation	O
3	of	O
4	spermatozoa	O
5	in	O
6	a	O
7	medium	O
8	containing	O
9	neither	O
10	SP	O
11	nor	O
12	biological	O
13	substances	O
14	could	O
15	offer	O
16	an	O
17	acceptable	O
18	cryoprotection	O
19	of	O
20	spermatozoa	O
21	to	O
22	be	O
23	used	O
24	in	O
25	assisted	O
26	fertilization	O
27	procedures	O
28	,	O
29	especially	O
30	for	O
31	intracytoplasmic	O
32	sperm	O
33	injection	O
34	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	evaluate	O
7	how	O
8	couplers	O
9	and	O
10	their	O
11	placement	O
12	affect	O
13	the	O
14	ALGO2	O
15	click	O
16	spectral	O
17	properties	O
18	.	O

1	Two	O
2	experiments	O
3	(	O
4	N	O
5	=	O
6	20	O
7	each	O
8	)	O
9	were	O
10	carried	O
11	out	O
12	to	O
13	explore	O
14	the	O
15	nature	O
16	of	O
17	ERP	B
18	negativities	I
19	in	O
20	a	O
21	visuospatial	O
22	memory	O
23	task	O
24	and	O
25	in	O
26	an	O
27	auditory	O
28	spatial	O
29	memory	O
30	task	O
31	,	O
32	respectively	O
33	.	O

1	He	O
2	was	O
3	administered	O
4	recombinant	B
5	IFN	B
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O

1	The	O
2	selenium	O
3	level	O
4	and	O
5	glutathione	B
6	peroxidase	I
7	activity	O
8	in	O
9	the	O
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	RESULTS	O
2	:	O
3	Glaucoma	O
4	suspects	O
5	were	O
6	divided	O
7	into	O
8	two	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	SWAP	O
14	results	O
15	:	O
16	high	O
17	risk	O
18	(	O
19	with	O
20	SWAP	O
21	abnormalities	O
22	)	O
23	and	O
24	low	O
25	risk	O
26	(	O
27	with	O
28	normal	O
29	SWAP	O
30	result	O
31	).	O

1	In	O
2	6	O
3	of	O
4	24	O
5	infants	O
6	studied	O
7	(	O
8	27th	O
9	-	O
10	40th	O
11	weeks	O
12	of	O
13	gestation	O
14	),	O
15	acquired	O
16	and	O
17	congenital	O
18	structural	O
19	anomalies	O
20	of	O
21	the	O
22	airways	O
23	were	O
24	detected	O
25	with	O
26	an	O
27	ultrathin	B
28	flexible	I
29	fiberscope	I
30	(	O
31	Olympus	B
32	PF18	I
33	S	I
34	,	O
35	1	O
36	.	O
37	8	O
38	mm	O
39	).	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	O
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	the	O
5	importance	O
6	of	O
7	phosphate	O
8	and	O
9	calcium	O
10	in	O
11	influencing	O
12	the	O
13	secretion	O
14	of	O
15	PTH	B
16	and	O
17	CT	O
18	in	O
19	uremia	O
20	.	O

1	Cardiac	B
2	myosin	I
3	-	I
4	binding	I
5	protein	I
6	C	I
7	(	O
8	MyBP	B
9	-	I
10	C	I
11	):	O
12	identification	O
13	of	O
14	protein	I
15	kinase	I
16	A	I
17	and	O
18	protein	I
19	kinase	I
20	C	I
21	phosphorylation	O
22	sites	O
23	.	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	O
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	O
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	O
43	.	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	O
13	and	O
14	PACE2	O
15	.	O

1	IA	O
2	-	O
3	CT	O
4	with	O
5	cisplatin	O
6	50	O
7	mg	O
8	and	O
9	doxorubicin	O
10	30	O
11	mg	O
12	was	O
13	administered	O
14	by	O
15	one	O
16	shot	O
17	method	O
18	in	O
19	bilateral	O
20	internal	O
21	iliac	O
22	arteries	O
23	.	O

1	In	O
2	8	O
3	healthy	O
4	volunteers	O
5	there	O
6	were	O
7	no	O
8	significant	O
9	differences	O
10	in	O
11	AUC	O
12	,	O
13	peak	O
14	plasma	O
15	concentrations	O
16	or	O
17	time	O
18	to	O
19	peak	O
20	concentration	O
21	when	O
22	OXC	O
23	was	O
24	administered	O
25	either	O
26	with	O
27	or	O
28	without	O
29	ERY	O
30	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	O
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	Experimental	O
2	data	O
3	showed	O
4	that	O
5	these	O
6	abnormal	O
7	proteins	O
8	are	O
9	constitutively	O
10	localized	O
11	in	O
12	the	O
13	nucleus	O
14	,	O
15	have	O
16	lost	O
17	the	O
18	transcriptional	O
19	repressor	O
20	functions	O
21	typical	O
22	of	O
23	normal	O
24	NF	B
25	-	I
26	kappa	I
27	B2p52	I
28	and	O
29	may	O
30	be	O
31	capable	O
32	of	O
33	transactivation	O
34	activity	O
35	.	O

1	Epstein	O
2	-	O
3	Barr	O
4	virus	I
5	-	I
6	encoded	I
7	latent	I
8	membrane	I
9	protein	I
10	1	O
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	extreme	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	TRADD	B
25	and	O
26	TRAF2	B
27	.	O

1	Courses	O
2	were	O
3	repeated	O
4	monthly	O
5	upon	O
6	recovery	O
7	of	O
8	myelosuppression	O
9	.	O

1	The	O
2	human	B
3	2	I
4	',	O
5	5	B
6	'-	I
7	oligoadenylate	I
8	(	O
9	2	B
10	-	I
11	5A	I
12	)	O
13	synthetases	B
14	are	O
15	members	O
16	of	O
17	a	O
18	family	O
19	interferon	B
20	(	O
21	IFN	B
22	)-	I
23	inducible	O
24	anti	I
25	-	I
26	viral	I
27	proteins	I
28	.	O

1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	thrombin	B
9	-	O
10	stimulated	O
11	vascular	O
12	smooth	O
13	muscle	O
14	proliferation	O
15	is	O
16	delayed	O
17	and	O
18	requires	O
19	the	O
20	de	O
21	novo	O
22	expression	O
23	of	O
24	one	O
25	or	O
26	more	O
27	autocrine	O
28	mitogens	O
29	.	O

1	Influence	O
2	of	O
3	cyclo	B
4	-	I
5	oxygenase	I
6	inhibition	O
7	and	O
8	of	O
9	leukotriene	O
10	receptor	O
11	blockade	O
12	on	O
13	pulmonary	O
14	vascular	O
15	pressure	O
16	/	O
17	cardiac	O
18	index	O
19	relationships	O
20	in	O
21	hyperoxic	O
22	and	O
23	in	O
24	hypoxic	O
25	dogs	O
26	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	significant	O
6	reduction	O
7	in	O
8	blood	O
9	pressure	O
10	,	O
11	the	O
12	angiotensin	B
13	converting	I
14	enzyme	I
15	(	I
16	ACE	B
17	)	I
18	inhibitor	O
19	ramipril	O
20	caused	O
21	a	O
22	significant	O
23	regression	O
24	of	O
25	pathologic	O
26	left	O
27	ventricular	O
28	hypertrophy	O
29	demonstrated	O
30	by	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	and	O
35	echocardiography	O
36	.	O

1	Genomic	O
2	and	O
3	cDNA	O
4	clones	O
5	homologous	O
6	to	O
7	the	O
8	yeast	B
9	GCN2	I
10	eIF	I
11	-	I
12	2alpha	I
13	kinase	I
14	(	O
15	yGCN2	B
16	)	O
17	were	O
18	isolated	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	.	O

1	Cocaine	O
2	-	O
3	treated	O
4	rats	O
5	acquired	O
6	a	O
7	preference	O
8	for	O
9	cocaine	O
10	-	O
11	associated	O
12	contextual	O
13	stimuli	O
14	(	O
15	CS	O
16	)	O
17	relative	O
18	to	O
19	saline	O
20	-	O
21	injected	O
22	control	O
23	rats	O
24	.	O

1	Ethylene	O
2	glycol	O
3	and	O
4	diethylene	O
5	glycol	O
6	were	O
7	each	O
8	administered	O
9	once	O
10	weekly	O
11	subcutaneously	O
12	to	O
13	groups	O
14	of	O
15	100	O
16	female	O
17	NMRI	O
18	mice	O
19	at	O
20	3	O
21	dosages	O
22	(	O
23	30	O
24	;	O
25	10	O
26	und	O
27	3	O
28	mg	O
29	single	O
30	dose	O
31	per	O
32	mouse	O
33	).	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	B
6	cDNA	I
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	An	O
2	immunologic	O
3	test	O
4	using	O
5	stomach	O
6	and	O
7	tumor	O
8	antigens	O
9	for	O
10	screening	O
11	of	O
12	those	O
13	at	O
14	high	O
15	risk	O
16	for	O
17	stomach	O
18	cancer	O
19	is	O
20	suggested	O
21	.	O

1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	B
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	B
16	-	I
17	C	I
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	B
25	-	I
26	RS	I
27	are	O
28	mutated	O
29	.	O

1	Mutations	O
2	in	O
3	three	O
4	loci	O
5	(	O
6	SIC1	B
7	,	O
8	SWI5	B
9	,	O
10	and	O
11	RIC3	B
12	)	O
13	were	O
14	identified	O
15	.	O

1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	After	O
2	declamping	O
3	of	O
4	the	O
5	aorta	O
6	,	O
7	there	O
8	were	O
9	also	O
10	severe	O
11	edema	O
12	,	O
13	local	O
14	fibre	O
15	necrosis	O
16	,	O
17	and	O
18	adhesion	O
19	of	O
20	leucocytes	O
21	,	O
22	whereas	O
23	muscle	O
24	fibre	O
25	areas	O
26	became	O
27	3	O
28	,	O
29	935	B
30	.	O
31	18	O
32	micro	O
33	531	I
34	microm	O
35	(	O
36	2	O
37	)	O
38	for	O
39	type	O
40	I	O
41	and	O
42	5	O
43	,	O
44	804	O
45	+/-	O
46	1	O
47	,	O
48	075	O
49	microm	O
50	(	O
51	2	O
52	)	O
53	for	O
54	type	O
55	II	O
56	.	O

1	Levels	O
2	of	O
3	serum	B
4	IgE	I
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O

1	Hand	O
2	-	O
3	held	O
4	,	O
5	continuous	O
6	-	O
7	wave	O
8	Doppler	O
9	probes	O
10	,	O
11	coupled	O
12	with	O
13	sound	O
14	spectral	O
15	analysis	O
16	,	O
17	can	O
18	successfully	O
19	predict	O
20	carotid	O
21	artery	O
22	stenosis	O
23	.	O

1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	O
8	platelet	B
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	B
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O

1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	B
11	transcriptase	I
12	-	O
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	B
31	and	O
32	Y88L	B
33	RNAs	O
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O

1	The	O
2	transmembrane	O
3	topology	O
4	of	O
5	Na	B
6	(+)/	I
7	H	I
8	(+)	I
9	exchanger	I
10	NHE3	I
11	has	O
12	been	O
13	studied	O
14	using	O
15	in	O
16	vitro	O
17	transcription	O
18	/	O
19	translation	O
20	of	O
21	two	O
22	types	O
23	of	O
24	fusion	O
25	vectors	O
26	designed	O
27	to	O
28	test	O
29	membrane	O
30	insertion	O
31	properties	O
32	of	O
33	cDNA	O
34	sequences	O
35	encoding	O
36	putative	O
37	NHE3	B
38	membrane	I
39	spanning	O
40	domains	O
41	(	O
42	msds	O
43	).	O

1	The	O
2	micromethod	B
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	B
15	.	O

1	Disruption	O
2	demonstrates	O
3	that	O
4	CDC14	B
5	is	O
6	an	O
7	essential	O
8	gene	O
9	.	O

1	We	O
2	conclude	O
3	that	O
4	Hansel	O
5	'	O
6	s	O
7	stain	O
8	substantially	O
9	improves	O
10	the	O
11	recognition	O
12	of	O
13	eosinophiluria	O
14	as	O
15	compared	O
16	with	O
17	Wright	O
18	'	O
19	s	O
20	stain	O
21	.	O

1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	I
17	glucocerebrosidase	I
18	enzyme	I
19	.	O

1	The	O
2	Jenkins	O
3	Activity	O
4	Survey	O
5	and	O
6	the	O
7	CPI	O
8	-	O
9	revised	O
10	:	O
11	further	O
12	evidence	O
13	of	O
14	adaptive	O
15	and	O
16	maladaptive	O
17	type	O
18	A	O
19	traits	O
20	.	O

1	The	O
2	primer	O
3	is	O
4	generated	O
5	by	O
6	a	O
7	cleavage	O
8	that	O
9	occurs	O
10	between	O
11	bases	O
12	11	O
13	and	O
14	12	O
15	of	O
16	the	O
17	Tf1	B
18	mRNA	O
19	.	O

1	The	O
2	role	O
3	of	O
4	'	O
5	scientific	O
6	psychiatry	O
7	'	O
8	in	O
9	understanding	O
10	patients	O
11	with	O
12	chronic	O
13	schizophrenia	O
14	or	O
15	severe	O
16	personality	O
17	disorder	O
18	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	I
19	R2LC	I
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	O
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	I
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	B
32	(	I
33	2	I
34	'-	I
35	5	I
36	')	I
37	oligoadenylate	I
38	synthetase	I
39	gene	I
40	interferon	I
41	response	O
42	element	O
43	as	O
44	a	O
45	probe	O
46	.	O

1	The	O
2	effect	O
3	of	O
4	emotional	O
5	-	O
6	painful	O
7	stress	O
8	(	O
9	EPS	O
10	)	O
11	on	O
12	myocardial	O
13	extensibility	O
14	and	O
15	contractility	O
16	was	O
17	studied	O
18	on	O
19	an	O
20	isolated	O
21	rat	O
22	atrium	O
23	.	O

1	Protein	B
2	S	I
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	folate	O
6	compounds	O
7	decrease	O
8	formate	O
9	accumulation	O
10	after	O
11	methanol	O
12	by	O
13	stimulating	O
14	formate	O
15	oxidation	O
16	or	O
17	utilization	O
18	and	O
19	suggest	O
20	a	O
21	possible	O
22	use	O
23	for	O
24	folates	O
25	in	O
26	the	O
27	treatment	O
28	of	O
29	certain	O
30	cases	O
31	of	O
32	human	O
33	methanol	O
34	poisoning	O
35	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	Inhibition	O
2	of	O
3	the	O
4	apolipoprotein	B
5	B	I
6	mRNA	I
7	editing	I
8	enzyme	I
9	-	I
10	complex	I
11	by	O
12	hnRNP	B
13	C1	I
14	protein	I
15	and	O
16	40S	B
17	hnRNP	I
18	complexes	I
19	.	O

1	As	O
2	pleural	B
3	thickening	O
4	is	O
5	seen	O
6	commonly	O
7	in	O
8	asbestosis	O
9	and	O
10	may	O
11	influence	O
12	lung	O
13	volumes	O
14	and	O
15	the	O
16	ratio	O
17	of	O
18	transfer	B
19	factor	I
20	to	O
21	effective	O
22	alveolar	O
23	volume	O
24	,	O
25	the	O
26	results	O
27	of	O
28	these	O
29	measurements	O
30	were	O
31	compared	O
32	only	O
33	in	O
34	the	O
35	cases	O
36	showing	O
37	absent	O
38	or	O
39	minimal	O
40	pleural	O
41	thickening	O
42	.	O

1	Antibodies	O
2	against	O
3	this	O
4	purified	O
5	protein	O
6	localize	O
7	RIM1	I
8	to	O
9	mitochondria	O
10	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	Very	O
2	good	O
3	accuracy	O
4	(	O
5	r	O
6	greater	O
7	than	O
8	0	O
9	.	O
10	9	O
11	)	O
12	was	O
13	found	O
14	when	O
15	except	O
16	comparing	O
17	H	O
18	*	I
19	2	O
20	with	O
21	the	O
22	other	O
23	machine	O
24	and	O
25	the	O
26	reference	O
27	methods	O
28	,	O
29	except	O
30	for	O
31	MCHCH	O
32	and	O
33	basophil	O
34	count	O
35	.	O

1	Discrimination	O
2	between	O
3	HIV	O
4	-	O
5	1	O
6	and	O
7	HIV	O
8	-	O
9	2	O
10	showed	O
11	evidence	O
12	for	O
13	the	O
14	presence	O
15	of	O
16	HIV	O
17	-	O
18	1	I
19	only	O
20	.	O

1	The	O
2	spectrum	O
3	of	O
4	histologically	O
5	diagnosed	O
6	malignant	O
7	neoplasms	O
8	in	O
9	Sabah	O
10	,	O
11	1983	O
12	-	O
13	1988	O
14	.	O

1	Thioredoxin	B
2	(	O
3	TR	B
4	)	O
5	is	O
6	a	O
7	small	O
8	ubiquitous	O
9	dithiol	B
10	-	I
11	reductase	I
12	enzyme	O
13	first	O
14	identified	O
15	in	O
16	bacteria	O
17	and	O
18	plants	O
19	.	O

1	Targeted	O
2	disruption	O
3	of	O
4	the	O
5	OGG1	B
6	gene	I
7	in	O
8	yeast	O
9	revealed	O
10	a	O
11	second	O
12	OG	B
13	glycosylase	I
14	/	I
15	lyase	I
16	protein	I
17	,	O
18	tentatively	O
19	named	O
20	Ogg2	O
21	,	O
22	which	O
23	differs	O
24	from	O
25	Ogg1	B
26	in	O
27	that	O
28	it	O
29	preferentially	O
30	acts	O
31	on	O
32	OG	O
33	:	O
34	G	O
35	.	O

1	Ras	B
2	-	I
3	and	O
4	ultra	B
5	-	I
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	I
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	I
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	Three	O
2	high	O
3	mobility	I
4	group	O
5	-	O
6	like	O
7	sequences	O
8	within	O
9	a	O
10	48	O
11	-	O
12	base	O
13	pair	O
14	enhancer	O
15	of	O
16	the	O
17	Col2a1	B
18	gene	I
19	are	O
20	required	O
21	for	O
22	cartilage	O
23	-	O
24	specific	O
25	expression	O
26	in	O
27	vivo	O
28	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	B
6	and	O
7	F	B
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	I
15	.	I
16	S	I
17	.	O
18	R	I
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	B
30	.	I
31	sporotrichioides	I
32	var	I
33	.	O
34	tricinctum	I
35	from	O
36	U	O
37	.	O
38	S	I
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O

1	Sequences	O
2	required	O
3	for	O
4	interaction	O
5	of	O
6	mu2	B
7	and	O
8	CTLA	B
9	-	I
10	4	I
11	were	O
12	localized	O
13	to	O
14	residues	O
15	,	O
16	161TTGVY	B
17	in	O
18	CTLA	B
19	-	I
20	4	I
21	;	O
22	this	O
23	sequence	O
24	is	O
25	N	O
26	-	O
27	terminal	O
28	to	O
29	,	O
30	but	O
31	overlaps	O
32	with	O
33	,	O
34	a	O
35	previously	O
36	identified	O
37	SH2	B
38	binding	I
39	motif	I
40	,	O
41	165YVKM	B
42	,	O
43	involved	O
44	in	O
45	CTLA	B
46	-	I
47	4	I
48	signaling	O
49	.	O

1	Thus	O
2	,	O
3	hGRbeta	O
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	O
13	activity	O
14	.	O

1	Hepatitis	O
2	C	O
3	virus	O
4	infection	O
5	and	O
6	lymphoproliferative	O
7	diseases	O
8	in	O
9	France	O
10	:	O
11	a	O
12	national	O
13	study	O
14	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	B
10	gene	I
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	O
43	.	O

1	Goodpasture	O
2	'	O
3	s	O
4	-	O
5	like	O
6	syndrome	O
7	and	O
8	effect	O
9	of	O
10	extracorporeal	O
11	membrane	O
12	oxygenator	O
13	support	O
14	.	O

1	The	O
2	direct	O
3	effects	O
4	of	O
5	transmitter	O
6	release	O
7	were	O
8	(	O
9	a	O
10	)	O
11	an	O
12	early	O
13	fall	O
14	in	O
15	MAP	O
16	followed	O
17	by	O
18	a	O
19	late	O
20	pressor	O
21	effect	O
22	;	O
23	and	O
24	(	O
25	b	O
26	)	O
27	an	O
28	early	O
29	bradycardia	O
30	followed	O
31	by	O
32	a	O
33	late	O
34	tachycardia	O
35	.	O

1	Analysis	O
2	by	O
3	cell	O
4	surface	O
5	immunofluorescence	O
6	showed	O
7	that	O
8	the	O
9	UL28	B
10	gene	I
11	is	O
12	not	O
13	required	O
14	for	O
15	expression	O
16	of	O
17	viral	O
18	glycoproteins	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	infected	O
24	cells	O
25	.	O

1	Taken	O
2	together	O
3	,	O
4	they	O
5	uphold	O
6	the	O
7	emerging	O
8	concern	O
9	that	O
10	women	O
11	with	O
12	ER	B
13	(+)	I
14	cancers	O
15	may	O
16	not	O
17	benefit	O
18	significantly	O
19	from	O
20	endocrine	O
21	treatment	O
22	if	O
23	the	O
24	tumors	O
25	also	O
26	overexpress	B
27	HER	I
28	-	I
29	2	I
30	.	O

1	The	O
2	interferon	B
3	-	I
4	inducible	I
5	protein	I
6	kinase	I
7	PKR	I
8	modulates	O
9	the	O
10	transcriptional	O
11	activation	O
12	of	O
13	immunoglobulin	B
14	kappa	I
15	gene	I
16	.	O

1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	B
6	and	O
7	Zn	B
8	to	O
9	Mg	B
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O

1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	B
17	promoter	I
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O

1	Abundant	O
2	infiltration	O
3	of	O
4	lymphocytes	O
5	and	O
6	plasma	O
7	cells	O
8	was	O
9	also	O
10	wide	O
11	-	O
12	spread	O
13	beneath	O
14	the	O
15	carcinoma	O
16	in	O
17	situ	O
18	,	O
19	together	O
20	with	O
21	the	O
22	lymphoid	O
23	follicles	O
24	.	O

1	The	O
2	half	O
3	-	O
4	life	O
5	of	O
6	the	O
7	serum	O
8	-	O
9	induced	O
10	CBP	B
11	/	I
12	tk	I
13	binding	I
14	activity	O
15	was	O
16	estimated	O
17	to	O
18	be	O
19	less	O
20	than	O
21	1	O
22	h	O
23	.(	O
24	ABSTRACT	O
25	TRUNCATED	O
26	AT	O
27	400	O
28	WORDS	O
29	)	O

1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	B
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	B
19	E6	I
20	/	I
21	E7	I
22	genes	I
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	B
32	protein	O
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	B
42	immunoprecipitated	O
43	with	O
44	anti	B
45	-	I
46	E7	I
47	antibodies	I
48	were	O
49	observed	O
50	.	O

1	An	O
2	apparent	O
3	ufo	B
4	mRNA	O
5	overexpression	O
6	was	O
7	not	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	positive	O
14	leukemia	O
15	cell	O
16	lines	O
17	,	O
18	but	O
19	was	O
20	identified	O
21	in	O
22	the	O
23	drug	O
24	-	O
25	resistant	O
26	subclones	O
27	of	O
28	the	O
29	cervix	O
30	carcinoma	O
31	cell	O
32	line	O
33	HeLa	O
34	.	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O

1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	SCA	O
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	O
9	aspartyl	B
10	,	O
11	and	O
12	metalloproteases	O
13	,	O
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	The	O
2	minus	O
3	-	O
4	end	O
5	-	O
6	directed	O
7	microtubule	B
8	motors	I
9	,	O
10	the	O
11	dyneins	O
12	,	O
13	may	O
14	also	O
15	constitute	O
16	a	O
17	superfamily	O
18	of	O
19	force	O
20	-	O
21	generating	O
22	proteins	O
23	with	O
24	distinct	O
25	attachment	O
26	domains	O
27	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Diazepam	O
2	(	O
3	3	O
4	mg	O
5	/	O
6	kg	O
7	)	O
8	generalized	O
9	to	O
10	Ro	O
11	11	O
12	-	O
13	6896	O
14	whereas	O
15	the	O
16	structurally	O
17	related	O
18	Ro	O
19	5	O
20	-	O
21	4864	O
22	(	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	and	O
28	30	O
29	mg	O
30	/	O
31	kg	O
32	)	O
33	did	O
34	not	O
35	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Lrp	B
6	binds	O
7	a	O
8	central	O
9	palindromic	O
10	site	O
11	,	O
12	interacting	O
13	predominantly	O
14	with	O
15	the	O
16	major	O
17	groove	O
18	of	O
19	its	O
20	DNA	O
21	target	O
22	,	O
23	and	O
24	that	O
25	additional	O
26	dimers	O
27	bind	O
28	to	O
29	flanking	O
30	sites	O
31	to	O
32	form	O
33	a	O
34	nucleoprotein	O
35	activation	O
36	complex	O
37	.	O

1	A	O
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	B
16	WWW	I
17	server	I
18	.	O

1	Magnetically	O
2	induced	O
3	optical	O
4	self	O
5	-	O
6	pulsing	O
7	in	O
8	a	O
9	nonlinear	O
10	resonator	O
11	.	O

1	The	O
2	mHIF	B
3	-	I
4	1	I
5	alpha	I
6	structural	I
7	gene	I
8	is	O
9	composed	O
10	of	O
11	15	O
12	exons	O
13	.	O

1	INTERVENTION	O
2	(	O
3	S	O
4	):	O
5	Twenty	O
6	-	O
7	six	O
8	hemostasis	O
9	parameters	O
10	evaluated	O
11	repeatedly	O
12	in	O
13	patients	O
14	undergoing	O
15	IVF	O
16	-	O
17	ET	O
18	.	O

1	Univariate	O
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	O
7	-	O
8	Meier	O
9	-	O
10	estimates	O
11	and	O
12	Log	O
13	-	O
14	Rank	O
15	-	O
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	O
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	O
51	alkaline	B
52	phosphatase	I
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	O
68	albumin	I
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O

1	Biol	O
2	.	O

1	Alignment	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	surrounding	O
8	Tyr	O
9	-	O
10	766	O
11	with	O
12	corresponding	O
13	regions	O
14	of	O
15	other	O
16	FGFRs	O
17	revealed	O
18	conserved	O
19	tyrosine	O
20	residues	O
21	in	O
22	all	O
23	known	O
24	members	O
25	of	O
26	the	O
27	FGFR	B
28	family	I
29	.	O

1	RESULTS	O
2	:	O
3	Basal	O
4	plasma	O
5	IGF	B
6	-	O
7	I	O
8	levels	O
9	as	O
10	well	O
11	as	O
12	body	O
13	mass	O
14	index	O
15	(	O
16	BMI	O
17	)	O
18	were	O
19	lower	O
20	in	O
21	amenorrheic	O
22	patients	O
23	than	O
24	in	O
25	healthy	O
26	controls	O
27	.	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	O
5	/	O
6	T	O
7	(	O
8	L	O
9	)	O
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	O
29	/	O
30	T	O
31	(	O
32	F	O
33	)	O
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	The	O
2	transit	O
3	time	O
4	was	O
5	significantly	O
6	shortened	O
7	.	O

1	The	O
2	remaining	O
3	RAD	O
4	+	O
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	I
18	cells	O
19	.	O

1	Neither	O
2	verapamil	O
3	nor	O
4	nifedipine	O
5	changed	O
6	collateral	O
7	myocardial	O
8	blood	O
9	flow	O
10	from	O
11	0	O
12	.	O
13	10	O
14	+/-	O
15	0	O
16	.	O
17	02	O
18	in	O
19	the	O
20	subendocardium	O
21	and	O
22	0	O
23	.	O
24	17	O
25	+/-	O
26	0	O
27	.	O
28	03	O
29	ml	O
30	/	O
31	min	O
32	/	O
33	g	O
34	in	O
35	the	O
36	subepicardium	O
37	.	O

1	The	O
2	"	O
3	28	O
4	percent	O
5	"	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O

1	Catha	B
2	edulis	I
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	O
12	/	O
13	PGS2	O
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O

1	Chimeras	O
2	containing	O
3	IE1	B
4	peptides	O
5	dramatically	O
6	activated	O
7	transcription	O
8	of	O
9	the	O
10	basal	O
11	promoter	O
12	only	O
13	when	O
14	lac	B
15	operator	I
16	sequences	O
17	were	O
18	present	O
19	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	B
26	)-	I
27	4	I
28	and	I
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	Timing	O
2	of	O
3	symptoms	O
4	and	O
5	oocyst	O
6	excretion	O
7	in	O
8	human	O
9	cryptosporidiosis	O
10	.	O

1	A	O
2	novel	O
3	Drosophila	B
4	A	I
5	kinase	I
6	anchor	I
7	protein	I
8	,	O
9	Drosophila	B
10	A	I
11	kinase	I
12	anchor	I
13	protein	O
14	200	O
15	(	O
16	DAKAP200	O
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	O
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	O
25	chromosome	O
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	O
36	(	O
37	breakpoint	O
38	cluster	O
39	region	O
40	).	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	I
23	dependent	I
24	kinases	I
25	(	O
26	CDKs	B
27	).	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	Genetic	O
2	analysis	O
3	has	O
4	subsequently	O
5	identified	O
6	subpathways	O
7	of	O
8	the	O
9	DNA	O
10	structure	O
11	checkpoints	O
12	,	O
13	including	O
14	the	O
15	reversible	O
16	arrest	O
17	of	O
18	DNA	O
19	synthesis	O
20	.	O

1	Analyses	O
2	of	O
3	tyrosine	O
4	residue	O
5	-	I
6	mutated	I
7	PDGF	B
8	receptors	I
9	show	O
10	that	O
11	Src	B
12	homology	I
13	2	I
14	domain	I
15	-	I
16	containing	I
17	proteins	I
18	including	O
19	Src	B
20	family	I
21	kinases	I
22	,	O
23	phosphatidylinositol	B
24	3	I
25	-	I
26	kinase	I
27	,	O
28	the	O
29	GTPase	B
30	-	I
31	activating	I
32	protein	I
33	of	O
34	Ras	B
35	,	O
36	the	O
37	Src	B
38	homology	I
39	2	I
40	domain	I
41	-	I
42	containing	I
43	phosphatase	I
44	SHP	I
45	-	I
46	2	I
47	,	O
48	phospholipase	B
49	C	I
50	-	I
51	gamma	I
52	,	O
53	and	O
54	Crk	B
55	do	O
56	not	O
57	play	O
58	a	O
59	major	O
60	role	O
61	in	O
62	mediating	O
63	the	O
64	PDGF	O
65	-	O
66	induced	O
67	activation	O
68	of	O
69	p38	B
70	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	O
22	.	O

1	Human	B
2	LAF	I
3	-	I
4	4	I
5	readily	O
6	hybridized	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	B
19	family	I
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O

1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	B
21	.	O
22	5kb	I
23	transcript	I
24	size	O
25	.	O

1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	I
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O

1	An	O
2	even	O
3	greater	O
4	inflammatory	O
5	response	O
6	was	O
7	observed	O
8	after	O
9	intratracheal	O
10	instillation	O
11	of	O
12	ufCB	O
13	,	O
14	but	O
15	not	O
16	after	O
17	CB	O
18	instillation	O
19	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	O
6	alpha	I
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	Calcitriol	O
2	therapy	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	decrease	O
8	in	O
9	serum	O
10	iPTH	B
11	levels	O
12	(	O
13	701	O
14	+/-	O
15	103	O
16	.	O
17	9	O
18	vs	O
19	.	O

1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O

1	It	O
2	was	O
3	not	O
4	possible	O
5	to	O
6	study	O
7	the	O
8	basis	O
9	for	O
10	tissue	O
11	-	O
12	specific	O
13	expression	O
14	of	O
15	this	O
16	gene	O
17	,	O
18	because	O
19	the	O
20	beta	B
21	3	I
22	gene	I
23	promoter	I
24	had	O
25	not	O
26	been	O
27	isolated	O
28	previously	O
29	.	O

1	The	O
2	genome	O
3	organization	O
4	of	O
5	the	O
6	mite	O
7	-	O
8	transmitted	O
9	wheat	O
10	streak	O
11	mosaic	O
12	virus	O
13	(	O
14	WSMV	O
15	)	O
16	appears	O
17	to	O
18	parallel	O
19	that	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Potyviridae	O
25	with	O
26	monopartite	O
27	genomes	O
28	,	O
29	but	O
30	there	O
31	are	O
32	substantial	O
33	amino	O
34	acid	O
35	dissimilarities	O
36	with	O
37	other	O
38	potyviral	B
39	polyproteins	I
40	.	O

1	Circulating	O
2	thrombomodulin	B
3	:	O
4	current	O
5	knowledge	O
6	and	O
7	future	O
8	prospects	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	O
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	Ultrastructural	O
2	studies	O
3	of	O
4	retinopathy	O
5	of	O
6	premature	O
7	infants	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	that	O
6	scanthrough	O
7	translation	O
8	,	O
9	where	O
10	the	O
11	initiating	O
12	AUG	O
13	of	O
14	a	O
15	primary	O
16	open	O
17	reading	O
18	frame	I
19	is	O
20	bypassed	O
21	,	O
22	is	O
23	most	O
24	likely	O
25	to	O
26	account	O
27	for	O
28	the	O
29	presentation	O
30	of	O
31	cryptic	O
32	epitopes	O
33	from	O
34	alternative	O
35	reading	O
36	frames	O
37	within	O
38	the	O
39	influenza	O
40	A	I
41	PR	I
42	/	I
43	8	I
44	/	I
45	34	I
46	nucleoprotein	I
47	gene	O
48	.	O

1	Recombinant	O
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Catheter	O
2	transit	O
3	slows	O
4	the	O
5	response	O
6	to	O
7	a	O
8	step	O
9	increase	O
10	in	O
11	concentration	O
12	by	O
13	about	O
14	0	O
15	.	O
16	13	O
17	s	O
18	(	O
19	from	O
20	10	O
21	per	O
22	cent	O
23	-	O
24	90	O
25	per	O
26	cent	O
27	)	O
28	and	O
29	prolongs	O
30	the	O
31	transit	O
32	time	O
33	through	O
34	the	O
35	catheter	O
36	for	O
37	a	O
38	volatile	O
39	anesthetic	O
40	by	O
41	about	O
42	0	O
43	.	O
44	04	O
45	s	O
46	more	O
47	than	O
48	N2	O
49	.	O

1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O

1	40	O
2	,	O
3	000	O
4	).	O

1	To	O
2	further	O
3	define	O
4	the	O
5	structural	O
6	requirements	O
7	for	O
8	ZAP	B
9	-	O
10	70	O
11	interaction	O
12	with	O
13	the	O
14	TCR	B
15	,	O
16	we	O
17	developed	O
18	a	O
19	binding	O
20	assay	O
21	using	O
22	immobilized	O
23	glutathione	B
24	S	I
25	-	I
26	transferase	I
27	fusion	I
28	proteins	O
29	containing	O
30	the	O
31	NH2	O
32	-	O
33	and	O
34	/	O
35	or	O
36	COOH	O
37	-	O
38	terminal	O
39	SH2	I
40	domains	I
41	of	O
42	ZAP	B
43	-	I
44	70	I
45	,	O
46	and	O
47	soluble	O
48	synthetic	O
49	peptides	O
50	with	O
51	the	O
52	sequence	O
53	of	O
54	the	O
55	cytoplasmic	O
56	region	O
57	of	O
58	the	O
59	TCR	B
60	zeta	I
61	chain	I
62	(	I
63	TCR	B
64	zeta	I
65	cyt	I
66	)	O
67	or	O
68	individual	O
69	TCR	B
70	zeta	I
71	and	O
72	CD3	B
73	epsilon	I
74	TAM	I
75	motifs	I
76	.	O

1	The	O
2	activation	O
3	and	O
4	injury	O
5	of	O
6	endothelial	O
7	cells	O
8	induced	O
9	by	O
10	TNF	B
11	and	O
12	other	O
13	proinflammatory	O
14	cytokines	O
15	may	O
16	underlie	O
17	the	O
18	local	O
19	effects	O
20	of	O
21	these	O
22	mediators	O
23	in	O
24	vivo	O
25	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	ERP	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	instructions	O
18	.	O

1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O

1	Low	O
2	NA	O
3	and	O
4	A	O
5	may	O
6	participate	O
7	in	O
8	lowering	O
9	the	O
10	plasma	B
11	renin	I
12	activity	O
13	which	O
14	in	O
15	PA	O
16	in	O
17	suppressed	O
18	,	O
19	sometimes	O
20	disproportionately	O
21	to	O
22	the	O
23	actual	O
24	body	O
25	sodium	O
26	content	O
27	.	O

1	Residual	O
2	amphotericin	O
3	B	O
4	was	O
5	detected	O
6	in	O
7	the	O
8	feces	O
9	of	O
10	the	O
11	mice	O
12	only	O
13	while	O
14	they	O
15	were	O
16	receiving	O
17	the	O
18	0	O
19	.	O
20	3	O
21	mg	O
22	/	O
23	ml	O
24	dose	O
25	level	O
26	.	O

1	The	O
2	core	O
3	of	O
4	this	O
5	enhancer	O
6	contains	O
7	two	O
8	evolutionarily	O
9	conserved	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	homeodomain	B
15	protein	I
16	Tinman	I
17	(	O
18	Tin	B
19	),	O
20	expressed	O
21	in	O
22	developing	O
23	cardiac	O
24	,	O
25	somatic	O
26	,	O
27	and	O
28	visceral	O
29	muscle	O
30	lineages	O
31	.	O

1	However	O
2	,	O
3	changing	O
4	the	O
5	half	O
6	-	O
7	site	O
8	to	O
9	the	O
10	consensus	O
11	sequence	O
12	AGGTCA	O
13	(	O
14	IRper	O
15	-	O
16	1	O
17	)	O
18	increased	O
19	binding	O
20	of	O
21	AaEcR	B
22	.	O
23	AaUSP	O
24	10	O
25	-	O
26	fold	O
27	over	O
28	IRhsp	O
29	-	O
30	1	O
31	and	O
32	,	O
33	at	O
34	the	O
35	same	O
36	time	O
37	,	O
38	reduced	O
39	the	O
40	stringency	O
41	of	O
42	the	O
43	spacer	O
44	length	O
45	requirement	O
46	,	O
47	with	O
48	IRper	O
49	-	O
50	0	O
51	to	O
52	IRper	O
53	-	O
54	5	O
55	showing	O
56	detectable	O
57	binding	O
58	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	I
20	.	O

1	Using	O
2	bovine	O
3	and	O
4	murine	B
5	c	I
6	-	I
7	myb	I
8	clones	I
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O

1	During	O
2	heat	O
3	exposure	O
4	,	O
5	chicks	O
6	that	O
7	had	O
8	been	O
9	subjected	O
10	to	O
11	early	O
12	60	O
13	%	O
14	restriction	O
15	with	O
16	non	O
17	-	O
18	metyrapone	O
19	-	O
20	treated	O
21	food	O
22	had	O
23	lower	O
24	H	O
25	/	O
26	L	O
27	ratios	O
28	and	O
29	improved	O
30	resistance	O
31	to	O
32	marble	O
33	spleen	O
34	disease	O
35	infection	O
36	.	O

1	Pneumothorax	O
2	during	O
3	laparoscopic	O
4	dissection	O
5	of	O
6	the	O
7	diaphragmatic	O
8	hiatus	O
9	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O

1	Addition	O
2	of	O
3	phalloidin	B
4	-	I
5	stabilized	I
6	F	I
7	-	I
8	actin	I
9	nuclei	I
10	and	O
11	phalloidin	B
12	restored	O
13	L266D	B
14	actin	I
15	'	I
16	s	O
17	ability	O
18	to	O
19	polymerize	O
20	at	O
21	4	O
22	degrees	O
23	C	O
24	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	O
8	c	B
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	I
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	I
26	cell	I
27	receptor	I
28	stimulation	O
29	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	B
21	EFP	O
22	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	four	O
5	known	O
6	acyl	B
7	-	I
8	CoA	I
9	synthetases	I
10	(	O
11	fatty	B
12	acid	O
13	activation	O
14	proteins	O
15	,	O
16	Faaps	O
17	).	O

1	Control	O
2	experiments	O
3	showed	O
4	that	O
5	each	O
6	fusion	O
7	protein	O
8	had	O
9	a	O
10	high	O
11	affinity	O
12	binding	O
13	site	O
14	for	O
15	estradiol	O
16	-	O
17	17	O
18	beta	O
19	and	O
20	could	O
21	transactivate	O
22	an	O
23	ERE	O
24	-	O
25	LacZ	B
26	reporter	O
27	gene	O
28	in	O
29	yeast	O
30	similar	O
31	to	O
32	the	O
33	wild	O
34	type	O
35	ER	I
36	.	O

1	Previous	O
2	studies	O
3	showed	O
4	that	O
5	mutations	O
6	in	O
7	the	O
8	6K	B
9	protein	O
10	led	O
11	to	O
12	the	O
13	slow	O
14	release	O
15	of	O
16	aberrant	O
17	,	O
18	multi	O
19	-	O
20	cored	O
21	infectious	O
22	virions	O
23	.	O

1	Disturbance	O
2	of	O
3	regeneration	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	tunica	O
15	propria	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	homeostasis	O
27	.	O

1	Investigated	O
2	the	O
3	reliability	O
4	,	O
5	validity	O
6	and	O
7	dimensionality	O
8	of	O
9	scores	O
10	obtained	O
11	by	O
12	acute	O
13	psychiatric	O
14	inpatients	O
15	(	O
16	N	O
17	=	O
18	120	O
19	)	O
20	on	O
21	the	O
22	Michigan	O
23	Alcoholism	O
24	Screening	O
25	Test	O
26	adapted	O
27	to	O
28	assess	O
29	lifetime	O
30	and	O
31	current	O
32	symptomatology	O
33	.	O

1	No	O
2	symptoms	O
3	other	O
4	than	O
5	hot	O
6	flush	O
7	showed	O
8	such	O
9	significant	O
10	correlation	O
11	with	O
12	plasma	O
13	epinephrine	O
14	or	O
15	norepinephrine	O
16	levels	O
17	.	O

1	A	O
2	mutational	O
3	analysis	O
4	has	O
5	resolved	O
6	a	O
7	region	O
8	of	O
9	seven	O
10	amino	O
11	acids	O
12	(	O
13	amino	O
14	acids	O
15	26	O
16	-	O
17	32	O
18	)	O
19	in	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	of	O
25	Bob1	O
26	that	O
27	are	O
28	important	O
29	for	O
30	contacting	O
31	the	O
32	DNA	O
33	binding	O
34	POU	B
35	domain	I
36	of	O
37	Oct	B
38	-	I
39	1	I
40	or	O
41	Oct	B
42	-	I
43	2	I
44	.	O

1	Interferon	B
2	stimulated	I
3	gene	I
4	factor	I
5	3	I
6	(	O
7	ISGF3	B
8	)	O
9	is	O
10	a	O
11	trimeric	O
12	transcription	O
13	factor	O
14	activated	O
15	on	O
16	treatment	O
17	of	O
18	cells	O
19	with	O
20	interferon	B
21	-	I
22	alpha	I
23	and	O
24	beta	I
25	(	O
26	type	B
27	I	I
28	IFNs	I
29	).	O

1	Factors	O
2	influencing	O
3	in	O
4	vitro	O
5	skin	O
6	permeability	O
7	factor	O
8	production	O
9	by	O
10	Vibrio	B
11	cholerae	O
12	.	O

1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O

1	A	O
2	deletion	O
3	series	O
4	of	O
5	the	O
6	5	O
7	'	O
8	flanking	O
9	region	O
10	was	O
11	created	O
12	from	O
13	position	O
14	-	O
15	1329	O
16	to	O
17	-	O
18	74	O
19	relative	O
20	to	O
21	the	O
22	transcriptional	O
23	initiation	O
24	site	O
25	and	O
26	similarly	O
27	examined	O
28	in	O
29	transgenic	O
30	tobacco	O
31	.	O

1	Effect	O
2	of	O
3	phenformin	O
4	on	O
5	gluconeogenesis	O
6	in	O
7	perfused	O
8	rat	O
9	liver	O
10	.	O

1	SCL	B
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	Recombinant	B
2	human	I
3	TFIID	I
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O

1	(	O
2	1997	O
3	)	O
4	Science	O
5	275	O
6	,	O
7	1927	O
8	-	O
9	1930	O
10	).	O

1	By	O
2	contrast	O
3	,	O
4	PvirE	B
5	or	O
6	Plac	B
7	promoter	I
8	constructs	I
9	yielded	O
10	functional	O
11	VirE2	O
12	only	O
13	if	O
14	virE1	O
15	was	O
16	coexpressed	O
17	with	O
18	virE2	O
19	.	O

1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	Autoionization	O
2	rates	O
3	and	O
4	energy	O
5	levels	O
6	of	O
7	triplet	O
8	nf	O
9	,	O
10	v	O
11	=	O
12	1	O
13	Rydberg	O
14	states	O
15	of	O
16	H2	O
17	.	O

1	Pneumothorax	O
2	following	O
3	lung	O
4	abscess	O
5	in	O
6	the	O
7	renal	O
8	transplant	O
9	patient	O
10	.	O

1	Crosstalk	O
2	among	O
3	the	O
4	pathways	O
5	may	O
6	explain	O
7	how	O
8	some	O
9	forms	O
10	of	O
11	stress	O
12	can	O
13	contribute	O
14	to	O
15	the	O
16	development	O
17	of	O
18	a	O
19	malignancy	O
20	.	O

1	Two	O
2	related	O
3	studies	O
4	conducted	O
5	over	O
6	a	O
7	five	O
8	week	O
9	period	O
10	measured	O
11	and	O
12	typed	O
13	HLA	B
14	-	O
15	DQA1	O
16	from	O
17	accumulated	O
18	DNA	O
19	on	O
20	autopsy	O
21	room	O
22	and	O
23	Forensic	O
24	DNA	O
25	Laboratory	O
26	structures	O
27	.	O

1	Autoimmune	O
2	neutropenia	O
3	(	O
4	AIN	B
5	)	O
6	is	O
7	a	O
8	frequent	O
9	cause	O
10	of	O
11	chronic	O
12	neutropenia	O
13	especially	O
14	in	O
15	youngest	O
16	children	O
17	.	O

1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O

1	Small	B
2	-	O
3	molecule	O
4	control	O
5	of	O
6	insulin	B
7	and	O
8	PDGF	B
9	receptor	I
10	signaling	O
11	and	O
12	the	O
13	role	O
14	of	O
15	membrane	O
16	attachment	O
17	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	type	O
5	-	O
6	specific	O
7	capsular	O
8	polysaccharide	O
9	biosynthesis	O
10	genes	O
11	of	O
12	Streptococcus	O
13	agalactiae	O
14	type	O
15	Ia	O
16	.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	O
5	HI	B
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	The	O
2	East	B
3	African	I
4	dik	I
5	-	I
6	dik	I
7	antelope	I
8	represents	O
9	a	O
10	miniature	O
11	model	O
12	ruminant	O
13	for	O
14	comparative	O
15	studies	O
16	.	O

1	Mutation	O
2	of	O
3	the	O
4	Sp1	B
5	element	I
6	,	O
7	which	O
8	abolishes	O
9	Sp1	B
10	binding	I
11	,	O
12	results	O
13	in	O
14	a	O
15	6	O
16	-	O
17	10	O
18	-	O
19	fold	O
20	reduction	O
21	in	O
22	reporter	O
23	activity	O
24	.	O

1	The	O
2	residue	O
3	functions	O
4	,	O
5	R	O
6	(	O
7	t	O
8	),	O
9	for	O
10	C	O
11	-	O
12	11	I
13	CPZ	I
14	and	O
15	In	O
16	-	O
17	113m	B
18	transferrin	I
19	were	O
20	plotted	O
21	against	O
22	time	O
23	for	O
24	selected	O
25	areas	O
26	of	O
27	interest	O
28	,	O
29	and	O
30	the	O
31	CPZ	O
32	area	O
33	-	O
34	weighted	O
35	extraction	O
36	,	O
37	E	O
38	(	O
39	t	O
40	),	O
41	was	O
42	computed	O
43	for	O
44	the	O
45	same	O
46	areas	O
47	every	O
48	250	O
49	msec	O
50	using	O
51	the	O
52	formula	O
53	:	O
54	E	O
55	(	O
56	t	O
57	)	O
58	=	O
59	[	O
60	RT	O
61	(	O
62	t	O
63	)	O
64	-	O
65	RR	O
66	(	O
67	t	B
68	)]/[	I
69	1	I
70	-	O
71	RR	O
72	(	O
73	t	O
74	)],	O
75	where	O
76	RT	B
77	and	O
78	RR	O
79	are	O
80	the	O
81	normalized	O
82	residue	O
83	functions	O
84	for	O
85	CPZ	O
86	and	O
87	transferrin	B
88	,	O
89	respectively	O
90	.	O

1	Grade	O
2	3	B
3	-	I
4	4	I
5	mucositis	I
6	was	O
7	present	O
8	in	O
9	13	O
10	%	O
11	of	O
12	the	O
13	cycles	O
14	.	O

1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	B
18	alpha	I
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	The	O
2	clinical	O
3	picture	O
4	and	O
5	laboratory	O
6	parameters	O
7	were	O
8	consistent	O
9	with	O
10	a	O
11	serum	O
12	sickness	O
13	reaction	O
14	.	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	B
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	The	O
2	Cox	O
3	proportional	O
4	hazards	O
5	model	O
6	was	O
7	applied	O
8	to	O
9	the	O
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	O
23	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	Lipid	O
2	hydroperoxide	O
3	levels	O
4	in	O
5	plasma	O
6	and	O
7	LDL	B
8	remained	O
9	unchanged	O
10	throughout	O
11	the	O
12	study	O
13	.	O

1	Toxicity	O
2	during	O
3	the	O
4	therapeutic	O
5	period	O
6	was	O
7	not	O
8	significant	O
9	in	O
10	the	O
11	study	O
12	group	O
13	compared	O
14	with	O
15	the	O
16	historical	O
17	control	O
18	,	O
19	treated	O
20	with	O
21	the	O
22	same	O
23	regimen	O
24	without	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	gene	O
10	encoding	O
11	human	B
12	K14	I
13	(	O
14	D	O
15	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	O
41	.	O

1	Long	O
2	-	O
3	term	O
4	effects	O
5	of	O
6	clofibrate	O
7	(	O
8	Atromid	B
9	-	O
10	S	O
11	)	O
12	on	O
13	serum	O
14	lipids	O
15	in	O
16	man	O
17	.	O

1	Hybridization	O
2	data	O
3	indicate	O
4	that	O
5	6F6	B
6	.	O
7	2	O
8	corresponds	O
9	to	O
10	the	O
11	previously	O
12	characterized	O
13	m6F6	B
14	cDNA	I
15	clone	I
16	and	O
17	that	O
18	6F6	B
19	.	I
20	1	I
21	and	O
22	6F6	B
23	.	O
24	3	I
25	,	O
26	but	O
27	not	O
28	6F6	B
29	.	O
30	2	O
31	,	O
32	are	O
33	adjacent	O
34	to	O
35	alpha	B
36	-	I
37	type	I
38	genes	I
39	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	B
5	IIDR	I
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	Corticostriatal	O
2	and	O
3	corticosubthalamic	O
4	input	O
5	zones	O
6	from	O
7	the	O
8	presupplementary	O
9	motor	O
10	area	O
11	in	O
12	the	O
13	macaque	B
14	monkey	O
15	:	O
16	comparison	O
17	with	O
18	the	O
19	input	O
20	zones	O
21	from	O
22	the	O
23	supplementary	O
24	motor	O
25	area	O
26	.	O

1	The	O
2	molecular	O
3	associations	O
4	dictating	I
5	INCENP	I
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O

1	We	O
2	conclude	O
3	that	O
4	cAMP	O
5	,	O
6	acting	O
7	through	O
8	PKA	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	regulator	O
14	of	O
15	basal	O
16	CFTR	B
17	gene	I
18	expression	O
19	and	O
20	may	O
21	mediate	O
22	an	O
23	induction	O
24	of	O
25	CFTR	B
26	in	O
27	responsive	O
28	cell	O
29	types	O
30	.	O

1	CONCLUSION	O
2	:	O
3	Intravenous	O
4	diazepam	O
5	administration	O
6	before	O
7	EGD	O
8	produces	O
9	a	O
10	significant	O
11	fall	O
12	in	O
13	SpO2	O
14	during	O
15	the	O
16	procedure	O
17	,	O
18	and	O
19	so	O
20	should	O
21	be	O
22	avoided	O
23	;	O
24	continuous	O
25	monitoring	O
26	of	O
27	SpO2	O
28	should	O
29	be	O
30	done	O
31	during	O
32	EGD	O
33	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	B
17	resistance	O
18	gene	O
19	region	O
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	Me	B
2	(	O
3	2	O
4	)	O
5	SO	O
6	-	O
7	induced	O
8	neuronal	O
9	differentiation	O
10	of	O
11	N1E	O
12	-	O
13	115	O
14	neuroblastoma	O
15	cells	O
16	increased	O
17	both	O
18	the	O
19	expression	O
20	of	O
21	the	O
22	endogenous	B
23	Ntr	I
24	-	I
25	1	I
26	gene	I
27	and	O
28	reporter	O
29	genes	O
30	driven	O
31	by	O
32	NTR	B
33	-	I
34	1	I
35	promoter	I
36	sequences	O
37	by	O
38	3	O
39	-	O
40	4	O
41	-	O
42	fold	O
43	.	O

1	The	O
2	relations	O
3	among	O
4	various	O
5	negative	O
6	emotional	O
7	and	O
8	behavioral	O
9	characteristics	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.,	O
15	aggression	O
16	,	O
17	anxiety	O
18	,	O
19	undercompliance	O
20	,	O
21	depressive	O
22	mood	O
23	)	O
24	and	O
25	adjustment	O
26	were	O
27	examined	O
28	through	O
29	use	O
30	of	O
31	data	O
32	from	O
33	the	O
34	31	O
35	-	O
36	year	O
37	-	O
38	old	O
39	New	O
40	York	O
41	Longitudinal	O
42	Study	O
43	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	This	O
2	model	O
3	is	O
4	supported	O
5	by	O
6	experiments	O
7	showing	O
8	that	O
9	Cdr2	O
10	associates	O
11	with	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	regulatory	O
17	domain	O
18	of	O
19	Wee1	B
20	in	O
21	cell	O
22	lysates	O
23	and	O
24	phosphorylates	O
25	Wee1	O
26	in	O
27	vitro	O
28	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	vinculin	B
7	cDNA	I
8	from	O
9	chick	O
10	-	O
11	embryo	O
12	fibroblasts	O
13	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	N	O
6	-	O
7	nitroso	O
8	compounds	O
9	can	O
10	be	O
11	formed	O
12	in	O
13	vivo	O
14	in	O
15	the	O
16	infected	O
17	bladder	O
18	,	O
19	which	O
20	could	O
21	explain	O
22	the	O
23	association	O
24	between	O
25	urinary	O
26	-	O
27	tract	O
28	infections	O
29	and	O
30	increased	O
31	risk	O
32	for	O
33	bladder	O
34	cancer	O
35	.	O

1	Chronic	O
2	renal	O
3	failure	O
4	patients	O
5	essentially	O
6	die	O
7	from	O
8	cardiovascular	O
9	causes	O
10	,	O
11	and	O
12	the	O
13	frequency	O
14	of	O
15	malignant	O
16	disease	O
17	responsible	O
18	for	O
19	death	O
20	is	O
21	estimated	O
22	to	O
23	be	O
24	10	O
25	%.	O

1	The	O
2	first	O
3	contains	O
4	ATF	B
5	/	O
6	CRE	O
7	and	O
8	TBP	B
9	/	O
10	TATA	O
11	sequence	O
12	motifs	O
13	within	O
14	an	O
15	87	O
16	-	O
17	bp	O
18	region	O
19	.	O

1	The	O
2	predicted	O
3	L	B
4	mRNA	I
5	was	O
6	6398	O
7	nucleotides	O
8	long	O
9	and	O
10	contained	O
11	a	O
12	single	O
13	open	O
14	reading	O
15	frame	O
16	corresponding	O
17	to	O
18	an	O
19	L	O
20	protein	O
21	encompassing	O
22	2109	O
23	amino	O
24	acids	O
25	with	O
26	a	O
27	MW	O
28	of	O
29	241	O
30	,	O
31	546	O
32	.	O

1	However	O
2	,	O
3	the	O
4	ratio	O
5	M	O
6	/	O
7	Pc	O
8	provides	O
9	a	O
10	useful	O
11	index	O
12	that	O
13	seems	O
14	to	O
15	be	O
16	independent	O
17	of	O
18	the	O
19	metabolic	O
20	demand	O
21	.	O

1	In	O
2	Mv1Lu	O
3	lung	O
4	epithelial	O
5	cells	O
6	,	O
7	ActR	B
8	-	I
9	IB	I
10	and	O
11	T	B
12	beta	I
13	R	I
14	-	I
15	I	I
16	signal	O
17	a	O
18	common	O
19	set	O
20	of	O
21	growth	O
22	-	O
23	inhibitory	O
24	and	O
25	transcriptional	O
26	responses	O
27	in	O
28	association	O
29	with	O
30	their	O
31	corresponding	O
32	ligands	O
33	and	O
34	type	O
35	II	O
36	receptors	I
37	.	O

1	Finding	O
2	of	O
3	Rhodnius	B
4	prolixus	I
5	Stal	I
6	,	O
7	1859	B
8	,	O
9	in	O
10	babassu	B
11	palm	I
12	trees	I

1	In	O
2	transient	O
3	assays	O
4	,	O
5	using	O
6	rice	O
7	suspension	O
8	-	O
9	cultured	O
10	cells	O
11	transformed	O
12	by	O
13	particle	O
14	bombardment	O
15	,	O
16	we	O
17	showed	O
18	previously	O
19	that	O
20	Oshox1	O
21	can	O
22	transcriptionally	O
23	repress	O
24	the	O
25	activity	O
26	of	O
27	reporter	O
28	gene	I
29	constructs	I
30	with	O
31	upstream	B
32	HD	I
33	-	I
34	Zip	I
35	binding	I
36	sites	I
37	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	Retinoid	O
2	-	O
3	dependent	O
4	activation	O
5	of	O
6	the	O
7	tissue	O
8	transglutaminase	O
9	promoter	O
10	depends	O
11	on	O
12	both	O
13	a	O
14	proximal	O
15	regulatory	O
16	region	O
17	containing	O
18	sequences	O
19	highly	O
20	conserved	O
21	between	O
22	the	O
23	human	O
24	and	O
25	the	O
26	mouse	O
27	tissue	O
28	transglutaminase	O
29	promoters	O
30	and	O
31	a	O
32	distal	O
33	region	O
34	that	O
35	includes	O
36	a	O
37	30	O
38	-	O
39	base	O
40	pair	O
41	retinoid	B
42	response	I
43	element	I
44	(	O
45	mTGRRE1	B
46	).	O
47	mTGRRE1	O
48	contains	O
49	three	O
50	hexanucleotide	O
51	half	O
52	-	O
53	sites	O
54	(	O
55	two	O
56	canonical	O
57	and	O
58	one	O
59	non	O
60	-	O
61	canonical	O
62	)	O
63	in	O
64	a	O
65	DR7	O
66	/	O
67	DR5	O
68	motif	O
69	that	O
70	bind	O
71	both	O
72	RAR	B
73	*	I
74	RXR	I
75	heterodimers	I
76	and	O
77	RXR	B
78	homodimers	O
79	.	O

1	TBP	B
2	can	O
3	be	O
4	phosphorylated	O
5	in	O
6	vitro	O
7	by	O
8	extracts	O
9	of	O
10	U937	O
11	cells	O
12	or	O
13	by	O
14	bacterially	O
15	expressed	O
16	activated	O
17	ERK2	B
18	;	O
19	the	O
20	phosphorylation	O
21	sites	I
22	were	O
23	mapped	O
24	to	O
25	ERK	B
26	kinase	I
27	consensus	I
28	sites	I
29	in	O
30	the	O
31	TBP	B
32	amino	O
33	-	O
34	terminal	O
35	domain	O
36	.	O

1	Negative	O
2	-	O
3	staining	O
4	,	O
5	refractile	O
6	mycobacteria	O
7	in	O
8	Romanowsky	B
9	-	O
10	stained	O
11	smears	O
12	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	binding	O
9	of	O
10	the	O
11	GA	B
12	-	I
13	binding	I
14	protein	I
15	(	O
16	GABP	B
17	)	O
18	to	O
19	ets	B
20	sequence	I
21	motifs	O
22	within	O
23	each	O
24	repeated	O
25	unit	I
26	is	O
27	required	O
28	for	O
29	transcriptional	O
30	activation	O
31	of	O
32	the	O
33	COXIV	B
34	promoter	I
35	.	O

1	(	O
2	iv	O
3	)	O
4	Although	O
5	UCRBP	B
6	has	O
7	been	O
8	previously	O
9	shown	O
10	to	O
11	act	O
12	as	O
13	a	O
14	transcriptional	O
15	repressor	O
16	,	O
17	we	O
18	show	O
19	here	O
20	that	O
21	UCRBP	B
22	can	O
23	also	O
24	act	O
25	as	O
26	a	O
27	positive	O
28	transactivator	O
29	of	O
30	a	O
31	reporter	O
32	driven	O
33	by	O
34	UCR	O
35	elements	O
36	when	O
37	used	O
38	in	O
39	co	O
40	-	O
41	transfection	O
42	assays	O
43	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	O
6	platelet	B
7	-	I
8	derived	I
9	growth	I
10	factor	I
11	receptor	I
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	Agranulocytosis	O
2	treatment	O
3	with	O
4	rhGM	B
5	-	I
6	CSF	I

1	Blood	O
2	GSH	O
3	-	O
4	Px	O
5	activity	O
6	was	O
7	measured	O
8	with	O
9	a	O
10	spectrophotometer	O
11	,	O
12	using	O
13	a	O
14	modification	O
15	of	O
16	a	O
17	previously	O
18	described	O
19	assay	O
20	.	O

1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	B
10	-	I
11	40	I
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	B
19	-	I
20	level	I
21	zeta	B
22	2	I
23	globin	I
24	promoter	I
25	activity	O
26	in	O
27	K562	O
28	cells	O
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	O
40	origin	O
41	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	example	O
6	of	O
7	a	O
8	eukaryotic	O
9	transcription	O
10	factor	I
11	complex	O
12	containing	O
13	both	O
14	a	O
15	MADS	B
16	-	I
17	box	I
18	and	O
19	a	O
20	forkhead	B
21	protein	O
22	,	O
23	and	O
24	it	O
25	has	O
26	important	O
27	implications	O
28	for	O
29	the	O
30	regulation	O
31	of	O
32	mammalian	B
33	gene	I
34	expression	O
35	.	O

1	The	O
2	C4BP	B
3	alpha	I
4	gene	I
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	I
24	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	B
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	O
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	O
29	/	O
30	Nup214	B
31	.	O

1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	O
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	B
21	stimulation	O
22	.	O

1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	O
9	mucosal	O
10	cyclooxygenase	B
11	(	O
12	COX	B
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O

1	Sixteen	O
2	patients	O
3	were	O
4	studied	O
5	within	O
6	24	O
7	hours	O
8	of	O
9	resuscitation	O
10	and	O
11	all	O
12	showed	O
13	depressed	O
14	right	O
15	ventricular	O
16	ejection	O
17	(	O
18	RVEF	O
19	)	O
20	and	O
21	/	O
22	or	O
23	an	O
24	increased	O
25	end	O
26	-	O
27	diastolic	O
28	volume	O
29	(	O
30	RVEDVI	O
31	).	O

1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O

1	The	O
2	coordinate	O
3	increase	O
4	in	O
5	cyclin	B
6	D1	I
7	and	O
8	p21	B
9	had	O
10	the	O
11	effect	O
12	of	O
13	decreasing	O
14	the	O
15	specific	O
16	but	O
17	not	O
18	absolute	O
19	activity	O
20	of	O
21	cyclin	B
22	D1	I
23	/	I
24	cdk4	I
25	.	I
26	p53	B
27	was	O
28	not	O
29	involved	O
30	since	O
31	CSF	B
32	-	O
33	1	O
34	induction	O
35	of	O
36	p21	B
37	was	O
38	unaffected	O
39	by	O
40	dominant	O
41	-	O
42	negative	O
43	p53	B
44	expression	O
45	.	O

1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O

1	Although	O
2	MAP	B
3	(	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	)	I
9	kinases	I
10	are	O
11	implicated	O
12	in	O
13	cell	O
14	proliferation	O
15	and	O
16	differentiation	O
17	in	O
18	many	O
19	cell	O
20	types	O
21	,	O
22	the	O
23	role	O
24	of	O
25	MAP	B
26	kinases	I
27	in	O
28	cardiac	O
29	hypertrophy	O
30	remains	O
31	unclear	O
32	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	O
14	ANA	O
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O

1	METHODS	O
2	:	O
3	All	O
4	these	O
5	30	O
6	non	O
7	-	O
8	responders	O
9	received	O
10	an	O
11	extra	O
12	dose	O
13	of	O
14	the	O
15	same	O
16	vaccine	O
17	2	O
18	months	O
19	after	O
20	primary	O
21	immunization	O
22	and	O
23	a	O
24	booster	O
25	dose	O
26	with	O
27	a	O
28	yeast	O
29	-	O
30	derived	O
31	vaccine	O
32	6	O
33	years	O
34	later	O
35	.	O

1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O

1	Furthermore	O
2	,	O
3	our	O
4	data	O
5	also	O
6	show	O
7	that	O
8	,	O
9	in	O
10	addition	O
11	to	O
12	TEF	B
13	-	I
14	1	I
15	,	O
16	another	O
17	HF	B
18	-	I
19	1a	I
20	-	I
21	related	I
22	factor	I
23	may	O
24	be	O
25	recognized	O
26	by	O
27	the	O
28	alpha	B
29	-	I
30	MHC	I
31	gene	I
32	EM	I
33	element	O
34	.	O

1	One	O
2	member	O
3	of	O
4	this	O
5	multigene	B
6	family	O
7	,	O
8	GATA	B
9	-	I
10	3	I
11	,	O
12	is	O
13	most	O
14	abundantly	O
15	expressed	O
16	in	O
17	T	O
18	lymphocytes	O
19	,	O
20	a	O
21	cellular	O
22	target	O
23	for	O
24	human	B
25	immunodeficiency	I
26	virus	I
27	type	I
28	1	I
29	(	O
30	HIV	O
31	-	I
32	1	I
33	)	O
34	infection	O
35	and	O
36	replication	O
37	.	O

1	Serodiagnosis	O
2	of	O
3	ectromelia	O
4	in	O
5	laboratory	O
6	mice	O

1	The	O
2	sacT	B
3	gene	I
4	regulating	O
5	the	O
6	sacPA	B
7	operon	I
8	in	O
9	Bacillus	I
10	subtilis	I
11	shares	O
12	strong	O
13	homology	O
14	with	O
15	transcriptional	O
16	antiterminators	O
17	.	O

1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O

1	The	O
2	combination	O
3	PIP	O
4	64	O
5	micrograms	O
6	-	O
7	PEF	O
8	4	O
9	micrograms	O
10	prevents	O
11	the	O
12	frequent	O
13	secondary	O
14	regrowth	O
15	seen	O
16	after	O
17	6	O
18	hours	O
19	with	O
20	the	O
21	antibiotics	O
22	used	O
23	alone	O
24	.	O

1	Analysis	O
2	of	O
3	the	O
4	intact	O
5	hGH	B
6	gene	I
7	or	O
8	hGH	B
9	5	I
10	'-	O
11	flanking	O
12	DNA	O
13	(	O
14	5	B
15	'-	O
16	FR	I
17	)	O
18	coupled	O
19	to	O
20	the	O
21	hGh	B
22	cDNA	I
23	or	O
24	chloramphenicol	B
25	acetyltransferase	I
26	or	O
27	luciferase	B
28	genes	I
29	,	O
30	indicated	O
31	that	O
32	cAMP	O
33	primarily	O
34	stimulated	O
35	hGH	B
36	promoter	I
37	activity	O
38	.	O

1	Slowed	B
2	lysosomal	I
3	enzyme	I
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	During	O
2	a	O
3	28	O
4	-	O
5	week	O
6	promotion	O
7	bioassay	O
8	,	O
9	groups	O
10	of	O
11	30	O
12	male	O
13	CD	O
14	-	O
15	1	O
16	mice	O
17	were	O
18	treated	O
19	once	O
20	with	O
21	50	O
22	microliter	O
23	of	O
24	either	O
25	DMBA	O
26	(	O
27	1	O
28	.	O
29	0	O
30	mg	O
31	/	O
32	ml	O
33	)	O
34	or	O
35	acetone	O
36	,	O
37	rested	O
38	for	O
39	2	O
40	weeks	O
41	,	O
42	and	O
43	then	O
44	treated	O
45	twice	O
46	per	O
47	week	O
48	with	O
49	test	O
50	material	O
51	for	O
52	the	O
53	remaining	O
54	25	O
55	weeks	O
56	.	O

1	Risk	O
2	of	O
3	HTLV	O
4	infection	O
5	in	O
6	patients	O
7	on	O
8	haemodialysis	O
9	.	O

1	The	O
2	DNA	O
3	sequences	O
4	predict	O
5	proteins	O
6	for	O
7	SRP54sc	O
8	and	O
9	SRP54sp	O
10	that	O
11	are	O
12	47	O
13	%	O
14	and	O
15	52	O
16	%	O
17	identical	O
18	to	O
19	SRP54mam	O
20	,	O
21	respectively	O
22	.	O

1	Vitrectomy	O
2	was	O
3	still	O
4	a	O
5	significant	O
6	risk	O
7	factor	O
8	when	O
9	macular	O
10	holes	O
11	were	O
12	excluded	O
13	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	O
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	I
21	ERRalpha1	I
22	fusion	I
23	protein	O
24	.	O

1	Typical	O
2	configurations	O
3	of	O
4	psychosocial	O
5	stress	O
6	factors	O
7	of	O
8	psychiatrically	O
9	conspicuous	O
10	children	O
11	and	O
12	adolescents	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	I
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	B
25	gene	O
26	expression	O
27	.	O

1	Connector	B
2	enhancer	O
3	of	O
4	KSR	B
5	(	O
6	CNK	B
7	)	O
8	is	O
9	a	O
10	multidomain	O
11	protein	O
12	required	O
13	for	O
14	RAS	O
15	signaling	O
16	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	Army	O
2	veterans	O
3	given	O
4	yellow	O
5	fever	O
6	vaccine	O
7	contaminated	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	1942	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	veterans	O
27	with	O
28	hepatocellular	O
29	carcinoma	O
30	in	O
31	Veterans	O
32	Affairs	O
33	hospitals	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	receipt	O
41	of	O
42	contaminated	O
43	vaccine	O
44	in	O
45	1942	O
46	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	reverse	O
5	transcribed	O
6	,	O
7	amplified	O
8	cDNA	O
9	generated	O
10	from	O
11	total	O
12	RNA	O
13	isolated	O
14	from	O
15	transfected	O
16	cells	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	abnormally	O
22	spliced	O
23	products	O
24	containing	O
25	13	O
26	and	O
27	78	O
28	additional	O
29	bases	O
30	as	O
31	well	O
32	as	O
33	the	O
34	accumulation	O
35	of	O
36	unspliced	O
37	mRNA	O
38	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	KAR1	O
2	encodes	O
3	an	O
4	essential	O
5	component	O
6	of	O
7	the	O
8	yeast	O
9	spindle	O
10	pole	O
11	body	O
12	(	O
13	SPB	O
14	)	O
15	that	O
16	is	O
17	required	O
18	for	O
19	karyogamy	O
20	and	O
21	SPB	O
22	duplication	O
23	.	O

1	RPS14	B
2	introns	O
3	3	O
4	and	O
5	4	O
6	both	O
7	contain	O
8	Alu	B
9	sequences	O
10	.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	I
7	core	I
8	region	I
9	and	O
10	transcription	B
11	factor	I
12	YY1	I
13	in	O
14	Rous	B
15	sarcoma	I
16	virus	I
17	long	I
18	terminal	I
19	repeat	I
20	promoter	I
21	activity	O
22	.	O

1	However	O
2	,	O
3	2	O
4	minimum	O
5	alveolar	O
6	concentration	O
7	anesthesia	O
8	did	O
9	significantly	O
10	decrease	O
11	the	O
12	calculated	O
13	VE	O
14	at	O
15	a	O
16	PCO2	O
17	of	O
18	60	O
19	mmHg	O
20	(	O
21	from	O
22	7	O
23	.	O
24	4	O
25	+/-	O
26	1	O
27	.	O
28	2	O
29	to	O
30	4	O
31	.	O
32	0	O
33	+/-	O
34	0	O
35	.	O
36	6	O
37	l	O
38	.	O
39	min	O
40	-	O
41	1	O
42	),	O
43	indicating	O
44	a	O
45	rightward	O
46	shift	O
47	in	O
48	the	O
49	response	O
50	relationship	O
51	.	O

1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	B
23	trochoidea	I
24	Stein	I
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	B
53	(	O
54	25	O
55	microEin	I
56	m	I
57	-	I
58	2	I
59	s	I
60	-	I
61	1	O
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	Adduction	O
2	of	O
3	the	O
4	human	B
5	N	I
6	-	I
7	ras	I
8	codon	O
9	61	O
10	sequence	O
11	with	O
12	(-)-(	B
13	7S	I
14	,	O
15	8R	B
16	,	O
17	9R	B
18	,	O
19	10S	B
20	)-	O
21	7	O
22	,	O
23	8	O
24	-	O
25	dihydroxy	O
26	-	O
27	9	O
28	,	O
29	10	O
30	-	O
31	epoxy	O
32	-	O
33	7	O
34	,	O
35	8	O
36	,	O
37	9	O
38	,	O
39	10	O
40	-	O
41	tetrahydrobenzo	O
42	[	O
43	a	O
44	]	O
45	pyrene	O
46	:	O
47	structural	O
48	refinement	O
49	of	O
50	the	O
51	intercalated	B
52	SRSR	I
53	(	O
54	61	O
55	,	O
56	2	B
57	)	O
58	(-)-(	B
59	7S	I
60	,	O
61	8R	B
62	,	O
63	9S	B
64	,	O
65	10R	B
66	)-	O
67	N6	O
68	-[	O
69	10	O
70	-(	O
71	7	O
72	,	O
73	8	O
74	,	O
75	9	O
76	,	O
77	10	O
78	-	O
79	tetrahydrobenzo	O
80	[	O
81	a	O
82	]	O
83	pyrenyl	O
84	)]-	I
85	2	I
86	'-	O
87	deoxyadenosyl	O
88	adduct	O
89	from	O
90	1H	O
91	NMR	O
92	.	O

1	The	O
2	small	O
3	monomeric	O
4	GTP	B
5	-	I
6	binding	I
7	proteins	O
8	of	O
9	the	O
10	RAB	B
11	subfamily	I
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O

1	Varicella	B
2	-	I
3	zoster	I
4	virus	I
5	(	O
6	VZV	B
7	)	I
8	glycoprotein	B
9	gI	I
10	is	O
11	a	O
12	type	B
13	1	I
14	transmembrane	I
15	glycoprotein	I
16	which	O
17	is	O
18	one	O
19	component	O
20	of	O
21	the	O
22	heterodimeric	B
23	gE	I
24	:	I
25	gI	I
26	Fc	I
27	receptor	I
28	complex	I
29	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	A	O
6	64	O
7	-	O
8	year	O
9	-	O
10	old	O
11	woman	O
12	with	O
13	confirmed	O
14	AV	O
15	nodal	O
16	reentrant	O
17	tachycardia	O
18	underwent	O
19	a	O
20	successful	O
21	"	O
22	slow	O
23	pathway	O
24	"	O
25	AV	O
26	modification	O
27	with	O
28	a	O
29	single	O
30	radiofrequency	O
31	application	O
32	.	O

1	Nerve	B
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	I
8	12	I
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	B
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	O
10	-	O
11	dependent	O
12	DNA	O
13	binding	O
14	,	O
15	TraM	B
16	inhibited	O
17	TraR	B
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	B
5	gene	I
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	B
16	-	I
17	terminal	I
18	GAL4	I
19	-	I
20	like	I
21	Zn	I
22	(	O
23	II	B
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	B
29	zinc	I
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	I
40	like	I
41	heptad	I
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	O
48	-	O
49	terminal	O
50	acidic	O
51	alpha	I
52	-	O
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	carried	O
6	out	O
7	in	O
8	156	O
9	unselected	O
10	patients	O
11	(	O
12	41	O
13	men	O
14	,	O
15	mean	O
16	age	O
17	67	O
18	.	O
19	5	O
20	years	O
21	,	O
22	115	O
23	women	O
24	,	O
25	mean	O
26	age	O
27	71	O
28	.	O
29	4	O
30	years	O
31	)	O
32	who	O
33	had	O
34	undergone	O
35	total	O
36	hip	O
37	joint	O
38	replacement	O
39	because	O
40	of	O
41	degenerative	O
42	or	O
43	inflammatory	O
44	arthritis	O
45	or	O
46	fracture	O
47	of	O
48	the	O
49	neck	O
50	of	O
51	the	O
52	femur	O
53	.	O

1	Nevertheless	O
2	,	O
3	inactivation	O
4	of	O
5	the	O
6	cyclin	B
7	E	I
8	-	I
9	Cdk2	I
10	complex	I
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	O
27	p27	B
28	gene	I
29	.	O

1	The	O
2	diagnosis	O
3	of	O
4	amyloidosis	O
5	was	O
6	determined	O
7	from	O
8	a	O
9	labial	O
10	salivary	O
11	gland	O
12	biopsy	O
13	.	O

1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	O
8	(	O
9	maturation	O
10	promoting	O
11	factor	O
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	B
18	/	I
19	28	I
20	-	I
21	cyclin	I
22	B	I
23	complexes	I
24	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	find	O
9	out	O
10	whether	O
11	it	O
12	was	O
13	possible	O
14	to	O
15	detect	O
16	normal	O
17	lymph	O
18	nodes	O
19	by	O
20	high	O
21	-	O
22	resolution	O
23	mediastinal	O
24	US	O
25	.	O

1	Studies	O
2	of	O
3	lipoprotein	O
4	-	O
5	X	O
6	(	O
7	LP	O
8	-	O
9	X	O
10	)	O
11	and	O
12	bile	O
13	acids	O
14	in	O
15	familial	O
16	LCAT	B
17	deficiency	O
18	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	B
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	Binding	O
2	to	O
3	sulphatides	B
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	O
19	modules	O
20	.	O

1	The	O
2	general	B
3	transcription	I
4	factor	I
5	IIA	I
6	(	O
7	TFIIA	B
8	)	O
9	interacts	O
10	with	O
11	the	O
12	TATA	B
13	binding	I
14	protein	I
15	(	I
16	TBP	B
17	)	I
18	and	O
19	promoter	O
20	DNA	O
21	to	O
22	mediate	O
23	transcription	O
24	activation	O
25	in	O
26	vitro	O
27	.	O

1	Genoa	O
2	,	O
3	Italy	O
4	,	O
5	24	O
6	-	O
7	28	O
8	August	O
9	1997	O
10	.	O

1	Surface	O
2	spin	O
3	waves	O
4	in	O
5	a	O
6	Heisenberg	O
7	ferrimagnet	O
8	with	O
9	a	O
10	single	O
11	-	O
12	ion	O
13	anisotropy	O
14	(	O
15	uniaxial	O
16	and	O
17	nonuniaxial	O
18	).	O

1	In	O
2	addition	O
3	,	O
4	double	O
5	mutants	O
6	with	O
7	either	O
8	dim1	B
9	-	I
10	delta	I
11	or	O
12	dim2	B
13	-	I
14	1	I
15	and	O
16	the	O
17	endocytosis	B
18	mutants	I
19	end4	I
20	-	I
21	1	I
22	or	O
23	act1	B
24	-	I
25	1	I
26	displayed	O
27	synthetic	O
28	growth	O
29	defects	O
30	,	O
31	indicating	O
32	that	O
33	the	O
34	DIM	B
35	gene	I
36	products	O
37	function	O
38	in	O
39	a	O
40	common	O
41	or	O
42	parallel	O
43	endocytic	O
44	pathway	O
45	.	O

1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	B
15	-	I
16	Joanes	I
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	It	O
2	contains	O
3	25	O
4	exons	O
5	coding	O
6	for	O
7	a	O
8	4	O
9	.	O
10	7kb	O
11	transcript	O
12	including	O
13	large	O
14	5	O
15	'-	O
16	and	O
17	3	O
18	'-	O
19	(	O
20	1218bp	O
21	and	O
22	701bp	O
23	,	O
24	respectively	O
25	)	O
26	untranslated	O
27	regions	O
28	(	O
29	UTRs	O
30	).	O

1	This	O
2	TC	B
3	-	I
4	II	I
5	enhanson	I
6	,	O
7	which	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	kappa	B
13	B	I
14	motif	I
15	from	O
16	the	O
17	kappa	B
18	chain	I
19	enhancer	I
20	,	O
21	was	O
22	active	O
23	in	O
24	both	O
25	lymphoid	O
26	and	O
27	non	O
28	-	O
29	lymphoid	O
30	cells	O
31	,	O
32	which	O
33	contrasts	O
34	with	O
35	the	O
36	previously	O
37	reported	O
38	lymphoid	O
39	cell	O
40	specificity	O
41	of	O
42	the	O
43	kappa	B
44	B	I
45	motif	I
46	.	O

1	HupI	O
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	B
7	and	O
8	rubredoxin	B
9	-	I
10	like	I
11	proteins	I
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	Analysis	O
2	of	O
3	the	O
4	DNA	O
5	from	O
6	15	O
7	cases	O
8	of	O
9	sporadic	O
10	and	O
11	familial	O
12	Wilms	B
13	'	O
14	tumor	O
15	did	O
16	not	O
17	reveal	O
18	any	O
19	changes	O
20	,	O
21	indicating	O
22	that	O
23	the	O
24	translocation	O
25	breakpoint	O
26	does	O
27	not	O
28	reside	O
29	in	O
30	this	O
31	gene	O
32	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	leukemia	O
6	/	O
7	lymphotropic	O
8	virus	O
9	type	O
10	1	I
11	Tax	I
12	protein	O
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	O
26	domain	O
27	of	O
28	p300	B
29	.	O

1	This	O
2	family	O
3	of	O
4	proteins	O
5	binds	O
6	GC	O
7	-	O
8	rich	O
9	motifs	O
10	widely	O
11	distributed	O
12	in	O
13	gene	O
14	promoters	O
15	,	O
16	resulting	O
17	in	O
18	distinct	O
19	activation	O
20	or	O
21	repression	O
22	of	O
23	transcriptional	O
24	activities	O
25	.	O

1	The	O
2	effects	O
3	of	O
4	oral	O
5	vanadyl	O
6	sulfate	O
7	(	O
8	VOSO4	O
9	)	O
10	(	O
11	0	O
12	.	O
13	5	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	on	O
21	anthropometry	O
22	,	O
23	body	O
24	composition	O
25	,	O
26	and	O
27	performance	O
28	were	O
29	investigated	O
30	in	O
31	a	O
32	12	O
33	-	O
34	week	O
35	,	O
36	double	O
37	-	O
38	blind	O
39	,	O
40	placebo	O
41	-	O
42	controlled	O
43	trial	O
44	involving	O
45	weight	O
46	-	O
47	training	O
48	volunteers	O
49	.	O

1	However	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	SF	O
9	levels	O
10	of	O
11	IL	B
12	-	I
13	8	I
14	with	O
15	those	O
16	of	O
17	lactate	B
18	,	O
19	LDH	B
20	,	O
21	beta	B
22	2	I
23	-	I
24	microglobulin	I
25	and	O
26	glucose	O
27	.	O

1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	B
18	gene	I
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	O
31	hydrolases	I
32	.	O

1	Difficulties	O
2	bound	O
3	to	O
4	measuring	O
5	of	O
6	sputum	O
7	viscosity	O

1	One	O
2	unit	O
3	encodes	O
4	traA	B
5	,	O
6	traF	B
7	,	O
8	and	O
9	traB	O
10	,	O
11	while	O
12	the	O
13	second	O
14	encodes	O
15	traC	B
16	,	O
17	traD	B
18	,	O
19	and	O
20	traG	B
21	.	O

1	Our	O
2	data	O
3	demonstrate	O
4	directly	O
5	that	O
6	Rpm1r	B
7	is	O
8	transcribed	O
9	with	O
10	its	O
11	substrates	O
12	,	O
13	tRNA	B
14	met	I
15	f	I
16	and	O
17	tRNAPro	B
18	,	O
19	from	O
20	a	O
21	promoter	O
22	located	O
23	upstream	O
24	of	O
25	the	O
26	tRNA	B
27	met	I
28	f	I
29	gene	I
30	and	O
31	suggest	O
32	that	O
33	a	O
34	portion	O
35	also	O
36	originates	O
37	from	O
38	a	O
39	second	O
40	promoter	O
41	,	O
42	located	O
43	between	O
44	the	O
45	tRNA	B
46	met	I
47	f	I
48	gene	I
49	and	O
50	RPM1	B
51	.	O

1	By	O
2	negatively	O
3	regulating	O
4	GRK	B
5	-	O
6	mediated	O
7	receptor	O
8	phosphorylation	O
9	,	O
10	beta	O
11	-	I
12	arrestin	I
13	-	I
14	mediated	O
15	processes	O
16	such	O
17	as	O
18	Src	B
19	recruitment	O
20	and	O
21	clathrin	B
22	-	O
23	mediated	O
24	internalization	O
25	,	O
26	which	O
27	are	O
28	required	O
29	for	O
30	GPCR	O
31	-	O
32	mediated	O
33	ERK	B
34	activation	O
35	,	O
36	are	O
37	inhibited	O
38	,	O
39	thus	O
40	dampening	O
41	further	O
42	ERK	B
43	activation	O
44	.	O

1	Our	O
2	evidence	O
3	derives	O
4	from	O
5	three	O
6	principal	O
7	observations	O
8	:	O
9	1	O
10	)	O
11	a	O
12	transfection	O
13	construct	O
14	containing	O
15	only	O
16	122	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	of	O
22	promoter	O
23	1	O
24	and	O
25	328	O
26	nt	O
27	of	O
28	the	O
29	5	O
30	'-	O
31	UTR	O
32	retained	O
33	full	O
34	PGE2	O
35	-	O
36	stimulated	O
37	reporter	O
38	expression	O
39	;	O
40	2	O
41	)	O
42	maximal	O
43	PGE2	O
44	-	O
45	driven	O
46	reporter	O
47	expression	O
48	required	O
49	the	O
50	presence	O
51	of	O
52	nt	O
53	196	O
54	to	O
55	328	O
56	of	O
57	exon	O
58	1	O
59	when	O
60	tested	O
61	within	O
62	the	O
63	context	O
64	of	O
65	IGF	B
66	-	I
67	I	I
68	promoter	I
69	1	I
70	;	O
71	3	O
72	)	O
73	cotransfection	O
74	of	O
75	IGF	B
76	-	I
77	I	I
78	promoter	I
79	-	I
80	luciferase	I
81	-	I
82	reporter	O
83	constructs	O
84	with	O
85	a	O
86	plasmid	O
87	encoding	O
88	the	O
89	alpha	O
90	-	O
91	isoform	O
92	of	O
93	the	O
94	catalytic	O
95	subunit	O
96	of	O
97	murine	B
98	cAMP	I
99	-	I
100	dependent	I
101	protein	I
102	kinase	I
103	(	O
104	PKA	B
105	)	O
106	produced	O
107	results	O
108	comparable	O
109	to	O
110	those	O
111	seen	O
112	with	O
113	PGE2	O
114	treatment	O
115	,	O
116	whereas	O
117	cotransfection	O
118	with	O
119	a	O
120	plasmid	O
121	encoding	O
122	a	O
123	mutant	O
124	regulatory	O
125	subunit	O
126	of	O
127	PKA	B
128	that	O
129	cannot	O
130	bind	O
131	cAMP	O
132	blocked	O
133	PGE2	O
134	-	O
135	induced	O
136	reporter	O
137	expression	O
138	.	O

1	Hrs	O
2	has	O
3	a	O
4	FYVE	B
5	double	O
6	zinc	O
7	finger	O
8	domain	O
9	,	O
10	which	O
11	specifically	O
12	binds	O
13	phosphatidylinositol	B
14	(	O
15	3	I
16	)-	O
17	phosphate	O
18	and	O
19	is	O
20	conserved	O
21	in	O
22	several	O
23	proteins	O
24	involved	O
25	in	O
26	vesicular	O
27	traffic	O
28	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O

1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	I
8	(	O
9	His128Asn	B
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	I
11	2alpha	I
12	kinases	I
13	.	O

1	Effect	O
2	of	O
3	tracheal	O
4	insufflation	O
5	of	O
6	deferoxamine	O
7	on	O
8	acute	O
9	ozone	O
10	toxicity	O
11	in	O
12	rats	O
13	.	O

1	Investigation	O
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	O
10	human	B
11	Igs	I
12	and	O
13	gp120	B
14	shows	O
15	that	O
16	the	O
17	viral	B
18	gp120	I
19	SAg	I
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	O
27	human	B
28	V	I
29	(	O
30	H	B
31	)	I
32	3	I
33	+	I
34	Igs	I
35	.	O

1	The	O
2	sequence	O
3	up	O
4	to	O
5	-	O
6	267	O
7	bp	O
8	relative	O
9	to	O
10	the	O
11	transcription	O
12	start	O
13	site	O
14	was	O
15	sufficient	O
16	to	O
17	enhance	O
18	reporter	O
19	gene	O
20	expression	O
21	depending	O
22	on	O
23	the	O
24	mesodermal	O
25	differentiation	O
26	of	O
27	P19	O
28	cells	O
29	.	O

1	Following	O
2	2	O
3	.	O
4	5	O
5	Gy	O
6	,	O
7	HbO2	B
8	changes	O
9	were	O
10	minimal	O
11	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	The	O
2	MRS	O
3	II	O
4	meets	I
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	B
9	-	I
10	1	I
11	mRNA	I
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	B
21	-	I
22	2	I
23	mRNA	I
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	S2F	O
2	,	O
3	a	O
4	leaf	O
5	-	O
6	specific	O
7	trans	O
8	-	O
9	acting	O
10	factor	O
11	,	O
12	binds	O
13	to	O
14	a	O
15	novel	O
16	cis	O
17	-	O
18	acting	O
19	element	O
20	and	O
21	differentially	O
22	activates	O
23	the	O
24	RPL21	B
25	gene	I
26	.	O

1	2	O
2	cases	O
3	of	O
4	type	B
5	II	I
6	tyrosinosis	I
7	(	O
8	Richner	B
9	-	I
10	Hanhart	I
11	syndrome	O
12	)	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Osteosarcoma	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	benzopyrene	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	O
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	O
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	B
12	-	I
13	1	I
14	isoforms	O
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	B
7	-	I
8	1	I
9	represses	O
10	HIV	O
11	-	I
12	1	I
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	B
20	to	O
21	the	O
22	TATA	B
23	box	I
24	.	O

1	All	O
2	other	O
3	ejaculate	O
4	parameters	O
5	(	O
6	density	O
7	,	O
8	motility	O
9	,	O
10	swelling	O
11	test	O
12	,	O
13	penetration	O
14	test	O
15	)	O
16	remained	O
17	unchanged	O
18	,	O
19	and	O
20	there	O
21	was	O
22	only	O
23	one	O
24	post	O
25	-	O
26	therapeutic	O
27	pregnancy	O
28	.	O

1	RNA	O
2	of	O
3	GBV	B
4	-	I
5	C	I
6	was	O
7	detected	O
8	in	O
9	14	O
10	(	O
11	18	O
12	%)	O
13	patients	O
14	before	O
15	BMT	O
16	.	O

1	Definite	B
2	JPsA	I
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	O
16	coincident	O
17	,	O
18	with	O
19	a	O
20	typical	O
21	psoriatic	O
22	rash	O
23	,	O
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	The	O
2	exodomain	O
3	alone	O
4	has	O
5	the	O
6	high	O
7	affinity	O
8	hormone	B
9	binding	O
10	site	O
11	but	O
12	is	O
13	not	O
14	capable	O
15	of	O
16	generating	O
17	hormonal	O
18	signal	O
19	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	article	O
6	is	O
7	to	O
8	discuss	O
9	the	O
10	factors	O
11	involved	O
12	in	O
13	the	O
14	selection	O
15	of	O
16	antibodies	O
17	,	O
18	radionuclides	O
19	and	O
20	labeling	O
21	methods	O
22	in	O
23	the	O
24	development	O
25	of	O
26	radioimmunotherapy	O
27	(	O
28	RIT	O
29	)	O
30	for	O
31	non	O
32	-	O
33	Hodgkin	O
34	'	O
35	s	O
36	lymphoma	O
37	(	O
38	NHL	O
39	)	O
40	from	O
41	a	O
42	single	O
43	clinical	O
44	study	O
45	site	O
46	through	O
47	multicenter	O
48	trials	O
49	and	O
50	commercialization	O
51	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	B
6	genes	I
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	O
23	Mig1p	B
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O

1	The	O
2	reduction	O
3	in	O
4	saturated	O
5	fatty	O
6	acids	O
7	intake	O
8	led	O
9	to	O
10	modest	O
11	(	O
12	but	O
13	in	O
14	group	O
15	1	O
16	significant	O
17	)	O
18	0	O
19	.	O
20	15	O
21	mmol	O
22	/	O
23	l	O
24	(	O
25	2	O
26	.	O
27	5	O
28	%)	O
29	reduction	O
30	in	O
31	total	O
32	serum	O
33	cholesterol	O
34	level	O
35	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	In	O
2	the	O
3	pRb	B
4	(-)	O
5	SAOS	B
6	-	I
7	2	I
8	cell	O
9	line	O
10	transiently	O
11	transfected	O
12	with	O
13	a	O
14	reporter	O
15	plasmid	O
16	containing	O
17	six	O
18	tal	B
19	-	I
20	1	I
21	binding	I
22	site	I
23	,	O
24	pRb	B
25	enhances	O
26	the	O
27	transcriptional	O
28	activity	O
29	of	O
30	tal	B
31	-	I
32	1	I
33	-	I
34	E12	I
35	-	I
36	Lmo2	I
37	and	O
38	tal	B
39	-	I
40	1	I
41	-	I
42	E12	I
43	-	I
44	Lmo2	I
45	-	I
46	Ldb1	I
47	complexes	O
48	but	O
49	not	O
50	that	O
51	of	O
52	a	O
53	tal	B
54	-	I
55	1	I
56	-	I
57	E12	I
58	heterodimer	O
59	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<.	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	Cox	O
20	multivariate	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	hazard	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	confidence	O
39	interval	O
40	[	O
41	CI	O
42	],	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	Karnofsky	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	adjuvant	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	adjuvant	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	metastases	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	B
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	approaches	O
193	significance	O
194	])	O
195	vs	O
196	soft	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	incomplete	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O

1	Altogether	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	Ypt51p	B
8	,	O
9	Ypt52p	B
10	,	O
11	and	O
12	Ypt53p	B
13	are	O
14	required	O
15	for	O
16	transport	O
17	in	O
18	the	O
19	endocytic	O
20	pathway	O
21	and	O
22	for	O
23	correct	O
24	sorting	O
25	of	O
26	vacuolar	O
27	hydrolases	I
28	suggesting	O
29	a	O
30	possible	O
31	intersection	O
32	of	O
33	the	O
34	endocytic	O
35	with	O
36	the	O
37	vacuolar	O
38	sorting	O
39	pathway	O
40	.	O

1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	O
7	element	O
8	linked	O
9	to	O
10	the	O
11	SV40	B
12	promoter	I
13	responded	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O

1	A	O
2	point	O
3	mutation	O
4	in	O
5	Galphao	B
6	and	O
7	Galphai1	O
8	blocks	O
9	interaction	O
10	with	O
11	regulator	O
12	of	O
13	G	B
14	protein	I
15	signaling	O
16	proteins	O
17	.	O

1	The	O
2	cop	B
3	region	O
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	O
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	B
23	promoter	I
24	,	O
25	Prep	O
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	B
33	binding	I
34	sites	I
35	,	O
36	BD	B
37	-	I
38	1	I
39	and	O
40	BD	B
41	-	I
42	2	I
43	.	O

1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O

1	Piperacillin	B
2	-	O
3	tazobactam	I
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	B
13	to	O
14	3	B
15	),	O
16	apocytochrome	B
17	b	I
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	B
30	to	O
31	6	O
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	I
38	(	O
39	atp6	B
40	and	O
41	atp9	B
42	),	O
43	three	O
44	ribosomal	B
45	RNAs	I
46	(	O
47	rrn5	B
48	,	O
49	srn	B
50	and	O
51	lrn	B
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	B
58	proteins	I
59	(	O
60	rps3	B
61	,	O
62	rps11	B
63	,	O
64	rps12	B
65	and	O
66	rpl16	B
67	).	O

1	Regulators	O
2	responsible	O
3	for	O
4	the	O
5	pervasive	O
6	,	O
7	nonsex	B
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	I
13	mRNA	I
14	splicing	O
15	characteristic	O
16	of	O
17	metazoans	O
18	are	O
19	almost	O
20	entirely	O
21	unknown	O
22	or	O
23	uncertain	O
24	.	O

1	Thus	O
2	,	O
3	TRAF2	B
4	initiates	O
5	SAPK	B
6	and	O
7	p38	B
8	activation	O
9	by	O
10	binding	O
11	two	O
12	proximal	B
13	protein	I
14	kinases	I
15	:	O
16	GCK	O
17	and	O
18	RIP	O
19	.	O

1	This	O
2	region	O
3	contains	O
4	a	O
5	motif	O
6	with	O
7	partial	O
8	identity	O
9	with	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	the	O
15	ubiquitous	O
16	transcription	I
17	factor	I
18	upstream	I
19	stimulatory	I
20	factor	I
21	(	O
22	USF	B
23	),	O
24	which	O
25	binds	O
26	to	O
27	the	O
28	human	B
29	insulin	I
30	promoter	I
31	.	O

1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O

1	Production	O
2	costs	O
3	included	O
4	feed	O
5	,	O
6	non	O
7	-	O
8	feed	O
9	operating	O
10	,	O
11	fixed	O
12	,	O
13	and	O
14	replacement	O
15	stock	O
16	costs	O
17	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	O
12	-	O
13	bp	O
14	BAL	O
15	cDNA	O
16	structure	O
17	.	O

1	Treatment	O
2	and	O
3	staining	O
4	of	O
5	smears	O
6	and	O
7	sections	O
8	for	O
9	detection	O
10	of	O
11	microorganisms	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	two	O
7	overlapping	O
8	cDNA	O
9	fragments	I
10	which	O
11	could	O
12	encode	O
13	the	O
14	complete	O
15	amino	O
16	acid	O
17	sequence	O
18	of	O
19	rat	B
20	testis	I
21	fructose	I
22	-	I
23	6	I
24	-	I
25	phosphate	I
26	,	O
27	2	B
28	-	I
29	kinase	I
30	:	O
31	fructose	O
32	-	O
33	2	O
34	,	O
35	6	O
36	-	O
37	bisphosphatase	O
38	.	O

1	The	O
2	importance	O
3	of	O
4	posttranslational	O
5	regulation	O
6	of	O
7	p15INK4B	B
8	by	O
9	TGF	B
10	-	I
11	beta	I
12	is	O
13	underlined	O
14	by	O
15	the	O
16	observation	O
17	that	O
18	in	O
19	TGF	B
20	-	I
21	beta	I
22	-	I
23	resistant	O
24	184A1L5R	O
25	,	O
26	although	O
27	the	O
28	p15	B
29	transcript	O
30	increased	O
31	,	O
32	p15INK4B	B
33	protein	O
34	was	O
35	not	O
36	stabilized	O
37	and	O
38	did	O
39	not	O
40	accumulate	O
41	,	O
42	and	O
43	cyclin	B
44	D1	I
45	-	I
46	cdk	I
47	association	O
48	and	O
49	kinase	O
50	activation	O
51	were	O
52	not	O
53	inhibited	O
54	.	O

1	Thirty	O
2	cadaver	O
3	brains	O
4	were	O
5	examined	O
6	under	O
7	X	O
8	6	O
9	to	O
10	16	O
11	magnification	O
12	in	O
13	order	O
14	to	O
15	define	O
16	the	O
17	microsurgical	O
18	anatomy	O
19	of	O
20	the	O
21	pineal	O
22	region	O
23	,	O
24	particularly	O
25	the	O
26	relationship	O
27	of	O
28	the	O
29	pineal	O
30	body	O
31	,	O
32	posterior	O
33	cerebral	O
34	artery	O
35	,	O
36	superior	O
37	cerebellar	O
38	artery	O
39	,	O
40	vein	O
41	of	O
42	Galen	O
43	,	O
44	basal	O
45	vein	O
46	of	O
47	Rosenthal	O
48	,	O
49	internal	O
50	cerebral	O
51	vein	O
52	,	O
53	straight	O
54	sinus	O
55	,	O
56	bridging	O
57	vein	O
58	,	O
59	the	O
60	size	O
61	of	O
62	the	O
63	tentorial	O
64	notch	O
65	,	O
66	and	O
67	the	O
68	third	O
69	and	O
70	the	O
71	fourth	O
72	cranial	O
73	nerves	O
74	.	O

1	However	O
2	,	O
3	further	O
4	analyses	O
5	of	O
6	the	O
7	data	O
8	indicate	O
9	that	O
10	increasing	O
11	VO2	O
12	AT	O
13	(	O
14	r	O
15	=	O
16	-	O
17	0	O
18	.	O
19	63	O
20	,	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	rather	O
29	than	O
30	VO2max	O
31	(	O
32	r	O
33	=	O
34	-	O
35	0	O
36	.	O
37	15	O
38	)	O
39	could	O
40	result	O
41	in	O
42	improving	O
43	the	O
44	10	O
45	,	O
46	000	O
47	m	O
48	race	O
49	performance	O
50	to	O
51	a	O
52	larger	O
53	extent	O
54	,	O
55	and	O
56	that	O
57	the	O
58	absolute	O
59	amount	O
60	of	O
61	change	O
62	(	O
63	delta	B
64	)	O
65	in	O
66	the	O
67	10	O
68	,	O
69	000	O
70	m	O
71	run	O
72	time	O
73	is	O
74	best	O
75	accounted	O
76	for	O
77	by	O
78	a	O
79	combination	O
80	of	O
81	delta	O
82	VO2	O
83	AT	O
84	and	O
85	delta	B
86	5	O
87	,	O
88	000	O
89	m	O
90	run	O
91	time	O
92	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	I
15	RXR	B
16	)	I
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O

1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	Crry	B
7	gene	I
8	encompass	O
9	over	O
10	25	O
11	kb	O
12	of	O
13	DNA	O
14	,	O
15	whereas	O
16	the	O
17	Crry	O
18	-	O
19	ps	O
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	O
27	.	O
28	6	O
29	-	O
30	kb	O
31	Eco	O
32	-	O
33	R1	O
34	fragment	O
35	.	O

1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	B
6	albumin	I
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O

1	Alanine	B
2	aminotransferase	I
3	(	O
4	ALT	B
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	B
21	functional	I
22	antithrombin	I
23	III	I
24	(	O
25	AT	B
26	III	I
27	)	O
28	activity	O
29	.	O

1	We	O
2	conclude	O
3	that	O
4	DNA	O
5	ploidy	O
6	is	O
7	a	O
8	major	O
9	objective	O
10	prognostic	O
11	factor	O
12	and	O
13	therapeutic	O
14	determinant	O
15	for	O
16	endometrial	O
17	carcinoma	O
18	.	O

1	This	O
2	DNA	O
3	containing	O
4	promoter	O
5	activity	O
6	has	O
7	been	O
8	sequenced	O
9	in	O
10	its	O
11	entirety	O
12	and	O
13	found	O
14	to	O
15	contain	O
16	multiple	O
17	putative	O
18	regulatory	O
19	sites	O
20	.	O

1	The	O
2	mammalian	B
3	phosphoinositide	I
4	3	I
5	-	I
6	kinases	I
7	(	O
8	PI3Ks	B
9	)	O
10	p110alpha	I
11	,	O
12	beta	O
13	,	O
14	and	O
15	delta	O
16	form	O
17	heterodimers	O
18	with	O
19	Src	B
20	homology	I
21	2	I
22	(	O
23	SH2	B
24	)	O
25	domain	O
26	-	O
27	containing	O
28	adaptors	O
29	such	O
30	as	O
31	p85alpha	B
32	or	O
33	p55	B
34	(	O
35	PIK	B
36	).	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	demonstrates	O
6	that	O
7	reduced	O
8	inotropy	O
9	with	O
10	timolol	O
11	helped	O
12	uniform	O
13	local	O
14	contraction	O
15	as	O
16	estimated	O
17	by	O
18	the	O
19	increased	O
20	LONG	O
21	/	O
22	CIRC	O
23	ratio	O
24	,	O
25	a	O
26	transition	O
27	that	O
28	could	O
29	improve	O
30	contraction	O
31	efficacy	O
32	.	O

1	Studies	O
2	on	O
3	the	O
4	life	O
5	cycle	O
6	of	O
7	Haplorchis	B
8	pumilio	I
9	(	O
10	Looss	B
11	,	O
12	1896	B
13	)	O
14	Looss	O
15	,	O
16	1899	O
17	with	O
18	morphological	O
19	redescription	O
20	of	O
21	larval	O
22	and	O
23	adult	O
24	stages	O
25	.	O

1	The	O
2	nit	B
3	-	I
4	3	I
5	gene	I
6	of	O
7	the	O
8	filamentous	O
9	fungus	B
10	Neurospora	I
11	crassa	I
12	encodes	O
13	nitrate	B
14	reductase	I
15	,	O
16	the	O
17	enzyme	O
18	which	O
19	catalyzes	O
20	the	O
21	first	O
22	step	O
23	in	O
24	nitrate	O
25	assimilation	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	B
4	prolactin	I
5	concentrations	O
6	show	O
7	age	O
8	related	O
9	variations	O
10	in	O
11	presumably	O
12	fertile	O
13	men	O
14	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	Mutations	O
2	truncating	O
3	as	O
4	many	O
5	as	O
6	143	O
7	C	O
8	-	O
9	terminal	O
10	residues	O
11	from	O
12	the	O
13	transcriptional	O
14	activator	O
15	encoded	O
16	by	O
17	the	O
18	areA	B
19	gene	I
20	,	O
21	mediating	O
22	nitrogen	O
23	metabolite	O
24	repression	O
25	in	O
26	Aspergillus	O
27	nidulans	O
28	,	O
29	do	O
30	not	O
31	significantly	O
32	reduce	O
33	the	O
34	ability	O
35	of	O
36	the	O
37	areA	B
38	product	I
39	to	O
40	activate	O
41	expression	O
42	of	O
43	most	O
44	genes	O
45	under	O
46	areA	B
47	control	O
48	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	Workplace	O
2	violence	O
3	--	O
4	nurses	O
5	at	O
6	risk	O
7	.	O

1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	B
8	promoter	I
9	-	I
10	PLAP	I
11	constructs	I
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	B
44	'-	I
45	promoter	I
46	region	O
47	.	O

1	TSC1	O
2	mutations	O
3	include	O
4	two	O
5	nonsense	O
6	mutations	O
7	,	O
8	four	O
9	insertions	O
10	,	O
11	and	O
12	three	O
13	splice	O
14	mutations	O
15	.	O

1	Gonadotropin	O
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	O
12	twins	O
13	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	THOV	O
6	NP	O
7	contains	O
8	a	O
9	motif	O
10	(	O
11	KRxxxxxxxxxKTKK	B
12	)	O
13	at	O
14	amino	O
15	acid	O
16	positions	O
17	179	O
18	-	O
19	193	O
20	that	O
21	represents	O
22	a	O
23	classical	O
24	bipartite	O
25	nuclear	O
26	localization	O
27	signal	O
28	(	O
29	NLS	O
30	).	O

1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	B
10	p105	I
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	I
16	generates	I
17	I	I
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	O
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O

1	Oncogenic	B
2	Raf	I
3	-	I
4	1	I
5	activates	I
6	p70	B
7	S6	I
8	kinase	I
9	via	O
10	a	O
11	mitogen	B
12	-	I
13	activated	I
14	protein	I
15	kinase	I
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	However	O
2	,	O
3	little	O
4	was	O
5	understood	O
6	about	O
7	the	O
8	normal	O
9	function	O
10	of	O
11	CREB	B
12	-	I
13	2	I
14	in	O
15	mammalian	O
16	development	O
17	or	O
18	organ	O
19	physiology	O
20	.	O

1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O

1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	O
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	Scanning	O
2	electron	O
3	microscopic	O
4	investigations	O
5	on	O
6	the	O
7	formation	O
8	of	O
9	Reissner	O
10	'	O
11	s	O
12	fiber	O
13	in	O
14	Rattus	O
15	rattus	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	Plasma	O
2	leptin	B
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	sites	O
6	of	O
7	recombinational	O
8	resolution	O
9	is	O
10	inversely	O
11	correlated	O
12	with	O
13	that	O
14	of	O
15	the	O
16	gradient	O
17	of	O
18	sequence	O
19	divergence	O
20	,	O
21	with	O
22	only	O
23	approximately	O
24	7	O
25	%	O
26	of	O
27	the	O
28	X	O
29	recombinants	I
30	resolved	O
31	within	O
32	the	O
33	3	O
34	'	O
35	third	O
36	of	O
37	the	O
38	X	O
39	blocks	O
40	where	O
41	two	O
42	diverged	B
43	Alu	I
44	family	I
45	repeats	I
46	reside	O
47	.	O

1	This	O
2	work	O
3	unravels	O
4	a	O
5	new	O
6	model	O
7	for	O
8	the	O
9	ets	B
10	-	I
11	1	I
12	/	I
13	ets	I
14	-	I
15	2	I
16	gene	I
17	'	O
18	s	O
19	evolution	O
20	,	O
21	based	O
22	for	O
23	the	O
24	first	O
25	time	O
26	on	O
27	both	O
28	structural	O
29	and	O
30	functional	O
31	evidences	O
32	.	O

1	Spontaneous	O
2	burst	O
3	firing	O
4	in	O
5	cat	O
6	primary	O
7	auditory	O
8	cortex	O
9	:	O
10	age	O
11	and	O
12	depth	O
13	dependence	O
14	and	O
15	its	O
16	effect	O
17	on	O
18	neural	O
19	interaction	O
20	measures	O
21	.	O

1	Studies	O
2	on	O
3	the	O
4	hereditary	O
5	nature	O
6	of	O
7	sole	O
8	prints	O
9	--	O
10	with	O
11	special	O
12	reference	O
13	to	O
14	interdigital	B
15	and	O
16	triradii	O

1	It	O
2	is	O
3	postulated	O
4	that	O
5	altered	O
6	blood	O
7	flow	O
8	,	O
9	mediated	O
10	through	O
11	the	O
12	well	O
13	-	O
14	known	O
15	prostaglandin	O
16	synthetase	B
17	inhibitory	O
18	effects	O
19	of	O
20	ibuprofen	O
21	,	O
22	resulted	O
23	in	O
24	tubular	O
25	necrosis	O
26	.	O

1	Protein	B
2	kinase	I
3	A	I
4	-	O
5	Ialpha	O
6	subunit	O
7	-	O
8	directed	O
9	antisense	O
10	inhibition	O
11	of	O
12	ovarian	O
13	cancer	O
14	cell	O
15	growth	I
16	:	O
17	crosstalk	O
18	with	O
19	tyrosine	B
20	kinase	I
21	signaling	O
22	pathway	O
23	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	O
15	E	O
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	O
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	Sera	O
2	from	O
3	euthyroid	O
4	post	O
5	-	O
6	menopausal	O
7	or	O
8	pregnant	O
9	women	O
10	yielded	O
11	TSH	B
12	levels	O
13	within	O
14	the	O
15	normal	O
16	range	O
17	.	O

1	Ha	B
2	-	I
3	RasV12	I
4	and	O
5	activated	O
6	proteins	O
7	in	O
8	both	O
9	the	O
10	extra	O
11	-	O
12	cellular	O
13	regulated	I
14	kinase	I
15	(	O
16	ERK	B
17	)	O
18	and	O
19	the	O
20	stress	B
21	-	I
22	activated	I
23	protein	I
24	kinase	I
25	(	O
26	SAPK	B
27	)	O
28	or	O
29	Jun	B
30	N	I
31	-	I
32	terminal	I
33	kinase	I
34	(	O
35	JNK	B
36	)	O
37	cascades	O
38	independently	O
39	stimulated	O
40	PEA3	B
41	-	O
42	mediated	O
43	gene	O
44	expression	O
45	.	O

1	Substantial	O
2	evidence	O
3	supports	O
4	a	O
5	critical	O
6	role	O
7	for	O
8	the	O
9	activation	O
10	of	O
11	the	O
12	Raf	B
13	-	I
14	1	I
15	/	I
16	MEK	I
17	/	O
18	mitogen	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	pathway	O
24	in	O
25	oncogenic	O
26	Ras	I
27	-	O
28	mediated	O
29	transformation	O
30	.	O

1	Surprisingly	O
2	,	O
3	3	B
4	full	O
5	-	I
6	length	I
7	murine	I
8	survivin	I
9	cDNA	I
10	clones	O
11	were	O
12	isolated	O
13	,	O
14	predicting	O
15	the	O
16	existence	O
17	of	O
18	3	O
19	distinct	O
20	survivin	B
21	proteins	I
22	.	O

1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	B
5	reagin	I
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	O
14	and	O
15	FTA	B
16	antibodies	O

1	Using	O
2	a	O
3	v	O
4	-	O
5	erbA	B
6	probe	O
7	,	O
8	we	O
9	obtained	O
10	a	O
11	cDNA	O
12	which	O
13	encodes	O
14	a	O
15	novel	O
16	445	O
17	-	O
18	amino	I
19	-	I
20	acid	I
21	protein	I
22	,	O
23	RLD	B
24	-	I
25	1	I
26	,	O
27	that	O
28	contains	O
29	the	O
30	characteristic	O
31	domains	O
32	of	O
33	nuclear	B
34	receptors	I
35	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	O
14	MLL	O
15	products	O
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	MLL	B
22	-	I
23	LTG9	I
24	and	O
25	MLL	B
26	-	I
27	LTG19	I
28	,	O
29	localizes	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	leukemogenesis	O
46	.	O

1	Detection	O
2	of	O
3	poisoning	O
4	by	O
5	Impila	B
6	(	O
7	Callilepis	B
8	laureola	I
9	)	O
10	in	O
11	a	O
12	mother	O
13	and	O
14	child	O
15	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	O
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	There	O
2	was	O
3	significant	O
4	correlation	O
5	of	O
6	LVM	O
7	/	O
8	M2	O
9	and	O
10	PWVn	O
11	for	O
12	pre	O
13	-	O
14	AVR	O
15	and	O
16	post	O
17	AVR	O
18	studies	O
19	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	O
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	Digestion	O
2	of	O
3	NF	B
4	-	I
5	IL6	I
6	with	O
7	endoprotease	B
8	Asp	O
9	-	O
10	N	O
11	produced	O
12	a	O
13	domain	O
14	smaller	O
15	than	O
16	the	O
17	TCD	B
18	(	O
19	NF	B
20	-	I
21	IL6	I
22	bZIP	I
23	domains	I
24	(	O
25	NFBD	B
26	)	O
27	(	O
28	272	O
29	-	O
30	345	O
31	)),	O
32	a	O
33	domain	O
34	identified	O
35	either	O
36	in	O
37	the	O
38	absence	O
39	or	O
40	the	O
41	presence	O
42	of	O
43	DNA	O
44	.	O

1	Blocked	O
2	shift	O
3	/	O
4	supershift	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	I
10	member	I
11	proteins	I
12	especially	O
13	Fra	B
14	-	I
15	1	I
16	and	O
17	Fra	B
18	-	I
19	2	I
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	I
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	I
42	1	I
43	/	O
44	DNA	O
45	binding	O
46	complex	O
47	.	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	I
40	subregion	I
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	The	O
2	dominant	O
3	negative	O
4	mutant	O
5	of	O
6	SHP	B
7	-	I
8	2	I
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	the	O
14	induction	O
15	of	O
16	tyrosine	O
17	phosphorylation	O
18	and	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	m	B
25	-	I
26	Stat5a	I
27	,	O
28	m	B
29	-	I
30	Stat5b	I
31	,	O
32	and	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	O
37	deletion	O
38	variant	O
39	m	I
40	-	O
41	Stat5adelta749	I
42	,	O
43	as	O
44	well	O
45	as	O
46	the	O
47	transactivation	O
48	potential	O
49	of	O
50	m	B
51	-	I
52	Stat5a	I
53	and	O
54	m	B
55	-	I
56	Stat5b	I
57	.	O

1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	lymphotropic	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	All	O
2	33	O
3	subjects	O
4	were	O
5	given	O
6	psychometric	O
7	instruments	O
8	for	O
9	measuring	O
10	various	O
11	components	O
12	of	O
13	anger	O
14	and	O
15	anxiety	O
16	:	O
17	Spielberger	O
18	'	O
19	s	O
20	State	O
21	-	O
22	Trait	O
23	Personality	O
24	Inventory	O
25	,	O
26	the	O
27	Anger	O
28	Expression	O
29	Scale	O
30	,	O
31	and	O
32	the	O
33	State	O
34	Anger	O
35	Reaction	O
36	Scale	O
37	.	O

1	The	O
2	PDGFR	B
3	mutants	I
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O

1	This	O
2	interaction	O
3	is	O
4	mediated	O
5	by	O
6	the	O
7	SH2	B
8	domain	I
9	of	O
10	Crk	B
11	and	O
12	can	O
13	be	O
14	inhibited	O
15	with	O
16	a	O
17	phosphopeptide	O
18	containing	O
19	the	O
20	Crk	B
21	-	I
22	SH2	I
23	binding	I
24	motif	I
25	.	O

1	CONCLUSIONS	O
2	:	O
3	Use	O
4	of	O
5	the	O
6	first	O
7	method	O
8	was	O
9	associated	O
10	with	O
11	a	O
12	reduction	O
13	in	O
14	the	O
15	time	O
16	patients	O
17	remained	O
18	in	O
19	the	O
20	ICU	O
21	before	O
22	transfer	O
23	to	O
24	another	O
25	unit	O
26	and	O
27	savings	O
28	in	O
29	nursing	O
30	time	O
31	,	O
32	but	O
33	the	O
34	two	O
35	methods	O
36	did	O
37	not	O
38	differ	O
39	according	O
40	to	O
41	clinical	O
42	outcomes	O
43	.	O

1	The	O
2	elevated	O
3	Viso	B
4	V	I
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	Statins	O
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	Chemotherapy	O
2	of	O
3	metastasizing	O
4	breast	O
5	cancer	O

1	Later	O
2	in	O
3	development	O
4	,	O
5	Tbx6	B
6	expression	O
7	is	O
8	restricted	O
9	to	O
10	presomitic	O
11	,	O
12	paraxial	O
13	mesoderm	O
14	and	O
15	to	O
16	the	O
17	tail	O
18	bud	O
19	,	O
20	which	O
21	replaces	O
22	the	O
23	streak	O
24	as	O
25	the	O
26	source	O
27	of	O
28	mesoderm	O
29	.	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	Neither	O
2	side	O
3	effect	O
4	nor	O
5	abnormal	O
6	laboratory	O
7	findings	O
8	due	O
9	to	O
10	this	O
11	drug	O
12	were	O
13	observed	O
14	.	O

1	The	O
2	attainment	O
3	of	O
4	sexual	O
5	maturity	O
6	in	O
7	terms	O
8	of	O
9	secondary	O
10	sexual	O
11	characteristics	O
12	,	O
13	the	O
14	production	O
15	of	O
16	spermatozoa	O
17	in	O
18	the	O
19	male	O
20	,	O
21	and	O
22	the	O
23	cyclical	O
24	female	O
25	pattern	O
26	with	O
27	release	O
28	of	O
29	ova	O
30	are	O
31	end	O
32	-	O
33	points	O
34	of	O
35	the	O
36	developmental	O
37	process	O
38	.	O

1	The	O
2	mechanism	O
3	underlying	O
4	such	O
5	analgesia	O
6	has	O
7	been	O
8	suggested	O
9	to	O
10	involve	O
11	the	O
12	interaction	O
13	between	O
14	the	O
15	two	O
16	separate	O
17	but	O
18	interconnected	O
19	motivational	O
20	systems	O
21	"	O
22	defense	O
23	"	O
24	and	O
25	"	O
26	pain	O
27	."	O
28	To	O
29	determine	O
30	the	O
31	developmental	O
32	course	O
33	of	O
34	defense	O
35	and	O
36	nociception	O
37	,	O
38	these	O
39	processes	O
40	were	O
41	analyzed	O
42	during	O
43	early	O
44	ontogeny	O
45	in	O
46	rats	O
47	.	O

1	Intravenous	O
2	gamma	B
3	globulins	I

1	Deformities	O
2	of	O
3	the	O
4	tip	O
5	of	O
6	the	O
7	olecranon	O
8	and	O
9	of	O
10	the	O
11	coronoid	B
12	process	O
13	are	O
14	also	O
15	described	O
16	(	O
17	De	O
18	Palma	B
19	1956	I
20	,	O
21	Jordan	B
22	1958	I
23	,	O
24	Ahlberg	B
25	1965	O
26	,	O
27	Weseloh	O
28	1973	O
29	).	O

1	We	O
2	analysed	O
3	two	O
4	regions	O
5	involved	O
6	in	O
7	preS2	B
8	/	O
9	S	B
10	gene	I
11	transcription	O
12	of	O
13	the	O
14	HBV	O
15	adw	O
16	subtype	O
17	:	O
18	the	O
19	diverged	O
20	TATA	O
21	box	O
22	and	O
23	a	O
24	putative	O
25	initiator	O
26	element	O
27	.	O

1	TaV	O
2	particles	O
3	have	O
4	a	O
5	buoyant	O
6	density	O
7	of	O
8	1	O
9	.	O
10	296	O
11	g	O
12	/	O
13	cm3	O
14	in	O
15	CsCl	O
16	and	O
17	consist	O
18	of	O
19	two	O
20	capsid	B
21	proteins	O
22	of	O
23	56	O
24	and	O
25	6	O
26	kDa	O
27	.	O

1	However	O
2	,	O
3	the	O
4	serum	O
5	TNF	B
6	-	I
7	a	O
8	concentration	O
9	decreased	O
10	significantly	O
11	in	O
12	patients	O
13	receiving	O
14	pentoxifylline	O
15	(	O
16	basal	O
17	623	O
18	+/-	O
19	366	O
20	pg	O
21	/	O
22	ml	O
23	;	O
24	6th	O
25	month	O
26	562	O
27	+/-	O
28	358	O
29	pg	O
30	/	O
31	ml	O
32	,	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	),	O
39	but	O
40	not	O
41	in	O
42	the	O
43	control	O
44	group	O
45	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	The	O
2	existence	O
3	of	O
4	threshold	O
5	concentrations	O
6	,	O
7	above	O
8	which	O
9	certain	O
10	phenomena	O
11	may	O
12	occur	O
13	,	O
14	strengthens	O
15	the	O
16	role	O
17	of	O
18	sentinels	O
19	.	O

1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	O
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O

1	Sci	O
2	.	O

1	Identification	O
2	of	O
3	p40x	B
4	-	O
5	responsive	O
6	regulatory	O
7	sequences	O
8	within	O
9	the	O
10	human	O
11	T	I
12	-	I
13	cell	I
14	leukemia	I
15	virus	I
16	type	I
17	I	I
18	long	I
19	terminal	O
20	repeat	O
21	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	B
16	-	I
17	R	I
18	-	I
19	R	I
20	pseudoisochromatic	I
21	plates	O
22	.	O

1	Here	O
2	,	O
3	we	O
4	alter	O
5	the	O
6	dimerization	O
7	specificity	O
8	of	O
9	Fos	B
10	by	O
11	precisely	O
12	replacing	O
13	its	O
14	leucine	O
15	zipper	O
16	with	O
17	that	O
18	from	O
19	GCN4	B
20	.	O

1	Recent	O
2	developments	O
3	in	O
4	drugs	O
5	antagonistic	O
6	to	O
7	factors	O
8	causing	O
9	peptic	O
10	ulcer	O
11	--	O
12	clinical	O
13	efficacy	O
14	and	O
15	problems	O
16	;	O
17	gastrin	B
18	receptor	I
19	blockaders	I

1	Nevertheless	O
2	,	O
3	protein	B
4	kinase	I
5	A	O
6	stimulation	O
7	induces	O
8	CREMalpha	O
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	I
15	in	O
16	the	O
17	phosphoenolpyruvate	B
18	carboxykinase	I
19	(	I
20	PEPCK	B
21	)	I
22	gene	I
23	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	402	O
6	consecutive	O
7	autopsies	O
8	,	O
9	parietal	O
10	pleural	I
11	plaques	I
12	(	O
13	PP	B
14	)	O
15	were	O
16	found	O
17	in	O
18	68	O
19	individuals	O
20	above	O
21	40	O
22	years	O
23	of	O
24	age	O
25	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	B
9	-	I
10	responsive	I
11	gene	I
12	,	O
13	rd22	B
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O

1	New	O
2	diagnostic	O
3	strategies	O
4	for	O
5	lupus	O
6	anticoagulants	O
7	and	O
8	antiphospholipid	O
9	antibodies	O
10	.	O

1	The	O
2	effects	O
3	of	O
4	systemic	O
5	glucose	O
6	concentration	O
7	on	O
8	brain	O
9	metabolism	O
10	following	O
11	repeated	O
12	brain	O
13	ischemia	O
14	.	O

1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	B
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	Specifically	O
2	,	O
3	by	O
4	the	O
5	type	O
6	of	O
7	adjuvant	O
8	therapy	O
9	,	O
10	the	O
11	median	O
12	disease	O
13	-	O
14	free	O
15	interval	O
16	and	O
17	survival	O
18	from	O
19	stage	O
20	IVA	O
21	for	O
22	23	O
23	patients	O
24	receiving	O
25	Corynebacterium	O
26	parvum	O
27	were	O
28	6	O
29	.	O
30	9	O
31	and	O
32	19	O
33	months	O
34	;	O
35	for	O
36	39	O
37	patients	O
38	receiving	O
39	BCG	O
40	,	O
41	eight	O
42	months	O
43	and	O
44	26	O
45	months	O
46	;	O
47	for	O
48	24	O
49	patients	O
50	receiving	O
51	BCG	O
52	+	O
53	DTIC	O
54	,	O
55	eight	O
56	and	O
57	17	O
58	.	O
59	4	O
60	months	O
61	;	O
62	and	O
63	for	O
64	all	O
65	51	O
66	DTIC	O
67	treated	O
68	patients	O
69	6	O
70	.	O
71	3	O
72	and	O
73	17	O
74	.	O
75	8	O
76	months	O
77	,	O
78	respectively	O
79	.	O

1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	I
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O

1	Similarly	O
2	,	O
3	overexpression	O
4	of	O
5	increasing	O
6	concentration	O
7	of	O
8	COUP	B
9	-	I
10	TFI	I
11	,	O
12	but	O
13	not	O
14	COUP	B
15	-	I
16	TFI	I
17	delta35	I
18	,	O
19	can	O
20	squelch	O
21	the	O
22	silencing	O
23	activity	O
24	of	O
25	the	O
26	unliganded	O
27	TRbeta	O
28	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	B
18	bp	O
19	was	O
20	determined	O
21	.	O

1	The	O
2	results	O
3	support	O
4	earlier	O
5	reports	O
6	that	O
7	collagenase	B
8	inhibitors	O
9	are	O
10	useful	O
11	in	O
12	controlling	O
13	blister	O
14	formation	O
15	in	O
16	recessive	O
17	dystrophic	O
18	epidermolysis	O
19	bullosa	O
20	.	O

1	We	O
2	have	O
3	now	O
4	shown	O
5	that	O
6	in	O
7	vivo	O
8	phosphorylation	O
9	of	O
10	14	B
11	-	I
12	3	I
13	-	I
14	3	I
15	zeta	I
16	at	O
17	the	O
18	CKIalpha	B
19	site	I
20	(	O
21	Thr	O
22	-	O
23	233	O
24	)	O
25	negatively	O
26	regulates	O
27	its	O
28	binding	O
29	to	O
30	c	B
31	-	I
32	Raf	I
33	,	O
34	and	O
35	may	O
36	be	O
37	important	O
38	in	O
39	Raf	B
40	-	O
41	mediated	O
42	signal	O
43	transduction	O
44	.	O

1	They	O
2	consisted	O
3	of	O
4	behavioural	O
5	disorders	O
6	,	O
7	tetraparesis	O
8	,	O
9	incontinence	O
10	and	O
11	oculomotor	O
12	paralysis	O
13	.	O

1	Cp	B
2	is	O
3	normally	O
4	the	O
5	main	O
6	promoter	O
7	for	O
8	EBNA	B
9	mRNA	I
10	initiation	O
11	,	O
12	so	O
13	it	O
14	appears	O
15	that	O
16	EBNA3C	O
17	contributes	O
18	to	O
19	a	O
20	negative	O
21	autoregulatory	O
22	control	O
23	loop	O
24	.	O

1	Sequences	O
2	downstream	O
3	of	O
4	the	O
5	two	O
6	human	B
7	CA	I
8	genes	I
9	,	O
10	possibly	O
11	containing	O
12	homologous	O
13	enhancer	I
14	elements	I
15	,	O
16	have	O
17	not	O
18	yet	O
19	been	O
20	reported	O
21	.	O

1	Rearrangements	O
2	of	O
3	the	O
4	NFKB2	B
5	gene	I
6	are	O
7	associated	O
8	with	O
9	lymphoid	O
10	malignancies	O
11	,	O
12	but	O
13	the	O
14	functional	O
15	significance	O
16	of	O
17	these	O
18	alterations	O
19	is	O
20	not	O
21	known	O
22	.	O

1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	B
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O

1	Deletion	O
2	of	O
3	the	O
4	apeA	B
5	gene	I
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	B
15	(	O
16	protease	I
17	IV	I
18	and	O
19	aminopeptidase	B
20	N	O
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O

1	However	O
2	,	O
3	mutations	O
4	in	O
5	the	O
6	HNF	B
7	-	I
8	4	I
9	binding	I
10	site	I
11	on	O
12	element	O
13	CIIB	I
14	and	O
15	inhibition	O
16	of	O
17	HNF	B
18	-	I
19	4	I
20	synthesis	I
21	in	O
22	HepG2	O
23	cells	O
24	by	O
25	antisense	B
26	HNF	I
27	-	I
28	4	I
29	constructs	I
30	decreased	O
31	the	O
32	apoCII	B
33	promoter	I
34	activity	O
35	to	O
36	25	O
37	-	O
38	40	O
39	%	O
40	of	O
41	the	O
42	control	O
43	,	O
44	indicating	O
45	that	O
46	HNF	B
47	-	I
48	4	I
49	is	O
50	a	O
51	positive	O
52	regulator	O
53	of	O
54	the	O
55	apoCII	B
56	gene	I
57	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	O
30	mutants	O
31	.	O

1	Separation	O
2	of	O
3	ninhydrin	O
4	-	O
5	positive	O
6	compounds	O
7	in	O
8	urine	O
9	by	O
10	the	O
11	combined	O
12	methods	O
13	of	O
14	medium	O
15	-	O
16	tension	O
17	intophoresis	O
18	and	O
19	partition	O
20	chromatography	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	Electrocardiographic	O
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	Additional	B
2	exonuclease	I
3	III	I
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	O
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	I
11	-	I
12	1	I
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	I
24	AP1	I
25	(	I
26	activator	I
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	I
48	protein	I
49	kinase	I
50	C	I
51	pathways	O
52	.	O

1	Discrepant	O
2	results	O
3	with	O
4	a	O
5	latex	O
6	agglutination	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	cytomegalovirus	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O

1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	B
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	organization	O
7	of	O
8	functional	O
9	units	O
10	of	O
11	the	O
12	72	O
13	-	O
14	bp	O
15	repeat	O
16	required	O
17	for	O
18	transcriptional	O
19	enhancement	O
20	of	O
21	the	O
22	early	B
23	promoter	I
24	is	O
25	different	O
26	from	O
27	that	O
28	required	O
29	for	O
30	late	O
31	promoter	O
32	function	O
33	.	O

1	R	O
2	-	O
3	wave	O
4	voltage	O
5	in	O
6	the	O
7	right	O
8	precordial	O
9	leads	O
10	in	O
11	anthracycline	O
12	cardiomyopathy	O
13	:	O
14	a	O
15	clinical	O
16	study	O
17	.	O

1	Identification	O
2	of	O
3	a	O
4	spliced	O
5	gene	O
6	from	O
7	Kaposi	O
8	'	O
9	s	O
10	sarcoma	O
11	-	O
12	associated	O
13	herpesvirus	O
14	encoding	O
15	a	O
16	protein	O
17	with	O
18	similarities	O
19	to	O
20	latent	B
21	membrane	I
22	proteins	I
23	1	I
24	and	O
25	2A	O
26	of	O
27	Epstein	O
28	-	O
29	Barr	O
30	virus	O
31	.	O

1	The	O
2	antigen	B
3	-	I
4	specific	I
5	IgG4	I
6	antibody	I
7	seems	O
8	to	O
9	be	O
10	an	O
11	index	O
12	in	O
13	evaluating	O
14	immunotherapy	O
15	objectively	O
16	.	O

1	Significance	O
2	of	O
3	cytokine	O
4	production	O
5	and	O
6	adhesion	O
7	molecules	O
8	in	O
9	malarial	O
10	immunopathology	O
11	.	O

1	Diagnostic	O
2	importance	O
3	of	O
4	determining	O
5	the	O
6	complement	O
7	constituents	O
8	in	O
9	children	O
10	with	O
11	autoimmune	O
12	thyroiditis	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	NTP	O
6	-	O
7	binding	O
8	motif	O
9	is	O
10	important	O
11	for	O
12	Rad24	O
13	function	O
14	,	O
15	we	O
16	mutated	O
17	the	O
18	conserved	O
19	lysine	O
20	(	O
21	115	O
22	)	O
23	residue	O
24	in	O
25	this	O
26	motif	O
27	.	O

1	Secretory	O
2	IgA	B
3	and	O
4	serum	O
5	immunoglobulins	I
6	as	O
7	indices	O
8	of	O
9	the	O
10	local	O
11	immunity	O
12	of	O
13	the	O
14	intestinal	O
15	mucosa	O
16	in	O
17	acute	O
18	leukemias	O

1	The	O
2	protein	O
3	mixtures	O
4	of	O
5	sesame	O
6	flour	O
7	and	O
8	soybean	O
9	flour	O
10	were	O
11	well	O
12	accepted	O
13	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	I
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	SPA	O
2	from	O
3	PAG	B
4	sites	O
5	was	O
6	associated	O
7	with	O
8	aversion	O
9	.	O

1	In	O
2	supine	O
3	position	O
4	,	O
5	plasma	O
6	ANP	B
7	levels	O
8	ranged	O
9	from	O
10	12	O
11	pg	O
12	/	O
13	ml	O
14	to	O
15	51	O
16	.	O
17	5	O
18	pg	O
19	/	O
20	ml	O
21	,	O
22	with	O
23	an	O
24	average	O
25	level	O
26	of	O
27	35	O
28	.	O
29	3	O
30	+/-	O
31	11	O
32	.	O
33	5	O
34	pg	O
35	/	O
36	ml	O
37	.	O

1	Relationship	O
2	between	O
3	mitochondrial	B
4	NADH	I
5	-	I
6	ubiquinone	I
7	reductase	I
8	and	O
9	a	O
10	bacterial	B
11	NAD	I
12	-	I
13	reducing	O
14	hydrogenase	B
15	.	O

1	Pao2	O
2	increased	O
3	from	O
4	15	O
5	.	O
6	5	O
7	+/-	O
8	5	O
9	.	O
10	6	O
11	kPa	O
12	(	O
13	116	O
14	+/-	O
15	42	O
16	mm	O
17	Hg	O
18	)	O
19	to	O
20	17	O
21	.	O
22	3	O
23	+/-	O
24	6	O
25	.	O
26	3	O
27	kPa	O
28	(	O
29	130	O
30	+/-	O
31	47	O
32	mm	O
33	Hg	O
34	)	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	05	O
41	).	O

1	Glucagon	O
2	also	O
3	induced	O
4	LUC	O
5	activity	O
6	very	O
7	strongly	O
8	when	O
9	the	O
10	CRE1	O
11	and	O
12	CRE2	B
13	sites	O
14	were	O
15	combined	O
16	;	O
17	induction	O
18	of	O
19	the	O
20	(	O
21	CRE1	B
22	)	I
23	3	I
24	(	O
25	CRE2	B
26	)	O
27	2SV40	B
28	-	I
29	LUC	I
30	constructs	I
31	was	O
32	positively	O
33	modulated	O
34	by	O
35	the	O
36	pO2	O
37	.	O

1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	O
29	.	O

1	The	O
2	XS2	B
3	gene	I
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	B
14	genes	I
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O

1	This	O
2	indicates	O
3	that	O
4	recruitment	O
5	of	O
6	large	O
7	T	I
8	antigen	I
9	to	O
10	the	O
11	rRNA	B
12	promoter	I
13	by	O
14	SL1	B
15	constitutes	O
16	a	O
17	crucial	O
18	step	O
19	in	O
20	the	O
21	activation	O
22	process	O
23	.	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	O
8	-	I
9	type	I
10	Fus3	I
11	intensifies	I
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	I
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	This	O
2	brief	O
3	hypercapnic	O
4	challenge	O
5	induced	O
6	a	O
7	rapid	O
8	increase	O
9	in	O
10	CBF	B
11	in	O
12	the	O
13	absence	O
14	of	O
15	any	O
16	change	O
17	in	O
18	MABP	O
19	.	O

1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	B
21	thyrotropin	I
22	secretion	I
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O

1	Gains	O
2	increased	O
3	3	O
4	.	O
5	5	O
6	%	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	10	O
13	)	O
14	and	O
15	feed	O
16	conversion	O
17	improved	O
18	5	O
19	.	O
20	9	O
21	%	O
22	(	O
23	P	O
24	less	O
25	than	O
26	.	O
27	07	O
28	)	O
29	in	O
30	steers	O
31	fed	O
32	.	O
33	28	O
34	%	O
35	AS	O
36	-	O
37	VFA	O
38	compared	O
39	with	O
40	gain	O
41	and	O
42	feed	O
43	conversion	O
44	of	O
45	the	O
46	control	O
47	steers	O
48	.	O

1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	B
9	pre	I
10	-	I
11	T	I
12	-	I
13	cell	I
14	receptor	I
15	alpha	I
16	gene	I
17	.	O

1	Before	O
2	birth	O
3	,	O
4	there	O
5	were	O
6	a	O
7	few	O
8	perivascular	O
9	adrenergic	O
10	nerves	O
11	and	O
12	correspondingly	O
13	low	O
14	ovarian	O
15	NE	O
16	levels	O
17	.	O

1	The	O
2	magnitude	O
3	of	O
4	the	O
5	early	O
6	response	O
7	was	O
8	241	O
9	+/-	O
10	51	O
11	%	O
12	in	O
13	A	O
14	(%	O
15	baseline	O
16	RL	O
17	;	O
18	mean	O
19	+/-	O
20	SE	O
21	),	O
22	and	O
23	significantly	O
24	less	O
25	in	O
26	B	O
27	(	O
28	119	O
29	+/-	O
30	7	O
31	%)	O
32	and	O
33	C	O
34	(	O
35	131	O
36	+/-	O
37	16	O
38	%)	O
39	(	O
40	p	O
41	<	O
42	0	O
43	.	O
44	01	O
45	).	O

1	A	O
2	cDNA	O
3	for	O
4	a	O
5	newly	O
6	discovered	O
7	pseudogene	O
8	,	O
9	closely	O
10	related	O
11	to	O
12	the	O
13	mouse	O
14	mast	O
15	cell	O
16	chymases	I
17	was	O
18	isolated	O
19	by	O
20	polymerase	O
21	chain	O
22	reaction	O
23	amplification	O
24	from	O
25	a	O
26	mouse	O
27	connective	O
28	tissue	O
29	-	O
30	like	O
31	mast	O
32	cell	O
33	line	O
34	.	O

1	This	O
2	information	O
3	,	O
4	together	O
5	with	O
6	estimation	O
7	of	O
8	the	O
9	size	O
10	of	O
11	the	O
12	deglycosylated	B
13	A	O
14	subunit	O
15	relative	O
16	to	O
17	a	O
18	series	O
19	of	O
20	C	B
21	-	I
22	terminal	I
23	truncated	I
24	TSHR	I
25	ectodomain	I
26	variants	I
27	,	O
28	places	B
29	cleavage	O
30	Site	I
31	1	I
32	in	O
33	the	O
34	vicinity	O
35	of	O
36	,	O
37	or	O
38	closely	O
39	upstream	O
40	to	O
41	,	O
42	residue	O
43	317	O
44	.	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	O
8	,	O
9	two	O
10	,	O
11	or	O
12	multiple	O
13	nuclei	O
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	O
24	and	O
25	also	O
26	a	O
27	defect	O
28	in	O
29	cytokinesis	O
30	and	O
31	/	O
32	or	O
33	cell	O
34	separation	O
35	.	O

1	Model	O
2	IV	O
3	:	O
4	primary	O
5	abutments	O
6	with	O
7	the	O
8	lateral	O
9	incisor	O
10	and	O
11	the	O
12	second	O
13	molar	O
14	as	O
15	secondary	O
16	abutments	O
17	.	O

1	Observers	O
2	with	O
3	brain	O
4	injury	O
5	and	O
6	control	O
7	participants	O
8	performed	O
9	a	O
10	vigilance	O
11	task	O
12	during	O
13	which	O
14	they	O
15	received	O
16	periodic	O
17	whiffs	O
18	of	O
19	unscented	O
20	air	O
21	or	O
22	air	O
23	scented	O
24	with	O
25	peppermint	O
26	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Associations	O
6	of	O
7	factor	O
8	analysis	O
9	-	O
10	derived	O
11	syndromes	O
12	with	O
13	risk	O
14	factors	O
15	for	O
16	chemical	O
17	interactions	O
18	that	O
19	inhibit	O
20	butyrylcholinesterase	B
21	and	O
22	neuropathy	B
23	target	I
24	esterase	I
25	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	100	O
6	-	O
7	bp	O
8	Col2a1	B
9	enhancer	O
10	revealed	O
11	several	O
12	sequence	O
13	motifs	O
14	similar	O
15	to	O
16	motifs	O
17	present	O
18	within	O
19	the	O
20	regulatory	O
21	region	O
22	of	O
23	the	O
24	link	B
25	protein	I
26	gene	I
27	,	O
28	another	O
29	cartilage	O
30	gene	O
31	.	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	The	O
2	GRE	B
3	at	O
4	nucleotide	O
5	7640	I
6	is	O
7	a	O
8	composite	O
9	GRE	B
10	(	O
11	cGRE	B
12	)	O
13	containing	O
14	an	O
15	overlapping	O
16	activator	I
17	protein	I
18	-	I
19	1	I
20	(	O
21	AP	B
22	-	I
23	1	I
24	)	O
25	motif	O
26	for	O
27	the	O
28	c	B
29	-	I
30	jun	I
31	homodimer	I
32	and	O
33	c	B
34	-	I
35	jun	I
36	/	I
37	c	B
38	-	I
39	fos	I
40	heterodimer	O
41	.	O

1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	B
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	DMVA	O
6	does	O
7	not	O
8	cause	O
9	more	O
10	myocardial	O
11	trauma	O
12	than	O
13	CPB	O
14	when	O
15	used	O
16	to	O
17	provide	O
18	resuscitative	O
19	circulatory	O
20	support	O
21	.	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	Escherichia	O
2	coli	O
3	JRG582	I
4	is	O
5	an	O
6	ampD	B
7	ampE	I
8	deletion	O
9	derivative	O
10	of	O
11	strain	O
12	HfrH	O
13	and	O
14	accordingly	O
15	it	O
16	is	O
17	derepressed	O
18	for	O
19	expression	O
20	of	O
21	the	O
22	cloned	O
23	inducible	O
24	beta	I
25	-	I
26	lactamase	I
27	gene	I
28	of	O
29	Citrobacter	B
30	freundii	I
31	,	O
32	carried	O
33	on	O
34	plasmid	O
35	pNU305	O
36	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	B
13	Drinking	I
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	This	O
2	result	O
3	supports	O
4	the	O
5	argument	O
6	that	O
7	the	O
8	beta	O
9	'	O
10	subunit	O
11	plays	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	determining	O
17	the	O
18	progress	O
19	of	O
20	transcription	O
21	elongation	O
22	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	B
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	B
13	-	I
14	density	I
15	lipoprotein	I
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	absolutely	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	B
29	-	I
30	density	I
31	lipoproteins	I
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	infarcts	O
38	and	O
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	O
8	,	O
9	i	O
10	.	O
11	e	O
12	.,	O
13	rigidity	O
14	,	O
15	tremor	O
16	and	O
17	akinesia	O
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	I
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	O
44	the	O
45	disease	O
46	in	O
47	relation	O
48	to	O
49	the	O
50	neuropathological	O
51	findings	O
52	within	O
53	the	O
54	substantia	O
55	nigra	O
56	zona	O
57	compacta	O
58	(	O
59	SNc	O
60	).	O

1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	B
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	O
13	heptamers	O
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O

1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	I
38	hepatitis	I
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O

1	The	O
2	results	O
3	imply	O
4	that	O
5	kindling	O
6	does	O
7	not	O
8	produce	O
9	its	O
10	facilitating	O
11	effect	O
12	on	O
13	acquisition	O
14	of	O
15	HPC	O
16	SS	O
17	by	O
18	removing	O
19	a	O
20	disruptive	O
21	effect	O
22	of	O
23	the	O
24	stimulation	O
25	.	O

1	These	O
2	cells	O
3	produce	O
4	a	O
5	low	O
6	level	O
7	of	O
8	IL	B
9	-	I
10	5	I
11	when	O
12	stimulated	O
13	with	O
14	PMA	O
15	alone	O
16	;	O
17	however	O
18	,	O
19	N6	O
20	,	O
21	O2	O
22	-	O
23	dibutyryl	O
24	cAMP	O
25	(	O
26	Bt2cAMP	O
27	),	O
28	in	O
29	combination	O
30	with	O
31	PMA	O
32	,	O
33	augmented	O
34	by	O
35	more	O
36	than	O
37	tenfold	O
38	the	O
39	IL	B
40	-	I
41	5	I
42	production	O
43	at	O
44	the	O
45	mRNA	O
46	and	O
47	the	O
48	protein	O
49	levels	O
50	.	O

1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	I
11	domain	I
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	I
23	domain	O
24	of	O
25	c	B
26	-	I
27	IAP1	I
28	and	O
29	induced	O
30	apoptosis	O
31	.	O

1	The	O
2	Ishasha	O
3	samples	O
4	show	O
5	a	O
6	range	O
7	encompassing	O
8	three	O
9	trophic	O
10	levels	O
11	.	O

1	Interestingly	O
2	,	O
3	although	O
4	E	O
5	domains	O
6	of	O
7	these	O
8	two	O
9	receptors	O
10	are	O
11	much	O
12	less	O
13	conserved	O
14	,	O
15	replacement	O
16	of	O
17	this	O
18	domain	O
19	in	O
20	rtER	O
21	by	O
22	its	O
23	human	O
24	counterpart	O
25	resulted	O
26	in	O
27	higher	O
28	estradiol	O
29	sensitivity	O
30	but	O
31	no	O
32	increase	O
33	in	O
34	the	O
35	magnitude	O
36	of	O
37	transactivation	O
38	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	B
21	dept	I
22	.	O
23	of	O
24	Bologna	B
25	'	I
26	s	I
27	"	I
28	Ospedale	I
29	Maggiore	I
30	"	O
31	General	I
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	B
7	in	O
8	pallid	B
9	bats	I
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	The	O
2	bZP2	B
3	cDNA	I
4	(	O
5	115	O
6	-	O
7	1914	I
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	B
36	-	O
37	Sal1	O
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	B
47	promoter	I
48	under	O
49	the	O
50	lac	B
51	operator	I
52	control	I
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O

1	188	O
2	patients	O
3	received	O
4	cimetidine	O
5	400	O
6	mg	O
7	q	B
8	.	O
9	i	O
10	.	O
11	d	O
12	.	O
13	intravenously	O
14	and	O
15	1	O
16	,	O
17	000	O
18	mg	O
19	daily	O
20	orally	O
21	in	O
22	divided	O
23	doses	O
24	.	O

1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	O
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	anthraquinone	B
6	sennoside	I
7	B	I
8	and	O
9	rhein	B
10	are	O
11	weakly	O
12	genotoxic	O
13	.	O

1	Eucaryotic	B
2	transcription	O
3	factors	O
4	that	O
5	stimulate	O
6	RNA	B
7	polymerase	I
8	II	I
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	I
21	chains	I
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	B
5	-	O
6	inducible	O
7	HIV	I
8	-	I
9	1	I
10	gene	I
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	B
32	terminal	I
33	repeat	I
34	(	O
35	LTR	B
36	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	B
6	glycosylasparaginase	O
7	with	O
8	a	O
9	mammalian	B
10	glycosylasparaginase	I
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	B
6	from	O
7	heviz	O

1	Since	O
2	AP	B
3	-	I
4	1	I
5	is	O
6	an	O
7	important	O
8	mediator	O
9	of	O
10	tumor	O
11	promoter	O
12	action	O
13	,	O
14	these	O
15	findings	O
16	may	O
17	explain	O
18	the	O
19	anti	B
20	-	I
21	tumor	I
22	-	I
23	promoting	O
24	activity	O
25	of	O
26	phenolic	B
27	antioxidants	I
28	.	O

1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O

1	Using	O
2	5	O
3	'	O
4	RACE	O
5	and	O
6	reverse	O
7	transcription	O
8	-	O
9	PCR	O
10	(	O
11	RT	O
12	-	O
13	PCR	O
14	)	O
15	methodologies	O
16	,	O
17	we	O
18	cloned	O
19	these	O
20	sequences	O
21	from	O
22	brain	O
23	and	O
24	placenta	O
25	and	O
26	found	O
27	this	O
28	material	O
29	to	O
30	be	O
31	composed	O
32	of	O
33	alternatively	O
34	spliced	O
35	exons	O
36	using	O
37	a	O
38	previously	O
39	reported	O
40	noncoding	O
41	exon	O
42	(	O
43	1A	O
44	)	O
45	and	O
46	a	O
47	novel	O
48	97	O
49	-	O
50	bp	O
51	noncoding	O
52	exon	O
53	(	O
54	1B	O
55	).	O

1	Oligonucleotide	O
2	competitors	O
3	were	O
4	used	O
5	to	O
6	evaluate	O
7	the	O
8	accessibility	O
9	of	O
10	the	O
11	TATA	B
12	-	I
13	binding	I
14	site	I
15	in	O
16	TIF	B
17	-	I
18	IB	I
19	,	O
20	TFIID	B
21	,	O
22	and	O
23	TFIIIB	B
24	.	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	O
8	16	O
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	O
23	Zn	I
24	-	O
25	15	O
26	.	O

1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O

1	Nutritional	O
2	cataracts	O
3	in	O
4	timber	B
5	wolves	I
6	.	O

1	Anterior	O
2	body	O
3	pattern	O
4	in	O
5	Drosophila	O
6	is	O
7	specified	O
8	by	O
9	the	O
10	graded	O
11	distribution	O
12	of	O
13	the	O
14	bicoid	B
15	protein	O
16	(	O
17	bcd	O
18	),	O
19	which	O
20	activates	O
21	subordinate	B
22	genes	O
23	in	O
24	distinct	O
25	anterior	O
26	domains	O
27	.	O

1	Stable	O
2	association	O
3	of	O
4	U2	B
5	snRNP	I
6	with	O
7	the	O
8	branchpoint	O
9	sequence	O
10	of	O
11	mammalian	B
12	pre	I
13	-	I
14	mRNAs	I
15	requires	O
16	binding	O
17	of	O
18	a	O
19	non	O
20	-	I
21	snRNP	I
22	protein	O
23	to	O
24	the	O
25	polypyrimidine	O
26	tract	O
27	.	O

1	Forskolin	O
2	significantly	O
3	enhanced	O
4	heregulin	O
5	-	O
6	stimulated	O
7	expression	O
8	of	O
9	cyclin	B
10	D	I
11	and	O
12	phosphorylation	O
13	of	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	.	O

1	In	O
2	a	O
3	stepwise	O
4	logistic	O
5	regression	O
6	analysis	O
7	of	O
8	SPT	O
9	and	O
10	RAST	O
11	data	O
12	,	O
13	the	O
14	occurrence	O
15	of	O
16	serum	B
17	IgE	I
18	antibodies	I
19	to	O
20	P	O
21	.	O
22	orbiculare	O
23	had	O
24	the	O
25	highest	O
26	explanatory	O
27	value	O
28	for	O
29	current	O
30	eczema	O
31	.	O

1	The	O
2	following	O
3	evidence	O
4	indicates	O
5	that	O
6	the	O
7	69	O
8	-	O
9	kD	I
10	protein	I
11	is	O
12	a	O
13	common	O
14	,	O
15	rather	O
16	than	O
17	a	O
18	U1	B
19	-	O
20	specific	O
21	,	O
22	protein	O
23	,	O
24	possibly	O
25	associating	O
26	with	O
27	the	O
28	snRNP	B
29	core	I
30	particles	O
31	by	O
32	protein	O
33	-	O
34	protein	O
35	interaction	O
36	.	O

1	Rather	O
2	,	O
3	complete	O
4	skipping	O
5	of	O
6	exon	O
7	V	O
8	and	O
9	subsequent	O
10	joining	O
11	of	O
12	exon	O
13	IV	O
14	to	O
15	exon	O
16	VI	O
17	caused	O
18	a	O
19	shift	O
20	in	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	which	O
27	remodeled	O
28	GPHe	O
29	(	O
30	P2	O
31	)	O
32	with	O
33	an	O
34	elongated	O
35	new	O
36	hydrophobic	O
37	sequence	O
38	for	O
39	membrane	O
40	anchoring	O
41	.	O

1	We	O
2	introduced	O
3	the	O
4	gel	O
5	technique	O
6	as	O
7	a	O
8	routine	O
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	An	O
2	increase	O
3	in	O
4	bone	O
5	mineral	O
6	density	O
7	at	O
8	the	O
9	spine	O
10	,	O
11	total	O
12	hip	O
13	,	O
14	and	O
15	total	O
16	body	O
17	has	O
18	been	O
19	reported	O
20	with	O
21	raloxifene	O
22	but	O
23	seems	O
24	to	O
25	be	O
26	less	O
27	than	O
28	that	O
29	seen	O
30	with	O
31	estrogen	O
32	or	O
33	alendronate	O
34	therapy	O
35	.	O

1	The	O
2	TYAC	B
3	/	O
4	P1	O
5	resource	O
6	,	O
7	derivative	O
8	STSs	O
9	,	O
10	and	O
11	polymorphisms	O
12	constitute	O
13	an	O
14	enabling	O
15	resource	O
16	to	O
17	further	O
18	studies	O
19	of	O
20	telomere	O
21	structure	O
22	and	O
23	function	O
24	and	O
25	a	O
26	means	O
27	for	O
28	physical	O
29	and	O
30	genetic	O
31	map	O
32	integration	O
33	and	O
34	closure	O
35	.	O

1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	B
6	spans	O
7	15	O
8	.	O
9	2	O
10	kb	O
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O

1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	I
11	myc	I
12	mRNA	I
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	B
25	myc	I
26	genes	I
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	B
34	sequences	O
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	B
40	beta	I
41	-	I
42	globin	I
43	gene	I
44	or	O
45	to	O
46	the	O
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	O
51	CAT	B
52	)	I
53	gene	I
54	.	O

1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	B
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O

1	We	O
2	also	O
3	localized	O
4	the	O
5	Fra	B
6	-	I
7	2	I
8	phosphorylation	O
9	sites	O
10	by	O
11	MAPK	B
12	to	O
13	three	O
14	threonine	O
15	and	O
16	three	O
17	serine	O
18	residues	O
19	in	O
20	the	O
21	COOH	O
22	-	O
23	terminal	O
24	region	O
25	by	O
26	means	O
27	of	O
28	site	O
29	-	O
30	directed	O
31	mutagenesis	O
32	and	O
33	showed	O
34	that	O
35	the	O
36	threonine	O
37	residues	O
38	were	O
39	more	O
40	susceptible	O
41	to	O
42	MAPK	B
43	.	O

1	Propafenone	O
2	is	O
3	well	O
4	tolerated	O
5	in	O
6	the	O
7	majority	O
8	of	O
9	young	O
10	patients	O
11	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	O
15	-	I
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	multivariate	O
6	analysis	O
7	considering	O
8	age	O
9	,	O
10	gender	O
11	,	O
12	and	O
13	a	O
14	previous	O
15	history	O
16	of	O
17	cardiovascular	O
18	diseases	O
19	,	O
20	female	O
21	gender	O
22	was	O
23	not	O
24	independently	O
25	associated	O
26	with	O
27	death	O
28	.	O

1	The	O
2	PSS	B
3	gene	I
4	was	O
5	subcloned	O
6	into	O
7	a	O
8	1	O
9	.	O
10	1	O
11	-	O
12	kb	O
13	fragment	O
14	of	O
15	the	O
16	yeast	O
17	DNA	O
18	on	O
19	the	O
20	YEp13	O
21	vector	O
22	.	O

1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	B
7	saginata	O
8	taeniasis	I
9	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	O
15	murine	B
16	gammaHV68	I
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	O
57	v	B
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	I
63	,	O
64	v	B
65	-	I
66	GCR	I
67	gene	I
68	,	O
69	and	O
70	gene	O
71	73	O
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	O
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	The	O
2	highest	O
3	postoperative	O
4	CK	B
5	-	I
6	MB	I
7	level	O
8	was	O
9	less	O
10	after	O
11	BC	O
12	(	O
13	BC	O
14	,	O
15	31	O
16	+/-	O
17	17	O
18	U	O
19	/	O
20	L	O
21	;	O
22	CC	O
23	,	O
24	56	O
25	+/-	O
26	13	O
27	U	O
28	/	O
29	L	O
30	;	O
31	p	O
32	less	O
33	than	O
34	0	O
35	.	O
36	05	O
37	).	O

1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O

1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O

1	Regulation	O
2	of	O
3	pituitary	B
4	vasopressin	I
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	Responsiveness	O
2	to	O
3	beta	O
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O

1	The	O
2	calcium	O
3	ratio	O
4	(	O
5	mean	O
6	ratio	O
7	of	O
8	the	O
9	predicted	O
10	to	O
11	measured	O
12	TBCa	O
13	)	O
14	in	O
15	men	O
16	was	O
17	1	O
18	.	O
19	000	O
20	+/-	O
21	7	O
22	.	O
23	8	O
24	%	O
25	and	O
26	in	O
27	women	O
28	0	O
29	.	O
30	996	O
31	+/-	O
32	7	O
33	.	O
34	1	O
35	%.	O

1	The	O
2	novel	O
3	protein	B
4	kinases	I
5	,	O
6	c	B
7	-	I
8	Jun	I
9	NH2	I
10	-	I
11	terminal	I
12	kinases	I
13	(	O
14	JNKs	B
15	)/	O
16	stress	B
17	-	I
18	activated	I
19	protein	I
20	kinases	I
21	,	O
22	are	O
23	also	O
24	activated	O
25	by	O
26	TNF	B
27	-	I
28	alpha	I
29	,	O
30	IL	B
31	-	I
32	1	I
33	,	O
34	and	O
35	CD28	O
36	costimulation	O
37	.	O

1	RVEF	O
2	and	O
3	LVEF	O
4	both	O
5	increased	O
6	by	O
7	about	O
8	14	O
9	%	O
10	(	O
11	p	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	and	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	01	O
24	).	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	I
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O

1	In	O
2	Denmark	O
3	only	O
4	1	O
5	-	O
6	3	O
7	cases	O
8	of	O
9	transfusion	O
10	-	O
11	associated	O
12	hepatitis	O
13	NANB	O
14	(	O
15	TAH	O
16	-	O
17	NANB	O
18	)	O
19	are	O
20	registered	O
21	annually	O
22	or	O
23	about	O
24	1	O
25	case	O
26	per	O
27	100	O
28	,	O
29	000	O
30	units	O
31	transfused	O
32	.	O

1	Umweltchem	O
2	.	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	O
9	Leu	B
10	-	I
11	tRNA	I
12	precursor	I
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	O
18	tau	O
19	element	O
20	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	B
20	protein	O
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	B
36	protein	I
37	.	O

1	Zatebradine	O
2	weakly	O
3	depressed	O
4	the	O
5	ectopic	O
6	ventricular	O
7	rate	O
8	but	O
9	not	O
10	the	O
11	arrhythmic	O
12	ratio	O
13	of	O
14	the	O
15	ventricular	O
16	arrhythmias	O
17	induced	O
18	by	O
19	two	O
20	-	O
21	stage	O
22	coronary	O
23	ligation	O
24	24	O
25	h	O
26	after	O
27	the	O
28	ligation	O
29	in	O
30	conscious	O
31	dogs	O
32	.	O

1	Evaluation	O
2	of	O
3	desmopressin	O
4	for	O
5	dental	O
6	extractions	O
7	in	O
8	patients	O
9	with	O
10	hemostatic	O
11	disorders	O
12	.	O

1	Codon	O
2	usage	O
3	in	O
4	C	O
5	.	O
6	reinhardtii	B
7	mitochondria	I
8	is	O
9	highly	O
10	biased	O
11	,	O
12	with	O
13	eight	O
14	codons	O
15	entirely	O
16	absent	O
17	from	O
18	all	O
19	protein	O
20	-	O
21	coding	O
22	genes	O
23	;	O
24	however	O
25	,	O
26	even	O
27	though	O
28	codon	O
29	usage	O
30	is	O
31	restricted	O
32	,	O
33	it	O
34	appears	O
35	that	O
36	C	O
37	.	O
38	reinhardtii	O
39	mtDNA	O
40	cannot	O
41	encode	O
42	the	O
43	minimum	O
44	number	O
45	of	O
46	tRNAs	O
47	needed	O
48	to	O
49	support	O
50	mitochondrial	O
51	protein	O
52	synthesis	O
53	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O

1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	Avicel	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	patriciarum	O
14	showed	O
15	that	O
16	xynB	O
17	hybridized	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O

1	Oxygen	O
2	tension	O
3	of	O
4	the	O
5	small	O
6	lymph	O
7	vessels	O
8	(	O
9	PLO2	O
10	)	O
11	of	O
12	the	O
13	rabbit	B
14	hind	I
15	limb	O
16	was	O
17	measured	O
18	with	O
19	both	O
20	a	O
21	flow	O
22	-	O
23	through	O
24	micro	O
25	chamber	O
26	and	O
27	a	O
28	polarographic	O
29	catheter	O
30	-	O
31	tip	O
32	oxygen	O
33	electrode	O
34	to	O
35	obtain	O
36	experimental	O
37	data	O
38	on	O
39	the	O
40	source	O
41	of	O
42	oxygen	O
43	in	O
44	the	O
45	lymph	O
46	.	O

1	Magnetic	O
2	storm	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	medicine	O
9	,	O
10	in	O
11	geophysics	O
12	and	O
13	for	O
14	special	O
15	purposes	O
16	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	I
6	reporter	I
7	construct	I
8	,	O
9	(	O
10	PRDII	B
11	)(	I
12	4	I
13	)-	O
14	CAT	B
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	O
27	by	O
28	Tat	B
29	.	O

1	The	O
2	FFA	O
3	levels	O
4	were	O
5	not	O
6	affected	O
7	(	O
8	P	O
9	greater	O
10	than	O
11	.	O
12	1	O
13	)	O
14	by	O
15	meal	O
16	interval	O
17	.	O

1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O

1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	I
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O

1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O

1	Volume	O
2	of	O
3	distribution	O
4	of	O
5	total	O
6	DMDZ	O
7	(	O
8	range	O
9	,	O
10	1	O
11	.	O
12	33	O
13	to	O
14	6	O
15	.	O
16	30	O
17	l	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	of	O
23	unbound	O
24	DMDZ	O
25	after	O
26	correction	O
27	for	O
28	protein	O
29	binding	O
30	(	O
31	range	O
32	,	O
33	43	O
34	to	O
35	243	O
36	l	O
37	/	O
38	kg	O
39	)	O
40	was	O
41	larger	O
42	in	O
43	women	O
44	than	O
45	in	O
46	men	O
47	of	O
48	all	O
49	ages	O
50	,	O
51	and	O
52	in	O
53	the	O
54	elderly	O
55	as	O
56	opposed	O
57	to	O
58	the	O
59	young	O
60	.	O

1	CONCLUSION	O
2	:	O
3	Patients	O
4	wit	O
5	clinically	O
6	palpable	O
7	neck	O
8	disease	O
9	(	O
10	N1	O
11	-	O
12	3	O
13	),	O
14	histological	O
15	evidence	O
16	of	O
17	metastatic	O
18	nodal	O
19	disease	O
20	,	O
21	extracapsular	O
22	spread	O
23	,	O
24	and	O
25	three	O
26	or	O
27	more	O
28	positive	O
29	lymph	O
30	nodes	O
31	are	O
32	at	O
33	greater	O
34	risk	O
35	of	O
36	developing	O
37	failure	O
38	at	O
39	distant	O
40	sites	O
41	.	O

1	E3	B
2	/	O
3	19K	O
4	resides	O
5	in	O
6	the	O
7	endoplasmic	O
8	reticulum	O
9	where	O
10	it	O
11	binds	O
12	to	O
13	MHC	B
14	class	I
15	I	I
16	molecules	I
17	,	O
18	thereby	O
19	preventing	O
20	their	O
21	transport	O
22	to	O
23	the	O
24	cell	O
25	surface	O
26	.	O

1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O

1	Both	O
2	GH	B
3	deficiency	O
4	and	O
5	impaired	O
6	spinal	O
7	growth	O
8	may	O
9	result	O
10	in	O
11	short	O
12	stature	O
13	,	O
14	whereas	O
15	the	O
16	occurrence	O
17	of	O
18	early	O
19	puberty	O
20	in	O
21	association	O
22	with	O
23	GH	B
24	deficiency	O
25	reduces	O
26	the	O
27	time	O
28	available	O
29	for	O
30	GH	B
31	therapy	O
32	.	O

1	TATA	O
2	and	O
3	CCAAT	B
4	boxes	O
5	are	O
6	located	O
7	34	O
8	-	O
9	bp	O
10	and	O
11	68	O
12	-	O
13	bp	O
14	,	O
15	respectively	O
16	,	O
17	upstream	O
18	of	O
19	the	O
20	transcription	O
21	start	O
22	site	O
23	,	O
24	the	O
25	5	O
26	'-	O
27	untranslated	O
28	leader	O
29	is	O
30	78	O
31	nucleotides	O
32	long	O
33	,	O
34	and	O
35	the	O
36	intronless	O
37	gene	O
38	has	O
39	at	O
40	least	O
41	two	O
42	different	O
43	polyadenylation	O
44	sites	O
45	.	O

1	However	O
2	,	O
3	the	O
4	action	O
5	of	O
6	each	O
7	cognate	O
8	ligand	O
9	and	O
10	the	O
11	accessory	O
12	cellular	O
13	factors	O
14	that	O
15	can	O
16	differentially	O
17	regulate	O
18	the	O
19	transcriptional	O
20	responses	O
21	of	O
22	a	O
23	heterodimer	O
24	-	O
25	DNA	O
26	complex	O
27	are	O
28	not	O
29	well	O
30	understood	O
31	.	O

1	A	O
2	simple	O
3	registration	O
4	as	O
5	an	O
6	incentive	O
7	for	O
8	improvement	O

1	Five	O
2	patients	O
3	developed	O
4	metastatic	O
5	spread	O
6	,	O
7	and	O
8	all	O
9	of	O
10	them	O
11	died	O
12	of	O
13	tumor	O
14	.	O

1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	B
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O

1	Yusuf	B
2	Dawood	I
3	Docrat	I
4	L	I
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O

1	Vibrio	B
2	cholerae	I
3	O139	I
4	in	O
5	Calcutta	O
6	.	O

1	The	O
2	immuno	B
3	-	O
4	purified	O
5	mRNA	O
6	in	O
7	the	O
8	polysome	O
9	complex	O
10	was	O
11	used	O
12	to	O
13	prepare	O
14	cDNA	O
15	with	O
16	which	O
17	to	O
18	probe	O
19	a	O
20	D	O
21	.	O
22	melanogaster	O
23	genomic	O
24	library	O
25	.	O

1	In	O
2	rats	O
3	bearing	O
4	Walker	O
5	-	O
6	256	O
7	-	O
8	carcinosarcoma	O
9	4	O
10	-	O
11	EPI	O
12	was	O
13	effective	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	E2F	B
2	is	O
3	a	O
4	heterodimeric	O
5	complex	O
6	consisting	O
7	of	O
8	E2F	B
9	family	I
10	members	I
11	(	I
12	1	I
13	-	I
14	5	I
15	)	I
16	and	O
17	DP	B
18	proteins	I
19	(	O
20	1	O
21	-	O
22	3	I
23	).	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O

1	Serum	O
2	gastrin	B
3	levels	O
4	did	O
5	not	O
6	change	O
7	in	O
8	either	O
9	group	O
10	;	O
11	however	O
12	,	O
13	background	O
14	serum	O
15	gastrin	B
16	concentrations	O
17	were	O
18	significantly	O
19	greater	O
20	for	O
21	V	O
22	&	O
23	P	O
24	patients	O
25	than	O
26	V	O
27	&	O
28	A	O
29	patients	O
30	throughout	O
31	the	O
32	study	O
33	.	O

1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O

1	The	O
2	COL7A1	B
3	gene	I
4	,	O
5	which	O
6	encodes	O
7	type	B
8	VII	I
9	collagen	I
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	B
26	epidermolysis	I
27	bullosa	I
28	.	O

1	Hematology	O
2	problem	O
3	of	O
4	the	O
5	month	O
6	:	O
7	band	O
8	or	O
9	seg	O
10	?	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	Optically	B
2	detected	O
3	librons	B
4	and	O
5	phonons	O
6	in	O
7	crystalline	O
8	C60	O
9	.	O

1	Mean	O
2	growth	O
3	changes	O
4	in	O
5	this	O
6	Class	O
7	II	O
8	sample	O
9	were	O
10	comparable	O
11	to	O
12	those	O
13	previously	O
14	reported	O
15	for	O
16	male	O
17	subjects	O
18	with	O
19	Class	O
20	I	O
21	malocclusions	O
22	over	O
23	the	O
24	same	O
25	age	O
26	period	O
27	,	O
28	suggesting	O
29	a	O
30	similarity	O
31	in	O
32	postpubertal	O
33	development	O
34	between	O
35	these	O
36	two	O
37	groups	O
38	.	O

1	Transient	O
2	,	O
3	high	O
4	-	O
5	level	O
6	Ras	B
7	-	O
8	expression	O
9	induces	O
10	transcriptional	O
11	activation	O
12	of	O
13	p21	B
14	mediated	O
15	by	O
16	a	O
17	GC	O
18	-	O
19	rich	O
20	region	O
21	in	O
22	p21	B
23	promoter	I
24	-	I
25	83	I
26	-	O
27	54	I
28	bp	O
29	relative	O
30	to	O
31	the	O
32	transcription	O
33	initiation	O
34	site	O
35	containing	O
36	binding	O
37	sites	O
38	for	O
39	Sp1	B
40	-	I
41	family	I
42	transcription	I
43	factors	O
44	.	O

1	Brief	O
2	report	O
3	.	O

1	Unrecognized	B
2	amnionitis	I
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	the	O
6	ADH2	O
7	upstream	O
8	regulatory	O
9	region	O
10	,	O
11	including	O
12	UAS1	O
13	,	O
14	working	O
15	in	O
16	concert	O
17	with	O
18	the	O
19	ADH2	O
20	basal	O
21	promoter	O
22	elements	O
23	,	O
24	UAS2	O
25	-	O
26	dependent	O
27	gene	O
28	activation	O
29	was	O
30	dependent	O
31	on	O
32	orientation	O
33	,	O
34	copy	O
35	number	O
36	,	O
37	and	O
38	helix	O
39	phase	O
40	.	O

1	Plasma	B
2	fibrinogen	I
3	was	O
4	measured	O
5	by	O
6	the	O
7	turbidimetric	O
8	method	O
9	in	O
10	timol	O
11	turbidimetric	O
12	units	O
13	.	O

1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O

1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	immunohistochemical	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	"	B
19	smoothelin	I
20	."	I
21	A	I
22	human	I
23	smooth	I
24	muscle	I
25	cDNA	O
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	B
32	antibody	I
33	R4A	I
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O

1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	O
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O

1	Expression	O
2	of	O
3	thiamin	B
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	B
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	I
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O

1	The	O
2	Fas	B
3	receptor	I
4	mediates	O
5	a	O
6	signalling	O
7	cascade	O
8	resulting	O
9	in	O
10	programmed	O
11	cell	O
12	death	O
13	(	O
14	apoptosis	O
15	)	O
16	within	O
17	hours	O
18	of	O
19	receptor	O
20	cross	O
21	-	O
22	linking	O
23	.	O

1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	I
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	I
10	site	I
11	can	O
12	support	O
13	growth	I
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	O	O
2	.	O
3	novo	O
4	-	O
5	ulmi	O
6	RNA	O
7	-	O
8	7	O
9	,	O
10	previously	O
11	believed	O
12	to	O
13	be	O
14	a	O
15	satellite	O
16	-	O
17	like	O
18	RNA	O
19	,	O
20	is	O
21	shown	O
22	to	O
23	be	O
24	a	O
25	defective	O
26	RNA	O
27	,	O
28	derived	O
29	from	O
30	OnuMV4	B
31	-	I
32	Ld	I
33	RNA	I
34	by	O
35	multiple	O
36	internal	O
37	deletions	O
38	.	O

1	313	O
2	,	O
3	98	O
4	-	O
5	102	O
6	).	O

1	Re	O
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O

1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O

1	Reperfusion	O
2	caused	O
3	a	O
4	transient	O
5	reduction	O
6	in	O
7	lactate	O
8	production	O
9	and	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	LDH	B
15	release	O
16	.	O

1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	O
6	elongation	O
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	B
33	Tat	I
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	O
42	-	O
43	TEFb	I
44	.	O

1	In	O
2	the	O
3	studies	O
4	reported	O
5	here	O
6	,	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	the	O
14	human	B
15	gp130	I
16	gene	I
17	was	O
18	isolated	O
19	and	O
20	the	O
21	transcription	O
22	initiation	O
23	sites	O
24	were	O
25	mapped	O
26	.	O

1	The	O
2	247	O
3	-	O
4	kDa	O
5	complex	O
6	appears	O
7	to	O
8	contain	O
9	two	O
10	distinct	O
11	protein	O
12	-	O
13	DNA	O
14	complexes	O
15	of	O
16	approximately	O
17	232	O
18	and	O
19	256	O
20	kDa	O
21	and	O
22	represents	O
23	two	O
24	proteins	O
25	covalently	O
26	cross	O
27	-	O
28	linked	O
29	to	O
30	a	O
31	single	O
32	DRE	O
33	oligonucleotide	O
34	,	O
35	while	O
36	the	O
37	97	O
38	,	O
39	105	O
40	,	O
41	and	O
42	115	O
43	-	O
44	kDa	O
45	complexes	O
46	represent	O
47	single	O
48	protein	O
49	-	O
50	DRE	O
51	cross	O
52	-	O
53	links	O
54	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	PBSX	O
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	B
10	response	O
11	.	O

1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	QO2	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	ARDS	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	ARDS	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	slope	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	slope	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	To	O
2	determine	O
3	whether	O
4	food	O
5	and	O
6	/	O
7	or	O
8	water	O
9	in	O
10	the	O
11	gastrointestinal	O
12	tract	O
13	affects	O
14	restitution	O
15	of	O
16	blood	O
17	volume	O
18	and	O
19	plasma	O
20	protein	O
21	after	O
22	hemorrhage	O
23	,	O
24	fed	O
25	and	O
26	24	O
27	-	O
28	h	O
29	-	O
30	fasted	O
31	awake	O
32	rats	O
33	received	O
34	a	O
35	20	O
36	ml	O
37	.	O
38	kg	O
39	-	O
40	1	O
41	x	O
42	3	O
43	min	O
44	-	O
45	1	O
46	hemorrhage	O
47	,	O
48	and	O
49	restitution	O
50	of	O
51	blood	O
52	volume	O
53	was	O
54	measured	O
55	by	O
56	Evans	O
57	blue	O
58	dye	O
59	and	O
60	dilution	O
61	of	O
62	hematocrit	O
63	.	O

1	Natl	O
2	.	O

1	Piroximone	O
2	is	O
3	a	O
4	new	O
5	phosphodiesterase	B
6	III	I
7	inhibitor	O
8	that	O
9	combines	O
10	inotropic	O
11	and	O
12	vasodilator	O
13	properties	O
14	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	was	O
6	determined	O
7	to	O
8	be	O
9	residues	O
10	716	O
11	-	O
12	724	I
13	and	O
14	hence	O
15	lysine	O
16	residue	O
17	721	O
18	is	O
19	located	O
20	within	O
21	the	O
22	ATP	B
23	-	I
24	binding	I
25	site	I
26	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	the	O
7	simultaneous	O
8	determination	O
9	of	O
10	1	O
11	,	O
12	alpha	O
13	-	O
14	acetylmethadol	O
15	(	O
16	LAAM	O
17	)	O
18	and	O
19	five	O
20	active	O
21	metabolites	O
22	--	O
23	noracetylmethadol	O
24	,	O
25	dinoracetylmethadol	O
26	,	O
27	methadol	B
28	,	O
29	normethadol	O
30	,	O
31	and	O
32	dinormethadol	O
33	--	O
34	in	O
35	biofluids	O
36	by	O
37	high	O
38	-	O
39	performance	O
40	liquid	O
41	chromatography	O
42	using	O
43	a	O
44	normal	O
45	-	O
46	phase	O
47	column	O
48	and	O
49	a	O
50	UV	O
51	detector	O
52	at	O
53	218	O
54	nm	O
55	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	B
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	Carnitine	B
2	palmitoyltransferase	I
3	(	O
4	CPT	B
5	)	I
6	II	I
7	deficiency	O
8	is	O
9	the	O
10	most	O
11	common	O
12	inherited	O
13	disorder	O
14	of	O
15	lipid	O
16	metabolism	O
17	affecting	O
18	skeletal	O
19	muscle	O
20	.	O

1	Each	O
2	sample	O
3	was	O
4	analysed	O
5	as	O
6	soon	O
7	as	O
8	possible	O
9	,	O
10	and	O
11	repeated	O
12	15	O
13	,	O
14	30	O
15	,	O
16	60	O
17	and	O
18	120	O
19	min	O
20	after	O
21	sampling	O
22	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	O
5	alpha	B
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	O
16	2	B
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	B
24	II	I
25	;	O
26	EC	B
27	2	I
28	.	I
29	4	I
30	.	I
31	1	I
32	.	O
33	143	O
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Unlike	O
2	most	O
3	other	O
4	members	O
5	of	O
6	the	O
7	Bcl	B
8	-	I
9	2	I
10	family	I
11	,	O
12	BAD	B
13	(	O
14	Bcl	B
15	-	I
16	xL	I
17	/	I
18	Bcl	I
19	-	I
20	2	I
21	associated	I
22	death	I
23	promoter	I
24	),	O
25	a	O
26	death	B
27	enhancer	O
28	,	O
29	has	O
30	no	O
31	C	O
32	-	O
33	terminal	O
34	transmembrane	O
35	domain	O
36	for	O
37	targeting	O
38	to	O
39	the	O
40	outer	B
41	mitochondrial	I
42	membrane	I
43	and	O
44	nuclear	O
45	envelope	I
46	.	O

1	A	O
2	single	O
3	N	O
4	-	O
5	glycosylation	O
6	site	O
7	present	O
8	in	O
9	chicken	O
10	gp42	O
11	is	O
12	conserved	O
13	among	O
14	all	O
15	five	O
16	of	O
17	these	O
18	proteins	O
19	:	O
20	carbohydrate	O
21	analysis	O
22	of	O
23	gp42	O
24	revealed	O
25	the	O
26	presence	O
27	of	O
28	a	O
29	complex	O
30	type	O
31	glycan	O
32	chain	O
33	at	O
34	this	O
35	site	O
36	.	O

1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	I
6	Cdk	I
7	complexes	I
8	in	O
9	Rb	B
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	B
19	/	I
20	MTS1	I
21	tumour	I
22	suppressor	I
23	gene	I
24	product	I
25	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	These	O
2	protective	O
3	influences	O
4	were	O
5	observed	O
6	throughout	O
7	the	O
8	range	O
9	of	O
10	filling	O
11	pressures	O
12	measured	O
13	,	O
14	from	O
15	0	O
16	to	O
17	30	O
18	mmHg	O
19	.	O

1	All	O
2	four	O
3	doubly	O
4	tyrosine	O
5	phosphorylated	O
6	TAM	O
7	peptides	O
8	cross	O
9	-	O
10	compete	O
11	with	O
12	each	O
13	other	O
14	for	O
15	binding	O
16	to	O
17	the	O
18	tandem	O
19	SH2	B
20	domains	I
21	of	O
22	ZAP	B
23	-	I
24	70	I
25	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	22	O
6	,	O
7	846	O
8	bp	O
9	of	O
10	the	O
11	left	O
12	arm	O
13	of	O
14	chromosome	O
15	IV	O
16	is	O
17	described	O
18	.	O

1	Delta	O
2	-	O
3	aminolevulinic	O
4	acid	O
5	in	O
6	physiological	O
7	conditions	O
8	and	O
9	some	O
10	diseases	O
11	in	O
12	children	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	B
7	and	O
8	tyrosine	B
9	kinases	I
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	O
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O

1	This	O
2	study	O
3	demonstrates	O
4	that	O
5	alteration	O
6	of	O
7	CDKN2	O
8	is	O
9	one	O
10	of	O
11	the	O
12	most	O
13	frequent	O
14	genetic	O
15	abnormalities	O
16	in	O
17	prostate	O
18	cancer	O
19	and	O
20	may	O
21	contribute	O
22	to	O
23	prostate	O
24	carcinogenesis	O
25	.	O

1	DtxR	O
2	is	O
3	an	O
4	iron	O
5	-	O
6	dependent	O
7	sequence	O
8	-	O
9	specific	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	the	O
18	tox	B
19	operator	I
20	,	O
21	an	O
22	inverted	O
23	-	O
24	repeat	O
25	nucleotide	O
26	sequence	O
27	located	O
28	upstream	O
29	from	O
30	the	O
31	diphtheria	B
32	toxin	I
33	gene	I
34	.	O

1	We	O
2	used	O
3	deletion	O
4	analysis	O
5	and	O
6	transfection	O
7	assays	O
8	with	O
9	reporter	O
10	gene	O
11	constructs	I
12	to	O
13	examine	O
14	the	O
15	transcription	O
16	control	O
17	elements	O
18	in	O
19	the	O
20	5	O
21	'	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	EpoR	I
28	gene	I
29	.	O

1	Nursing	O
2	education	O
3	--	O
4	the	O
5	computer	O
6	obligation	O
7	.	O

1	Finger	B
2	associated	I
3	box	I
4	-	I
5	zinc	I
6	finger	I
7	proteins	I
8	(	O
9	FAX	B
10	-	O
11	ZFPs	B
12	)	O
13	constitute	O
14	a	O
15	subfamily	O
16	of	O
17	the	O
18	many	O
19	C2H2	O
20	type	O
21	ZFPs	B
22	in	O
23	Xenopus	B
24	laevis	I
25	.	O

1	Previously	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	51	O
7	-	O
8	bp	O
9	promoter	O
10	fragment	O
11	,	O
12	oligo31	O
13	/	O
14	32	O
15	,	O
16	which	O
17	conferred	O
18	heat	O
19	shock	O
20	inducibility	O
21	on	O
22	the	O
23	heterologous	O
24	CYC1	B
25	-	I
26	lacZ	I
27	reporter	I
28	gene	I
29	in	O
30	S	O
31	.	O
32	cerevisiae	O
33	(	O
34	N	O
35	.	O

1	The	O
2	upTRE	B
3	binds	O
4	more	O
5	T3R	B
6	homodimers	O
7	and	O
8	less	O
9	T3R	B
10	-	I
11	RXR	I
12	heterodimers	O
13	than	O
14	the	O
15	dnTRE	O
16	,	O
17	and	O
18	T3	O
19	more	O
20	readily	O
21	facilitates	O
22	heterodimer	O
23	binding	O
24	to	O
25	the	O
26	dn	O
27	-	O
28	than	O
29	to	O
30	the	O
31	upTRE	O
32	.	O

1	DAF16	O
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	I
25	IGF	I
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	I
7	-	I
8	related	I
9	sequences	I
10	and	O
11	a	O
12	small	B
13	Ig	I
14	-	I
15	related	I
16	sequence	I
17	.	O

1	Sp1	B
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	B
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	O
12	P	B
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	I
21	p50	B
22	homodimers	I
23	replace	O
24	Sp1	B
25	from	O
26	the	O
27	P	B
28	-	I
29	selectin	I
30	promoter	I
31	by	O
32	binding	O
33	site	I
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	B
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	B
50	-	I
51	3	I
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	regenerative	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	alcoholic	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	263	O
17	patients	O
18	with	O
19	severe	O
20	alcoholic	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	B
30	growth	I
31	factor	I
32	(	O
33	HGF	B
34	)	O
35	and	O
36	alpha	B
37	-	I
38	fetoprotein	I
39	(	O
40	AFP	B
41	).	O

1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	B
13	plasma	I
14	PSA	I
15	levels	O
16	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	O
26	interaction	O
27	.	O

1	Experiments	O
2	with	O
3	recombinant	B
4	proteins	O
5	showed	O
6	that	O
7	p50	B
8	/	I
9	p65	B
10	and	O
11	high	B
12	-	I
13	mobility	I
14	-	I
15	group	I
16	I	I
17	(	O
18	Y	B
19	)	O
20	protein	O
21	cooperatively	O
22	facilitated	O
23	the	O
24	binding	O
25	of	O
26	IRF	B
27	-	I
28	1	I
29	to	O
30	the	O
31	VCAM1	B
32	IRF	I
33	binding	I
34	site	I
35	and	O
36	that	O
37	IRF	B
38	-	I
39	1	I
40	physically	I
41	interacted	O
42	with	O
43	p50	B
44	and	O
45	with	O
46	high	B
47	-	I
48	mobility	I
49	-	I
50	group	I
51	I	I
52	(	O
53	Y	B
54	)	O
55	protein	O
56	.	O

1	On	O
2	the	O
3	diagnosis	O
4	of	O
5	bovine	O
6	leucosis	O
7	and	O
8	its	O
9	control	O
10	in	O
11	southern	O
12	Lower	O
13	Saxony	O

1	It	O
2	contains	O
3	three	O
4	putative	O
5	binding	O
6	sites	O
7	for	O
8	transcription	O
9	factor	O
10	Sp1	I
11	as	O
12	well	O
13	as	O
14	several	O
15	short	O
16	sequences	O
17	that	O
18	are	O
19	similar	O
20	to	O
21	known	O
22	cis	O
23	-	O
24	acting	O
25	enhancers	O
26	or	O
27	binding	O
28	sites	O
29	for	O
30	transcription	O
31	factors	O
32	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	dietary	O
6	safflower	O
7	phospholipids	O
8	may	O
9	be	O
10	a	O
11	valuable	O
12	ingredient	O
13	to	O
14	layers	O
15	for	O
16	reducing	O
17	liver	O
18	triglycerides	O
19	and	O
20	serum	O
21	cholesterol	O
22	without	O
23	any	O
24	adverse	O
25	effects	O
26	.	O

1	Carbohydrate	O
2	metabolism	O
3	and	O
4	the	O
5	semen	O
6	profile	O
7	:	O
8	glucose	O
9	,	O
10	insulin	B
11	,	O
12	and	O
13	sperm	O
14	studies	O
15	.	O

1	A	O
2	third	O
3	one	O
4	is	O
5	homologous	O
6	in	O
7	half	O
8	of	O
9	its	O
10	length	O
11	to	O
12	the	O
13	prokaryotic	O
14	hydantoinase	I
15	HyuA	I
16	and	O
17	in	O
18	the	O
19	other	O
20	half	O
21	to	O
22	hydatoinase	B
23	HyuB	I
24	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	Domain	O
2	switch	O
3	experiments	O
4	reveal	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	beta	I
10	proteins	I
11	containing	O
12	either	O
13	the	O
14	leucine	O
15	zipper	O
16	or	O
17	the	O
18	activation	O
19	domain	I
20	of	I
21	C	I
22	/	I
23	EBP	I
24	alpha	I
25	are	O
26	unable	O
27	to	O
28	stimulate	O
29	the	O
30	2D5	B
31	promoter	I
32	yet	O
33	are	O
34	fully	O
35	capable	O
36	of	O
37	transactivating	O
38	an	O
39	artificial	O
40	promoter	O
41	bearing	O
42	a	O
43	high	O
44	-	O
45	affinity	O
46	C	B
47	/	I
48	EBP	I
49	site	I
50	.	O

1	GH	B
2	deficiency	O
3	may	O
4	be	O
5	absolute	O
6	,	O
7	but	O
8	often	O
9	is	O
10	not	O
11	and	O
12	the	O
13	diagnosis	O
14	may	O
15	be	O
16	complicated	O
17	by	O
18	a	O
19	constellation	O
20	of	O
21	physical	O
22	and	O
23	hormonal	O
24	findings	O
25	that	O
26	are	O
27	along	O
28	a	O
29	spectrum	O
30	from	O
31	low	O
32	normal	O
33	GH	B
34	sufficiency	I
35	to	O
36	absent	O
37	GH	B
38	secretion	I
39	.	O

1	Diltiazem	O
2	resulted	O
3	in	O
4	a	O
5	significant	O
6	increase	O
7	in	O
8	epicardial	O
9	diameter	O
10	(+	O
11	10	O
12	%;	O
13	p	O
14	=	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	in	O
21	coronary	O
22	blood	O
23	flow	O
24	(	O
25	CBF	B
26	)	O
27	(+	O
28	30	O
29	%;	O
30	p	O
31	=	O
32	0	O
33	.	O
34	0001	O
35	).	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	temperature	O
7	-	O
8	sensitive	O
9	rad54	I
10	-	I
11	3	I
12	allele	I
13	blocks	O
14	mitotic	O
15	recombination	O
16	between	O
17	tandemly	O
18	repeated	O
19	DYZ3	O
20	satellite	O
21	sequences	O
22	and	O
23	significantly	O
24	stabilizes	O
25	a	O
26	human	O
27	DYZ5	O
28	satellite	O
29	-	O
30	containing	O
31	YAC	O
32	clone	O
33	.	O

1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	B
15	ODC	I
16	mRNA	I
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O

1	The	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	Pur	B
7	alpha	I
8	recognition	I
9	element	I
10	disrupts	O
11	these	O
12	complexes	O
13	.	O

1	Fission	B
2	yeast	I
3	mal2	I
4	+	I
5	is	O
6	required	O
7	for	O
8	chromosome	O
9	segregation	O
10	.	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	B
7	K1F	I
8	tail	I
9	gene	I
10	encoding	O
11	endo	B
12	-	I
13	N	I
14	-	I
15	acylneuraminidase	I
16	(	O
17	endo	B
18	-	O
19	N	I
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	B
26	-	I
27	N	I
28	homolog	I
29	in	O
30	bacteriophage	B
31	PK1E	I
32	.	O

1	HS	B
2	inducibility	O
3	required	O
4	the	O
5	HSE	O
6	which	O
7	was	O
8	bound	O
9	by	O
10	HS	B
11	transcription	I
12	factor	I
13	-	I
14	1	I
15	(	O
16	HSF	B
17	-	I
18	1	I
19	)	O
20	present	O
21	in	O
22	extracts	O
23	prepared	O
24	from	O
25	cells	O
26	exposed	O
27	to	O
28	HS	B
29	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Failures	O
2	of	O
3	colorimetric	O
4	additivity	O
5	under	O
6	these	O
7	experimental	O
8	conditions	O
9	are	O
10	discussed	O
11	.	O

1	Expression	O
2	of	O
3	the	O
4	CYP11A1	B
5	gene	I
6	is	O
7	increased	O
8	by	O
9	hormones	O
10	,	O
11	such	O
12	as	O
13	adrenocorticotropin	B
14	and	O
15	luteinizing	B
16	hormone	I
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	number	O
24	of	O
25	growth	O
26	factors	O
27	,	O
28	suggesting	O
29	that	O
30	its	O
31	promoter	O
32	may	O
33	contain	O
34	regulatory	O
35	elements	O
36	that	O
37	respond	O
38	to	O
39	multiple	O
40	signal	O
41	transduction	O
42	pathways	O
43	.	O

1	The	O
2	clinical	O
3	application	O
4	of	O
5	the	O
6	antibody	O
7	-	O
8	targeted	O
9	Phthalocyanine	O
10	was	O
11	performed	O
12	in	O
13	3	O
14	patients	O
15	suffering	O
16	from	O
17	an	O
18	advanced	O
19	ovarian	O
20	carcinoma	O
21	(	O
22	FIGO	O
23	III	O
24	).	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	toxicological	O
11	tests	O
12	conducted	O
13	on	O
14	plastic	O
15	materials	O
16	(	O
17	polyethylene	O
18	)	O
19	activated	O
20	with	O
21	tetraphenylbutadiene	O
22	(	O
23	TPB	O
24	)	O
25	an	O
26	additive	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	sensitizer	O
32	capable	O
33	of	O
34	photodegrading	O
35	plastic	O
36	materials	O
37	.	O

1	Polymyxin	B
2	B	I
3	was	O
4	given	O
5	intravenously	O
6	for	O
7	1	O
8	week	O
9	postburn	O
10	in	O
11	doses	O
12	designed	O
13	to	O
14	neutralize	O
15	circulating	O
16	endotoxemia	O
17	.	O

1	The	O
2	different	O
3	holoenzyme	B
4	RNA	I
5	polymerases	I
6	generated	O
7	upon	O
8	reconstituting	O
9	these	O
10	mutants	O
11	independently	O
12	with	O
13	core	B
14	RNA	I
15	polymerase	I
16	(	O
17	alpha2beta	B
18	beta	I
19	')	O
20	have	O
21	shown	O
22	reduced	O
23	transcriptional	O
24	activity	O
25	in	O
26	comparison	O
27	to	O
28	the	O
29	enzyme	O
30	containing	O
31	wild	B
32	-	I
33	type	I
34	sigma	I
35	factor	I
36	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	O
7	-	O
8	kDa	O
9	nuclear	O
10	pore	O
11	glycoprotein	O
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	O
31	pore	O
32	glycoproteins	O
33	.	O

1	The	O
2	other	O
3	transmembrane	O
4	regions	O
5	as	O
6	well	O
7	as	O
8	the	O
9	nucleoplasmic	B
10	domain	O
11	are	O
12	not	O
13	required	O
14	for	O
15	sorting	O
16	.	O

1	The	O
2	phi	B
3	AP3	I
4	factor	I
5	is	O
6	a	O
7	nuclear	O
8	phosphoprotein	O
9	;	O
10	the	O
11	extent	O
12	of	O
13	its	O
14	phosphorylation	O
15	is	O
16	regulated	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	.	O

1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O

1	What	O
2	'	O
3	s	O
4	new	O
5	in	O
6	gynecologic	O
7	and	O
8	obstetrical	O
9	surgery	O
10	.	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	O
7	,	O
8	kinase	O
9	interaction	O
10	sites	O
11	,	O
12	and	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	the	O
17	LMP2A	B
18	homologs	I
19	have	O
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	O
25	heterogeneity	O
26	in	O
27	the	O
28	preterminal	O
29	repeat	O
30	regions	O
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	Our	O
2	results	O
3	confirm	O
4	the	O
5	participation	O
6	of	O
7	intron	O
8	1	O
9	in	O
10	transcriptional	O
11	regulation	O
12	of	O
13	the	O
14	c	B
15	-	I
16	myb	I
17	gene	I
18	(	O
19	in	O
20	mouse	O
21	and	O
22	human	O
23	)	O
24	and	O
25	implicate	O
26	multiple	O
27	and	O
28	complex	O
29	regulatory	O
30	mechanisms	O
31	of	O
32	activation	O
33	during	O
34	myelomonocytic	O
35	differentiation	O
36	and	O
37	leukemic	O
38	cell	O
39	growth	O
40	control	O
41	.	O

1	In	O
2	the	O
3	ePTFE	O
4	specimens	O
5	,	O
6	tissue	O
7	coverage	O
8	had	O
9	increased	O
10	.	O

1	60th	B
2	birthday	I
3	of	O
4	colonel	B
5	prof	I
6	.	O
7	e	O
8	.	O
9	cerny	I
10	m	I
11	.	O
12	d	O
13	.	O

1	Internal	O
2	amino	O
3	acid	O
4	sequence	O
5	has	O
6	now	O
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	O
12	which	O
13	shares	O
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	B
25	G	I
26	alpha	I
27	11	I
28	and	I
29	G	B
30	alpha	I
31	q	I
32	cDNAs	I
33	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O

1	A	O
2	polymorphic	O
3	bipartite	O
4	motif	O
5	signals	O
6	nuclear	O
7	targeting	O
8	of	O
9	early	O
10	auxin	I
11	-	I
12	inducible	I
13	proteins	I
14	related	I
15	to	O
16	PS	B
17	-	I
18	IAA4	I
19	from	O
20	pea	B
21	(	O
22	Pisum	B
23	sativum	I
24	).	O

1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O

1	Collectively	O
2	,	O
3	the	O
4	results	O
5	suggest	O
6	that	O
7	ARF	B
8	binding	I
9	to	O
10	Mdm2	O
11	induces	O
12	a	O
13	conformational	O
14	change	O
15	that	O
16	facilitates	O
17	nucleolar	O
18	import	O
19	of	O
20	the	O
21	ARF	B
22	-	I
23	Mdm2	I
24	complex	I
25	and	O
26	p53	B
27	-	I
28	dependent	O
29	cell	O
30	cycle	O
31	arrest	O
32	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	B
8	kinase	I
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	B
23	-	I
24	2	I
25	.	O

1	Supraventricular	O
2	arrhythmias	O
3	--	O
4	digoxin	O
5	and	O
6	quinidine	O
7	revisited	O
8	.	O

1	C	O
2	-	O
3	SP	I
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	The	O
2	active	O
3	open	O
4	reading	O
5	frame	O
6	in	O
7	the	O
8	clone	O
9	maps	O
10	at	O
11	27	O
12	min	O
13	on	O
14	the	O
15	E	O
16	.	O
17	coli	O
18	chromosome	O
19	and	O
20	is	O
21	identical	O
22	in	O
23	sequence	O
24	to	O
25	a	O
26	wild	O
27	type	O
28	counterpart	O
29	.	O

1	While	O
2	the	O
3	latter	O
4	corresponded	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	824	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	uORF	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	comparison	O
6	of	O
7	the	O
8	hCHLR	B
9	gene	I
10	sequences	O
11	with	O
12	available	O
13	databases	O
14	indicates	O
15	that	O
16	a	O
17	large	O
18	portion	O
19	of	O
20	these	O
21	genes	O
22	,	O
23	including	O
24	exons	O
25	encoding	O
26	two	O
27	functional	O
28	domains	O
29	of	O
30	the	O
31	carboxyl	O
32	-	O
33	terminal	O
34	region	O
35	of	O
36	these	O
37	proteins	O
38	,	O
39	has	O
40	been	O
41	duplicated	O
42	as	O
43	part	O
44	of	O
45	a	O
46	larger	O
47	human	O
48	telomeric	O
49	repeat	O
50	sequence	O
51	found	O
52	on	O
53	many	O
54	human	O
55	chromosomes	O
56	.	O

1	This	O
2	report	O
3	expands	O
4	on	O
5	previous	O
6	work	O
7	with	O
8	interferon	B
9	alfa	I
10	-	I
11	2b	I
12	(	O
13	Intron	O
14	A	O
15	;	O
16	Schering	B
17	-	I
18	Plough	I
19	)	O
20	in	O
21	the	O
22	treatment	O
23	of	O
24	hairy	O
25	cell	O
26	leukemia	O
27	(	O
28	HCL	O
29	).	O

1	All	O
2	mutant	O
3	JCV	O
4	T	O
5	antigens	O
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	Six	O
2	healthy	O
3	male	O
4	subjects	O
5	received	O
6	single	O
7	oral	O
8	doses	O
9	of	O
10	regular	O
11	release	O
12	(	O
13	RR	O
14	)	O
15	quinidine	O
16	sulfate	O
17	,	O
18	sustained	O
19	release	O
20	(	O
21	SR	B
22	)	O
23	quinidine	O
24	bisulfate	O
25	and	O
26	the	O
27	same	O
28	dose	O
29	of	O
30	the	O
31	SR	B
32	product	I
33	with	O
34	food	O
35	(	O
36	SR	B
37	-	O
38	F	I
39	).	O

1	Study	O
2	of	O
3	the	O
4	alterations	O
5	of	O
6	intestinal	O
7	absorption	O
8	,	O
9	by	O
10	means	O
11	of	O
12	I	O
13	-	O
14	131	O
15	-	O
16	triolein	O
17	,	O
18	in	O
19	the	O
20	whole	O
21	body	O
22	irradiated	O
23	rat	O

1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	B
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O

1	Furthermore	O
2	,	O
3	the	O
4	potency	O
5	of	O
6	Dacarbacine	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	carcinoid	O
12	tumors	O
13	seems	O
14	to	O
15	be	O
16	underestimated	O
17	up	O
18	to	O
19	now	O
20	.	O

1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O

1	Patterns	O
2	defined	O
3	by	O
4	combinations	O
5	of	O
6	normal	O
7	and	O
8	abnormal	O
9	laboratory	O
10	results	O
11	had	O
12	decreased	O
13	the	O
14	likelihood	O
15	of	O
16	PEM	O
17	from	O
18	an	O
19	all	O
20	-	O
21	2	O
22	to	O
23	all	O
24	-	O
25	0	O
26	pattern	O
27	.	O

1	The	O
2	relevance	O
3	of	O
4	these	O
5	elements	O
6	in	O
7	conferring	O
8	anaerobic	O
9	induction	O
10	of	O
11	gpc4	B
12	gene	I
13	expression	O
14	is	O
15	discussed	O
16	.	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	B
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	Lithium	O
2	phthalocyanine	B
3	(	O
4	LiPc	B
5	)	O
6	is	O
7	a	O
8	prototype	O
9	of	O
10	another	O
11	generation	O
12	of	O
13	synthetic	O
14	,	O
15	metallic	O
16	-	O
17	organic	O
18	,	O
19	paramagnetic	O
20	crystallites	O
21	that	O
22	appear	O
23	very	O
24	useful	O
25	for	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	electron	O
32	paramagnetic	O
33	resonance	O
34	oximetry	O
35	.	O

1	The	O
2	pretransplant	O
3	regimen	O
4	consisted	O
5	of	O
6	cyclophosphamide	O
7	(	O
8	120	O
9	mg	O
10	/	O
11	kg	O
12	)	O
13	and	O
14	total	O
15	body	O
16	irradiation	O
17	.	O

